

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Chico, RM (2018) Intermittent preventive treatment of malaria in pregnancy and infectious causes of adverse birth outcomes in sub-Saharan Africa. PhD thesis, London School of Hygiene & Tropical Medicine. DOI: <https://doi.org/10.17037/PUBS.04646716>

Downloaded from: <http://researchonline.lshtm.ac.uk/4646716/>

DOI: [10.17037/PUBS.04646716](https://doi.org/10.17037/PUBS.04646716)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



**Intermittent preventive treatment of malaria in
pregnancy and infectious causes of adverse birth
outcomes in sub-Saharan Africa**

RAYMUND MATTHEW CHICO

*Submitted in accordance
with requirements for the degree of
Doctor of Philosophy*

**Department of Disease Control
Faculty of Infectious and Tropical Diseases
London School of Hygiene and Tropical Medicine
University of London**

December 2017

Declaration

I, Raymund Matthew Chico, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.

Signature:  Date: 5 January 2018

List of abbreviations	
-----------------------	--

ANC	Antenatal care
BPG	Benzathine penicillin G
CI	Confidence interval
<i>Pfdhfr</i>	<i>Plasmodium falciparum</i> dihydrofolate reductase
<i>Pfdhps</i>	<i>Plasmodium falciparum</i> dihydropteroate synthase
HIV	Human immunodeficiency virus
IPTp	Intermittent preventive treatment of malaria in pregnancy
ITN	Insecticide treated net
GRADE	Grading of Evidence, Assessment, Development and Evaluation
LBW	Low birth weight
MAP	Malaria Atlas Project
MIC	Minimum inhibitory concentration
OR	Odds ratio
PCR	Polymerase chain reaction
<i>PfPR</i> ₂₋₁₀	<i>Plasmodium falciparum</i> prevalence rate amongst 2-10 year olds
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCT	Randomised controlled trial
RPR	Rapid plasma reagin
RR	Risk ratio
RTI	Reproductive tract infection
SP	Sulphadoxine-pyrimethamine
STI	Sexually transmitted infection
STIs/RTIs	Sexually transmitted and reproductive tract infections
TPHA	<i>Treponema pallidum</i> haemagglutination assay
TRUST	Toluidine red unheated serum test
WHO	World Health Organization

Abstract

Background

The World Health Organization recommends intermittent preventive treatment of malaria in pregnancy (IPTp) using sulphadoxine-pyrimethamine (SP) during antenatal visits in moderate to high transmission areas. In some areas of Africa, recent efforts to control and eliminate malaria have yielded historic reductions in transmission intensity that have occurred alongside concomitant increases in parasite resistance to SP, compromising the efficacy of IPTp. Nevertheless, IPTp-SP continues to have beneficial effect on birth outcomes, and there is a suspicion that SP may protect against adverse birth outcomes attributable to curable sexually transmitted and reproductive tract infections (STIs/RTIs). This doctoral thesis explores five research questions related to IPTp with methods noted in parentheses.

Research questions and methods

1. In the context of declining malaria transmission, is there a threshold of malaria transmission intensity below which IPTp-SP may no longer protect against the incidence of low birth weight? (Methods: systematic review, meta-analysis, and meta-regression analysis)
2. In the context of declining parasite sensitivity to SP, is there a threshold of the *Plasmodium falciparum* resistance to SP defined by the prevalence of *dhps* mutation at codon A581G above which IPTp-SP may no longer protect against the incidence of low birth weight? (Methods: systematic review and meta-analysis)
3. In the context of declining malaria transmission and parasite sensitivity to SP, might protection conferred by IPTp-SP be explained partially by an effect against malaria infection as well as STIs/RTIs? (Methods: descriptive analysis and multivariate logistic regression)

4. In the context of pregnant women attending antenatal care in sub-Saharan Africa, what is the prevalence of malaria infection and curable STIs/RTIs? (Methods: systematic review and meta-analysis)
5. In the context of a high dual burden of malaria infection and curable STIs/RTIs amongst pregnant women in sub-Saharan Africa, would azithromycin be an efficacious drug to be included as part of IPTp? (Methods: systematic review and selected meta-analysis)

Results

Evidence suggests that IPTp-SP protects against low birth weight in all gravaide regardless of transmission intensity. This protection persists among primi- and secundigravidae irrespective of the prevalence of the A581G mutation. Protection appears to wane, however, as there is no evidence of protective effect against low birth weight amongst multigravidae where the prevalence of A581G is >10.1%. Despite this finding, data from Zambia suggests that the protective effect of IPTp-SP may safeguard pregnancies against more than just the effects of malaria infection; women who received more doses of IPTp-SP during pregnancy were protected against adverse birth outcomes attributable to co-infection with malaria and several curable STIs/RTIs. Meta-analysis of data from pregnant women attending antenatal care facilities in sub-Saharan Africa suggests that malaria infection and curable STIs/RTIs amongst pregnant women attending antenatal care facilities in sub-Saharan Africa is very high and, when considered collectively, curable STIs/RTIs may be more prevalent than malaria infection during pregnancy. A potential response to this dual burden of disease in pregnancy is to explore combination therapies that address malaria and curable STIs/RTIs jointly and more effectively than IPTp-SP. Research presented in this thesis suggests that curable

STIs/RTIs are sensitive to azithromycin and that policymakers need additional evidence to consider adding azithromycin to IPTp regimens.

Conclusions

Despite evidence of parasite resistance, IPTp-SP remains protective against the effects of malaria infection in most pregnant women, even where transmission intensities are very low, and may also reduce the burden of curable STIs/RTIs. However, this protection is likely sub-optimal and, given the high prevalence of malaria and curable STIs/RTIs among pregnant women in sub-Saharan Africa, alternative therapies that include azithromycin merit investigation in clinical trials with robust microbiological components.

Table of contents

Abstract.....	4
Table of contents.....	7
List of tables and figures	11
Acknowledgements	13
Contributions	16
Introduction	20
Literature review	23
Epidemiology of malaria in pregnancy	23
Entomological considerations.....	23
Physiological considerations	24
Chemoprevention	26
Chloroquine and pyrimethamine monotherapies	26
Sulphadoxine-pyrimethamine.....	26
Decreasing malaria transmission	26
Table 1. Selected studies of placebo vs. IPTp-SP with and without ITNs.....	29
Decreasing parasite sensitivity.....	30
Potential for azithromycin use in IPTp	31
Azithromycin monotherapy	31
Table 2. Azithromycin chemoprophylactic efficacy relative to placebo	33
Azithromycin plus sulphadoxine-pyrimethamine	34
Azithromycin plus chloroquine	35
Table 3. Key IPTp studies of azithromycin	37
Epidemiology of STIs/RTIs in pregnancy.....	38
Management of curable STIs/RTIs in pregnancy	39
Table 4. Effect of curable STIs/RTIs on birth outcomes	41
Rationale and research questions.....	43
Q 1. Malaria transmission intensity threshold	43
Q 2. A581G prevalence threshold.....	43
Q 3. Effect of IPTp-SP on malaria and curable STIs/RTIs in pregnancy.....	44
Q 4. Prevalence of malaria and curable STIs/RTIs in pregnancy	46
Q 5. Effect of azithromycin on curable STIs/RTIs in pregnancy.....	49
Methods outline and monograph structure	50
Methods, results and discussion by research question.....	51

Q 1. Malaria transmission intensity threshold	51
Methods	51
Table 1.1 Medical subject headings and free text terms	51
Table 1.2 Matching rules	55
Table 1.3 Age structure of paediatric data matched to gravidity	55
Results	56
Systematic review	56
Figure 1.1 PRISMA flowchart for systematic review	57
Table 1.4 Summary of included studies by gravidae	58
Figure 1.2 PRISMA flowchart for matching studies	59
Figure 1.3 Funnel plot	60
Table 1.5 Risk of bias amongst individual pregnancy studies	61
Figure 1.4 Risk of bias amongst individual pregnancy studies	70
Figure 1.5 Risk of bias across pregnancy studies	70
Meta-analysis	71
Table 1.6 Malaria transmission estimates based on matching rules	72
Meta-regression analysis	73
Discussion	73
Q 2. A581G prevalence threshold	75
Methods	75
Results	76
Table 2.1 A581G Prevalence at IPTp-SP study sites	78
Figure 2.1 Forest plot – primi- and secundigravidae	79
Figure 2.2 Forest plot – multigravidae	80
Discussion	81
Q 3. Effect of IPTp-SP on malaria and curable STIs/RTIs in pregnancy	82
Methods	82
Table 3.1 Potential confounding factors for any adverse birth outcome	86
Table 3.2 Potential confounding factors for stillbirth	88
Table 3.3 Potential confounding factors for low birth weight	90
Table 3.4 Potential confounding factors for preterm delivery	92
Table 3.5 Potential confounding factors for intrauterine growth retardation	94
Results	96
Table 3.6 Participant characteristics at enrolment: 0-1 dose vs. > 2 doses of IPTp-SP	98
Table 3.7 Participant characteristics at delivery: 0-1 dose vs. > 2 doses of IPTp-SP	100
Table 3.8 Participant characteristics at enrolment: 2 doses vs. > 3 doses of IPTp-SP	101

Table 3.9 Participant characteristics at delivery: 2 doses vs. > 3 doses of IPTp-SP	103
Table 3.10 Adverse birth outcomes: 0-1 dose vs. 2 doses vs. > 3 doses of IPTp-SP	104
Table 3.11 Infections and adverse birth outcomes: 0-1 doses vs. > 2 doses IPTp-SP.....	107
Table 3.12 Infections and adverse birth outcomes: 2 doses vs. > 3 doses IPTp-SP	109
Discussion.....	111
Q 4. Prevalence of malaria and curable STIs/RTIs in pregnancy	115
Methods	115
Table 4.a Medical subject headings and free text terms	117
Results	120
Figure 4.1 PRISMA flowchart for systematic review	121
Table 4.1 Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa	122
Figure 4.1a Curable STIs/RTIs and malaria infection: East and Southern Africa.....	125
Figure 4.1b Curable STIs/RTIs and malaria infection: West and Central Africa	126
Syphilis prevalence	127
Table 4.2 Syphilis point estimates: sub-Saharan Africa	128
Figure 4.2a Syphilis pooled estimates: East and Southern Africa	130
Figure 4.2b Syphilis pooled estimates: West and Central Africa	131
<i>Neisseria gonorrhoeae</i> prevalence	132
Table 4.3 <i>Neisseria gonorrhoeae</i> point estimates: sub-Saharan Africa	133
Figure 4.3a <i>Neisseria gonorrhoeae</i> pooled estimates: East and Southern Africa	134
Figure 4.3b <i>Neisseria gonorrhoeae</i> pooled estimates: West and Central Africa	135
<i>Chlamydia trachomatis</i> prevalence	136
Table 4.4 <i>Chlamydia trachomatis</i> point estimates: sub-Saharan Africa	137
Figure 4.4a <i>Chlamydia trachomatis</i> pooled estimates: East and Southern Africa	138
Figure 4.4b <i>Chlamydia trachomatis</i> pooled estimates: West and Central Africa	139
<i>Trichomonas vaginalis</i> prevalence	140
Table 4.5 <i>Trichomonas vaginalis</i> point estimates: sub-Saharan Africa	141
Figure 4.5a <i>Trichomonas vaginalis</i> pooled estimates: East and Southern Africa	142
Figure 5.5b <i>Trichomonas vaginalis</i> pooled estimates: West and Central Africa	143
Bacterial vaginosis prevalence	144
Table 4.6 Bacterial vaginosis point estimates: sub-Saharan Africa	145
Figure 4.6a Bacterial vaginosis pooled estimates: East and Southern Africa	146
Figure 4.6b Bacterial vaginosis pooled estimates: West and Central Africa	147
Peripheral malaria prevalence	148
Table 4.7 Peripheral malaria point estimates: sub-Saharan Africa.....	149

Figure 4.7a Peripheral malaria pooled estimates: East and Southern Africa	151
Figure 4.7b Peripheral malaria pooled estimates: West and Central Africa	152
Placental malaria prevalence	153
Table 4.8 Placental malaria point estimates at ANC: sub-Saharan Africa	154
Figure 4.8a Placental malaria at ANC: East and Southern Africa	155
Figure 4.8b Placental malaria at ANC: West and Central Africa	156
Table 4.9 Diagnostic methods used: sensitivity and specificity	157
Discussion.....	159
Q 5. Effect of azithromycin on curable STIs/RTIs in pregnancy.....	165
Methods.....	165
Table 5.1 Medical subject headings and free text terms.....	166
Results	167
Figure 5.1 PRISMA flowchart for systematic review	167
Syphilis and azithromycin.....	168
Table 5.2a Syphilis RCTs of azithromycin vs. benzathine penicillin G	169
Table 5.2b Azithromycin and syphilis: low-risk populations.....	173
Table 5.2c Azithromycin and syphilis: high- and mixed-risk populations	174
<i>Neisseria gonorrhoeae</i> and azithromycin	175
Table 5.3a <i>Neisseria gonorrhoeae</i> RCTs of azithromycin.....	177
Table 5.3b Azithromycin and <i>Neisseria gonorrhoeae</i> : low-risk populations	179
Table 5.3c Azithromycin and <i>Neisseria gonorrhoeae</i> : high-risk populations	180
<i>Chlamydia trachomatis</i> and azithromycin	182
Table 5.4a Azithromycin and <i>Chlamydia trachomatis</i> in pregnant women	183
Table 5.4b Azithromycin and <i>Chlamydia trachomatis</i> : low-risk populations	186
<i>Trichomonas vaginalis</i>	187
Table 5.5a RCTs of azithromycin combinations amongst pregnant women	188
Table 5.5b RCTs of azithromycin combinations amongst commercial sex workers	189
Bacterial vaginosis.....	191
Table 5.6 Macrolides and isolates of key organisms in bacterial vaginosis	193
Discussion.....	194
Summary discussion	198
Conclusions	205
References	206

List of tables and figures

Literature review	
Table 1.	Selected studies of placebo versus IPTp-SP with and without ITNs
Table 2.	Azithromycin use as chemoprophylaxis
Table 3.	Selected IPTp studies of azithromycin
Table 4.	Effect of curable STIs/RTIs on birth outcomes
Methods, results and discussion	
Q 1. Malaria transmission intensity threshold	
Methods	
Table 1.1	Medical subject headings and free text terms
Table 1.2	Matching rules
Table 1.3	Age structure of paediatric data matched to gravidity
Results	
Figure 1.1	PRISMA flowchart for systematic review
Table 1.4	Summary of included studies by gravidae
Figure 1.2	PRISMA flowchart for matching pregnancy studies
Figure 1.3	Funnel plot
Table 1.5	Risk of bias amongst individual pregnancy studies
Figure 1.4	Risk of bias amongst individual pregnancy studies
Figure 1.5	Risk of bias across pregnancy studies
Table 1.6	Malaria transmission estimates based on matching rules
Q 2. A581G prevalence threshold	
Results	
Table 2.1	A581G Prevalence at IPTp-SP study sites
Figure 2.1	Forest plot – primi- and secundigravidae
Figure 2.2	Forest plot – multigravidae
Q 3. Prevalence of malaria and curable STIs/RTIs in pregnancy	
Methods	
Table 3.1	Potential confounding factors for any adverse birth outcome
Table 3.2	Potential confounding factors for stillbirth
Table 3.3	Potential confounding factors for low birth weight
Table 3.4	Potential confounding factors for preterm birth
Table 3.5	Potential confounding factors for intrauterine growth retardation
Results	
Table 3.6	Participant characteristics at enrolment: 0-1 dose vs. ≥ 2 doses of IPTp-SP
Table 3.7	Participant characteristics at delivery: 0-1 dose vs. ≥ 2 doses of IPTp-SP
Table 3.8	Participant characteristics at enrolment: 2 doses vs. ≥ 3 doses of IPTp-SP
Table 3.9	Participant characteristics at delivery: 2 doses vs. ≥ 3 doses of IPTp-SP
Table 3.10	Adverse birth outcomes: 0-1 dose vs. 2 doses vs. ≥ 3 doses of IPTp-SP
Table 3.11	Infections and adverse birth outcomes: 0-1 doses vs. ≥ 2 doses IPTp-SP
Table 3.12	Infections and adverse birth outcomes: 2 doses vs. ≥ 3 doses IPTp-SP

Q 4. Prevalence of malaria and curable STIs/RTIs in pregnancy	
Methods	
Table 4.a	Medical subject headings and free text terms
Results	
Figure 4.1	PRISMA flowchart for systematic review
Table 4.1	Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa
Figure 4.1a	Curable STIs/RTIs and malaria infection: East and Southern Africa
Figure 4.1b	Curable STIs/RTIs and malaria infection: West and Central Africa
Table 4.2	Syphilis point estimates: sub-Saharan Africa
Figure 4.2a	Syphilis point estimates: East and Southern Africa
Figure 4.2a	Syphilis point estimates: West and Central Africa
Table 4.3	<i>Neisseria gonorrhoeae</i> point estimates: sub-Saharan Africa
Figure 4.3a	<i>Neisseria gonorrhoeae</i> : East and Southern Africa
Figure 4.3b	<i>Neisseria gonorrhoeae</i> : West and Central Africa
Table 4.4	<i>Chlamydia trachomatis</i> point estimates: sub-Saharan Africa
Figure 4.4a	<i>Chlamydia trachomatis</i> : East and Southern Africa
Figure 4.4b	<i>Chlamydia trachomatis</i> : West and Central Africa
Table 4.5	<i>Trichomonas vaginalis</i> point estimates: sub-Saharan Africa
Figure 4.5a	<i>Trichomonas vaginalis</i> : East and Southern Africa
Figure 4.5b	<i>Trichomonas vaginalis</i> : West and Central Africa
Table 4.6	Bacterial vaginosis point estimates: sub-Saharan Africa
Figure 4.6a	Bacterial vaginosis: East and Southern Africa
Figure 4.6b	Bacterial vaginosis: West and Central Africa
Table 4.7	Peripheral malaria point estimates: sub-Saharan Africa
Figure 4.7a	Peripheral malaria: East and Southern Africa
Figure 4.7b	Peripheral malaria: West and Central Africa
Table 4.8	Placental malaria point estimates: sub-Saharan Africa
Figure 4.8a	Placental malaria: East and Southern Africa
Figure 4.8b	Placental malaria: West and Central Africa
Table 4.9	Diagnostic methods used: sensitivity and specificity
Q 5. Effect of azithromycin on curable STIs/RTIs in pregnancy	
Results	
Figure 5.1	PRISMA flowchart for systematic review
Table 5.2a	Syphilis RCTs of azithromycin vs. benzathine penicillin G
Table 5.2b	Azithromycin and syphilis: low-risk populations
Table 5.2c	Azithromycin and syphilis: high- and mixed-risk populations
Table 5.3a	<i>Neisseria gonorrhoeae</i> RCTs of azithromycin
Table 5.3b	Azithromycin and <i>Neisseria gonorrhoeae</i> : low-risk populations
Table 5.3c	Azithromycin and <i>Neisseria gonorrhoeae</i> : high-risk populations
Table 5.4a	Azithromycin and <i>Chlamydia trachomatis</i> in pregnant women
Table 5.4b	Azithromycin and <i>Chlamydia trachomatis</i> : low-risk populations
Table 5.5a	RCTs of azithromycin combinations amongst pregnant women
Table 5.5b	RCTs of azithromycin combinations amongst commercial sex workers
Table 5.	Macrolides and isolates of key organisms in bacterial vaginosis

Acknowledgements

For anyone who knows Professor Daniel Chandramohan, my supervisor and line manager at the London School of Hygiene & Tropical Medicine, it is not a surprise to hear that he has had a profound influence on me as student and faculty member. Daniel has nurtured my scientific curiosity and has shown me that sound research requires a commitment to following the path of evidence. He taught me to present my findings dispassionately and to remain open to alternative interpretations. Daniel is patient and knows that insights can take time incubate.

I also want to acknowledge my advisor Sir Professor Brian Greenwood. Despite facing perpetual demands for his time and expertise, Brian has always been generous with substantive guidance on proposals, protocols, and manuscripts. He routinely pushed me to consider the broader policy implications of my research and facilitated an opportunity for me to present preliminary results from my analysis of malaria transmission intensity and IPTp-SP protection to the Evidence Review Group on Malaria in Pregnancy hosted by the World Health Organization in Geneva in July of 2013. I was fortunate to have been invited back in July of 2017 to the same Evidence Review Group to present four published papers of mine as listed on pages 16-19. I am also grateful to Cono Ariti who has provided me with steadfast guidance on a range of statistical matters. His passion for data precision rubbed off on me, as did his penchant for ANZAC biscuits at Store Street Espresso. Enesia Banda Chaponda kindly allowed me to use data from Zambia to explore the protection conferred by sulphadoxine-pyrimethamine against adverse birth outcomes associated with malaria and curable sexually transmitted and reproductive tract infections. I have received advice and support from other colleagues including Professors Philippe Mayaud, David Mabey, Cally Roper, Carine Ronsmans, Jorge Cano Ortega, Tim Collier, and Rudiger Pittrof. The Contributions section on pages 16 to 19 provides further detail.

Laura Karr Shipler Chico, my wife, has been unequivocally supportive of this journey, something that I do not take for granted. She has been my anchor and companion for over 20 years, through spring and neap tides. Along the way, she has acquired an impressive knowledge of malariology, enough so that in social settings she is often the one who can more succinctly explain my research! She is rock solid with core beliefs that have been a ballast for me through the stormiest seas. Long ago, she introduced me to the poem *Ithaca*, an apt metaphor, I hope, for my approach to research and, well, this life. Benjamin Karr Chico and Dylan Robinson Chico, my two wonderful sons, were born during this journey, in 2007 and 2011, respectively. They have been a constant source of joy and balance in my life. I have many wishes for them and their years ahead, not the least of which is that they harbour a keen curiosity about the world and a desire to make it a better place.



Ithaca

When you start on your journey to Ithaca,
then pray that the road is long,
full of adventure, full of knowledge.
Do not fear the Lestrygonians
And the Cyclopes and the angry Poseidon.
You will never meet such as these on your path,
if your thoughts remain lofty, if a fine
emotion touches your body and your spirit.
You will never meet the Lestrygonians
And the Cyclopes and the fierce Poseidon,
if you do not carry them within your soul,
if your soul does not raise them up before you.

Then pray that the road is long,
That the summer mornings are many,
That you will enter ports seen for the first time
With such pleasure, with such joy!
Stop at the Phoenician markets,
and purchase fine merchandise,
mother-of-pearl and corals, amber and ebony,
and pleasurable perfumes of all kinds,
buy as many pleasurable perfumes as you can;
visit hosts of Egyptian cities,
to learn and learn from those who have knowledge.

Always keep Ithaca fixed in your mind.
To arrive there is your ultimate goal.
But do not hurry the voyage at all.
It is better to let it last for long years;
and even to anchor at the isle when you are old,
rich with all that you have gained on the way,
not expecting that Ithaca will offer you riches.

Ithaca has given you the beautiful voyage.
Without her you would never have taken the road.
But she has nothing more to give you.

And if you find her poor, Ithaca has not defrauded you.
With the great wisdom you have gained, with so much experience,
you must surely have understood by then what Ithaca means.

Constantine P. Cavafy (1911)

Contributions

In preparing this doctoral thesis, I have drawn from several of the peer-reviewed papers that I have published as first and corresponding author during my tenure at the London School of Hygiene & Tropical Medicine. Where applicable, I have re-written text from these publications to present a single monograph that addresses five inter-connected research questions. The matrix below summarises the sections in this thesis where I have adapted content from these publications and presentations along with a brief summary of contributions made by others. Note that I recently presented four of these papers to the World Health Organization's Evidence Review Group on Intermittent Preventive Treatment of Malaria in Pregnancy between 12 and 14 July 2017 in Geneva, Switzerland.

Section	Publication	Presentation	Contribution
Literature review	Chico RM , Pittrof R, Greenwood B, Chandramohan D. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. <i>Malaria Journal</i> . 2008;7(1):255. ¹	NA	Rudi Pittrof offered me comments on the manuscript, as did Professor Brian Greenwood. Professor Daniel Chandramohan provided guidance on my analysis and interpretation.
	Chico RM , Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. <i>Expert Opinion on Drug Metabolism & Toxicology</i> 2011; 7(9): 1153-67. ²	Chico RM presented this paper to the World Health Organization's Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy (12-14 July 2017). Geneva, Switzerland.	Professor Daniel Chandramohan provided guidance on my analysis and interpretation.

Section	Publication	Presentation	Contribution
Literature review	Chico RM and Chandramohan D, Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. <i>Tropical Medicine and International Health</i> , 2011;16(7): p. 774–785. ³	NA	Professor Daniel Chandramohan provided guidance on my analysis and interpretation.
Q 1	Chico RM , Cano J, Ariti C, Collier TJ, Chandramohan D, Roper C, et al. Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis. <i>Tropical Medicine and International Health</i> . 2015;20(12):1621-33. ⁴	Chico RM presented preliminary findings to the World Health Organization's Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy (11-13 July 2013). Geneva, Switzerland. ⁵ Chico RM presented refined results at the 63rd annual meeting of the American Society of Tropical Medicine and Hygiene (2-6 November 2014). New Orleans, USA. ⁶	Jorge Cano offered assistance in the use of raster data from the Malaria Atlas Project; Cono Ariti and Timothy Collier assisted me with data analyses; Professors Daniel Chandramohan and Brian Greenwood guided me in study design, analysis and interpretation of results.
Q 2	Chico RM , Cano J, Ariti C, Collier TJ, Chandramohan D, Roper C, et al. Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis. <i>Tropical Medicine and International Health</i> . 2015;20(12):1621-33. ⁴	NA	Professor Cally Roper provided me with prevalence data specific to the 581G mutation.

Section	Publication	Presentation	Contribution
Q 3	<p>Chico RM, Chaponda EB, Ariti C, Chandramohan D, Sulfadoxine-pyrimethamine exhibits dose-response protection against malaria and sexually transmitted and reproductive tract infections and related adverse birth outcomes. <i>Clinical Infectious Diseases</i>.2017;64(8):1043-1051.⁷</p>	<p>Chico RM presented preliminary results at the 65rd annual meeting of the American Society of Tropical Medicine and Hygiene (13-17 November 2016). Atlanta, USA.⁸</p> <p>Chico RM presented this paper to the World Health Organization's Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy (12-14 July 2017). Geneva, Switerland.</p>	Enesia Chaponda provided me data from Zambia for analyses; Cono Ariti assisted me with data analysis. Professor Daniel Chandramohan assisted me with my study design, analysis and interpretation.
Q 4	<p>Chico RM, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: A systematic review. <i>JAMA: Journal of the American Medical Association</i>. 2012;307(19):2079-86.⁹</p> <p><u>Results have been re-published in:</u> Mabey D, Gill G, Parry E, Weber MW & Whitty CJM. <i>Principles of Medicine in Africa</i>. 4th edition (Cambridge University Press, 2013).¹⁰</p>	<p>Chico RM presented results as part of a seminar sponsored by Maternal Adolescent Reproductive and Child Health Centre. London School of Hygiene & Tropical Medicine. (18 June 2012) London, UK.¹¹</p> <p>Chico RM presented this paper to the World Health Organization's Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy (12-14 July 2017). Geneva, Switerland.</p>	Professors Philippe Mayaud and David Mabey provided me with guidance specific to curable sexually transmitted and reproductive tract infections; Professor Carine Ronsmans offered helpful comments and suggestions specific to maternal health and systematic reviews; Cono Ariti assisted me with data analysis. Professor Daniel Chandramohan assisted me with my study design, analysis and interpretation.

Section	Publication	Presentation	Contribution
Q 5	Chico RM , Hack BB, Newport MJ, Ngulube E, Chandramohan D. On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections. <i>Expert Reviews on Anti-Infective Therapy</i> . 2013;11(12):1303-32. ¹²	Chico RM presented this paper to the World Health Organization's Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy (12-14 July 2017). Geneva, Switzerland.	Birken Hack contributed to the document review; Professor Melanie Newport offered comments on the manuscript; Enesia Ngulube provided me data on the effect of curable STIs/RTIs on pregnancy outcomes. Professor Daniel Chandramohan assisted me with analysis and interpretation.
Discussion	Chico RM and Moss WJ. Prevention of malaria in pregnancy: a fork in the road? <i>The Lancet</i> . 2015. ¹³	NA	Professors Chandramohan and Greenwood reviewed the first draft. Professor Moss provided helpful comments and suggestions.

Introduction

Some 2,400 years ago in ancient Greece, Hippocrates observed that pregnant women were vulnerable to life-threatening fevers.¹⁴ The extent to which these fevers were attributable to malaria is unknown since the aetiology of malaria infection was poorly understood until 1880 when Alphonse Laveran, aided by crude microscopy, first observed *Plasmodium falciparum* in the blood-film slides of febrile patients under his care in Algeria.¹⁵ Two years later he reported that women who experienced symptoms associated with *P. falciparum* infection had higher placental parasite densities than mothers who had been free of malarial symptoms throughout their pregnancies.¹⁶ In sub-Saharan Africa, one of the earliest published descriptions of the burden of malaria infection during pregnancy comes from D.B. Blacklock and R.M. Gordon who estimated in 1925 that women in Sierra Leone with placental parasitaemia at delivery were five times more likely to have their newborn die than mothers whose placentas had not been parasitised.¹⁷ Steketee *et al.* calculated that each year 75,000 to 200,000 infant deaths in sub-Saharan Africa are attributable to malaria infection during pregnancy, whereas Murphy and Breman estimated that malaria-induced low birth weight (LBW) kills 62,000 to 363,000 newborns each year in the region.^{18,19} This mortality is largely attributable to the effect of malaria infection during pregnancy on low birth weight (LBW) associated with preterm birth (population attributable risk: 8% to 36%) and LBW associated with intrauterine growth retardation (population attributable risk: 13% to 70%).¹⁸

To safeguard pregnant women against the consequences of malaria infection during pregnancy who are resident in areas of moderate (stable) to high transmission, the

World Health Organization (WHO) recommends the provision of intermittent preventive treatment in pregnancy (IPTp) using sulphadoxine-pyrimethamine (SP) at every scheduled antenatal care (ANC) visit from the second trimester until delivery.²⁰ Meta-analysis suggests that any chemoprophylaxis reduces the incidence of LBW amongst primi- and secundigravidae by 27% (Relative Risk [RR] = 0.73; 95% Confidence Intervals [CI]: 0.61, 0.87; 8 trials; N = 3,619), severe maternal anaemia by 40% (RR 0.60, 95% CI: 0.47, 0.75; 3 trials, N = 2,503), and neonatal mortality 38% (RR = 0.62; 95% CI: 0.37, 1.05; 2 trials; N = 2,156).²¹ The intervention also protects against asymptomatic parasitaemia, peripheral and placental infection that may be present at the time of dosing while, separately, shielding against new malaria infections that may occur after dosing and before the next ANC visit.²² The parasitocidal effect of SP against *P. falciparum* relies on pharmacological synergy between both drug components.²³ Sulphadoxine inhibits dihydropteroate synthase (*Pfdhps*), an enzyme required by *P. falciparum* to biosynthesize folate, whereas pyrimethamine inhibits dihydrofolate reductase (*Pfdhfr*), an essential enzyme used by *P. falciparum* to produce tetrahydrofolate, a cofactor the parasite needs to biosynthesize DNA and protein.^{24,25} Several parasite mutations are associated with decreased SP sensitivity that vary geographically by type and prevalence.²⁶ In West Africa, ‘partially resistant’ biomarkers are found in combinations of *Pfdhfr* N51I, N59R, and S108N with *Pfdhps* A437G, whereas parasites in East Africa express ‘fully resistant’ combinations of *Pfdhfr* N51I, N59R, and S108N with *Pfdhps* A437G and K540E.²⁶ Epigenetic analyses suggest that there are three foci in East Africa where parasite populations have acquired the additional mutation of *Pfdhps* A581G to become ‘super resistant’ to SP.²⁶

There have been historic reductions in malaria transmission intensity in some locales of sub-Saharan Africa over the past decade, accelerated by malaria control interventions that have included the use of indoor residual spraying, artemisinin-combination therapies, and mass distribution of insecticide treated nets (ITNs). Of the 35 sub-Saharan countries where IPTp-SP is national policy, ITNs have been made available to pregnant women at no direct cost in 33 countries.²⁷ This has resulted in an estimated 10.5 million women using ITNs during their pregnancies in 2010 across 37 sub-Saharan countries, representing 38.8% of all births in the region (95% CI: 34.6%, 43.0%).⁵ The concurrent increase in SP drug resistance and decline in malaria transmission intensity in some settings has raised competing questions of where and when IPTp-SP should be replaced with a more efficacious antimalarial drug – or where and when the intervention should be discontinued all together. This doctoral thesis addresses these and other related questions.

Literature review

Epidemiology of malaria in pregnancy

Malaria infection during pregnancy is associated with a variety of adverse birth outcomes including maternal anaemia,²⁸⁻³¹ stillbirth,³²⁻³⁴ intrauterine growth retardation,^{35,36} preterm birth,^{36,37} and LBW,^{32,35,37-39} and infant mortality.³⁹ Amongst these adverse birth outcomes, LBW is the most frequently reported outcome because of its ease and precision of measurement. Arvo Ylppö, the acclaimed Finnish paediatrician and early advocate for child welfare clinics, defined LBW as newborns weighing less than 2.5 kg at delivery.⁴⁰ A landmark cohort study in the 1980s showed that LBW infants in low-income settings were 4.3 times more likely to die during the neonatal period than newborns who were delivered weighing 2.5 kg or more.⁴¹ Low-birth weight babies who survive infancy then go on to experience higher rates of respiratory infection and diarrhoeal disease than peers who were born above the 2.5 kg threshold^{42,43} and, when fully grown, are more likely to suffer from micro-vascular conditions.⁴⁴⁻⁴⁶ Low birth weight girls, as adults, are at greater risk of developing pre-eclampsia and delivering LBW babies themselves.⁴⁷ Thus, reducing the incidence of LBW has public health implications that are lifelong and intergenerational.

Entomological considerations

Female *Anopheles* mosquitoes are the primary vectors of malaria parasites. While in the process of collecting blood meals for egg development, infected *Anopheles* inject *P. falciparum* sporozoites into humans. *Anopheles* are more likely to target expecting mothers compared to non-pregnant women for several reasons. Female *Anopheles* are attracted to the carbon dioxide that humans exhale,⁴⁸ with and without any

accompanying human scent.⁴⁹ Although the extent to which emitted carbon dioxide and temperature may vary over the course of pregnancy, researchers in the Gambia found that expecting mothers with a mean gestational age of 28 weeks had 21% more expiratory lung volume and abdomens that were also 0.7° Celsius warmer compared to non-pregnant women.⁵⁰ A separate study, also in The Gambia, showed the extent to which pregnant women attract more *A. gambiae*, the most common malaria vectors in sub-Saharan Africa. In total, 72 women, 36 pregnant and 36 non-pregnant, were given malaria chemoprophylaxis and bed-nets prior to sleeping in identical experimental huts. Over three consecutive nights, twice as many *Anopheles* entered the huts of pregnant participants compared to non-pregnant women ($P < 0.000$). Adding to the risk of malaria exposure, pregnant women were observed stepping out of their protective nets an average of twice per night versus once amongst non-pregnant participants ($P = 0.019$).⁵¹

Physiological considerations

In addition to being at elevated risk of exposure, pregnant women are at greater risk of adverse consequences resulting from malaria infection compared to non-pregnant women. During pregnancy, maternal inflammatory responses are down-regulated for the benefit of embryonic implantation and foetal survival.⁵² Hence, pregnant women may be more vulnerable to new infections, relapsed infections (from latent or dormant phases), recrudescence infections (delayed clearance of infection), and re-activated infections (from persistent chronic infections).⁵³ Maternal parasitaemia triggers inflammatory responses that increase circulation of tumour necrosis factor alpha (TNF- α) and interleukin-10⁵⁴ which are independently associated with adverse

birth outcomes.⁵⁵ Chronic parasitaemia is associated with intrauterine growth retardation, while acute infection is more commonly the cause of miscarriage or stillbirth.⁵⁶ Although placental malaria does not appear to interfere with the transport of vitamin A,⁵⁷ iron,⁵⁸ folic acid or vitamin B-12,⁵³ general placental insufficiency may compromise the exchange of other vital nutrients required for healthy foetal development.^{59,60} In addition, parasitic invasion of the trophoblast may have an effect similar to pre-eclampsia, decreasing placental circulation by undermining normal remodelling of spiral arteries into utero-placental vessels.⁶¹ The risk of maternal hypertension may increase amongst primigravidae exposed to chronic placental malaria, potentially triggered by a foetal response to placental inflammation.⁶²

Amongst the five malaria parasites known to infect humans, *P. falciparum* is unique. Erythrocytes penetrated by *P. falciparum* in pregnant women will commonly adhere to chondroitin sulphate A (CSA) molecules and sequester along the endothelial and syncytiotrophoblast cells of the placenta.⁶³ As a consequence, infected erythrocytes may not be detected with conventional assays that rely on samples of peripheral blood.⁶⁴ Even still, malaria infection does not affect all pregnant women equally. Parasites that bind to CSA molecules also transcribe the var 2 CSA gene,⁶⁵⁻⁶⁷ triggering development of protective immunoglobulin G that is associated with maternal parity in malaria-endemic areas.⁶⁸ Thus, multigravidae exposed to CSA-binding parasites during previous pregnancies are better able to control parasite densities than primi- and secundigravidae. Maternal infection with the human immunodeficiency virus (HIV) compromises the acquisition of semi-immunity against malaria infection during pregnancy.⁶³

Chemoprevention

Chloroquine and pyrimethamine monotherapies

The WHO first recommended the provision of chemoprophylaxis to all pregnant women living in malaria-endemic areas in 1986. This involved weekly, self-administered doses of 300 mg chloroquine or 25 mg pyrimethamine.⁶⁹ Compliance with these regimens proved difficult,^{70,71} and the spread of *P. falciparum* resistance to chloroquine and, separately, to pyrimethamine undermined the protective effect of both regimens.⁷⁰⁻⁷²

Sulphadoxine-pyrimethamine

In 1993, Malawi became the first country to adopt a national strategy of directly-observed chemoprevention using SP administered to pregnant women during ANC visits.⁷³ This operational experience, coupled with clinical trial data from Kenya^{74,75} and Malawi,^{38,76} was sufficient for the WHO to make its first IPTp-SP policy recommendation.²² At present, 35 of the 36 countries worldwide that have an IPTp-SP policy are in sub-Saharan Africa.²⁷

Decreasing malaria transmission

Over the past decade, as ITN provision has become part of the standard of care, nets have been used in IPTp-SP trials. This has greatly affected trial outcomes and the transmission intensity to which participants have been exposed. A randomised placebo-controlled trial in Mozambique conducted between 2003 and 2005 (N = 1,030) amongst women of all gravidae, 90% of whom used ITNs, showed that two doses of IPTp-SP had no protective effect against LBW (Relative Risk [RR], 0.99; 95% CI: 0.70, 1.39), nor against placental infection (RR = 1.0; 95% CI: 0.88, 1.13; *P* = 0.964)

when compared to placebo. It is not clear the extent to which this observation was attributable to lost parasite sensitivity to SP, or to women having been exposed less malaria infection, or both. Despite these findings, IPTp-SP conferred some important benefits. Women who received SP versus no doses had 40% fewer clinical malaria cases (95% CI: 7.4%, 61.2%]; $P = 0.02$), and one-half the prevalence of peripheral parasitaemia (7.10% versus 15.15%) ($P = 0.001$). Moreover, compared to ITNs alone, IPTp-SP provided greater protection against parasitaemia (RR = 0.52; 95% CI: 0.27, 0.99; $P = 0.044$) in the first eight weeks post-partum,⁷⁷ representing an important chemoprophylactic effect because the maternal risk of malaria infection has been shown to increase following delivery into the early post-partum period.⁷⁸ Specifically, the risk of malaria infection is three times greater in the second (adjusted risk ratio = 2.8; range 1.1 to 7.4; $P = 0.04$) and third trimesters (adjusted risk ratio = 3.1; range 1.2 to 7.9; $P = 0.02$) compared to the first trimester, and is four times greater in the 60-day post-partum period (adjusted risk ratio = 4.1; range 1.8 to 9.5; $P = 0.001$).⁷⁸ Secondary analysis of data from a Mozambique trial noted above found that IPTp-SP reduced early neonatal (≤ 7 days of life) mortality by 61.3% (95% CI: 7.4%, 83.8%); $P = 0.024$] (20 deaths overall; 15 in the placebo group versus five in the IPTp-SP group; $P = 0.039$).⁷⁹ Protection was also reported against neonatal (≤ 28 days of life) mortality (25 deaths overall; 18 in the placebo group versus seven in the IPTp-SP group; $P = 0.041$), a trend that was no longer statistically significant against infant (first 12 months of life) mortality (58 deaths overall; 35 in the placebo group versus 23 in the IPTp-SP group; $P = 0.136$).⁷⁹

Another placebo-controlled trial amongst pregnant multigravidae ($N = 1,035$) conducted in The Gambia between 2002 and 2004 showed that IPTp-SP offered no

greater protection against LBW than ITNs alone (effect difference = 28 g; 95% CI: 11, 67; $P = 0.16$); 78% of women in both groups reported using ITNs.⁸⁰ Researchers reported no protective effect of IPTp-SP in an un-blinded randomised trial carried out from 2004 to 2007 amongst women of all gravidae ($N = 5,775$) in a low-transmission area of Uganda. No difference in the percentage of LBW infants was seen across the three intervention groups: IPTp-SP alone (6.48%), ITNs alone (6.28%) and IPTp-SP plus ITNs (6.85%); $P = 0.80$.⁸¹ Table 1 contains selected studies that illustrate outcomes following the provision of placebo verses IPTp-SP with and without ITNs . The first three are trials that suggest IPTp-SP may be no better than placebo in settings where ITN coverage is very high, thereby reducing exposure to malaria transmission. The fourth is an observational study in which ITN use was low and, unexpectedly, SP use appeared to increase the risk of placental parasitaemia.

Table 1. Selected studies of placebo vs. IPTp-SP with and without ITNs

Country [ref]	Site	Gravidae	Placebo (with ITNs)			SP (2 doses without ITN)			SP (2 doses with ITNs)			Malaria transmission and ITN use	Key findings
			LBW	Peripheral	Placental	LBW	Peripheral	Placental	LBW	Peripheral	Placental		
Mozambique ⁷⁷	Manhiça	Primigravidae	20.7% (25/121)	23.6% (30/127)	52.3% (219/419)	-	-	-	21.8% (29/133)	13.5% (18/133)	52.1% (222/426)	Perennial transmission with seasonal variation; self-reported use of ITNs was 90% in both treatment groups	SP as effective as placebo
		1-3 pregnancies	6.7% (13/195)	16.1% (31/193)	-	-	-	-	10.3% (20/194)	6.3% (12/192)			
		≥4 pregnancies	11.7% (21/180)	8.0% (14/175)	-	-	-	-	5.4% (9/167)	30.4% (51/168)			
The Gambia ⁸⁰	Farafenni	Secundigravidae	6.9% (63/917)	3.3% (34/1,035)	-	-	-	-	5.5% (51/931)	9.0% (91/1,010)	-	Ben-net usage including ITNs was ~ 70%	SP as effective as placebo
		Multigravidae											
Uganda ⁸¹	Kabale	Primigravidae	5.5% (18/329)	12.9% (201/1,559)	2.6% (16/622)	5.1% (16/313)	14.6% (231/1,580)	4.3% (28/651)	8.1% (27/333)	15.3% (231/1,510)	3.1% (19/613)	ITN coverage was estimated to be > 97%	ITNs alone, SP-IPTp alone, and ITNs plus SP-IPTp were non-inferior to each other
		Secundigravidae	5.8% (16/277)	-	-	7.7% (22/287)	-	-	5.1% (14/276)	-	-		
		2 to 4 previous pregnancies	5.9% (37/631)	-	-	6.6% (40/610)	-	-	7.2% (44/614)	-	-		
		≥5 pregnancies	8.3% (27/325)	-	-	6.1% (21/347)	-	-	6.7% (21/315)	-	-		
Tanzania ⁸²	Muheza	Primigravidae	-	-	35.3% ^a (6/17)	-	-	45.5% ^b (35/77)	-	-	50.0% ^c (5/10)	Perennial transmission; ITN use summarised in the table notes.	SP use increased the risk of placental parasitaemia
		Secundigravidae	-	-	41.2% ^a (7/17)	-	-	28.6% ^b (22/77)	-	-	40.0% ^c (4/10)		
		Multigravidae	-	-	23.5% ^a (4/17)	-	-	26.0% ^b (20/77)	-	-	10.0% ^c (1/10)		

Notes:

^a Women who never received IPTp-SP and 0% used ITNs

^b Women who received 'early' IPTp-SP as noted on ANC card and 14% used ITNs

^c Women who received 'recent' IPTp-SP as noted on ANC card and 30% used ITNs

Decreasing parasite sensitivity

Several factors have contributed to the decline in the protective effect of IPTp-SP.

Historic use of pyrimethamine monotherapy is partially responsible for the emergence of parasite resistance. The experience of Tanzania is illustrative. During the 1950s, Tanzania introduced pyrimethamine monotherapy. At the time, treatment for uncomplicated malaria infection was a single 25 mg dose which produced a clinical cure within seven days.⁸³ The first known treatment failure was recorded in 1953 during a clinical trial in Mingeza village, near Muheza town, north-east Tanzania.⁸³ Unrestricted pyrimethamine use continued in the area until 1965 when treatment failures were observed 160 kilometres from the original foci of resistance.⁸⁴ In the same year, Tanzania suspended imports of pyrimethamine, as well as proguanil, an antimalarial drug that can select for pyrimethamine resistance.⁸⁵ No *Pf dhfr*/*Pf dhps* inhibitors were available in Tanzania for malaria chemoprevention or treatment purposes until 1980 when researchers conducted a trial in Bagamoyo, 137 kilometres south of Muheza, where there had never been any previously reported treatment failures involving pyrimethamine. In this setting, despite 15 years of suspended SP drug pressure, 47.8% (N = 23; 95% CI: 26.8%, 69.4%) of patients with uncomplicated malaria experienced recrudescence within seven days of pyrimethamine treatment. This suggests that the fitness-cost of mutating in response to pyrimethamine exposure is minimal and, consequently, parasite reversion to a sensitive state may not occur following the withdrawal of SP drug pressure.

Alarming evidence of SP resistance comes from a cross-sectional survey conducted in Muheza, Tanzania, between 2002 and 2005. Placental parasitaemia was significantly

higher in women given any dose of IPTp-SP compared to women who received no doses, 84% [87 of 104] versus 16% [17 of 104], respectively ($P = 0.03$). Bed-net use was lowest amongst those who received no IPTp-SP doses (23.5%) in contrast to women given treatment early in pregnancy (36%) or shortly before delivery (30%).^{82,86,87} Investigators suggest that the increase in placental parasitaemia amongst women given IPTp-SP was likely the result of extreme drug resistance. The day-28 treatment failure rate was 82% amongst children under five-years of age in an area near Muheza where the parasite population exhibited near saturation of the *Pf dhfr*/*Pf dhps* quintuple mutation with concurrent mutation along *Pf dhps* gene at codon 581.⁸⁸ Investigators in the IPTp study postulated that parasites in locales with very high pyrimethamine resistance may be able to repopulate a human host more rapidly than parasites in the same area that remain sensitive to pyrimethamine, thereby increasing overall parasite densities amongst recipients of preventive treatment.^{89,90} Despite these findings of apparent 'harm' attributable to IPTp-SP exposure, a more recent study in Malawi did not observe similar results.⁹¹

Potential for azithromycin use in IPTp

Several trials over the past decade have tried to identify therapies to replace SP where parasite resistance is high. Azithromycin-based combination therapies have been amongst these candidates and may confer dual protection against malaria infection and curable STIs/RTIs.

Azithromycin monotherapy

Synthesised in the 1980s, azithromycin is the first compound of the azalide family of antibiotics. Animal studies have shown that quantities 2 to 4 times the human daily

dose do not reduce fertility, nor cause foetal harm.⁹² Pregnant women have received up to 2 g azithromycin in a single dose in all trimesters without teratogenic effect.⁹² In adults, a one-time dose of 1 g azithromycin is associated with mild to moderate side-effects including diarrhoea or loose stools (7%), nausea (5%), vomiting (2%), and vaginitis (2%) with fewer than 1% of recipients experiencing dizziness, headache, vertigo, and/or somnolence.⁹² Azithromycin has demonstrated better tolerability than erythromycin with shorter dosing regimens required to achieve the same therapeutic effect.⁹³ HIV-infected patients, however, poorly tolerate azithromycin when taken long-term as chemoprophylaxis.^{94,95}

Azithromycin functions as a slow-acting macrolide that causes the progeny of exposed parasites to inherit an apicoplast that is incapable of protein synthesis, thereby producing a delayed-death in parasites.⁹⁶ This slow clinical response makes azithromycin monotherapy an unsuitable choice for treating uncomplicated or severe *P. falciparum* infections.⁹⁷ However, azithromycin monotherapy is efficacious against *P. vivax* with 1 g to 2 g^{98,99} and, against *P. falciparum*,¹⁰⁰ has been used as a chemoprophylaxis in Kenya, Indonesia and Thailand conferring modest protection as shown in Table 2.

Table 2. Azithromycin chemoprophylactic efficacy relative to placebo

Country	Treatment regimen and protective efficacy relative to placebo						
	AZ 250 mg daily		AZ 1 g weekly		750 mg loading 250 mg daily		Notes
	PE%	95% CIs	PE%	95% CIs	PE%	95% CIs	
Kenya ¹⁰⁰	82.7	68.5, 91.1	64.2	47.1, 77.1	-	-	<i>Plasmodium</i> species unspecified 59 subjects = 250 mg daily dose 58 subjects = 1 g weekly dose 10 week follow-up
Indonesia ⁹⁸	-	-	-	-	71.6 98.9 84.7	50.3, 83.8 93.1, 99.9 75.6, 90.7	<i>Plasmodium falciparum</i> <i>Plasmodium vivax</i> All malaria 148 subjects 20 week follow-up period
Thailand ⁹⁹	-	-	-	-	70.8 98.0 91.8	-14.0, 93.7 87.8, 99.9 78.6, 97.5	<i>Plasmodium falciparum</i> <i>Plasmodium vivax</i> All malaria 179 subjects 20 week follow-up period

PE = Protective efficacy; CI = Confidence interval

Not all potential partner compounds are pharmacologically compatible. An *in vitro* study suggests that azithromycin has an additive effect against *P. falciparum* when combined with either mefloquine or pyronaridine.¹⁰¹ Artesunate and azithromycin, in contrast, have demonstrated antagonism when combined against fresh *P. falciparum* samples.^{101,102} Antagonism, and resultant poor efficacy, may partially explain why a paediatric trial that used azithromycin plus artesunate was halted prematurely,¹⁰³ although two studies of semi-immune adults have shown favourable results.^{104,105} Azithromycin could be combined with piperaquine, a quinolone compound related to chloroquine, but better tolerated.¹⁰⁶ The combination of azithromycin and dihydroartemisinin has shown additive-to-synergistic *in vitro* effect.¹⁰⁴ Only two azithromycin combination therapies have undergone investigation in clinical trials: SP plus azithromycin, and azithromycin plus chloroquine. There is burgeoning interest in combining azithromycin with dihydroartemisinin-piperaquine for use in IPTp. The European & Developing Countries Clinical Trials Partnership (EDCTP) and the Medical

Research Council in the UK are currently supporting two such trials that will begin recruitment by early 2018.

Azithromycin plus sulphadoxine-pyrimethamine

To date, three clinical trials have compared birth outcomes following exposure to the standard of care, IPTp-SP, versus IPTp-SP plus azithromycin as summarised in Table 3. Two of these trials were conducted in Malawi and yielded contradictory results. The first was a three-arm trial between 2002 and 2006 in which pregnant women received routine IPTp-SP, or monthly IPTp-SP, or monthly IPTp-SP plus 1 g azithromycin two times during the antenatal period. The prevalence of LBW was 12.9% (52 of 402), 9.1% (36 of 394), and 7.9% (32 of 406) in women receiving IPTp-SP, monthly IPTp-SP or monthly IPTp plus azithromycin, respectively, and primi- and secundigravidae were protected more by preventive therapy against the consequences of malaria infection during pregnancy than multigravidae.¹⁰⁷ In contrast, the APPLe study (Azithromycin for the Prevention of Preterm Labour) in Malawi, carried out between 2004 and 2005 showed that 1 g azithromycin, administered twice during the antenatal period, had no effect on birth-weight, nor on the incidence of preterm delivery.¹⁰⁸ These results require cautious interpretation. There were several differences between the studies. The APPLe trial combined azithromycin with IPTp-SP given two times, whereas women in the other Malawi trial received IPTp-SP monthly, either with or without azithromycin. In addition, participants in the APPLe trial were more often primigravidae and were more likely to have syphilis at enrolment. Finally, syphilis treatment administered to women in the APPLe trial was not in accordance with WHO recommendations for pregnant women. These women were given 1g benzyl penicillin,

treatment for individuals with neurosyphilis,¹⁰⁹ instead of 2.4 mμ of benzathine penicillin G.¹¹⁰ Moreover, treatment with azithromycin may have cleared maternal syphilis, but may not have altered birth outcomes; the compound does not perfuse the placenta in sufficient concentrations. Thus, neither the benzyl penicillin nor the azithromycin administered twice were likely to have cured congenital syphilis.¹¹¹ A recent trial in Papua New Guinea, also summarised in Table 3, compared monthly SP plus azithromycin (1 g twice daily for 2 days; 4 g AZ total during antenatal period) against SP and chloroquine (450 to 600 mg, daily for three days) given once, followed by SP and chloroquine placebo (control). Intention-to-treat analysis showed the incidence of LBW to be 12.8% (130 of 1,013) amongst women given SP plus azithromycin and 17.4% (175 of 1,008) for women who received SP plus chloroquine. Per-protocol analysis was comparable; LBW was 12.6% (122 of 967) amongst women administered SP plus azithromycin versus 16.7% for women given SP plus chloroquine (159/952).¹¹²

Azithromycin plus chloroquine

The combination of azithromycin plus chloroquine has demonstrated an additive-to-synergistic effect *in vitro* against *P. falciparum*.¹⁰¹ When used against chloroquine-sensitive strains, azithromycin plus chloroquine produced an additive effect, and synergy when exposed to chloroquine-resistant *P. falciparum*. Two studies have been conducted using azithromycin plus chloroquine amongst pregnant women with a three-day regimen involving a daily dose of 1 g azithromycin and 620 mg chloroquine base (four tablets of azithromycin plus chloroquine each containing 250 mg/155 mg). A single-arm parasite clearance trial amongst 163 women with asymptomatic

infections showed the day 28 cure rate to be 99.4% (95% CI: 97.8, 100) when corrected using polymerase chain reaction (PCR) methods and intention-to-treat analysis.¹¹³ At day 35 and day 42, PCR-corrected cure rates dropped slightly to 96.7% (95% CI: 93.4%, 99.9%), and 95.2% (95% CI: 91.3%, 99.0%), respectively. The uncorrected PCR prevalence rates at day 28, day 35, and day 42 were 95.5% (95% CI: 91.8%, 99.1%), 87.7% (95% CI: 82.1%, 93.2%), and 78.4% (95% CI: 71.6%, 85.3%), respectively.¹¹³ A multi-centre IPTp trial compared azithromycin plus chloroquine versus SP with the primary endpoint being the proportion of sub-optimal pregnancy outcomes (LBW, premature birth, stillbirth, abortion, lost to follow-up prior to observation of pregnancy outcome, or missing birth weight) under intention-to-treat analysis. The trial was terminated early on grounds of futility; the prevalence of sub-optimal birth outcome amongst recipients of azithromycin plus chloroquine was 26.2% (95% CI: 23.9%, 28.4%) versus 23.7% (95% CI: 21.5%, 25.9%) for women given SP.¹¹⁴

Table 3. Selected IPTp studies of azithromycin

Country [ref]	Site	Gravidae	IPTp (standard)		IPTp monthly		IPTp monthly + AZ x 2		AZ+CQ		Malaria transmission and ITN use	Key notes
			LBW	Preterm	LBW	Preterm	LBW	Preterm	LBW	Preterm		
Malawi ¹⁰⁷	Mangochi	0 previous pregnancies	12.9% 52/402	30.0% 33/110	9.1% 36/394	18.7% 20/107	7.9% 32/406	14.6% 13/89	-	-	Holoendemic-transmission; self-reported use of nets previous night ranged between 59.4% and 61.0% across treatment groups (data not collected on whether nets were treated)	<i>T. vaginalis</i> was 16.8% (69/411) in IPTp (standard) group vs. 11.0% (46/419) amongst women who received IPTp monthly plus AZ x 2.
		1 previous pregnancy		17.4% 15/86		24.4% 19/78		18.8% 15/80	-	-		
		2 previous pregnancies		12.6% 30/239		11.3% 29/256		8.9% 24/271	-	-		
		All gravidae		17.9% 78/435		15.4% 68/441		11.88% 52/440	-	-		
Malawi ¹⁰⁸	Southern	All gravidae	2.99 kg (n=769)	17.4% 189/1,087	-	-	3.03 kg (n=739)	16.8% 184/1,096	-	-	Malaria transmission not reported; net use not reported	AZ+SP was no more protective than SP alone, but sub-optimal Rx was given to women with syphilis in both groups.
Papua New Guinea ¹¹²	Madang Province	All gravidae	17.4% ² 175/1,008	-	-	-	12.8% 130/1,013	RR = 0.62 95% CI: 0.43,0.89, <i>P</i> = 0.010	-	-	Women without nets were given an ITN; due to local stock-outs 8% of women did not have or receive an ITN.	Prevalence in cross-sectional survey ¹¹⁵ : <i>N. gonorrhoeae</i> = 9.7% <i>C. trachomatis</i> = 11.1% <i>T. vaginalis</i> = 21.3% 33.7% had at least one infection.
Pfizer ¹¹⁶	Multicentre	All gravidae	5.7% 68/1188	3.7% 45/1211	-	-	-	-	5.0% 57/1138	4.0% 47/1164	Field workers verified installation of new ITNs during home visits following enrolment: AZCQ (98.5%) and SP (98.3%)	Per regulatory requirement, all participants for whom there was a missing birth outcome were categorised as a treatment failure (ITT analysis versus per protocol analysis)

Note: (1) participants were given insecticide treated bed nets unless otherwise noted; (2) The control group in Papua New Guinea received SP+CQ per national policy

IPTp = Intermittent preventive treatment of malaria in pregnancy; SP = sulphadoxine-pyrimethamine; AZ = azithromycin; CQ = chloroquine; LBW = low birth weight; ITT = Intention to treat

Epidemiology of STIs/RTIs in pregnancy

The infective agent of syphilis is *Treponema pallidum*, a highly motile, Gram-negative spirochete bacterium that can be transmitted from mother to child by placental invasion or through contact of a maternal syphilitic lesion during delivery. Although vertical transmission is uncommon prior to 18 weeks of gestation,¹¹⁷ *T. pallidum* can gain access to the foetal compartment as early as 9 to 10 weeks.^{123,124} In some populations, 40% of spontaneous abortions are attributable to untreated syphilis during pregnancy.^{118,119} Syphilis infection is associated with an 18-fold increase in the risk of stillbirth (Risk ratio [RR] = 18.1; 95% CI: 5.5, 59.6), double the risk of intrauterine growth retardation (RR = 2.1; 95% CI: 1.0, 4.2), a six-fold increase in the risk of preterm birth (RR = 6.1; 95% CI: 2.5, 15.3), and treble the risk of LBW (RR = 3.3; 95% CI: 2.0, 5.4).¹²⁰

Transmission of the Gram-negative diplococci bacterium *Neisseria gonorrhoeae* usually occurs from mother to child during delivery, although foetal infection can occur during prolonged rupture of the membranes. Maternal infection with *N. gonorrhoeae* was associated with a two-fold increase in the odds of preterm birth in the United States (OR = 2.0; 95% CI: 1.0, 4.0)¹²¹ and a three-fold increase in Kenya (OR = 3.2; 95% CI: 1.3, 8.4).¹²² These same studies also reported a statistically significant increase in LBW amongst babies born to infected women. A common co-infection with *N. gonorrhoeae*, *Chlamydia trachomatis* is also a Gram-negative bacterium and is associated with intrauterine growth retardation (OR = 2.4; 95% CI: 1.3, 4.2),¹²³ preterm delivery (OR 1.6; 95% CI: 1.0, 2.5),¹²³ LBW (OR = 2.7; 95% CI: 1.3, 5.7),¹²⁴ premature

rupture of the membranes (OR = 2.4; 95% CI: 1.1, 5.4),¹²⁴ and preterm birth (OR = 4.0; 95% CI: 1.7, 9.2).¹²⁴

Trichomonas vaginalis, a protozoan parasite, is responsible for one-half of all curable STIs worldwide¹²⁵ and has been shown to increase the odds of preterm delivery between 30% (OR = 1.3; 95% CI: 1.1, 1.4),¹²⁶ 40% (OR = 1.4; 95% CI: 0.7, 2.8),¹²¹ and 50% (OR = 1.5; 95% CI: 0.1, 8.1).¹²⁷ Infection by *T. vaginalis* increases the odds of LBW by 30% (OR = 1.3; 95% CI: 1.1, 1.5),¹²⁶ by 50% (OR = 1.5; 95% CI: 0.9, 2.6),¹²¹ by two-fold (OR = 2.1; 95% CI: 1.0, 4.7).¹²⁸ Bacterial vaginosis is a syndrome caused by a disequilibrium in the vaginal microbiota with a concomitant decline in the number of naturally occurring lactobacilli, and is widely associated with adverse birth outcomes. Meta-analysis suggests that bacterial vaginosis increases the odds of a spontaneous abortion by ten-fold (OR = 9.9; 95% CI: 2.0, 49.3)¹²⁹ and has been shown to increase the risk of premature rupture of the membranes by 3.5-times (3.5 = RR; 95% CI: 1.4, 8.9).¹³⁰ One study in the United Kingdom associated bacterial vaginosis infection with a 13-fold increase in risk of preterm birth (RR = 13.1; 95% CI: 4.0, 42.6),¹³¹ although most studies suggest that the risk of preterm birth attributable to bacterial vaginosis is increased by one- or two-fold, levels that are similar for LBW. The effects of these five curable STIs/RTIs on pregnancy outcomes are summarised in Table 4.

Management of curable STIs/RTIs in pregnancy

As noted earlier, the WHO recommends syphilis screening and treatment for pregnant women at their first antenatal visit. For other curable STIs/RTIs, the WHO suggests using syndrome-based algorithms to guide diagnosis and treatment. The approach has

been useful amongst men for whom STIs/RTIs are more commonly symptomatic. In contrast, the vast majority of gonococcal (80%) and chlamydial (70% to 75%) infections amongst women are asymptomatic¹²⁵ and, therefore, never diagnosed. Consequently, the algorithm based on vaginal discharge syndrome has a low sensitivity (30% to 80%) and specificity (40% to 80%) for *N. gonorrhoeae* and *C. trachomatis* amongst pregnant women.¹³²⁻¹³⁴ Syndromic management has slightly higher sensitivity for *T. vaginalis* (54% to 83%) and bacterial vaginosis (51% to 69%) with moderate specificity (40% to 54% for *T. vaginalis*; 40% to 58% for bacterial vaginosis).

Table 4. Effect of curable STIs/RTIs on birth outcomes

Reference	Country	Year(s)	Spontaneous abortion (95% CI)	Stillbirth (95% CI)	IUGR (95% CI)	PROM (95% CI)	Preterm birth (95% CI)	LBW (95% CI)
<i>Treponema pallidum</i>								
Watson-Jones (2002) ¹²⁰	Tanzania	1998-2000	NR	18 (5.5, 59.6) RR	2.1 (1.0, 4.2) RR	NR	6.1 (2.5, 15.3) RR	3.3 (2.0, 5.4) ^a
Temmerman (1995) ¹³⁵	Kenya	1991	NR	3.34 RR	NR	NR	NR	4.01 ^a
McDermott (1993) ¹³⁶	Malawi	1987-1990	NR	10.98	NR	NR	NR	NR
Donders (1993) ¹³⁷	South Africa	1988	NR	NR	NR	NR	33%; 5 of 15 cases	NR
Elliott (1990) ¹²²	Kenya	1985	NR	NR	NR	NR	1.4 (0.5, 4.1)	NR
Ratnam (1982) ¹¹⁹	Zambia	NR	42% of cases	NR	NR	NR	NR	NR
Williams (1923) ¹¹⁸	United States	1923	40% of cases	NR	NR	NR	NR	NR
<i>Neisseria gonorrhoeae</i>								
Johnson (2011) ¹²¹	United States	1996-2002	NR	NR	NR	NR	2.0 (1.0, 4.0)	0.8 (0.3, 2.3)
Donders (1993) ¹³⁷	South Africa	1988	NR	NR	NR	NR	56%; 5 of 9 cases	<i>P</i> <0.005
Elliott (1990) ¹²²	Kenya	1985	NR	NR	NR	NR	3.2 (1.3, 8.4)	NR
<i>Chlamydia trachomatis</i>								
Rours (2011) ¹³⁸	Netherlands	2003-2005	NR	NR	NR	NR	4.4 (1.3, 15.2) ^a ; 2.7 (1.1, 6.5) ^b ; 1.17 (0.6, 2.4) ^c	1.0 (0.4, 2.2)
Silveira (2009) ¹³⁹	United States	2005-2008	NR	NR	NR	NR	0.7 (0.4 to 1.4)	NR
Wilkowska-Trojniel (2009) ¹⁴⁰	Poland	2003-2006	12 v 2% <i>P</i> =0.029	NR	NR	NR	NR	NR
Blas (2007) ¹⁴¹	United States	2003	NR	NR	NR	1.5 (1.0, 2.2) RR	1.5 (1.1, 2.0) RR	1.1 (0.7, 1.7)
Odendaal (2006) ¹⁴²	South Africa	2002-2003	NR	NR	NR	NR	22.2%; 8 of 36 cases vs. 10.4%; 32 of 307 cases; <i>P</i> =0.037	NR
Johnson (2011) ¹²¹	United States	1996-2002	NR	NR	NR	NR	1.0 (0.6, 2.0)	2.1 (1.0, 4.2)
Kovacs (1998) ¹⁴³	Hungary	1994-1995	NR	NR	7.3 v 5.8% <i>P</i> >0.05	20 v 21% <i>P</i> >0.05	NR	15.5% vs. 13.2% <i>P</i> >0.05
Donders (1993) ¹³⁷	South Africa	1988	NR	NR	NR	NR	27%; 6 of 22 cases	NR
Elliott (1990) ¹²²	Kenya	1985	NR	NR	NR	NR	0.7 (0.4, 1.4)	NR
Johns Hopkins (1989) ¹²³	United States	1983-1985	NR	NR	2.4 (1.3 to 4.2) aOR	NR	1.6 (1.0, 4.2)	NR
Gravett (1986) ¹²⁴	United States	1983	NR	NR	NR	2.4 (1.7, 5.4) aOR	4.0 (1.7, 9.2) aOR	2.7 (1.3, 5.7) aOR

Table 4. Effect of curable STIs/RTIs on birth outcomes (continued)

Reference	Country	Year(s)	Spontaneous abortion (95% CI)	Stillbirth (95% CI)	IUGR (95% CI)	PROM (95% CI)	Preterm birth (95% CI)	LBW (95% CI)
<i>Trichomonas vaginalis</i>								
Johnson (2011) ¹²¹	United States	1996-2002	NR	NR	NR	NR	1.4 (0.7, 2.8)	1.5 (0.9, 2.6)
Meis (1995) ¹²⁷	United States	1992-1994	NR	NR	NR	NR	1.5 (0.1, 8.1) wk 24; 0.9 (0.2, 3.6) wk 28	NR
Sutton (1999) ¹²⁸	DR Congo	1989-1990	NR	NR	NR	NR	NR	2.1 (1.0, 4.7)
Minkoff (1984) ¹⁴⁴	United States	NR	NR	NR	NR	P<0.03	NR	NR
Cotch (1997) ¹²⁶	United States	1984-1989	NR	NR	NR	NR	1.3 (1.1, 1.4)	1.3 (1.1, 1.5)
<i>Bacterial vaginosis</i>								
Johnson (2011) ¹²¹	United States	1996-2002	NR	NR	NR	NR	1.3 (0.9, 2.1)	1.1 (0.6, 1.8)
Svare (2006) ¹⁴⁵	Denmark	1998-2002	NR	NR	NR	NR	2.5 (1.6, 3.9)	2.0 (1.3, 2.9)
Watson-Jones (2007) ¹⁴⁶	Tanzania	1997-2000	NR	NR	NR	NR	3.0 (1.3, 6.6)	NR
Leitich meta-analysis (2003) ¹²⁹	Multiple	Multiple	9.9 (2.0, 49.3)	NR	NR	NR	2.2 (1.5, 3.1)	NR
Meis (1995) ¹²⁷	United States	1992-1994	NR	NR	NR	NR	1.4 (0.9, 2.05) wk 24; 1.8 (1.2, 3.0) wk 28	NR
McGregor (1995) ¹³⁰	United States	1991-1992	NR	NR	NR	3.5 (1.4, 8.9) RR	1.9 (1.2, 3.0); 1.5 (0.7, 3.0) ^e RR	NR
Hillier (1995) ¹⁴⁷	United States	1984-1989	NR	NR	NR	1.1 (0.8, 1.6)	1.4 (1.1, 1.8)	1.5 (1.2, 1.7)
Hay (1994) ¹³¹	United Kingdom	NR	5.5 (2.3, 13.3) ^f	NR	NR	NR	13.1 (4.0, 42.6) ^f	NR
Elliott (1990) ¹²²	Kenya	1985	NR	NR	NR	NR	1.0 (0.6, 1.8)	NR
Gravett (1986) ¹²⁴	United States	1983	NR	NR	NR	2.0 (1.1, 3.7)	NR	1.5 (0.8, 2.0)

Results reported as odds ratios unless otherwise noted and 95% confidence intervals are in parentheses; IUGR=Intrauterine growth retardation; PROM=Premature rupture of membranes; NR=Not reported; RR=Risk ratio; ^a Preterm delivery before 32 weeks; ^b Preterm delivery before 35 week; ^c Preterm delivery before 37 weeks; ^d Bacterial vaginosis at 16-20 weeks; ^e Bacterial vaginosis at 28-32 weeks; ^fIntermediate flora (Nugent score 4-7) and bacterial vaginosis (Nugent score 7-10); aOR = adjusted odds ratio

Rationale and research questions

The rationale underlying the five research questions to be addressed in this doctoral thesis is presented below along with a description of current knowledge gaps.

Q 1. Malaria transmission intensity threshold

The antenatal intervention of IPTp-SP was formally recommended by the WHO in 2004 to protect against the adverse effects of malaria infection amongst pregnant women who reside in areas of moderate (stable) to high transmission.²⁰ Meta-analysis suggests that chemoprophylaxis reduces the incidence of LBW amongst primi- and secundigravidae by 27% (RR = 0.73; 95% CI: 0.61, 0.87; 8 trials; N = 3,619).²¹ The same review reported a trend of protection against LBW in favour of IPTp-SP use amongst multigravidae, but neither the three trials included, nor the pooled analysis demonstrated standard levels of statistical significance (RR = 0.86, 95% CI 0.64 to 1.17; 3 trials; N = 2,743 participants). However, IPTp-SP does not feature in the WHO malaria elimination guidelines for countries with moderate and low endemicity.¹⁴⁸ Thus, what is the malaria transmission intensity-threshold below which IPTp-SP may no longer protect against the incidence of LBW and the intervention could be withdrawn?

Q 2. A581G prevalence threshold

The evidence supporting the original IPTp-SP policy recommendation in 2004 by the WHO originated from clinical trials and field experience in Kenya^{74,75} and Malawi^{38,76} dating to the 1990s when parasite epigenomics was in its infancy.

Accumulated mutations in the *P. falciparum* genes that encode *Pfdhfr* and *Pfdhps*, alleles implicated in SP resistance^{25,149-151} were present during this same period. Mutations at seven *Pfdhfr* codons (16, 50, 51, 59, 108, 140 and 164) and five *Pfdhps* codons (436, 437, 540, 581 and 613) have since been isolated as molecular markers for SP resistance.¹⁵² The protection conferred by IPTp-SP against LBW has been shown to decrease as the population prevalence of the *Pfdhps* K540E mutation increases—a proxy for the resistant quintuple *Pfdhfr* and *Pfdhps* mutants.¹⁵³ Of particular concern, however, in areas where the *Pfdhps* A581G mutation has emerged alongside the *Pfdhfr* and *Pfdhps* quintuple mutant, producing sextuple mutant parasites, IPTp-SP fails to inhibit the growth of parasites.⁹¹ Within the context of declining parasite sensitivity to SP, is there a threshold of *P. falciparum* resistance to SP defined by the prevalence of *Pfdhps* mutation at codon A581G above which IPTp-SP may no longer protect against the incidence of LBW?

Q 3. Effect of IPTp-SP on malaria and curable STIs/RTIs in pregnancy

Desai and colleagues recently reported outcomes from the first investigation of an artemisinin combination treatment, dihydroartemisinin–piperaquine (DP), in IPTp.¹⁵⁴ Women received IPTp-SP or IPTp-DP, or were screened for peripheral parasitaemia and treated, if infected, with DP. The trial was conducted in a region of western Kenya where 96% of parasites had the quintuple mutation and 5.8% carried the A581G mutation. This trial was designed to test parasite clearance with a sample size capable of detecting a 50% decrease in maternal malaria infection at delivery, defined as a composite of peripheral or placental parasitaemia as detected by placental histology, microscopy, or RDT. The prevalence of malaria infection at delivery was lowest

amongst women given IPTp-DP, 3.0% (15 of 457), followed by recipients of IPTp-SP, 10.2% (47 of 459), compared to 12.6% (57 of 452) of women who were provided screening and treatment services.

The incidence of any adverse birth outcome – a composite of small for gestational age, LBW, preterm birth or foetal loss – was comparable between recipients of IPTp-DP and IPTp-SP, 10.6% (48 of 452) and 11.9% (54 of 454), respectively. In contrast, stillbirth was experienced by 0.9% (4 of 452) of women in the IPTp-DP group compared to 3.5% (16 of 453) recipients of IPTp-SP, a statistically significant observation ($P = 0.013$).

IPTp-DP reduced the incidence of clinical malaria during pregnancy by 83.9% (37.9 vs 6.1 episodes) and the risk of maternal anaemia by 22.0% at delivery (crude prevalence ratio 0.78, 95% CI 0.64 to 0.96) compared to IPTp-SP. Secondary analysis showed that women given intermittent screening and treatment had the highest prevalence of peripheral or placental malaria at delivery: 42.5% (199 of 452) women versus 30.6% (140 of 457) women in the IPTp-DP group and 36.2% (166 of 459) women in the IPTp-SP group. Interestingly, despite the protective effect conferred by IPTp-DP against many secondary endpoints, recipients of IPTp-SP delivered babies weighing on average (corrected) 87.3 grams more, a statistically significant observation ($P = 0.001$). This was reflected in superior birth weight for gestational age (Z-score) among mothers who received IPTp-SP versus IPTp-DP ($P = 0.001$). The incidence of LBW, small-for-gestational age, and preterm birth were slightly lower amongst women given IPTp-SP compared to IPTp-DP, but the differences were too small to draw conclusions in these three secondary endpoints.

Sulphadoxine-pyrimethamine has been used to prevent *Pneumocystis jiroveci* pneumonia and *Toxoplasma gondii* infection.¹⁵⁵ Sulphadoxine is pharmacologically related to sulphamethoxazole, a compound co-formulated with trimethoprim for the treatment of urinary tract infections and to prevent *P. jiroveci* amongst HIV-infected patients.¹⁵⁶ Prior to the development of penicillin, sulphonamides were used to treat *N. gonorrhoeae*.¹⁵⁷ Based on historical use, sulphonamides could exert some effect on *C. trachomatis*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, amongst many other pathogens.¹⁵⁸ Sulphonamides have also been used to treat *Gardnerella vaginalis*,¹⁵⁹ a bacterium that is commonly found in high concentrations amongst women with bacterial vaginosis.

Thus, because IPTp-SP was more protective against the incidence of LBW, small-for-gestational age, and preterm birth, might the protection conferred to pregnant women by IPTp-SP be explained, in part, by an effect against curable STIs/RTIs as well as malaria infection? If so, what is the burden of STIs/RTIs in areas where IPTp-SP is being implemented?

Q 4. Prevalence of malaria and curable STIs/RTIs in pregnancy

The dual burden of malaria and curable STIs/RTIs in pregnancy has never before been characterised by systematic review and meta-analysis. In the case of malaria infection during pregnancy, two seminal reviews have defined the burden in the sub-Saharan Africa. Brabin's 1983 paper summarised prevalence estimates of peripheral and placental parasitaemia from 12 sub-Saharan studies conducted between 1925 and 1978.¹⁶⁰ Peripheral parasitaemia ranged from 5.5% (N = 3,582)¹⁶¹ in Freetown, Sierra Leone to 76.0% (N = 50)¹⁶² in the former Belgian Congo (present-day Kisangani,

Democratic Republic of Congo). The low and high estimates of placental parasitaemia were also from the former Belgian Congo, ranging between 2.0% (N = 55)¹⁶³ in Leopoldville (present-day Kinshasa) and 74.0% (N = 50) from Stanleyville.¹⁶²

The 2001 review by Steketee *et al.* contained data from 20 sub-Saharan countries collected between 1985 and 2000.¹⁸ The lowest maternal parasite prevalence across 16 studies from East and Southern Africa was 10.2% (N = 503) from Kilifi, Kenya.³⁰ However, authors of the Kilifi study stated their estimate was based on placental blood smears, and went on to report that 77.4% (n = 53) of women had placental infections which represents the highest point estimate included in the review. The lowest prevalence measure from East and Southern Africa was in Chikawa, Malawi, where 19.0% (N = 3,913) of pregnant women had peripheral malaria infections.¹⁶⁴ In West and Central Africa, the studies that had the highest prevalence of placental parasitaemia did not also report peripheral measures of infection. Estimates ranged from 19.0% (N = 904) in Banfora, Burkina Faso¹⁶⁵ to 57.8% (N = 120) in Ebolowa, Cameroon.¹⁶⁶

The review by Brabin separated peripheral versus placental infection estimates, while Steketee *et al.* did not. Neither review contained data more recent than the year 2000, nor attempted to pool the prevalence data. Moreover, both were published before the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) were created to standardise methods of conducting systematic reviews.¹⁶⁷ Thus, a contemporary systematic review and meta-analysis of malaria infection in pregnancy is overdue. Moreover, pooled estimates stratified by East and

West African sub-regions can assist policymakers and programme managers with planning and advocacy efforts related to malaria infection during pregnancy.

As for the burden of curable STIs/RTIs, there did not appear to have been a prior systematic review and meta-analysis of data from pregnant women attending ANC facilities in sub-Saharan Africa at the time this investigation was conducted. A review by Mullick *et al.*¹⁶⁸ in 2005 does contain a summary of point estimates for curable STIs/RTIs amongst pregnant women, although no attempt was made to pool the data. Thus, a systematic review to quantify the dual burden of malaria infection and STIs/RTIs in sub-Saharan Africa is needed to make rational choice of drug to replace SP in areas where the drug is failing to protect against adverse birth outcomes.

Q 5. Effect of azithromycin on curable STIs/RTIs in pregnancy

Potential replacements for SP will likely need to confer protection against adverse birth outcomes attributable to malaria infection and other non-malarial causes.

Azithromycin is a broad-spectrum antibiotic and a leading partner-drug for use with DP in IPTp. Azithromycin is the WHO-recommended treatment for pregnant women with *C. trachomatis* infections and *in vivo* studies amongst high- and low-risk populations with syphilis and *N. gonorrhoeae* suggest potential therapeutic value, despite shifts during the past two decades of *in vitro* sensitivity testing. It is relatively unknown whether azithromycin might confer some protective effect against *T. vaginalis* or bacterial vaginosis. In the context of a high dual burden of malaria infection and curable STIs/RTIs amongst pregnant women, would azithromycin be an efficacious drug to include as part of IPTp?

Methods outline and monograph structure

The methods used to address each research question are described in detail within their respective chapters. A brief outline is presented herein. Questions related to estimating the lower threshold of malaria transmission intensity and the upper prevalence threshold of the SP resistance were addressed first by a systematic review of published literature followed by relevant pooled analyses. The question about the effect of IPTp-SP on adverse birth outcomes attributable to malaria infection and curable STIs/RTIs was determined by secondary analysis of data collected for a prospective cohort study of the burden of malaria and curable STIs/RTIs in Zambia. The question related to the prevalence of malaria and curable STIs/RTIs in sub-Saharan Africa was addressed by a systematic review and meta-analyses, as was the last question concerning the efficacy of azithromycin against curable STIs/RTIs.

The next section of the monograph is entitled, “Methods, results and discussion by research question” and contains five sub-sections, one for each of the five research questions. Within each of the five sub-sections, the methods, results and discussion are presented in their entirety. The section thereafter, “Monograph discussion”, contains a broader discourse that relates to the research questions as a whole. The last section, “Monograph summary and conclusions”, highlights key findings from these research questions and closes with a research pathway forward.

Methods, results and discussion by research question

Q 1. Malaria transmission intensity threshold

Methods

Estimating the malaria transmission intensity below which IPTp-SP no longer protects against LBW would be straight forward if there were data from multiple placebo-controlled randomised clinical trials (RCTs) that had been conducted in malaria-endemic areas characterised by narrowly different strata of transmission. However, it would only be ethical to conduct such trials in countries that have not already adopted IPTp-SP as policy. Thus, the question must be addressed using data extracted from trials as found in the literature alongside robust estimates of transmission intensity at the trial sites.

For this, data from IPTp-SP studies were first compiled by systematic review of published literature from sources that included PubMed, MEDLINE, EMBASE, the WHO International Clinical Trials Registry, and reference lists from the identified texts. The medical subject headings and free text terms used are shown in Table 1.1 below.

Table 1.1 Medical subject headings and free text terms

Medical subject headings	Free text terms
Topic=("Malaria") AND Topic=(Prenatal OR Antenatal OR Pregnancy OR Pregnant) OR Topic=(women) AND Topic=(Africa)	Malaria AND Pregnant AND Africa Malaria AND Pregnancy AND Africa Screen AND Malaria AND Pregnant AND Africa Screen AND Malaria AND Pregnancy AND Africa Test AND Malaria AND Pregnant AND Africa Test AND Malaria AND Pregnancy AND Africa

Studies that had reported the: (i) proportion of pregnant women who were exposed to ≥ 2 doses of IPTp-SP compared to placebo, or to no doses of IPTp-SP, and (ii) the

incidence of LBW by treatment group and gravidae were included in this analysis. EndNote X7 software was used to import and manage records. Duplicates were removed and the remaining records were screened against eligibility criteria. Full-text articles were then reviewed against the same criteria. Data were abstracted without blinding author names or publication titles, and then appraised for quality using methods developed by Grading of Evidence, Assessment, Development and Evaluation (GRADE) Working Group. The resulting data set was analysed using Stata/IC version 13 software. This involved pooling of LBW estimates by gravidae (primi- and secundigravidae versus multigravidae) and exposure to IPTp-SP doses (≥ 2 doses versus placebo or no doses).

The optimal time to measure transmission intensity in IPTp-SP trials would be at enrolment when maternal parasitaemia is likely highest. Evidence suggests that parasite densities peak between gestational weeks nine and 16, tapering until delivery.¹⁶⁹ This is because the prevalence of malaria infection estimated from samples collected at ANC booking, rather than later in pregnancy, would not be biased by cumulative IPTp-SP exposure during the antenatal period, particularly near-to-term dosing that would skew downward the measurements of infection. Despite these reasons, parasitaemia is rarely measured at enrolment. Active screening with microscopy or rapid diagnostic tests obliges investigators to treat women who are found to have asymptomatic parasitaemia with an artemisinin combination treatment, thereby fundamentally altering the investigation. Thus, if parasitaemia is measured, it is done almost exclusively at delivery and, for reasons stated, fails to reflect the true

transmission intensity. Thus, a proxy measure is needed to define malaria transmission intensity at the trial sites to answer this research question.

To identify a proxy measure of the prevalence of malaria infection at the IPTp-SP study sites, data were used from the Malaria Atlas Project (MAP),¹⁷⁰ the largest repository of malaria prevalence estimates in the world. These data were used in two ways to estimate the malaria transmission intensity that was likely to have been present in each IPTp-SP study site. The first approach was simply to apply the 2007 prevalence estimates of *P. falciparum* infection amongst children 2 to 10 years of age (2007 PfPR₂₋₁₀) as calculated by the MAP for the same locations where IPTp-SP studies had been conducted. However, all IPTp-SP studies identified by the systematic review had been conducted prior to 2007, with the exception of one multi-year trial that ended in 2007. Thus, a second method was used to identify data that aligned better with the years of the IPTp-SP trials.

National cross-sectional survey datasets were obtained from MAP of *P. falciparum* prevalence estimates from each of the 12 countries where the IPTp-SP trials had been conducted, and neighbouring countries if pregnancy trials had been conducted near border areas. Four matching rules based on space and time parameters shown in Table 1.2 were then used to select point estimates from these surveys that were most likely to reflect the malaria transmission intensity to which pregnant women had been exposed. However, before applying these matching rules, geospatial coordinates were obtained for each IPTp-SP study and cross-sectional survey using the GEOnet Names Server.¹⁷¹ ArcGIS 10 software was then used to calculate straight-line distances

between the specific locations where IPTp-SP studies and cross-sectional surveys had been conducted. Doing so allowed matching the point estimates from surveys to within < 100 miles of IPTp-SP studies as described in rule 1. This same criterion of < 100 miles had been used in previous malaria modelling of pregnancy and paediatric data.¹⁷² In the same way, elevation estimates were obtained from the Consortium for Spatial Information¹⁷³ for locations of the IPTp-SP studies and survey data. These estimates were used as part of an elevation criterion in rule 3 based on evidence that malaria infection in children declines sharply at altitudes $\geq 1,200$ metres above sea level compared to lower elevations.¹⁷⁴ A temporal criterion was included, as well, in the matching rules stipulated survey data to have been collected within plus or minus two years of the IPTp-SP trials. To account for the possibility that IPTp-SP studies and cross-sectional surveys may have been conducted in proximate locations that happened to have had very different intensities of malaria transmission, the matching rules required that cross-sectional surveys and IPTp-SP trials had to have been conducted in areas from the same malaria transmission category as designated by MAP: high (> 40% *P. falciparum* prevalence amongst 2 to 10 year olds), intermediate (5 to 40%), and low (< 5%).

Table 1.2 Matching rules

Rules	Criteria
1	Prevalence estimates will be paired to IPTp-SP studies if they were both conducted:
	a. In an area with the same risk of malaria infection (high, intermediate or low), AND
	b. Within two years (\pm) of each other, AND
	c. < 100 miles of each other.
2	Prevalence estimates will be paired to IPTp-SP studies if they were both conducted:
	a. In an area with the same risk of malaria infection (high, intermediate or low), AND
	b. Within two years (\pm) of the pregnancy study, AND
	c. In the same country.
3	Prevalence estimates will be paired to IPTp-SP studies if they were both conducted:
	a. In an area with the same risk of malaria infection (high, intermediate or low), AND
	b. At the same elevation, either \leq 1200 metres OR $>$ 1201 metres, AND
	c. In the same sub-region of Africa (East/Southern OR West/Central)
4	If no prevalence estimates can be paired, then IPTp-SP studies will be matched to the 2007 PfPR₂₋₁₀ estimate

To reflect the gravidae-specific nature of parasitaemia amongst pregnant women when pairing prevalence estimates of malaria infection, assumptions were made based on old reports from Sierra Leone¹⁶¹ and Kenya¹⁶⁰ that suggest levels of parasitaemia amongst children are comparable to maternal parasitaemia as presented in Table 1.3.

Table 1.3 Age structure of paediatric data matched to gravidity

Paediatric description	Age structure	Gravidity
Infancy	Birth to < 1	Primigravidae
Childhood	1 to 4	Segundigravidae
School-aged	5 to 15	Multigravidae

Matching rules were then applied sequentially. If survey data could not be matched to an IPTp-SP study using rule 1, then rule 2 was applied, and so on until all point prevalence estimates had been identified from the survey data that could be considered the best possible matches for each IPTp-SP study. Survey data paired to IPTp-SP studies under rules 1, 2 or 3 were pooled using random-effects models.¹⁷⁵ If survey data could not be matched under these rules, then the 2007 PfPR₂₋₁₀ estimate

for the same location where the IPTp-SP study had been conducted was imposed on the model under rule 4. Whether based on the 2007 MAP estimate, or the pooled prevalence estimate, standard meta-regression models were applied to LBW outcomes from the IPTp-SP studies.

Results

Systematic review

A total of nine pregnancy studies met inclusion criteria involving 10,279 pregnant women. Figure 1.1, the PRISMA flowchart for the systematic review, summarises the selection process, the number of studies excluded and the reasons for their exclusion according to PRISMA guidelines. Pregnancy studies stratified by gravidae that met inclusion criteria are summarized in Table 1.4.^{77,80,81,176-181} As shown in Figure 1.2, the PRISMA flowchart for matching studies, data on LBW came from seven studies and 12 unique sites for primi- and secundigravidae who were exposed to ≥ 2 doses of IPTp-SP ($n = 2,314$) versus placebo or no doses ($n = 1,954$). In contrast, seven studies from 10 unique sites reported LBW outcomes amongst multigravidae who received ≥ 2 doses of IPTp-SP ($n = 2,941$) compared to placebo or no doses ($n = 3,070$).

Funnel-plot analysis in Figure 1.3 suggests that IPTp-SP studies that were comparatively small and failed to protect against LBW may have been under-represented in the sample. Risk of bias among individual studies was appraised using GRADE methods and is summarised in Table 1.5. Figure 1.4 illustrates the risk of bias within these individual IPTp-SP studies, and Figure 1.5 shows the combined risk of bias across IPTp-SP studies, both of which were prepared using RevMan 5.2 software.

Figure 1.1 PRISMA flowchart for systematic review




Table 1.4 Summary of included studies by gravidae

References	Countries	Sites	Years	Type	IPTp-SP (2 doses or more)				Placebo or no IPTp-SP			
					No. LBW	No. Weighed	LBW %	95% CI	No. LBW	No. Weighed	LBW %	95% CI
Primi- and secundigravidae												
Gies (2009) ¹⁷⁷	Burkina Faso	Boromo	2004-06	1	104	812	12.8	10.5, 15.1	19	52	36.5	23.5, 49.6
Likwela (2012) ¹⁷⁶	DR Congo	Kisangani	2007	2	2	28	7.1	-2.4, 16.7	7	12	58.3	30.4, 86.2
Likwela (2012) ¹⁷⁶	DR Congo	Mikalayi	2007	2	1	28	3.6	-3.3, 10.5	11	56	19.6	9.2, 30.0
Likwela (2012) ¹⁷⁶	DR Congo	Rutshuru	2007	2	11	94	11.7	6.0, 20.0	5	15	33.3	9.5, 57.2
Menendez (2008) ⁷⁷	Mozambique	Manhiça	2003-05	1	29	133	21.8	14.8, 28.8	25	121	20.7	13.5, 27.9
Ndyomugenyi (2011) ⁸¹	Uganda	Kabale	2004-07	1	16	313 ^a	5.1	2.7, 7.6	18	329	5.5	3.0, 7.9
Ramharter (2007) ¹⁷⁸	Gabon	Lambaréné	2006	2	4	49	8.2	0.5, 15.8	6	30	20.0	5.7, 34.3
Ramharter (2007) ¹⁷⁸	Gabon	Libreville	2006	2	14	168	8.3	4.2, 12.5	19	106	17.9	10.6, 25.2
Ndyomugenyi (2011) ⁸¹	Uganda	Kabale	2004-07	1	22	287 ^b	7.7	4.6, 10.7	16	277	5.8	3.0, 8.5
Sirima (2006) ¹⁸⁰	Burkina Faso	Koupéla	2004	2	21	173 ^a	12.1	7.3, 17.0	22	183	12.0	7.3, 16.7
Sirima (2006) ¹⁸⁰	Burkina Faso	Koupéla	2004	2	6	46 ^c	13.0	3.3, 22.8	23	186	12.4	7.6, 17.1
van Eijk (2004) ¹⁷⁹	Kenya	Kisumu	1999-2000	1	10	122	8.2	3.3, 13.1	78	513	15.2	12.1, 18.3
Sub-totals					241	2,253			249	1,880		
Multigravidae												
Likwela (2012) ¹⁷⁶	DR Congo	Kisangani	2007	2	4	59	6.8	0.4, 13.2	9	37	24.3	10.5, 38.1
Likwela (2012) ¹⁷⁶	DR Congo	Mikalayi	2007	2	1	86	1.2	-1.1, 3.4	24	307	7.8	4.8, 10.8
Likwela (2012) ¹⁷⁶	DR Congo	Rutshuru	2007	2	28	397	7.1	4.5, 9.6	11	162	6.8	2.9, 10.7
Mbaye (2006) ⁸⁰	The Gambia	Farafenni	2003-04	1	51	931	5.5	4.0, 6.9	63	917	6.9	5.2, 8.5
Menendez (2008) ⁷⁷	Mozambique	Manhiça	2003-05	1	29	361 ^e	8.0	5.2, 10.8	34	375	9.1	6.2, 12.0
Ndyomugenyi (2011) ⁸¹	Uganda	Kabale	2004-07	1	40	610 ^b	6.6	4.6, 8.5	37	631	5.9	4.0, 7.7
Ndyomugenyi (2011) ⁸¹	Uganda	Kabale	2004-07	1	21	347 ^d	6.1	3.5, 8.6	27	325	8.3	5.3, 11.3
Rogerson (2000) ¹⁸¹	Malawi	Blantyre	1997-99	2	30	291	10.3	6.8, 13.8	50	218	22.9	17.4, 28.5
Sirima (2006) ¹⁸⁰	Burkina Faso	Koupéla	2004	2	2	17	11.8	-3.6, 27.1	7	61	11.5	3.5, 19.5
van Eijk (2004) ¹⁷⁹	Kenya	Kisumu	1999-2000	1	2	36	5.6	-1.9, 13.0	23	232	9.9	6.1, 13.8
Sub-totals					208	3,135			285	3,265		

Note: Presented in alphabetical order based on reference; IPTp-SP = Intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; LBW = Low birth weight; CI = Confidence interval; NA = Not applicable; Study type 1 = Randomised trial and type 2 = Observational study; ^a = primigravidae; ^b = secundigravidae; ^c = 2-4 pregnancies; ^d = 5 or more pregnancies; ^e = 1-3 pregnancies (likely to have contained some secundigravidae) and 4 or more pregnancies

Figure 1.2 PRISMA flowchart for matching studies





Figure 1.3 Funnel plot



This figure is a funnel plot of low birth weight estimates from pregnancy studies identified through systematic review and that stratified results by gravidae. Data points extracted from the pregnancy studies show that SP-IPTp is protective against LBW and, therefore, the midline of the funnel has shifted to the left of the number zero. Larger studies cluster around the upper area of the funnel as expected, reflecting smaller standard errors in these studies and within the 95% CIs. In contrast, small studies that reported the failure of IPTp-SP to protect against the incidence of LBW may have been under-represented in the sample of eligible pregnancy studies. This is reflected by the comparatively empty space towards the bottom right-hand side of the funnel.

Table 1.5 Risk of bias amongst individual pregnancy studies

Reference	Type of bias	Description	Risk	Support for judgement of bias
Gies (2009) ¹⁷⁷	Selection	Random sequence generation	High	Although not randomised at the individual level, the study involved 12 peripheral health centres that had been selected for a community-based trial on IPTp-SP effectiveness; four health centres implemented IPTp-SP, while the others did not and served as controls. There was a statistically significant difference reported ($P < 0.05$) in the proportion of pregnant women residing > 5 km from the nearest health facility and the number of SP doses given: 0 doses (76.5%; 62/81) and ≥ 2 doses (23.0%; 202/877).
	Selection	Allocation concealment	Unclear	All primigravidae and secundigravidae enrolled in the study were identified by field assistants through monthly rounds in the villages. It is unclear whether the absence of allocation concealment introduced bias.
	Performance	Blinding of participants and personnel	Unclear	It is not clear how participants and personnel were blinded in this community-based trial.
	Detection	Blinding of outcome assessment	Low	Although outcome assessment did not appear to be blinded, newborns were weighed to the nearest 25 g as soon as possible after birth using a hanging scale; weights obtained 1–8 days after delivery were corrected for physiological change.
	Attrition	Incomplete outcome data	Low	The proportion of women lost to follow-up was low at 8.4% (158/1,883). Women not included into the analysis (9.6%; 181/1,883) did not differ in parity and age from women included.
	Reporting	Selective reporting	Low	There did not appear to be evidence of selective reporting.
	Other		Low	No other sources of potential bias were identified.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
Likwela (2012) ¹⁷⁶	Selection	Random sequence generation	Unclear	All women who gave birth in 2007 in the study maternity clinics, attended ANC at least once during pregnancy, and whose antenatal card was available for analysis were included in this study. Demographic and anthropometric characteristics of women are not stratified according to IPTp-SP exposure and, therefore, it is unclear whether there was selection bias.
	Selection	Allocation concealment	Low	Authors noted that each maternity unit kept the ANC cards for all pregnant women from their catchment area. Hospital records and ANC cards were fully reviewed and the information transcribed. Although this does not conceal group allocation, bias was not necessarily introduced as a result of these procedures.
	Performance	Blinding of participants and personnel	Low	Newborns were weighed by a standard procedure in the three maternity wards using mechanical baby scales with a precision of 10 g. As reported, "The tendency of rounding the birth weight probably occurred in all three sites and should not significantly affect the results."
	Detection	Blinding of outcome assessment	Low	Analysis appeared to minimise the potential for detection bias.
	Attrition	Incomplete outcome data	Unclear	As a retrospective analysis of birth weight following exposure to IPTp-SP, it is unclear how data may be incomplete and contribute to attrition bias.
	Reporting	Selective reporting	Low	There is no evidence of selective reporting and a dose-response relationship was observed across gravidae.
	Other		Unclear	It is unclear how a statistically significant difference in the age of women between sites in Kisangani and Mikalayi may affect pooled outcomes.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
Mbaye (2006) ⁸⁰	Selection	Random sequence generation	Low	Random sequence was maintained with the use of group assignments in locks of 12.
	Selection	Allocation concealment	Low	As a placebo-controlled trial, SP and placebo tablets were identical in shape and colour, and were pre-packed in envelopes that had been placed in a wallet bearing the subject's number and packet number.
	Performance	Blinding of participants and personnel	Low	Identical SP and placebo tablets were used.
	Detection	Blinding of outcome assessment	Unclear	Outcome assessment was blinded, although the method of measuring birth weight was not mentioned. It is unclear whether the fact that 87% of newborns were weighed between 3 and 5 days after birth introduced any detection bias.
	Attrition	Incomplete outcome data	Low	Attrition rate was not unlike other IPTp-SP trials. Loss to follow up of 17.1% (459/2,688) overall, 16.6% (223/1,346) in the SP group and 17.6% (236/1,342) in the placebo group.
	Reporting	Selective reporting	Low	There is no apparent risk of selective reporting.
	Other		Unclear	It is unclear what bias, if any, could have been introduced given the difference in ages amongst women 40-50 in the SP vs. placebo groups, 61% (28/1,346) vs. 39% (18/1,342), respectively.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
Menendez (2008) ⁷⁷	Selection	Random sequence generation	Low	A computer-generated sequential list contained the study numbers linked to treatment identification letters that were randomly ordered in blocks of 10.
	Selection	Allocation concealment	Low	SP and placebo tablets were 'identical in shape and colour'
	Performance	Blinding of participants and personnel	Low	Blinding was maintained with the use of placebo tablets.
	Detection	Blinding of outcome assessment	Low	Although outcome assessment was not blinded, group allocation was maintained and newborns were weighed on a digital scale, accurate to the nearest gram.
	Attrition	Incomplete outcome data	Low	Loss to follow up was minimal. In the SP group 6.8% (35/515) of women did not receive 2 doses and birth weight was not measured for 1.4% (7/501) live births, whereas 5.6% (29/515) of women in the placebo group did not receive 2 doses and birth weight was not measured for 1.4% (7/503) live births.
	Reporting	Selective reporting	Low	No evidence of selective reporting and the study protocol is available.
	Other		Unclear	A statistically significant difference in the prevalence of syphilis was reported between the IPTp-SP and placebo groups, 14% (72/515) vs. 10% (50/515). There was no discussion as to whether women were informed of the syphilis status, offered a referral or treatment and, if treatment, what therapy was administered.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
Ndyomugyenyei (2011) ⁸¹	Selection	Random sequence generation	Low	Selection bias was minimised by using a computer-generated random number list with individually sealed envelopes, arranged in blocks of 12.
	Selection	Allocation concealment	Low	Tablets of SP or placebo, identical in shape and colour, were used.
	Performance	Blinding of participants and personnel	Low	All study participants, health staff and researchers were blind to drug assignment (SP or placebo), and newborns were weighed on a digital scale that was accurate to the nearest 10 g.
	Detection	Blinding of outcome assessment	Low	Data were examined to identify any imbalances in covariates and potential confounders in a blinded manner.
	Attrition	Incomplete outcome data	Low	5,775 women were assigned to treatment groups; 4,713 women contributed to the final analysis of the primary endpoint. Attrition was 18.4% overall. However, data on birth weight were recorded for > 90% of women enrolled into the study
	Reporting	Selective reporting	Low	No evidence of selective reporting was observed.
	Other		Low	No other sources of potential bias were identified.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
Ramharter (2007) ¹⁷⁸	Selection	Random sequence generation	Unclear	Pregnant women attending health facilities for delivery at two different sites were invited to participate. General demographic data was presented for 2004 and 2006, but not stratified by IPTp dosing and gravidae, making it difficult to determine whether the selection process introduced a systematic bias.
	Selection	Allocation concealment	Unclear	It is unclear whether the lack of allocation concealment introduced selection bias.
	Performance	Blinding of participants and personnel	Low	Although participants and personnel were not blinded, newborn birth weights were measured to the nearest 5 g immediately after delivery.
	Detection	Blinding of outcome assessment	Unclear	It is unclear if analysis of birth weight outcomes and exposure to IPTp-SP was blinded.
	Attrition	Incomplete outcome data	Unclear	Amongst 389 women in 2004, birth weights were reported for 385 newborns (99.0%); amongst 1,014 women in 2006, birth weights were reported for 788 newborns (77.7%).
	Reporting	Selective reporting	Unclear	Comparison of data with historical controls may be affected by bias and confounding.
	Other		Unclear	One hundred thirty-one of 389 (33.7%) women reported regular chemoprophylaxis with chloroquine during pregnancy in survey 2004. To what extent this affected the outcomes of controls is unclear.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
Rogerson (2000) 182	Selection	Random sequence generation	Unclear	Pregnant women in active labour, and likely to deliver during working hours, were asked to participate in the study. From this group, data related to IPTp-SP exposure was collected. Although education on schooling was available for 50.4% of participants (526/1,044), demographic data were limited for comparing differences amongst women.
	Selection	Allocation concealment	Unclear	Allocation was based on prior exposure to IPTp-SP; it is unclear if this may have introduced any bias into the analysis.
	Performance	Blinding of participants and personnel	Unclear	Method and timing of weighing newborns was not reported.
	Detection	Blinding of outcome assessment	Unclear	It is unclear if analysis of birth weight outcomes and exposure to IPTp-SP was blinded.
	Attrition	Incomplete outcome data	Low	There appears to be no evidence of incomplete outcome data.
	Reporting	Selective reporting	Low	There is no evidence of selective reporting
	Other		Low	No apparent risk of other bias.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
Sirima (2006) ¹⁸⁰	Selection	Random sequence generation	Unclear	Pregnant women (n=826) from six antenatal care facilities and from two delivery units (n=1,188) were enrolled. Because 20 eligible women (2.4%) refused enrolment at antenatal care facilities and 33 (2.8%) at delivery units, selection bias is likely low amongst recipients of SP. However, it is unclear if and to what extent bias was introduced when comparing these women to who did not receive SP and demographic data did not appear to be used to control for potential differences.
	Selection	Allocation concealment	Unclear	It is unclear whether the lack of allocation concealment introduced selection bias.
	Performance	Blinding of participants and personnel	Low	Neonates were weighed to the nearest 10 grams using an electronic digital scale.
	Detection	Blinding of outcome assessment	Low	Although it is unknown whether outcome assessment was blinded, clear and consistent gravidae-specific trends were associated with malaria infection as well as a dose-response relationship between SP and low birth weight.
	Attrition	Incomplete outcome data	Low	Amongst enrolled women, 97.4% had a baby whose birth weight was measured.
	Reporting	Selective reporting	Low	There is no evidence of selective reporting.
	Other		Unclear	An unknown number of pregnant women took IPTp-SP doses at home rather than ingesting them while observed in at the health facility; it is possible that not all of these doses were actually taken as reported.

Table 1.5 Risk of bias amongst individual pregnancy studies (continued)

Reference	Type of bias	Description	Risk	Support for judgement of bias
van Eijk (2004) 179	Selection	Random sequence generation	Unclear	All women were invited to participate who received ANC services at the study hospital and delivered at the same facility between June 1999 and June 2000. The number of SP doses on the ANC card was confirmed with the mother.
	Selection	Allocation concealment	Unclear	See above
	Performance	Blinding of participants and personnel	Unclear	Methods of neonatal weighing and post-partum timing of weighing were not reported.
	Detection	Blinding of outcome assessment	Unclear	It is unclear if analysis of low birth weight was conducted in a blinded manner.
	Attrition	Incomplete outcome data	Low	Only women who delivered in the hospital, and had previously visited the ANC of the hospital, as well as complete information on their birth card (n=1,498) were included in the analysis, representing 89.5% of eligible women.
	Reporting	Selective reporting	Low	No selective reporting observed
	Other		Low	No apparent risk.

Figure 1.4 Risk of bias amongst individual pregnancy studies





Figure 1.5 Risk of bias across pregnancy studies



Meta-analysis

There was strong evidence of protection against LBW conferred by ≥ 2 doses versus placebo or no doses of IPTp-SP. Random-effects models showed that amongst primi- and secundigravidae ≥ 2 doses cut the odds in half of delivering a LBW newborn (odds ratio [OR] = 0.54; 95% CI: 0.35, 0.84; $P < 0.00$) compared to no doses or placebo. The odds of LBW were reduced by 30% amongst multigravidae (OR = 0.70; 95% CI: 0.51, 0.95; $P = 0.04$).

In order to estimate the transmission intensity at each of the IPTp-SP study sites, 12 national cross-sectional datasets were used from MAP containing 11,548 surveys. Pooled prevalence estimates were calculated as a second means of estimating the malaria transmission intensity at 10 sites under rule 1, and for eight sites by applying rule 3. The remaining four study sites were matched based on rule 4. Matching by gravidae was as follows: (i) six of 12 primi- and secundigravidae IPTp-SP study sites were matched under rule 1; (ii) three study sites were paired under rule 3; (iii) three study sites were matched using rule 4. Amongst studies with multigravidae, four were matched using rule 1, five were paired under rule 3, and one study site was matched based on rule 4. As shown in Table 1.6, parasite prevalence amongst primi- and secundigravidae derived from MAP estimates were between 20.5% and 66.4%, whereas the pooled prevalence estimates were slightly narrower, 25.1% and 59.1%. Amongst multigravidae, MAP estimates were between 20.5% and 66.4%, and the pooled prevalence estimates were also narrower from 6.7% and 39.3%.

Table 1.6 Malaria transmission estimates based on matching rules

References	Country	Site	Elevation	Rule used	Pooled prevalence (%)	2007 PfPR ₂₋₁₀ (%)
Primi- and secundigravidae						
Likwela (2012) ¹⁷⁶	DR Congo	Rutshuru	1212	4	29.6 ^a	29.6
Ndyomugyenyei (2011)* ⁸¹	Uganda	Kabale	2118	4	25.1 ^a	25.1
Ndyomugyenyei (2011) [†] ⁸¹	Uganda	Kabale	2118	4	25.1 ^a	25.1
Likwela (2012) ¹⁷⁶	DR Congo	Kisangani	401	1	30.4	40.2
Menendez (2008) ⁷⁷	Mozambique	Manhiça	21	1	31.2	48.1
Gies (2009) ¹⁷⁷	Burkina Faso	Boromo	258	1	44.2	57.4
Likwela (2012) ¹⁷⁶	DR Congo	Mikalayi	618	3	55.8	38.5
Ramharter (2007) ¹⁷⁸	Gabon	Libreville	13	3	55.8	37.1
Ramharter (2007) ¹⁷⁸	Gabon	Lambaréné	39	3	55.8	42.8
van Eijk (2004) ¹⁷⁹	Kenya	Kisumu	1166	1	57.5	20.5
Sirima (2006)* ¹⁸⁰	Burkina Faso	Koupéla	290	1	59.1	66.4
Sirima (2006) [†] ¹⁸⁰	Burkina Faso	Koupéla	290	1	59.1	66.4
Multigravidae						
Ndyomugyenyei (2011) [‡] ⁸¹	Uganda	Kabale	2118	3	6.7	25.1
Ndyomugyenyei (2011) [§] ⁸¹	Uganda	Kabale	2118	3	6.7	25.1
Mbaye (2006) ⁸⁰	The Gambia	Farafenni	25	1	8.3	23.9
Rogerson (2000) ¹⁸¹	Malawi	Blantyre	989	3	11.3	24.9
Menendez (2008) [¶] ⁷⁷	Mozambique	Manhiça	21	3	11.3	48.1
van Eijk (2004) ¹⁷⁹	Kenya	Kisumu	1166	1	25.0	20.5
Likwela (2012) ¹⁷⁶	DR Congo	Rutshuru	1212	4	29.6 ^a	29.6
Sirima (2006) ¹⁸⁰	Burkina Faso	Koupéla	290	1	32.9	66.4
Likwela (2012) ¹⁷⁶	DR Congo	Kisangani	401	3	34.0	40.2
Likwela (2012) ¹⁷⁶	DR Congo	Mikalayi	618	1	39.3	38.5

Note: Studies are presented in ascending order of malaria transmission intensity; ^a Under rules 1-3, no matches were made and, therefore, the 2007 PfPR₂₋₁₀ estimates from MAP are used. * = primigravidae; [†] = secundigravidae; [‡] = 2-4 pregnancies; [§] = 5 or more pregnancies; [¶] = 1-3 pregnancies (likely contained some secundigravidae) and 4 or more pregnancies

Meta-regression analysis

To explore the potential effect of malaria transmission intensity on the association between IPTp-SP and LBW, four separate meta-regression models were conducted. Models one and two applied the odds ratios of protection conferred by ≥ 2 doses of IPTp-SP versus placebo or no doses amongst primi- and secundigravidae with model one employing transmission intensity estimates from MAP, and model two using pooled prevalence estimates for transmission intensity. Models three and four were constructed using the odds ratios from analyses of multigravidae and transmission intensity estimates from MAP and, separately, pooled prevalence estimates derived from cross-sectional surveys. Not one of these four models suggested that variation in the ORs of LBW could be explained by malaria transmission intensity: model one ($P = 0.83$); model two ($P = 0.78$); model three ($P = 0.30$); model four ($P = 0.93$). Sensitivity testing amongst matching rules did not produce any statistically significant difference in these results.

Discussion

This analysis demonstrates that there is no level of malaria transmission intensity below which ≥ 2 doses of IPTp-SP no longer protects against the incidence of LBW. The inability of this study to detect a malaria transmission threshold may be a consequence of there being too few data points for analysis, particularly from lower transmission settings. Data from Ndyomugenyi *et al.* in Uganda complicates interpretation because women in the no-SP group were provided ITNs. Consequently, the difference between women in the 'protected' versus 'unprotected' groups was likely harder to detect because there was less total exposure to malaria infection rather than IPTp-SP being compromised. However, an unpublished analysis of

Multiple Indicator Cluster Surveys with several thousand data points also found that IPTp-SP continued to protect against LBW until very low levels of transmission and, similar to this study, could not define a cut-off point of transmission below which IPTp-SP is no longer protective against LBW (Eisele TP, personal communication).

There may be other factors that have contributed to not being able to detect a transmission threshold. Little is known about the prevalence of placental infection in very low transmission settings and it is entirely possible that declines in peripheral parasitaemia are not reflected in equivalent reductions in placental infection. If that is the case, then IPTp-SP may provide important and continued protection against placental carriage, as well as the incidence of LBW in areas of very low endemicity.

Another possible explanation is that the causal pathway to LBW is multifactorial and that IPTp-SP offers some protection against other non-malarial causes of LBW. Indeed, this is what was observed in the study conducted under Q 3. Although not common, SP can be used as an efficacious chemoprophylactic drug against *Pneumocystis jiroveci* pneumonia and *Toxoplasma gondii* infection.¹⁵⁵ Moreover, sulphadoxine is related to sulphamethoxazole, the partner compound used with trimethoprim to form cotrimoxazole, a treatment often provided to cure urinary tract infections and to prevent *P. jiroveci* in HIV-infected patients.¹⁵⁶ Sulphonamides have also been used to treat *Gardnerella vaginalis*,¹⁵⁹ a bacterium found in women with bacterial vaginosis that can double the odds of having a low birth weight baby (OR = 2.0; 95% CI: 1.3, 2.9) compared to pregnant women without bacterial vaginosis.¹²

The MAP *PfPR*₂₋₁₀ estimates from 2007 were not the best temporal match for the pregnancy studies; all but one of the studies occurred before 2007. However, individual survey data available through MAP did produce more precise estimates of parasitaemia with narrower confidence intervals. However, these data only contained the age range of participants from whom samples had been collected. Thus, it was sometimes necessary to make assumptions about which age group to assign survey data, i.e. 0 to > 5 years of age to primi- and secundigravidae versus 5-15 years of age to multigravidae, to create a binomial structure of data that might mirror the parity-specific epidemiology of malaria in pregnancy.

The results from this analysis should be interpreted with caution for several reasons. This analysis has been conducted with the limited data available that relate the efficacy of IPTp-SP to the intensity of malaria exposure during pregnancy and that can also be stratified by gravidae. Moreover, there may have been selection bias in six of the nine studies identified through systematic review for lack of random sequence generation or allocation concealment. In addition, there was considerable heterogeneity amongst IPTp-SP studies, making it more difficult to generalise about them as a group. However, stratifying studies by design, observational versus RCT, did not consistently reduce heterogeneity, nor change the observed results.

Q 2. A581G prevalence threshold

Methods

The data set of IPTp-SP studies developed to answer the first research question was used as the starting point to estimate the prevalence threshold of the *Pf dhps* mutation

at codon A581G above which IPTp-SP may no longer protect against the incidence of LBW. A geographical database of SP resistance markers¹⁸³, originally developed to guide policy recommendations specific to intermittent preventive treatment of malaria using SP amongst African infants, was used to identify surveys containing point prevalence estimates of the A581G mutation that had been collected from < 100 miles and plus or minus two years of the IPTp-SP trials. The geographic range was extended 100 to 250 miles if no data were available from < 100 miles. If multiple point estimates were found, then data were pooled using standard meta-analysis.

Results

Point prevalence estimates of *Pf dhps* A581G were identified from 44 sites having been measured within plus or minus two years of when the IPTp-SP trials had been conducted. Twenty sites were within < 100 miles of IPTp-SP trials and 24 sites within 100 to 250 miles. All IPTp-SP trial sites had at least one corresponding point estimate of A581G as shown in Table 2.1 between these two distance parameters.¹⁸⁴⁻¹⁹⁸ The highest prevalence of A581G was 52.6% (95% CI: 47.6, 57.5) based on 740 samples as measured at four sites < 100 miles of the IPTp-SP study in Kabale (Uganda). Prevalence estimates for the other sites ranged from 0.0% to 10.1% (95% CI: 3.5, 16.8).

There was a binomial structure in the A581G prevalence data that lent itself to stratification of IPTp-SP studies where there A581G prevalence of $\leq 10.1\%$ and $> 10.1\%$. Based on random-effects models, ≥ 2 doses of IPTp-SP reduced the odds of LBW amongst primi- and secundigravidae (OR = 0.49; 95% CI: 0.29, 0.81; $P < 0.00$) and multigravidae (OR = 0.56; 95% CI: 0.37, 0.86; $P < 0.03$) in areas where there A581G prevalence was $\leq 10.1\%$. Two or more doses of IPTp-SP continued to protect primi-

and secundigravidae against LBW (OR = 0.54; 95% CI: 0.35, 0.84). This protective effect was no longer statistically significant in areas where A581G prevalence was > 10.1% (OR = 0.73; 95% CI: 0.29, 1.18). There are also geographic areas where malaria transmission intensity was lowest according to pooled and MAP prevalence estimates (range: 25.1% to 29.6%). Amongst multigravidae, IPTp-SP conferred protection against LBW in areas where the prevalence of A581G was \leq 10.1% (OR = 0.56; 95% CI: 0.37, 0.86; $P = 0.07$). However, there was no evidence from fixed-effects or random-effects models that multigravidae continued to be protected against LBW where the prevalence of A581G was > 10.1% (OR = 0.96; 95% CI: 0.70, 1.34; $P < 0.47$). These results are illustrated in Figures 2.1 and 2.2. The interaction between malaria transmission intensity and the prevalence of A581G was borderline significant: $P = 0.06$ amongst primi- and secundigravidae, and $P = 0.04$ amongst multigravidae. Thus, meta-regression of malaria transmission, stratified by A581G prevalence, could only explain some variation in IPTp-SP protection against LBW.

Table 2.1 A581G Prevalence at IPTp-SP study sites

Pregnancy studies			Pfdhps codon A581G surveys								
References	Countries	Sites	Distance from IPTp-SP trial	No. sites	No. tested	No. positive	Prevalence (%)	95% CI	Heterogeneity (I^2)	Prevalence across sites (%)	Refs
Gies (2009)	Burkina Faso	Boromo	100-250 m	3	250	26	1.7*	0.2 to 3.2	93.8%	0.0 to 37.8	184-186
Likwela (2012)	DR Congo	Kisangani	100-250 m	1	18	1	5.6	-5.0 to 16.1	NA	NA	187
Likwela (2012)	DR Congo	Mikalayi	100-250 m	0	0	0	0.0	NA	NA	NA	187
Likwela (2012)	DR Congo	Rutshuru	< 100 m	6	747	367	52.4 ¹	47.5 to 57.4	79.6%	28.6 to 61.1	187-190
Mbaye (2006)	The Gambia	Farafenni	< 100 m	1	27	0	0.0 ¹	NA	NA	0.0	191
Menendez (2008)	Mozambique	Manhiça	100-250 m	4	279	0	0.0 ¹	NA	NA	0.0	192
Ndyomugenyi (2011)	Uganda	Kabale	< 100 m	5	740	365	52.6	47.6 to 57.5	83.3%	30.2 to 61.1	187-190
Ramharter (2007)	Gabon	Lambaréné	100-250 m	2	118	0	0.0	NA	NA	0.0	193,194
Ramharter (2007)	Gabon	Libreville	100-250 m	2	236	4	2.0 ²	0.06 to 3.9 ²	NA	0.0 to 2.0	11,12
Rogerson (2000)	Malawi	Blantyre	< 100 m	3	318	3	3.4 ²	-0.4 to 7.1 ²	100%	0.0 to 3.4	195,196
Sirima (2006)	Burkina Faso	Koupéla	< 100 m	1	79	8	10.1 ²	3.5 to 16.8 ²	NA	10.1	186
van Eijk (2004)	Kenya	Kisumu	< 100 m	6	825	4	2.7 [†]	0.1 to 5.4 ²	100%	0.0 to 2.7	197,198


NA = Not applicable

¹ No mutations were detected and, therefore, the prevalence shown is the point estimate of the one study that did yield positive samples

² Only one of the studies detected mutations; models exclude studies in which there are no positive tests and, therefore, the prevalence shown is a point estimate of the one study that did yield positive samples.

Figure 2.1 Forest plot – primi- and secundigravidae


Odds ratio of low birth-weight delivery amongst primi- and secundigravidae following two or more doses of IPTp-SP versus placebo or no IPTp-SP stratified by estimates of the A581G resistance mutation amongst malaria parasites at study sites



Note: Studies are presented in ascending order of malaria transmission intensity * Secundigravidae; † Primigravidae; Vertical red line (dashed) = Pooled odds ratio; I-V overall: fixed-effects estimate; D + L overall: random-effects estimate; Diamond shapes = Pooled estimate and 95% CIs

Figure 2.2 Forest plot – multigravidae

Odds ratio of low birth-weight delivery amongst multigravidae following two or more doses of IPTp-SP versus placebo or no IPTp-SP stratified by estimates of the A581G resistance mutation amongst malaria parasites at study sites



Note: Studies are presented in ascending order of malaria transmission intensity; * = 2-4 pregnancies; † = 5 or more pregnancies; Vertical red line (dashed) = Pooled odds ratio; I-V overall: fixed-effects estimate; D + L overall: random-effects estimate; Diamond shapes = Pooled estimate and 95% CIs

Discussion

In this analysis IPTp-SP studies were stratified by primi- and secundigravidae versus multigravidae, and the effect that the A581G mutation on protection conferred against LBW was investigated. This biomarker-based measure of SP resistance provides some clarity on where, geographically, a replacement for SP might be appropriate amongst multigravidae.

Given the lack of prevalence estimates for the A581G mutation between 10.1% and 52.4%, it is only reasonable to conclude that the prevalence threshold of this mutation is $> 10.1\%$ above which IPTp-SP no longer protects against the incidence of LBW amongst multigravidae. It may be tempting to state the cut-off should be $> 52.4\%$, or a convenient level such as 50%. The actual threshold may be much lower, however, especially considering the alarming results from Muheza, Tanzania, where researchers found placental infection significantly higher in 84% of women ($n = 104$) who were given any IPTp-SP compared to 16% of women ($n = 104$) who received no doses of IPTp-SP ($P = 0.03$).^{86,199} The prevalence of the A581G mutation in this study area was 55% (95% CI: 44.7, 65.2; $N = 87$).⁸⁸

The results from this analysis should be interpreted with caution for the same reasons noted in the investigation of transmission intensity. This analysis has been conducted with the limited data available. As previously mentioned, there may have been selection bias in six of the nine studies identified through systematic review for lack of random sequence generation or allocation concealment. In addition, there was considerable heterogeneity amongst IPTp-SP studies, making it more difficult to generalise about them as a group. However, stratifying studies by design did not consistently reduce heterogeneity, nor change the results.

The A581G mutation is not widely found throughout sub-Saharan Africa, although the codon has been detected in 10 countries¹⁵² and the codon can be selected rapidly. A study in Kenya reported the prevalence of A581G to be 85.1% (95% CI: 80.0%, 89.4%) where no parasites had expressed the mutation when surveillance testing was conducted three years earlier.²⁰⁰ However, before declaring a specific level of malaria transmission or A581G prevalence at which IPTp-SP no longer provides a cost-effective benefit, placebo-control trials may be needed in a range of low-transmission settings that are sufficiently powered for sub-analysis by gravidae.

Q 3. Effect of IPTp-SP on malaria and curable STIs/RTIs in pregnancy

Methods

To estimate the effect of IPTp-SP on malaria infection and curable STIs/RTIs in pregnancy, a secondary analysis was conducted using data collected for a prospective cohort study of the burden of malaria and curable STIs/RTIs carried out between November 2013 and April 2014 in the Nchelenge District of Zambia.^{201,202} Nchelenge is in the Luapula province, 290 km (180 miles) from Mansa, the provincial capital, and along the shores of Lake Mweru in north-east Zambia. In total, 1,086 pregnant women were recruited on their first ANC visit to health centres operated by the Zambian Ministry of Health. As part of determining eligibility for participation, women had their gestational age calculated according to their last menstrual period, symphysis-fundal height measurement, and sonography. Women who were not already known to have the AIDS virus were tested for HIV per Ministry practices. HIV-infected women were given triple antiretroviral therapy if their CD4 count dropped below 500 cells per cubic millimetre of blood, representing a variation on 'Option B' treatment originally

recommended by the WHO in 2010.²⁰³ Study staff tested women for syphilis using rapid plasma reagin (RPR) methods and, if positive, the results were sent to participants with a notice to return to the health facility with their partners for treatment. Biological samples for malaria and other curable STIs/RTIs were also collected at enrolment and transported to a reference laboratory for retrospective batch testing where PCR techniques were used. At delivery, placental samples were collected for malaria histology. During scheduled ANC visits, women received IPTp-SP and were followed by study staff until delivery to record birth outcomes. Women were encouraged to deliver at a health facility for maximum care and to ease data collection. If willing to do so, women were provided free transport to and from the only hospital in the district, Saint Paul's Mission Hospital, or Kashikishi Health Centre. At the time, Nchelenge Health Centre did not offer maternity services. Data were analysed using Stata version 13 (Stata Corp, College Station, Texas) software.

Descriptive analysis

Categorical variables were summarised as whole numbers and percentages, whereas continuous variables were described by means and standard deviations if the data appeared to be normally distributed. Differences in the characteristics of participants at the time of enrolment were compared between women who had received 0 to 1 dose and ≥ 2 doses of IPTp-SP and, separately, 2 doses versus ≥ 3 doses, using Wilcoxon test for continuous variables and Fisher's exact test for categorical variables. These variables are listed in Table 3.6. Crude odds ratios were then calculated of adverse birth outcomes amongst pregnant women who received 0 to 1 dose

compared ≥ 2 doses and, separately, 2 doses compared to ≥ 3 doses using logistic regression models.

Assessment of potential confounding and effect modification factors

HIV status and gravidae were considered to confound the protective effect of IPTp-SP on birth outcomes based on studies from the literature.^{204,205} Common statistical methods were applied to identify other potential confounders,²⁰⁶ entering variables into a logistic regression model that included categories of doses of IPTp-SP exposure. Variables were considered *a priori* to be confounders if they produced a change in the odds ratios of crude versus adjusted by 10% or more as shown in Tables 3.1 to 3.5. Effect modification was tested by adding an interaction term between these potential confounders and the number of IPTp-SP doses, and then applying a likelihood ratio test to determine whether there was evidence of interaction. Some evidence of effect modification with malaria and STI/RTI co-infection was observed which is dealt with separately below. The co-infection of malaria and STIs/RTIs was also considered a confounder. All confounding variables were entered in a multivariable logistic regression model to estimate overall adjusted odds ratios.

Assessment of association between IPTp-SP and maternal malaria and STIs/RTIs

Seven mutually exclusive maternal infection categories were constructed to examine the distribution of mono- and co-infection: (i) malaria only, (ii) malaria and *N. gonorrhoeae* and/or *C. trachomatis*, (iii) malaria and *T. vaginalis* and/or bacterial vaginosis, (iv) syphilis and any other infection(s), (v) *N. gonorrhoeae*, *C. trachomatis* only, (vi) *T. vaginalis* and/or bacterial vaginosis only, and (vii) no identified infection.

Odds of IPTp-SP exposure to 0-1 dose versus ≥ 2 doses of IPTp-SP were calculated for each infection category by adverse birth outcome using a multivariable logistic regression model that included all potential confounders and interaction terms.

Table 3.1 Potential confounding factors for any adverse birth outcome

Potential confounding variable	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
Gravidae	0.57	(0.38, 0.84)	0.004	0.52	(0.35, 0.77)	0.001	8.89	0.302	0
Prior preterm birth ¹	0.42	(0.15, 1.19)	0.092	0.38	(0.13, 1.11)	0.067	7.88	*	620
Sex of baby	0.57	(0.38, 0.84)	0.004	0.59	(0.40, 0.87)	0.007	3.86	0.240	0
Co-infection (malaria and/or STI/RTI)	0.57	(0.38, 0.84)	0.004	0.54	(0.37, 0.81)	0.002	3.81	0.125	0
Maternal age at enrolment (years)	0.57	(0.38, 0.84)	0.004	0.55	(0.36, 0.82)	0.003	3.55	0.736	0
Prior miscarriage ¹	0.42	(0.15, 1.19)	0.092	0.40	(0.14, 1.15)	0.079	3.39	0.424	620
Placental malaria (PCR diagnosis)	0.58	(0.39, 0.85)	0.005	0.56	(0.38, 0.83)	0.004	2.63	0.853	7
Delivery type	0.57	(0.38, 0.84)	0.004	0.58	(0.39, 0.86)	0.006	2.38	0.929	0
Treatment of malaria infection during pregnancy ²	0.58	(0.39, 0.86)	0.006	0.57	(0.38, 0.84)	0.004	2.23	0.256	3
Marital status	0.57	(0.38, 0.84)	0.004	0.55	(0.38, 0.81)	0.002	2.22	0.001	0
Number of lifetime sexual partners	0.56	(0.38, 0.83)	0.004	0.57	(0.39, 0.85)	0.005	2.06	0.564	6
Hypertension at enrolment or delivery	0.54	(0.36, 0.82)	0.003	0.55	(0.37, 0.83)	0.004	1.93	0.213	86
Type of personnel attending birth	0.57	(0.38, 0.84)	0.004	0.58	(0.39, 0.85)	0.005	1.78	0.042	0
HIV status	0.57	(0.38, 0.84)	0.004	0.57	(0.39, 0.85)	0.005	1.42	0.946	0
Age of sexual debut (years)	0.57	(0.38, 0.84)	0.004	0.57	(0.39, 0.85)	0.005	1.38	0.243	0
Prior stillbirth ¹	0.42	(0.15, 1.19)	0.092	0.42	(0.14, 1.25)	0.108	1.33	0.358	620
Indoor residual spraying in preceding 12 months	0.53	(0.36, 0.80)	0.002	0.53	(0.35, 0.79)	0.001	1.30	0.896	26
Syphilis at enrolment (high titre)	0.57	(0.38, 0.84)	0.004	0.56	(0.38, 0.83)	0.004	1.16	0.400	5
Labour type	0.57	(0.39, 0.85)	0.005	0.57	(0.38, 0.84)	0.004	1.14	*	15
Bed net ownership	0.57	(0.38, 0.84)	0.004	0.57	(0.39, 0.85)	0.005	1.10	0.750	0
Bed net usage (on night prior to survey)	0.56	(0.38, 0.83)	0.004	0.55	(0.37, 0.82)	0.003	1.09	0.826	3
Delivery location	0.57	(0.38, 0.84)	0.004	0.57	(0.38, 0.85)	0.005	1.05	0.070	0
<i>T. vaginalis</i> co-infection (malaria and/or STI/RTI)	0.57	(0.38, 0.84)	0.004	0.57	(0.39, 0.84)	0.004	0.89	0.011	0

Table 3.1 Potential confounding factors for any adverse birth outcome (continued)

Potential confounding variable	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
Wealth quintiles	0.57	(0.38, 0.84)	0.004	0.56	(0.38, 0.83)	0.004	0.84	0.503	0
Maternal haemoglobin level at delivery ³	0.60	(0.40, 0.90)	0.012	0.60	(0.40, 0.90)	0.012	0.56	0.101	32
Treatment of STIs/RTIs during pregnancy including syphilis	0.76	(0.46, 1.23)	0.259	0.76	(0.47, 1.23)	0.265	0.49	0.250	258
STI/RTI co-infection	0.57	(0.38, 0.84)	0.004	0.57	(0.38, 0.84)	0.004	0.39	0.483	5
<i>N. gonorrhoeae</i> co-infection (malaria and/or STI/RTI)	0.57	(0.38, 0.84)	0.004	0.56	(0.38, 0.84)	0.004	0.39	0.318	0
Bacterial vaginosis and STI co-infection	0.57	(0.38, 0.84)	0.004	0.57	(0.39, 0.84)	0.004	0.33	0.067	5
Recruitment site	0.57	(0.38, 0.84)	0.004	0.56	(0.38, 0.84)	0.004	0.24	0.991	0
Treatment of STIs/RTIs during pregnancy excluding syphilis	0.57	(0.38, 0.84)	0.004	0.57	(0.38, 0.84)	0.004	0.19	0.492	0
<i>C. trachomatis</i> co-infection (malaria or STI/RTI)	0.57	(0.38, 0.84)	0.004	0.57	(0.38, 0.84)	0.004	0.04	0.770	0

CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus

¹ Excludes women who have not been previously pregnant

² Therapy against malaria infection (apart from IPTp) after enrolment and before delivery

³ Anaemia was defined as haemoglobin level < 11grams/decilitre

⁴ Confounding is not reflected in *P*-values

⁵ Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio. When there is no difference (adjusted / crude – 1) between these two estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable. Variables with odds ratios that changed by 10% or more were considered *a priori* to be potential confounders and we retained for the multivariable model. In this table, only the variable. In this table, no variables demonstrated evidence of confounding on the outcome effect ‘any adverse birth outcome’.

⁶ Missing values were excluded from the crude odds ratio

* Insufficient events to perform stratified analysis for interaction

Table 3.2 Potential confounding factors for stillbirth

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
Hypertension at enrolment or delivery	0.88	(0.18, 4.21)	0.875	1.00	(0.19, 5.32)	1.000	13.39	0.422	86
Labour type	0.43	(0.13, 1.46)	0.163	0.39	(0.11, 1.35)	0.122	9.96	*	15
Treatment of malaria infection during pregnancy ²	0.56	(0.15, 2.15)	0.392	0.51	(0.13, 2.02)	0.328	9.31	0.333	3
Indoor residual spraying in preceding 12 months	0.43	(0.13, 1.46)	0.162	0.39	(0.11, 1.36)	0.128	8.22	0.584	26
Gravidae	0.42	(0.12, 1.42)	0.149	0.39	(0.11, 1.34)	0.121	7.42	0.573	0
Delivery location	0.42	(0.12, 1.42)	0.149	0.39	(0.11, 1.39)	0.132	6.08	0.459	0
HIV status	0.42	(0.12, 1.42)	0.149	0.44	(0.13, 1.49)	0.175	4.98	0.794	0
Wealth quintiles	0.42	(0.12, 1.42)	0.149	0.44	(0.14, 1.37)	0.144	4.92	0.043	0
Delivery type	0.42	(0.12, 1.42)	0.149	0.44	(0.13, 1.48)	0.173	4.55	*	0
Maternal haemoglobin level at delivery ³	0.57	(0.15, 2.17)	0.401	0.54	(0.14, 2.11)	0.369	4.29	0.694	32
Prior stillbirth ¹	0.30	(0.07, 1.39)	0.103	0.32	(0.07, 1.45)	0.117	4.20	*	192
Age of sexual debut (years)	0.42	(0.12, 1.42)	0.149	0.44	(0.13, 1.44)	0.161	4.15	0.178	0
Placental malaria (PCR diagnosis)	0.42	(0.13, 1.44)	0.155	0.44	(0.13, 1.48)	0.171	3.20	0.737	7
Type of personnel attending birth	0.42	(0.12, 1.42)	0.149	0.41	(0.12, 1.42)	0.145	3.09	0.433	0
Bed net ownership	0.42	(0.12, 1.42)	0.149	0.43	(0.13, 1.45)	0.161	2.96	0.324	0
<i>N. gonorrhoeae</i> co-infection (malaria and/or STI/RTI)	0.42	(0.12, 1.42)	0.149	0.43	(0.13, 1.46)	0.164	2.89	*	0
Co-infection (malaria and/or STI/RTI)	0.42	(0.12, 1.42)	0.149	0.43	(0.14, 1.36)	0.139	2.60	0.045	0
Recruitment site	0.42	(0.12, 1.42)	0.149	0.43	(0.13, 1.48)	0.168	2.59	0.330	0
<i>C. trachomatis</i> co-infection (malaria or STI/RTI)	0.42	(0.12, 1.42)	0.149	0.41	(0.12, 1.39)	0.139	2.19	*	0
Sex of baby	0.42	(0.12, 1.42)	0.149	0.43	(0.12, 1.48)	0.168	1.89	0.673	0
Number of lifetime sexual partners	0.42	(0.13, 1.43)	0.154	0.43	(0.13, 1.45)	0.161	1.81	0.461	6

Table 3.2 Potential confounding factors for stillbirth (continued)

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
STI/RTI co-infection	0.42	(0.13, 1.43)	0.153	0.43	(0.13, 1.43)	0.155	1.53	0.101	5
Treatment of STIs/RTIs during pregnancy including syphilis	0.55	(0.10, 2.88)	0.470	0.55	(0.11, 2.93)	0.481	1.35	*	258
Syphilis at enrolment (high titre)	0.42	(0.13, 1.43)	0.153	0.42	(0.13, 1.33)	0.128	1.14	0.007	5
Maternal age at enrolment (years)	0.42	(0.12, 1.42)	0.149	0.42	(0.12, 1.45)	0.158	0.78	0.433	0
Prior miscarriage ¹	0.30	(0.07, 1.39)	0.103	0.31	(0.07, 1.39)	0.104	0.60	0.337	192
Prior preterm birth ¹	0.30	(0.07, 1.39)	0.103	0.31	(0.07, 1.40)	0.105	0.52	*	192
Bed net usage (on night prior to survey)	0.42	(0.12, 1.43)	0.152	0.42	(0.12, 1.42)	0.151	0.34	0.408	3
Marital status	0.42	(0.12, 1.42)	0.149	0.42	(0.12, 1.44)	0.155	0.19	0.354	0
Bacterial vaginosis and STI co-infection	0.42	(0.13, 1.43)	0.153	0.42	(0.13, 1.43)	0.153	0.12	0.372	5
Treatment of STIs/RTIs during pregnancy excluding syphilis	0.43	(0.13, 1.45)	0.161	0.43	(0.13, 1.45)	0.162	0.07	*	13
<i>T. vaginalis</i> co-infection (malaria and/or STI/RTI)	0.42	(0.12, 1.42)	0.149	0.42	(0.12, 1.42)	0.149	0.00	0.998	0

CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus

¹Excludes women who have not been previously pregnant

²Therapy against malaria infection (apart from IPTp) after enrolment and before delivery

³Anaemia was defined as haemoglobin level < 11grams/decilitre

⁴Confounding is not reflected in *P*-values

⁵Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio. When there is no difference (adjusted / crude – 1) between these two estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable. Variables with odds ratios that changed by 10% or more were considered *a priori* to be potential confounders and we retained for the multivariable model. In this table, only the variable. ‘Hypertension at enrolment or delivery’ demonstrated evidence of confounding on the outcome effect ‘stillbirth’.

⁶Missing values were excluded from the crude odds ratio

* Insufficient events to perform stratified analysis for interaction

Table 3.3 Potential confounding factors for low birth weight

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
Gravidae	0.78	(0.49, 1.23)	0.279	0.69	(0.42, 1.11)	0.122	11.86	0.952	0
Prior miscarriage ¹	0.68	(0.21, 2.19)	0.513	0.64	(0.19, 2.14)	0.461	6.17	0.623	620
Treatment of malaria infection during pregnancy ²	0.78	(0.50, 1.23)	0.288	0.74	(0.47, 1.18)	0.207	4.87	0.034	3
Co-infection (malaria and/or STI/RTI)	0.78	(0.49, 1.23)	0.279	0.74	(0.47, 1.17)	0.202	4.43	0.211	0
Marital status	0.78	(0.49, 1.23)	0.279	0.75	(0.48, 1.18)	0.210	3.72	0.079	0
Placental malaria (PCR diagnosis)	0.79	(0.50, 1.25)	0.310	0.77	(0.49, 1.21)	0.255	2.98	0.964	7
Indoor residual spraying in preceding 12 months	0.73	(0.46, 1.15)	0.175	0.71	(0.45, 1.13)	0.142	2.78	0.450	26
HIV status	0.78	(0.49, 1.23)	0.279	0.80	(0.51, 1.26)	0.331	2.51	0.622	0
Sex of baby	0.78	(0.49, 1.23)	0.279	0.80	(0.51, 1.25)	0.322	2.16	0.364	0
Delivery location	0.78	(0.49, 1.23)	0.279	0.79	(0.50, 1.25)	0.321	1.90	0.021	0
Bed net ownership	0.78	(0.49, 1.23)	0.279	0.79	(0.50, 1.26)	0.324	1.88	0.354	0
Wealth quintiles	0.78	(0.49, 1.23)	0.279	0.77	(0.48, 1.21)	0.254	1.71	0.980	0
Maternal age at enrolment (years)	0.78	(0.49, 1.23)	0.279	0.77	(0.48, 1.23)	0.271	1.65	0.159	0
Number of lifetime sexual partners	0.77	(0.49, 1.22)	0.265	0.78	(0.50, 1.24)	0.295	1.58	0.010	6
Syphilis at enrolment (high titre)	0.78	(0.49, 1.23)	0.281	0.77	(0.49, 1.21)	0.253	1.54	*	5
Delivery type	0.78	(0.49, 1.23)	0.279	0.79	(0.50, 1.24)	0.305	1.30	0.546	0
Treatment of STIs/RTIs during pregnancy including syphilis	1.09	(0.60, 1.96)	0.777	1.10	(0.61, 1.99)	0.752	1.07	0.932	258
Bed net usage (on night prior to survey)	0.77	(0.49, 1.21)	0.253	0.76	(0.48, 1.21)	0.242	1.06	0.203	3
Age of sexual debut (years)	0.78	(0.49, 1.23)	0.279	0.78	(0.50, 1.24)	0.295	0.81	0.775	0
Labour type	0.78	(0.49, 1.23)	0.283	0.77	(0.49, 1.22)	0.271	0.70	*	15
<i>N.gonorrhoeae</i> co-infection (malaria and/or STI/RTI)	0.78	(0.49, 1.23)	0.279	0.78	(0.50, 1.23)	0.290	0.49	0.592	0

Table 3.3 Potential confounding factors for low birth weight (continued)

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
STI/RTI co-infection	0.78	(0.49, 1.23)	0.281	0.78	(0.49, 1.22)	0.273	0.40	0.693	5
<i>T. vaginalis</i> co-infection (malaria and/or STI/RTI)	0.78	(0.49, 1.23)	0.279	0.78	(0.50, 1.22)	0.279	0.31	0.035	0
Prior preterm birth ¹	0.72	(0.40, 1.29)	0.267	0.72	(0.41, 1.28)	0.266	0.29	0.019	192
Maternal haemoglobin level at delivery ³	0.80	(0.50, 1.28)	0.354	0.80	(0.50, 1.28)	0.349	0.21	0.120	32
Bacterial vaginosis and STI co-infection	0.78	(0.49, 1.23)	0.281	0.78	(0.50, 1.22)	0.272	0.21	0.060	5
<i>C. trachomatis</i> co-infection (malaria or STI/RTI)	0.78	(0.49, 1.23)	0.279	0.78	(0.49, 1.23)	0.284	0.17	0.435	0
Hypertension at enrolment or delivery	0.76	(0.48, 1.23)	0.264	0.76	(0.48, 1.23)	0.267	0.13	0.847	86
Type of personnel attending birth	0.78	(0.49, 1.23)	0.279	0.78	(0.50, 1.23)	0.279	0.10	0.004	0
Treatment of STIs/RTIs during pregnancy excluding syphilis	0.78	(0.49, 1.23)	0.279	0.78	(0.49, 1.23)	0.283	0.08	0.826	0
Recruitment site	0.78	(0.49, 1.23)	0.279	0.78	(0.50, 1.22)	0.277	0.07	0.053	0
Prior stillbirth ¹	0.68	(0.21, 2.19)	0.513	0.68	(0.20, 2.31)	0.531	0.02	0.876	620

CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus

¹Excludes women who have not been previously pregnant

²Therapy against malaria infection (apart from IPTp) after enrolment and before delivery

³Anaemia was defined as haemoglobin level < 11grams/decilitre

⁴Confounding is not reflected in *P*-values

⁵Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio. When there is no difference (adjusted / crude – 1) between these two estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable. Variables with odds ratios that changed by 10% or more were considered *a priori* to be potential confounders and we retained for the multivariable model. In this table, only the variable. ‘Hypertension at enrolment or delivery’ demonstrated evidence of confounding on the outcome effect ‘stillbirth’.

⁶Missing values were excluded from the crude odds ratio

* Insufficient events to perform stratified analysis for interaction

Table 3.4 Potential confounding factors for preterm delivery

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
Prior preterm birth ¹	0.35	(0.11, 1.08)	0.056	0.30	(0.09, 0.96)	0.031	14.04	*	620
Prior miscarriage ¹	0.35	(0.11, 1.08)	0.056	0.32	(0.10, 1.01)	0.040	8.67	0.326	620
Gravidae	0.36	(0.23, 0.55)	0.000	0.34	(0.22, 0.52)	0.000	5.63	0.794	0
Sex of baby	0.36	(0.23, 0.55)	0.000	0.37	(0.24, 0.57)	0.000	4.25	0.237	0
Maternal age at enrolment (years)	0.36	(0.23, 0.55)	0.000	0.34	(0.22, 0.53)	0.000	3.67	0.285	0
Prior stillbirth ¹	0.31	(0.19, 0.51)	0.000	0.30	(0.18, 0.50)	0.000	3.29	0.032	192
Labour type	0.36	(0.24, 0.56)	0.000	0.35	(0.23, 0.55)	0.000	2.43	*	15
Delivery type	0.36	(0.23, 0.55)	0.000	0.36	(0.24, 0.56)	0.000	2.29	0.336	0
Syphilis at enrolment (high titre)	0.36	(0.23, 0.55)	0.000	0.35	(0.23, 0.54)	0.000	2.23	*	5
Hypertension at enrolment or delivery	0.35	(0.22, 0.54)	0.000	0.36	(0.23, 0.55)	0.000	2.22	0.021	86
Co-infection (malaria and/or STI/RTI)	0.36	(0.23, 0.55)	0.000	0.35	(0.23, 0.54)	0.000	2.08	0.248	0
Type of personnel attending birth	0.36	(0.23, 0.55)	0.000	0.36	(0.24, 0.56)	0.000	1.87	0.128	0
Number of lifetime sexual partners	0.36	(0.23, 0.55)	0.000	0.36	(0.24, 0.56)	0.000	1.57	0.297	6
<i>N. gonorrhoeae</i> co-infection (malaria and/or STI/RTI)	0.36	(0.23, 0.55)	0.000	0.35	(0.23, 0.54)	0.000	1.56	0.331	0
Age of sexual debut (years)	0.36	(0.23, 0.55)	0.000	0.36	(0.24, 0.55)	0.000	1.37	0.734	0
Maternal haemoglobin level at delivery ³	0.37	(0.24, 0.57)	0.000	0.37	(0.24, 0.57)	0.000	1.35	0.212	32
Marital status	0.36	(0.23, 0.55)	0.000	0.35	(0.23, 0.54)	0.000	1.29	0.038	0
Placental malaria (PCR diagnosis)	0.36	(0.24, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	1.10	0.955	7
Bed net ownership	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	1.07	0.659	0
STI/RTI co-infection	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.91	0.984	5
<i>T. vaginalis</i> co-infection (malaria and/or STI/RTI)	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.89	0.053	0

Table 3.4 Potential confounding factors for preterm delivery (continued)

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
HIV status	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.84	0.805	0
Wealth quintiles	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.70	0.461	0
Recruitment site	0.36	(0.23, 0.55)	0.000	0.35	(0.23, 0.54)	0.000	0.66	0.316	0
Indoor residual spraying in preceding 12 months	0.32	(0.21, 0.50)	0.000	0.33	(0.21, 0.50)	0.000	0.57	0.450	26
Bed net usage (on night prior to survey)	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.57	0.894	3
Delivery location	0.36	(0.23, 0.55)	0.000	0.35	(0.23, 0.55)	0.000	0.49	0.089	0
Treatment of STIs/RTIs during pregnancy excluding syphilis	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.18	0.623	0
Bacterial vaginosis and STI co-infection	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.18	0.168	5
<i>C. trachomatis</i> co-infection (malaria or STI/RTI)	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.09	0.903	0
Treatment of STIs/RTIs during pregnancy including syphilis	0.46	(0.27, 0.77)	0.003	0.46	(0.27, 0.77)	0.003	0.09	0.384	258
Treatment of malaria infection during pregnancy ²	0.36	(0.23, 0.55)	0.000	0.36	(0.23, 0.55)	0.000	0.05	0.172	3

CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus

¹Excludes women who have not been previously pregnant

²Therapy against malaria infection (apart from IPTp) after enrolment and before delivery

³Anaemia was defined as haemoglobin level < 11grams/decilitre

⁴Confounding is not reflected in *P*-values

⁵Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio. When there is no difference (adjusted / crude – 1) between these two estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable. Variables with odds ratios that changed by 10% or more were considered *a priori* to be potential confounders and we retained for the multivariable model. In this table, only the variable ‘Hypertension at enrolment or delivery’ demonstrated evidence of confounding on the outcome effect ‘stillbirth’.

⁶Missing values were excluded from the crude odds ratio

* Insufficient events to perform stratified analysis for interaction

Table 3.5 Potential confounding factors for intrauterine growth retardation

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
Prior miscarriage ¹	0.71	(0.13, 3.92)	0.697	0.90	(0.13, 6.01)	0.912	25.73	0.938	620
Hypertension at enrolment or delivery	1.55	(0.68, 3.56)	0.295	1.68	(0.72, 3.94)	0.228	8.25	0.883	86
Gravidae	1.85	(0.82, 4.19)	0.134	1.70	(0.75, 3.87)	0.198	7.89	0.458	0
Maternal age at enrolment (years)	1.85	(0.82, 4.19)	0.134	1.72	(0.75, 3.90)	0.192	7.28	0.419	0
Number of lifetime sexual partners	1.82	(0.80, 4.12)	0.148	1.91	(0.83, 4.43)	0.124	5.34	0.332	6
Treatment of STIs/RTIs during pregnancy including syphilis	3.19	(0.95, 10.74)	0.048	3.32	(0.98, 11.29)	0.042	4.11	0.724	258
Placental malaria (PCR diagnosis)	1.88	(0.83, 4.27)	0.123	1.81	(0.79, 4.11)	0.153	4.10	0.981	7
Co-infection (malaria and/or STI/RTI)	1.85	(0.82, 4.19)	0.134	1.78	(0.79, 4.02)	0.161	3.93	0.348	0
Prior stillbirth ¹	0.71	(0.13, 3.92)	0.697	0.74	(0.13, 4.07)	0.729	3.70	*	620
Treatment of malaria infection during pregnancy ²	1.86	(0.82, 4.21)	0.131	1.79	(0.79, 4.07)	0.157	3.62	0.459	3
Bed net ownership	1.85	(0.82, 4.19)	0.134	1.90	(0.83, 4.33)	0.122	2.51	0.609	0
Indoor residual spraying in preceding 12 months	1.83	(0.81, 4.16)	0.142	1.79	(0.79, 4.06)	0.161	2.50	0.710	26
Sex of baby	1.85	(0.82, 4.19)	0.134	1.89	(0.84, 4.28)	0.120	2.24	0.582	0
Wealth quintiles	1.85	(0.82, 4.19)	0.134	1.81	(0.79, 4.13)	0.151	2.05	0.950	0
Marital status	1.85	(0.82, 4.19)	0.134	1.81	(0.83, 3.99)	0.132	1.95	0.037	0
Prior preterm birth ¹	0.71	(0.13, 3.92)	0.697	0.73	(0.13, 3.99)	0.713	1.82	*	620
<i>T. vaginalis</i> co-infection (malaria and/or STI/RTI)	1.85	(0.82, 4.19)	0.134	1.88	(0.84, 4.21)	0.117	1.74	0.171	0
Treatment of STIs/RTIs during pregnancy excluding syphilis	1.91	(0.84, 4.33)	0.116	1.94	(0.85, 4.41)	0.108	1.62	0.685	13
Delivery location	1.85	(0.82, 4.19)	0.134	1.88	(0.83, 4.26)	0.127	1.34	*	0
Maternal haemoglobin level at delivery ³	1.86	(0.82, 4.23)	0.130	1.89	(0.83, 4.27)	0.121	1.27	0.469	32
Labour type	1.86	(0.82, 4.21)	0.132	1.88	(0.83, 4.27)	0.125	1.27	*	15

Table 5.5 Potential confounding factors for intrauterine growth retardation (continued)

Potential confounder	Crude analysis			Adjusted analysis			% change in crude odds ratio ⁵	<i>P</i> -value for homogeneity	Missing values ⁶
	Odds ratio	95% CI	<i>P</i> -value ⁴	Odds ratio	95% CI	<i>P</i> -value ⁴			
HIV status	1.85	(0.82, 4.19)	0.134	1.87	(0.82, 4.23)	0.128	0.98	0.757	0
<i>N. gonorrhoeae</i> co-infection (malaria and/or STI/RTI)	1.85	(0.82, 4.19)	0.134	1.87	(0.82, 4.24)	0.129	0.91	*	0
Bed net usage (on night prior to survey)	1.81	(0.80, 4.10)	0.151	1.80	(0.79, 4.11)	0.159	0.59	0.328	3
Recruitment site	1.85	(0.82, 4.19)	0.134	1.84	(0.82, 4.14)	0.134	0.51	0.058	0
STI/RTI co-infection	1.87	(0.82, 4.24)	0.128	1.86	(0.82, 4.22)	0.129	0.31	0.407	5
<i>C. trachomatis</i> co-infection (malaria or STI/RTI)	1.85	(0.82, 4.19)	0.134	1.86	(0.82, 4.22)	0.134	0.26	0.398	0
Type of personnel attending birth	1.85	(0.82, 4.19)	0.134	1.85	(0.82, 4.17)	0.134	0.24	0.057	0
Age of sexual debut (years)	1.85	(0.82, 4.19)	0.134	1.85	(0.83, 4.17)	0.128	0.24	0.333	0
Bacterial vaginosis and STI co-infection	1.87	(0.82, 4.24)	0.128	1.87	(0.84, 4.19)	0.121	0.16	0.135	5
Syphilis at enrolment (high titre)	1.87	(0.82, 4.24)	0.128	1.87	(0.82, 4.24)	0.129	0.10	*	5
Delivery type	1.85	(0.82, 4.19)	0.134	1.85	(0.82, 4.16)	0.131	0.03	0.087	0

CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus

¹Excludes women who have not been previously pregnant

²Therapy against malaria infection (apart from IPTp) after enrolment and before delivery

³Anaemia was defined as haemoglobin level < 11grams/decilitre

⁴Confounding is not reflected in *P*-values

⁵Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio. When there is no difference (adjusted / crude – 1) between these two estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable. Variables with odds ratios that changed by 10% or more were considered *a priori* to be potential confounders and we retained for the multivariable model. In this table, only the variable ‘Hypertension at enrolment or delivery’ demonstrated evidence of confounding on the outcome effect ‘stillbirth’.

⁶Missing values were excluded from the crude odds ratio

* Insufficient events to perform stratified analysis for interaction

Results

In this analysis the effects of IPTp-SP on adverse birth outcomes were explored depending on the status of malaria infection and curable STIs/RTIs. Specifically, four adverse birth outcomes were investigated in a dose-response relationship: (i) stillbirth, (ii) LBW, (iii) preterm birth, and (iv) intrauterine growth retardation in seven categories of maternal malaria and STI/RTI categories.

There were no significant differences in the prevalence of malaria infection and curable STIs/RTIs at baseline across IPTp-SP exposure groups stratified by 0 to 1 dose (n=126) versus ≥ 2 doses (n=590) as shown in Table 3.6 (enrolment) and Table 3.7 (delivery) and, separately, 2 doses (n=310) versus ≥ 3 doses (n=280) in Table 3.8 (enrolment) and Table 3.9 (delivery). However, the odds of any adverse birth outcome amongst women who received ≥ 2 doses compared to 0-1, presented in Table 3.10, were reduced 45% (OR 0.55, 95% CI: 0.36, 0.86). The odds of any adverse birth outcome were reduced 12% further (57% total reduction) with ≥ 3 doses (OR 0.43, 95% CI 0.27, 0.68). Two doses, compared to 0 to 1 dose, reduced the odds of preterm delivery by 58% (OR 0.42, 95% CI: 0.27, 0.67). Three or more doses of IPTp reduced the odds of preterm birth 21% further (79% total reduction) (OR 0.21, 95% CI 0.13, 0.35) as shown in Table 3.10. A similar dose-response relationship was also observed against malaria infection and STIs/RTIs in dosing categories of 0-1 versus ≥ 2 doses, and 2 versus ≥ 3 doses.

Across 24 of 30 infection categories, ≥ 2 doses conferred greater protection against adverse birth outcomes than 0-1 dose, of which eight categories showed statistically significant effects as shown in Table 3.11; three categories related to any birth outcome (malaria only, *N. gonorrhoeae* and/or *C. trachomatis*, and no identified

infection), one was specific to LBW (no identified infection), and four were associated with preterm birth (malaria only, malaria and *T. vaginalis* and/or bacterial vaginosis, and no identified infection).

Table 3.6 Participant characteristics at enrolment: 0-1 dose vs. ≥ 2 doses of IPTp-SP

Characteristics at enrolment	Doses of SP received – number (%) [*]				P-value
	0-1 dose (n = 126)		≥ 2 doses(n = 590)		
Age of participants					0.498
Mean (SD)	25.8	(6.5)	25.4	(6.4)	
Median (IQR)	24.0	(20.0, 31.0)	24.0	(20.0, 30.0)	
Marital status					0.175
Single	19	(15.1)	123	(20.8)	
Married, divorced/separated or widowed	107	(84.9)	467	(79.2)	
Age at sexual debut					0.733
< 15 years of age	13	(10.3)	49	(8.3)	
≥ 15 years of age	96	(76.2)	455	(77.1)	
Unknown	17	(13.5)	86	(14.6)	
Number of lifetime sexual partners					0.362
1 partner	52	(41.3)	272	(46.6)	
2 partners	45	(35.7)	161	(27.6)	
3 partners	18	(14.3)	94	(16.1)	
4 or more partners	11	(8.7)	57	(9.8)	
Gravidae					0.301
Primigravidae	27	(21.4)	165	(28.0)	
Secundigravidae	19	(15.1)	77	(13.1)	
Multigravidae	80	(63.5)	348	(59.0)	
Wealth Quintiles					0.048
Lowest	21	(16.7)	115	(19.5)	
Second	32	(25.4)	111	(18.8)	
Middle	31	(24.6)	113	(19.2)	
Fourth	14	(11.1)	122	(20.7)	
Highest	28	(22.2)	129	(21.9)	
Bed net ownership					0.493
No	68	(54.0)	297	(50.3)	
Yes	58	(46.0)	293	(49.7)	
Used insecticide treated net on previous night					0.840
No	77	(61.1)	366	(62.4)	
Yes	49	(38.9)	221	(37.6)	
Missing	0		3		
Indoor residual spraying in the previous 12 months					0.186
No	103	(83.1)	439	(77.6)	
Yes	21	(16.9)	127	(22.4)	
Missing	2		24		

Table 3.6 Participant characteristics at enrolment: 0-1 dose vs. ≥ 2 doses of IPTp-SP (continued)

Characteristics at enrolment	Doses of SP received – number (%)*				P-value
	0-1 dose (n = 126)		≥ 2 doses(n = 590)		
Experienced miscarriage before					0.869
No	86	(86.9)	371	(87.3)	
Yes	13	(13.1)	54	(12.7)	
None reported by primigravidae	27		165		
Delivered a premature baby before					1.000
No	94	(94.9)	401	(94.4)	
Yes	5	(5.1)	24	(5.6)	
Not applicable to primigravidae	27		165		
Delivered a stillborn before					0.307
No	94	(94.9)	387	(91.1)	
Yes	5	(5.1)	38	(8.9)	
Not applicable to primigravidae	27		165		
HIV status					0.186
Negative	105	(83.3)	519	(88.0)	
Positive	21	(16.7)	71	(12.0)	
Malaria and curable STIs/RTIs					
Malaria (PCR diagnosis)	62	(49.2)	346	(59.3)	0.047
Syphilis (high titre)	1	(0.8)	17	(2.9)	0.223
<i>Neisseria gonorrhoeae</i>	1	(0.8)	21	(3.6)	0.152
<i>Chlamydia trachomatis</i>	8	(6.3)	26	(4.4)	0.357
<i>Trichomonas vaginalis</i>	30	(23.8)	140	(23.7)	1.000
Bacterial vaginosis	59	(46.8)	277	(46.9)	1.000

^{*} Age is shown as the median value with the interquartile range in parentheses. *P*-values are from Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). PCR = polymerase chain reaction

Table 3.7 Participant characteristics at delivery: 0-1 dose vs. ≥ 2 doses of IPTp-SP

Characteristics at delivery	Doses of SP received – number (%)*				P-value
	0 - 1 dose (n = 126)		≥ 2 doses (n = 590)		
Place of delivery					0.233
Hospital	119	(94.4)	551	(93.4)	
Clinic	1	(0.8)	19	(3.2)	
Home	6	(4.8)	20	(3.4)	
Delivery performed by					0.240
Doctor	3	(2.4)	38	(6.4)	
Midwife	115	(91.3)	524	(88.8)	
Family member	5	(4.0)	17	(2.9)	
Other	3	(2.4)	11	(1.9)	
Type of labour					0.296
Spontaneous	126	(100.0)	558	(97.4)	
Induced	0	(0.0)	9	(1.6)	
Augmented	0	(0.0)	6	(1.0)	
Type of delivery					0.092
Vaginal	123	(97.6)	551	(93.4)	
C-section	3	(2.4)	39	(6.6)	
Hypertension					0.296
No	110	(96.5)	506	(98.1)	
Yes	4	(3.5)	10	(1.9)	
Maternal haemoglobin					0.786
Normal	103	(85.1)	470	(83.5)	
Anaemic	18	(14.9)	93	(16.5)	
Sex of baby					0.008
Female	78	(61.9)	287	(48.6)	
Male	48	(38.1)	303	(51.4)	
Received curative treatment for malaria infection					0.102
No	115	(92.0)	508	(86.4)	
Yes	10	(8.0)	80	(13.6)	
Received curative treatment for any STI/RTI					1.000
Untreated	116	(92.1)	540	(91.5)	
Treated	10	(7.9)	50	(8.5)	

* Age is shown as the median value with the interquartile range in parentheses. *P*-values are from Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). PCR = polymerase chain reaction

Table 3.8 Participant characteristics at enrolment: 2 doses vs. ≥ 3 doses of IPTp-SP

Characteristics at enrolment	Doses of SP received – number (%)				P-value
	2 doses (n = 310)		≥ 3 doses (n = 280)		
Age of participants					0.521
Mean (SD)*	25.6	(6.4)	25.2	(6.4)	
Median (IQR)*	25.0	(20.0, 30.0)	24.0	(20.0, 30.0)	
Marital status					0.479
Single	61	(19.7)	62	(22.1)	
Married, divorced/separated or widowed	249	(80.3)	218	(77.9)	
Age at sexual debut					0.328
< 15 years of age	21	(6.8)	28	(10.0)	
≥ 15 years of age	241	(77.7)	214	(76.4)	
Unknown	48	(15.5)	38	(13.6)	
Number of lifetime sexual partners					0.460
1 partner	150	(49.0)	122	(43.9)	
2 partners	83	(27.1)	78	(28.1)	
3 partners	48	(15.7)	46	(16.5)	
4 or more partners	25	(8.2)	32	(11.5)	
Gravidae					0.936
Primigravidae	86	(27.7)	79	(28.2)	
Secundigravidae	42	(13.5)	35	(12.5)	
Multigravidae	182	(58.7)	166	(59.3)	
Wealth Quintiles					0.379
Lowest	68	(21.9)	47	(16.8)	
Second	58	(18.7)	53	(18.9)	
Middle	59	(19.0)	54	(19.3)	
Fourth	56	(18.1)	66	(23.6)	
Highest	69	(22.3)	60	(21.4)	
Bed net ownership					0.564
No	160	(51.6)	137	(48.9)	
Yes	150	(48.4)	143	(51.1)	
Used insecticide treated net on previous night					0.932
No	193	(62.7)	173	(62.0)	
Yes	115	(37.3)	106	(38.0)	
Missing	2		1		
Indoor residual spraying in the previous 12 months					0.002
No	247	(82.9)	192	(71.6)	
Yes	51	(17.1)	76	(28.4)	
Missing	12		12		

Table 3.8 Participant characteristics at enrolment: 2 doses vs. ≥ 3 doses of IPTp-SP (continued)

Characteristics at enrolment	Doses of SP received – number (%)				P-value
	2 doses (n = 310)		≥ 3 doses (n = 280)		
Experienced miscarriage before					0.470
No	193	(86.2)	178	(88.6)	
Yes	31	(13.8)	23	(11.4)	
None reported by primigravidae	86		79		
Delivered a premature baby before					0.297
No	214	(95.5)	187	(93.0)	
Yes	10	(4.5)	14	(7.0)	
Not applicable to primigravidae	86		79		
Delivered a stillborn before					0.737
No	205	(91.5)	182	(90.5)	
Yes	19	(8.5)	19	(9.5)	
Not applicable to primigravidae	86		79		
HIV status					0.528
Negative	270	(87.1)	249	(88.9)	
Positive	40	(12.9)	31	(11.1)	
Malaria and curable STIs/RTIs					
Malaria (PCR diagnosis)	171	(56.1)	175	(62.9)	0.092
Syphilis (high titre)	7	(2.3)	10	(3.6)	0.462
<i>Neisseria gonorrhoeae</i>	15	(4.8)	6	(2.1)	0.117
<i>Chlamydia trachomatis</i>	16	(5.2)	10	(3.6)	0.423
<i>Trichomonas vaginalis</i>	73	(23.5)	67	(23.9)	0.923
Bacterial vaginosis	145	(46.8)	132	(47.1)	0.934

* Age is shown as the median value with the interquartile range in parentheses. P-values are from Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). PCR = polymerase chain reaction

Table 3.9 Participant characteristics at delivery: 2 doses vs. ≥ 3 doses of IPTp-SP

Characteristics at enrolment	Doses of SP received – number (%)				P-value
	2 doses (n = 310)		≥ 3 doses (n = 280)		
Place of delivery					0.418
Hospital	292	(94.2)	259	(92.5)	
Clinic	7	(2.3)	12	(4.3)	
Home	11	(3.5)	9	(3.2)	
Delivery performed by					0.782
Doctor	20	(6.5)	18	(6.4)	
Midwife	277	(89.4)	247	(88.2)	
Family member	9	(2.9)	8	(2.9)	
Other	4	(1.3)	7	(2.5)	
Type of labour					0.920
Spontaneous	292	(97.7)	266	(97.1)	
Induced	4	(1.3)	5	(1.8)	
Augmented	3	(1.0)	3	(1.1)	
Type of delivery					0.870
Vaginal	290	(93.5)	261	(93.2)	
C-section	20	(6.5)	19	(6.8)	
Hypertension					0.198
No	276	(98.9)	230	(97.0)	
Yes	3	(1.1)	7	(3.0)	
Maternal haemoglobin					0.429
Normal	249	(84.7)	221	(82.2)	
Anaemic	45	(15.3)	48	(17.8)	
Sex of baby					1.000
Female	151	(48.7)	136	(48.6)	
Male	159	(51.3)	144	(51.4)	
Received curative treatment for malaria infection					0.810
No	269	(86.8)	239	(86.0)	
Yes	41	(13.2)	39	(14.0)	
Received curative treatment for any STI/RTI					0.038
Untreated	291	(93.9)	249	(88.9)	
Treated	19	(6.1)	31	(11.1)	

* Age is shown as the median value with the interquartile range in parentheses. *P*-values are from Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). PCR = polymerase chain reaction

Table 3.10 Adverse birth outcomes: 0-1 dose vs. 2 doses vs. ≥ 3 doses of IPTp-SP

Birth outcome	No. women	Outcomes	Unadjusted OR	95% CI	Adjusted OR ¹	95% CI	P-value ²
Any adverse outcome							
0-1 dose	126	58	1.00		1.00		0.002
2 doses	310	108	0.63	0.41, 0.96	0.55	0.36, 0.86	
≥ 3 doses	280	84	0.50	0.33, 0.78	0.43	0.27, 0.68	
Stillbirth							
0-1 dose	126	4	1.00		1.00		0.143
2 doses	310	2	0.20	0.04, 1.10	0.21	0.04, 1.19	
≥ 3 doses	280	6	0.67	0.19, 2.41	0.68	0.18, 2.57	
Low birth weight							
0-1 dose	126	32	1.00		1.00		0.261
2 doses	310	67	0.80	0.49, 1.30	0.71	0.42, 1.19	
≥ 3 doses	280	57	0.74	0.45, 1.22	0.64	0.37, 1.09	
Preterm delivery							
0-1 dose	126	50	1.00		1.00		<0.001
2 doses	310	71	0.45	0.29, 0.71	0.42	0.27, 0.67	
≥ 3 doses	280	37	0.23	0.14, 0.38	0.21	0.13, 0.35	
Intrauterine growth retardation							
0-1 dose	126	7	1.00		1.00		0.318
2 doses	310	34	1.64	0.70, 3.87	1.55	0.64, 3.77	
≥ 3 doses	280	43	2.12	0.91, 4.93	1.88	0.78, 4.54	

IPTp-SP = Intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; CI = Confidence Interval; OR = Odds Ratio

¹Adjusted for sexually transmitted and reproductive tract co-infection, gravidae and HIV co-infection.

²P-value for likelihood ratio test

Note: Confidence intervals that do not overlap the null value of OR = 1 are shown in bold.

Women who had malaria only at enrolment and received ≥ 2 doses of versus 0-1, had 76% lower odds of any adverse birth outcome (OR, 0.24; 95% CI 0.09, 0.66). Similarly, women who had *Neisseria gonorrhoeae* and/or *Chlamydia trachomatis* at enrolment and received ≥ 2 doses of versus 0-1, had 92% lower odds of any adverse birth outcome (OR, 0.08; 95% CI, 0.01, 0.64). Participants with neither a malaria infection nor STIs/RTIs and who received ≥ 2 doses, rather than 0-1 dose, had 73% fewer adverse birth outcomes (OR 0.27; 95% CI 0.11, 0.68). Similarly, women with no malaria infection nor STIs/RTIs and who received ≥ 2 doses had the odds of LBW reduced by 76% (OR 0.24; 95% CI 0.08, 0.68).

Women who had malaria only at enrolment and received ≥ 2 doses of versus 0-1, had 81% lower odds of preterm birth (OR, 0.19; 95% CI, 0.07, 0.53); women who had malaria plus *T. vaginalis* and/or bacterial vaginosis at enrolment and received ≥ 2 doses of versus 0-1, had 55% lower odds of preterm birth (OR, 0.45; 95% CI, 0.21, 0.97); women who had *N. gonorrhoeae* or *C. trachomatis* at enrolment and received ≥ 2 doses of versus 0-1, had 93% lower odds of preterm birth (OR, 0.07; 95% CI, 0.01, 0.73); finally, women who had neither malaria nor any curable STI/RTI at enrolment and received ≥ 2 doses of versus 0-1, had 80% lower odds of preterm birth (OR, 0.20; 95% CI, 0.07, 0.54).

Although less dramatic, analyses of ≥ 3 doses versus 2 doses suggest that this dose-response effect continued as shown in Table 3.11. There appeared to be a trend of protection in 17 of 31 infection categories conferred by ≥ 3 doses versus 2 doses. This protection, however, was only significant in two infection categories in Table 3.12.

Women who had malaria plus *T. vaginalis* and/or bacterial vaginosis at enrolment and

received ≥ 3 doses vs 2 doses had 67% lower odds of preterm birth (OR, 0.33; 95% CI, 0.15, 0.73); women who had *T. vaginalis* and/or bacterial vaginosis at enrolment and received ≥ 3 doses vs 2 doses had 66% lower odds of preterm birth (OR, 0.34; 95% CI, 0.13, 0.94).

Table 3.11 Infections and adverse birth outcomes: 0-1 doses vs. ≥ 2 doses IPTp-SP

Adverse birth outcomes <i>Categories of maternal infection</i>	0-1 dose IPTp-SP		≥ 2 doses IPTp-SP		Crude OR	95% CI	Adjusted OR ¹	95% CI
	No. women	No. outcomes	No. women	No. outcomes				
Any adverse outcome								
<i>Malaria only</i>	20	13	129	41	0.25	0.09, 0.88	0.24	0.09, 0.66
<i>Malaria and NG and/or CT</i>	3	1	27	11	1.38	0.11, 17.09	1.17	0.09, 15.89
<i>Malaria and TV and/or BV</i>	38	15	182	67	0.89	0.44, 1.83	0.96	0.45, 2.02
<i>Syphilis and any other infection(s)</i>	1	1	17	7	0.80	0.00, 31.20	0.80	0.00, 31.20
<i>NG and/or CT only</i>	6	4	14	2	0.08	0.01, 0.80	0.08	0.01, 0.64
<i>TV and/or BV only</i>	32	12	124	42	0.85	0.38, 1.91	0.72	0.32, 1.65
<i>No identified infection</i>	26	12	97	22	0.34	0.14, 0.85	0.27	0.11, 0.68
Stillbirth								
<i>Malaria only</i>	20	1	129	1	0.15	0.01, 2.54	0.15	0.01, 2.54
<i>Malaria and NG and/or CT</i>	3	0	27	0	NA	NA	NA	NA
<i>Malaria and TV and/or BV</i>	38	0	182	3	0.81	0.09, Inf	0.81	0.09, Inf
<i>Syphilis and any other infection(s)</i>	1	1	17	0	0.06	0.00, 2.29	0.06	0.00, 2.29
<i>NG and/or CT only</i>	6	0	14	0	NA	NA	NA	NA
<i>TV and/or BV only</i>	32	1	124	3	0.76	0.07, 7.86	0.76	0.07, 7.86
<i>No identified infection</i>	26	1	97	1	0.26	0.02, 4.31	0.22	0.01, 3.79
Low birth weight								
<i>Malaria only</i>	20	6	129	25	0.56	0.20, 1.60	0.59	0.19, 1.82
<i>Malaria and NG and/or CT</i>	3	1	27	7	0.7	0.05, 8.97	0.49	0.03, 7.35
<i>Malaria and TV and/or BV</i>	38	10	182	46	0.95	0.43, 2.10	1.08	0.46, 2.54
<i>Syphilis and any other infection(s)</i>	1	0	17	5	NA	NA	NA	NA
<i>NG and/or CT only</i>	6	2	14	1	0.15	0.01, 2.18	0.12	0.01, 1.90
<i>TV and/or BV only</i>	32	5	124	27	1.5	0.53, 4.27	1.22	0.41, 3.59
<i>No identified infection</i>	26	8	97	13	0.35	0.13, 0.96	0.24	0.08, 0.68

Table 3.11 Infections and adverse birth outcomes: 0-1 doses vs. ≥ 2 doses IPTp-SP (continued)

Adverse birth outcomes <i>Categories of maternal infection</i>	0-1 dose IPTp-SP		≥ 2 doses IPTp-SP		Crude OR	95% CI	Adjusted OR ¹	95% CI
	No. outcomes	No. women	No. outcomes	No. outcomes				
Preterm delivery								
<i>Malaria only</i>	20	10	129	21	0.19	0.07, 0.53	0.19	0.07, 0.53
<i>Malaria and NG and/or CT</i>	3	0	27	6	NA	NA	NA	NA
<i>Malaria and TV and/or BV</i>	38	14	182	37	0.44	0.21, 0.93	0.45	0.21, 0.97
<i>Syphilis and any other infection(s)</i>	1	1	17	5	0.50	0.00, 19.50	0.50	0.00, 19.50
<i>NG and/or CT only</i>	6	4	14	2	0.08	0.01, 0.80	0.07	0.01, 0.73
<i>TV and/or BV only</i>	32	11	124	25	0.48	0.21, 1.13	0.43	0.18, 1.03
<i>No identified infection</i>	26	10	97	12	0.23	0.08, 0.61	0.20	0.07, 0.54
Intrauterine growth retardation								
<i>Malaria only</i>	20	2	129	18	0.8	0.16, 4.08	0.75	0.14, 4.05
<i>Malaria and NG and/or CT</i>	3	1	27	5	0.62	0.05, 8.43	0.54	0.03, 8.43
<i>Malaria and TV and/or BV</i>	38	1	182	27	5.35	0.69, 41.40	6.11	0.76, 49.13
<i>Syphilis and any other infection(s)</i>	1	0	17	2	NA	NA	NA	NA
<i>NG and/or CT only</i>	6	0	14	0	NA	NA	NA	NA
<i>TV and/or BV only</i>	32	1	124	16	3.81	0.48, 30.44	3.13	0.38, 25.68
<i>No identified infection</i>	26	2	97	9	0.83	0.16, 4.25	0.66	0.12, 3.57

IPTp-SP = intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; CI = Confidence Interval; OR = Odds Ratio; NG = *Neisseria gonorrhoeae*; CT = *Chlamydia trachomatis*; TV = *Trichomonas vaginalis*; BV = bacterial vaginosis; N/A = not applicable is used where there are no observations in the reference group (0-1 doses); Inf. = infinity is used where the sub-sample of outcomes observed is too small to produce an outer limit with certainty.

¹Adjusted for sexually transmitted and reproductive tract co-infection, gravidae and HIV co-infection.

²Syphilis and any other infection(s) refers to any other curable sexually transmitted or reproductive tract infection and/or malaria

Notes: (1) Confidence intervals that do not overlap the null value of OR = 1 are shown in bold; (2) Syphilis and co-infection describes pregnant women who tested positive for syphilis using rapid plasma regain assays and were also infected with malaria and/or another curable STI/RTI.

Table 3.12 Infections and adverse birth outcomes: 2 doses vs. ≥ 3 doses IPTp-SP

Adverse birth outcomes <i>Categories of maternal infection</i>	2 doses IPTp-SP		≥ 3 doses IPTp-SP		Crude OR	95% CI	Adjusted OR ¹	95% CI
	No. women	No. outcomes	No. women	No. outcomes				
Any adverse outcome								
<i>Malaria only</i>	66	23	63	18	0.75	0.35, 1.58	0.72	0.33, 1.56
<i>Malaria and NG and/or CT</i>	18	7	9	4	1.26	0.25, 6.36	0.93	0.17, 5.16
<i>Malaria and TV and/or BV</i>	86	36	96	31	0.66	0.36, 1.21	0.66	0.35, 1.24
<i>Syphilis and any other infection(s)</i>	7	3	10	4	0.89	0.13, 6.31	0.5	0.07, 3.72
<i>NG and/or CT only</i>	12	1	2	1	11	0.35, 345.05	16.39	0.50, 541.53
<i>TV and/or BV only</i>	71	27	53	15	0.64	0.30, 1.38	0.64	0.29, 1.41
<i>No identified infection</i>	50	11	47	11	1.08	0.42, 2.80	1.28	0.48, 3.43
Stillbirth								
<i>Malaria only</i>	66	1	63	0	1.03	0.00, 40.32	1.03	0.00, 40.32
<i>Malaria and NG and/or CT</i>	18	0	9	0	N/A	-	N/A	-
<i>Malaria and TV and/or BV</i>	86	1	96	2	1.81	0.09, 107.93	1.81	0.09, 107.93
<i>Syphilis and any other infection(s)</i>	7	0	10	0	N/A	-	N/A	-
<i>NG and/or CT only</i>	12	0	2	0	N/A	-	N/A	-
<i>TV and/or BV only</i>	71	0	53	3	5.32	0.56, Inf	5.32	0.56, Inf
<i>No identified infection</i>	50	0	47	1	1.81	0.16, 20.30	2.18	0.19, 25.65
Low birth weight								
<i>Malaria only</i>	66	14	63	11	0.79	0.33, 1.89	0.74	0.30, 1.86
<i>Malaria and NG and/or CT</i>	18	5	9	2	0.74	0.11, 4.87	0.49	0.07, 3.62
<i>Malaria and TV and/or BV</i>	86	23	96	23	0.86	0.44, 1.68	0.91	0.45, 1.86
<i>Syphilis and any other infection(s)</i>	7	2	10	3	1.07	0.13, 8.98	0.53	0.06, 4.87
<i>NG and/or CT only</i>	12	1	2	0	6.00	0.00, 234	6.00	0.00, 234
<i>TV and/or BV only</i>	71	16	53	11	0.90	0.38, 2.14	0.90	0.38, 2.14
<i>No identified infection</i>	50	6	47	7	1.28	0.40, 4.14	1.59	0.47, 5.40

Table 3.12 Infections and adverse birth outcomes: 2 doses vs. ≥ 3 doses IPTp-SP (continued)

Adverse birth outcomes <i>Categories of maternal infection</i>	2 doses IPTp-SP		≥ 3 doses IPTp-SP		Crude OR	95% CI	Adjusted OR ¹	95% CI
	No. women	No. outcomes	No. women	No. outcomes				
Preterm delivery								
<i>Malaria only</i>	66	13	63	8	0.59	0.23, 1.55	0.59	0.22, 1.54
<i>Malaria and NG and/or CT</i>	18	4	9	2	1.00	0.15, 6.85	0.83	0.12, 5.82
<i>Malaria and TV and/or BV</i>	86	25	96	12	0.34	0.16, 0.74	0.33	0.15, 0.73
<i>Syphilis and any other infection(s)</i>	7	3	10	2	0.33	0.04, 2.87	0.23	0.03, 2.06
<i>NG and/or CT only</i>	12	1	2	1	11	0.35, 345.06	14.4	0.45, 463.93
<i>TV and/or BV only</i>	71	19	53	6	0.35	0.13, 0.95	0.34	0.13, 0.94
<i>No identified infection</i>	50	6	47	6	1.07	0.32, 3.59	1.19	0.35, 4.03
Intrauterine growth retardation								
<i>Malaria only</i>	66	9	63	9	0.96	0.35, 2.63	1.01	0.35, 2.89
<i>Malaria and NG and/or CT</i>	18	3	9	2	1.47	0.18, 11.72	0.64	0.07, 5.74
<i>Malaria and TV and/or BV</i>	86	9	96	18	1.52	0.63, 3.65	1.54	0.61, 3.88
<i>Syphilis and any other infection(s)</i>	7	0	10	2	1.31	0.09, Inf	1.31	0.09, Inf
<i>NG and/or CT only</i>	12	0	2	0	N/A	-	N/A	-
<i>TV and/or BV only</i>	71	8	53	8	1.15	0.40, 3.36	1.28	0.42, 3.89
<i>No identified infection</i>	50	5	47	4	0.84	0.21, 3.38	0.88	0.21, 3.70

IPTp-SP = intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; CI = Confidence Interval; OR = Odds Ratio; NG = *Neisseria gonorrhoeae*; CT = *Chlamydia trachomatis*; TV = *Trichomonas vaginalis*; BV = bacterial vaginosis; N/A = not applicable is used where there are no observations in the reference group (0-1 doses); Inf. = infinity is used where the sub-sample of outcomes observed is too small to produce an outer limit with certainty.

¹Adjusted for sexually transmitted and reproductive tract co-infection, gravidae and HIV co-infection.

²Syphilis and any other infection(s) refers to any other curable sexually transmitted or reproductive tract infection and/or malaria

Notes: (1) Confidence intervals that do not overlap the null value of OR = 1 are shown in bold; (2) Syphilis and co-infection describes pregnant women who tested positive for syphilis using rapid plasma regain assays and were also infected with malaria and/or another curable STI/RTI.

Discussion

For more than a decade, members of the malaria in pregnancy research community have attempted to identify safe alternatives to SP for use in IPTp because of known parasite resistance to the therapy. Several factors have complicated this task including the provision of ITNs to pregnant women as never before that have altered transmission dynamics. Evidence from Zambia – suggesting that IPTp-SP protects against adverse birth outcomes among women with malaria as well as curable STIs/RTIs – may help to explain why clinical trials to date have not yielded a clear superior alternative to SP.

One of the most interesting findings in this analysis was that women who received ≥ 2 doses and had neither malaria nor curable STIs/RTIs were more protected against any adverse birth outcome, LBW, and preterm delivery, compared to recipients of 0-1 dose. No additional benefit was conferred against non-malaria and non-STI/RTI causes of adverse birth outcomes when ≥ 3 doses were administered in this setting.

Although there were no statistically significant differences across IPTp-SP exposure groups in the baseline characteristics specific to malaria infection and curable STIs/RTIs, there were a few notable imbalances in sub-groups. Confounding, however, is not inherently produced by imbalances in size of groups. Rather, confounding is determined by comparing the difference between crude odds ratios and adjusted odds ratios specific to a variable of interest.²⁰⁶ In this way, three confounders were identified in three analyses, one in each:

- (i) Hypertension at enrolment or delivery (change in crude OR = 13.39%) in the stillbirth analysis of Table 3.2 (pages 88-89);
- (ii) Prior preterm birth (change in crude OR = 14.04%) in the preterm delivery analysis of Table 3.4 (pages 92-93); and
- (iii) Prior miscarriage (change in crude OR = 25.73%) in the intrauterine growth retardation analysis of Table 3.5 (pages 94-95).

Amongst women given 0-1 dose versus ≥ 2 dose in Table 3.6, there were three statistically significant differences in group size: the wealth quintiles ($P = 0.048$), (ii) sex of the baby ($P = 0.008$), and (iii) malaria infection ($P = 0.047$). The differences in wealth quintiles may not have had a consequential effect on outcomes because, upon closer review of the individual quintiles, the imbalance appears to have straddled the two exposure groups. The lowest (poorest) quintile had proportionately more women in the ≥ 2 dose-group; the second and third wealth quintiles had more women from the 0-1 dose-group; the fourth wealth quintile had more women from the ≥ 2 dose-group; and the highest (wealthiest) quintile has near equivalent representation from the two dose-groups. Another difference was that fewer males, compared to females, were in the 0-1 dose exposure group, 38.1% ($n = 48$) to 61.9% ($n = 78$), respectively, relative to 51.4% ($n = 303$) males and 48.6% ($n = 287$) females born to mothers who received ≥ 2 doses. However, this difference in the 0-1 dose-group did not influence the overall protective effect of IPTp-SP.

As for malaria infection at enrolment, 10% more women were parasitaemic who went on to receive ≥ 2 doses of IPTp-SP, compared to recipients of 0-1 dose (59.3% [$n = 346$] versus 49.2% [$n = 62$]; ($P = 0.047$)). This finding, interestingly, reflects the epidemiology

of malaria during pregnancy. Amongst women enrolled between 8 and 13 gestational weeks, 36.1% (95% CI: 22.5, 52.5) had peripheral parasitaemia. These same women went onto receive a mean of 2.6 doses of IPTp-SP over the course of their pregnancies. However, peripheral malaria was lower, 33.5% (95% CI: 29.1, 38.3), amongst participants who were enrolled between 14 and 20 gestational weeks and subsequently received a mean of 2.4 doses of IPTp-SP during their pregnancies. These two trends of parasitaemia and the number of IPTp-SP doses continued downward amongst women who were between 21 and 26 gestational weeks, and 27 to 31 gestational weeks, at their time of enrolment. Peripheral parasitaemia was 31.7% (95% CI: 27.5, 36.2) and 27.6% (95% CI: 21.9, 34.2), and the mean number of IPTp-SP doses administered until delivery was 2.2 and 1.8, respectively. In this analysis, parasite load was highest amongst women enrolled in gestational week 15 with a mean density of 4,752 parasites per microliter of blood. The peak parasite density observed was consistent with the known epidemiology of malaria infection during pregnancy. Prior reports suggest that peripheral parasitaemia peaks between weeks nine and 16, and tapers to term.^{160,169} Thus, pregnant women who sought ANC services earlier in pregnancy were more likely to have a malaria infection and they were also more likely to receive more doses of IPTp-SP during pregnancy for having engaged the health system earlier in pregnancy.

The last notable imbalance was in the proportion of pregnant women from households where indoor residual spraying had been applied in the previous 12 months (P -value = 0.002); 17.1% ($n = 51$) of women in the 2-dose group compared to 28.4% ($n = 76$) in

the ≥ 3 -dose group. Indoor residual spraying has reduced the incidence of infections by 54% over an 11-month period amongst children under the age of five in an area of stable transmission.²⁰⁷ Despite evidence of protection conferred by household spraying, the pregnant women resident in homes that had been sprayed and who went on to receive ≥ 3 doses of IPTp-SP had higher levels of parasitaemia at booking, 62.9% (n = 175), compared to women in the 2-dose group, 56.1% (n = 171), as measured by polymerase chain reaction.

Observations from this analysis are biologically plausible and compelling. Arguably, because only six women of the 126 in the 0-1 dose-group received no doses in study, the actual protective effect of IPTp-SP against malaria and curable STIs/RTIs is likely higher than observed levels. It is worth noting that the number of ANC visits were not included in the survey and, therefore, could not be controlled for in this analysis. Being the case, it is difficult to draw inferences related to a general ANC visit effect. With that said, there was no apparent confounding across treatment groups in three key variables that reflect use of ANC services: (1) STI/RTI treatment during pregnancy; (2) antibiotic treatment during the pregnancy; and (3) malaria treatment during the pregnancy.

Results from Zambia are insufficient to make broader policy or programmatic decisions. Curable STIs/RTIs were just measured once at booking; there was no test of cure. Some curable STIs/RTIs can be self-limiting which could, in part, explain observations. Thus, until a candidate replacement for SP has been able to demonstrate superior protection against malaria infection and curable STIs/RTIs, and attributable adverse birth outcomes, policymakers and programme managers should

continue to champion the scale up IPTp-SP as part of the ANC package. Moreover, it is difficult to separate the protective effect of IPTp-SP attributable to malaria versus curable STIs/RTIs in the absence of continuous parasite sampling throughout pregnancy. It is possible that many women were exposed to malaria infection repeatedly during pregnancy, irrespective of their STI/RTI status, and that the benefits of receiving more doses of IPTp-SP translated into having greater protection against the effects of malaria in pregnancy than curable STIs/RTIs. Repeated malaria infection may also help to explain the dose-response protective effect of IPTp-SP against adverse birth outcomes observed amongst pregnant women who had neither malaria infection nor STIs/RTIs at enrolment. These women could have been infected by malaria parasites later in pregnancy, but were protected against adverse birth outcomes attributable to malaria if they received more doses of IPTp-SP compared to fewer doses.

Q 4. Prevalence of malaria and curable STIs/RTIs in pregnancy

Methods

Surprisingly, the prevalence of malaria infection amongst pregnant women in sub-Saharan Africa has not been estimated recently. Brabin *et al.* summarised malaria infection data prior to 1980¹⁶⁰ and Steketee *et al.* published a review of data from 20 studies across eight countries conducted between 1985 and 2000.¹⁸ Neither review contains data from 2000 onward, nor applied the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) that were published in 2009 to create standard methods for systematic reviews.¹⁶⁷ There does not appear to have been any prior attempt to calculate pooled prevalence estimates for curable

STIs/RTIs amongst pregnant women in sub-Saharan Africa. Thus, a systematic review was conducted of malaria infection and curable STIs/RTIs amongst pregnant women attending ANC facilities from 1990 to 2011 in sub-Saharan Africa using medical subject headings and free text terms shown in Table 4.a. Databases included PubMed, Medline, and EMBASE, as well as the WHO International Clinical Trials Registry and reference lists from the identified publications.

Table 4.a Medical subject headings and free text terms

Infection	Medical search headings	Free text terms
Syphilis	<i>Treponema pallidum</i> OR Syphilis AND "Pregnant Women" AND "Africa South of the Sahara"	<i>Treponema pallidum</i> AND Pregnant AND Africa <i>Treponema pallidum</i> AND Pregnancy AND Africa Syphilis AND Pregnant AND Africa Syphilis AND Pregnancy AND Africa Screen AND Syphilis AND Pregnant AND Africa Screen AND Syphilis AND Pregnancy AND Africa Test AND Syphilis AND Pregnant AND Africa Test AND Syphilis AND Pregnancy AND Africa
<i>Neisseria gonorrhoeae</i>	<i>Neisseria gonorrhoeae</i> OR Gonorrhea OR Gonorrhoea AND Pregnant Women AND "Africa South of the Sahara"	<i>Neisseria gonorrhoeae</i> AND Pregnant AND Africa <i>Neisseria gonorrhoeae</i> AND Pregnancy AND Africa Gonorrhoea AND Pregnant AND Africa Gonorrhoea AND Pregnancy AND Africa Gonorrhea AND Pregnant AND Africa Gonorrhea AND Pregnancy AND Africa Screen AND Gonorrhea AND Pregnant AND Africa Screen AND Gonorrhoea AND Pregnant AND Africa Test AND Gonorrhea AND Pregnant AND Africa Test AND Gonorrhoea AND Pregnant AND Africa
<i>Chlamydia trachomatis</i>	<i>Chlamydia trachomatis</i> AND Pregnant Women AND "Africa South of the Sahara"	<i>Chlamydia trachomatis</i> AND Pregnant AND Africa <i>Chlamydia trachomatis</i> AND Pregnancy AND Africa <i>Chlamydia</i> AND Pregnant AND Africa <i>Chlamydia</i> AND Pregnancy AND Africa Screen AND Chlamydia AND Pregnant AND Africa Screen AND Chlamydia AND Pregnancy AND Africa Test AND Chlamydia AND Pregnant AND Africa Test AND Chlamydia AND Pregnancy AND Africa

Table 4. Medical subject headings and free text terms (continued)

Infection	Medical search headings	Free text terms	Infection
<i>Trichomonas vaginalis</i>	<i>Trichomonas vaginalis</i> AND Pregnant Women AND "Africa South of the Sahara"	Topic=("Trichomonas vaginalis OR Trichomoniasis") AND Topic=(Prenatal OR Antenatal OR Pregnant OR Pregnancy) OR Topic=(women) AND Topic=(Africa)	<i>Trichomonas vaginalis</i> AND Pregnant AND Africa <i>Trichomonas vaginalis</i> AND Pregnancy AND Africa Trichomoniasis AND Pregnant AND Africa Trichomoniasis AND Pregnancy AND Africa Screen AND Trichomoniasis AND Pregnant AND Africa Screen AND Trichomoniasis AND Pregnancy AND Africa Test AND Trichomoniasis AND Pregnant AND Africa Test AND Trichomoniasis AND Pregnancy AND Africa
Bacterial vaginosis	Bacterial vaginosis AND Pregnant Women AND "Africa South of the Sahara"	Topic=("Bacterial vaginosis") AND Topic=(Prenatal OR Antenatal OR Pregnant OR Pregnancy OR Pregnant) OR Topic=(women) AND Topic=(Africa)	Bacterial vaginosis AND Pregnant AND Africa Bacterial vaginosis AND Pregnancy AND Africa Screen AND Bacterial vaginosis AND Pregnant AND Africa Screen AND Bacterial vaginosis AND Pregnancy AND Africa Test AND Bacterial vaginosis AND Pregnant AND Africa Test AND Bacterial vaginosis AND Pregnancy AND Africa
Malaria	Malaria AND Pregnant Women AND "Africa South of the Sahara"	Topic=("Malaria") AND Topic=(Prenatal OR Antenatal OR Pregnancy OR Pregnant) OR Topic=(women) AND Topic=(Africa)	Malaria AND Pregnant AND Africa Malaria AND Pregnancy AND Africa Screen AND Malaria AND Pregnant AND Africa Screen AND Malaria AND Pregnancy AND Africa Test AND Malaria AND Pregnant AND Africa Test AND Malaria AND Pregnancy AND Africa

If two or more prevalence estimates had been reported – whether a study of comparative diagnostics, or use of the same diagnostic method on multiple occasions, or the subsequent use of a more sensitive assay – the higher/highest measurement was extracted. Studies that selectively enrolled women were excluded, e.g. only pregnant women with HIV infection, studies of commercial sex workers, studies of women seeking treatment at STI and/or family planning facilities, or studies of non-pregnant women tested in community-based surveys. Prevalence estimates from these populations may overstate the burden of disease amongst pregnant women at ANC facilities. Studies from South Africa were also excluded where malaria is no longer endemic, as well as multi-year studies that included pre-1990 data. Records retrieved were all in English, although several abstracts had been translated from Chinese, Danish, Dutch, French, German, Italian, Portuguese and Swedish languages. Data were abstracted without blinding author names or publication titles. Point prevalence estimates and 95% CIs were calculated for each study using the data that had been published. Then a standard method for correcting errors of magnitude with the known sensitivity and specificity of individual assays was applied to increase the precision of each point prevalence estimate.²⁰⁸ This is done using the formula below:

$$\text{Corrected Prevalence} = \frac{(\text{Observed Prevalence} + \text{Specificity} - 1)}{(\text{Sensitivity} + \text{Specificity} - 1)}$$

The corrected point prevalence data were then used to generate pooled prevalence estimates and corresponding 95% CIs. Results were stratified by sub-region, East and Southern Africa versus West and Central Africa. Sensitivity analyses were performed by dividing studies into two groups, those conducted from 1990 to 1999, and others from 2000 to 2011, to examine the potential for temporal changes in prevalence.

Results

In total 171 studies met inclusion criteria, containing a total of 307 individual point prevalence estimates for analysis. Search results are summarised in the PRISMA flowchart of Figure 4.1. Funnel plot analysis suggested there was no evidence of publication bias amongst results for malaria or any of the curable STIs/RTIs. Table 4.1 summarises the pooled prevalence estimates of 1990-2011 and sub-analysis of data from 1990-1999 and 2000-2011. Results that span the period 1990-2011 are presented in Figure 4.1a. and Figure 4.1b. plotted by sub-region along with the lowest and highest point estimates that were reported in the literature. Sub-analysis by infection and sub-region are presented in Figures 4.2 to 4.8 with 'a' corresponding to data from East and Southern Africa and 'b' reflecting studies conducted in West and Central Africa. Details of each study are presented in Tables 4.2 to 4.8 by infection. In all instances, point prevalence estimates have been corrected to account for the variability of precision associated with each diagnostic method used. The published sensitivity and specificity of these assays are summarised in Table 4.9.

Figure 4.1 PRISMA flowchart for systematic review




Table 4.1 Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa

Sub-region Infection	1990-2011									
	Pooled mean prevalence ¹	95% CI	No. of women positive	No. of women tested	Median positives ²	Range of study sizes	No. of countries	No. of studies	Range of ANC facilities (per study)	Heterogeneity
East and Southern Africa										
Syphilis	4.5	3.9, 5.1	8,346	136,686	54	85 – 52,405	11	41	1 – 57	*
<i>Neisseria gonorrhoeae</i>	3.7	2.8, 4.6	626	17,220	20	145 – 9,104	7	14	1 – 13	87.5%
<i>Chlamydia trachomatis</i>	6.9	5.1, 8.6	350	5,159	34	151 – 964	8	10	1 – 13	85.9%
<i>Trichomonas vaginalis</i>	29.1	20.9, 37.2	5,502	28,189	86	100 – 9,137	9	18	1 – 13	*
Bacterial vaginosis	50.8	43.3, 58.4	4,280	14,112	245	100 – 3,046	8	11	1 – 13	*
Peripheral parasitaemia	32.0	25.9, 38.0	11,688	47,443	195	86 – 5,093	8	35	1 – 10	*
Placental parasitaemia	25.8	19.7, 31.9	1,388	6,649	86	85 – 2,502	7	12	1 – 9	*
West and Central Africa										
Syphilis	3.5	1.8, 5.2	851	10,797	18	205 – 4,100	9	11	1 – 98	*
<i>Neisseria gonorrhoeae</i>	2.7	1.7, 3.7	73	2,737	17	230 – 1,160	8	5	1 – 4	67.2%
<i>Chlamydia trachomatis</i>	6.1	4.0, 8.3	357	5,414	35	261 – 1,160	8	10	1 – 4	94.7%
<i>Trichomonas vaginalis</i>	17.8	12.4, 23.1	822	9,806	57	86 – 2,657	7	12	1 – 4	*
Bacterial vaginosis	37.6	18.0, 57.2	1,208	7,435	138	350 – 2,657	6	7	1 – 3	*
Peripheral parasitaemia	38.2	32.3, 44.1	12,242	43,312	127	26 – 6,370	10	56	1 – 55	*
Placental parasitaemia	39.9	34.2, 45.7	4,658	27,535	168	36 – 8,310	8	23	1 – 6	*

¹Note that dividing the total positive diagnoses by the total tested women does not account for diagnostic errors. A standard method of correcting errors of known magnitude has been applied to these data based on the sensitivity and specificity of individual diagnostic tests.

²The median number of women with a positive diagnosis.

*Heterogeneity measure >97.0%

Table 4.1 Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa (continued)

Sub-region Infection	1990-1999									
	Pooled mean prevalence ¹	95% CI	No. of women positive	No. of women tested	Median positives ²	Range at study sizes	No. of countries	No. of studies	Range of facilities (per study)	Heterogeneity
East and Southern Africa										
Syphilis	6.1	5.0, 7.2	6,168	97,055	79	85 – 52,405	8	21	1 – 23	*
<i>Neisseria gonorrhoeae</i>	3.7	2.7, 4.6	547	15,446	18	151 – 9,104	6	9	1 – 12	82.5%
<i>Chlamydia trachomatis</i>	9.4	6.0, 12.7	194	2,395	36	151 – 964	4	5	1 – 12	88.2%
<i>Trichomonas vaginalis</i>	32.8	18.6, 47.1	4,314	17,710	74	100 – 9,137	5	10	1 – 12	*
Bacterial vaginosis	51.5	35.5, 67.5	1,876	7,039	109	100 – 3,046	5	6	1 – 1	*
Peripheral parasitaemia	34.9	25.1, 44.7	7,563	29,068	327	102 – 5,093	7	16	1 – 10	*
Placental parasitaemia	25.2	16.0, 34.3	588	3,271	124	232 – 2,502	3	3	1	*
West and Central Africa										
Syphilis	3.8	1.5, 6.2	773	7,106	13	205 – 4,100	6	17	1 – 4	*
<i>Neisseria gonorrhoeae</i>	3.0	1.8, 4.2	70	2,507	18	350 – 1,160	7	4	1 – 4	67.2%
<i>Chlamydia trachomatis</i>	7.5	4.6, 10.0	339	4,632	44	350 – 1,160	7	5	1 – 4	94.7%
<i>Trichomonas vaginalis</i>	23.5	15.6, 31.5	721	4,585	73	86 – 1,160	6	8	1 – 4	*
Bacterial vaginosis	46.0	24.2, 67.8	640	2,645	132	350 – 646	5	5	1 – 3	*
Peripheral parasitaemia	43.4	34.1, 52.7	5,543	16,671	178	26 – 2,104	7	19	1 – 17	*
Placental parasitaemia	42.6	34.9, 50.3	2,445	19,582	233	64 – 8,310	6	9	1 – 2	*

¹Note that dividing the total positive diagnoses by the total tested women does not account for diagnostic errors. A standard method of correcting errors of known magnitude has been applied to these data based on the sensitivity and specificity of individual diagnostic tests.

²The median number of women with a positive diagnosis.

*Heterogeneity measure >97.0%

Table 4.1 Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa (continued)

Sub-region Infection	2000-2011									
	Pooled mean prevalence ¹	95% CI	No. of women positive	No. of women tested	Median positives ²	Range at study sizes	No. of countries	No. of studies	Range of facilities (per study)	Heterogeneity
East and Southern Africa										
Syphilis	2.9	2.1, 3.6	2,178	39,631	32	245 – 17,277	8	17	1 – 57	*
<i>Neisseria gonorrhoeae</i>	4.9	1.8, 7.9	79	1,774	21	145 – 835	6	4	1 – 13	91.9%
<i>Chlamydia trachomatis</i>	5.2	3.4, 7.1	156	2,764	25	151 – 835	6	5	1 – 13	79.6%
<i>Trichomonas vaginalis</i>	24.9	18.3, 31.5	1,188	10,479	98	151 – 2,917	8	8	1 – 13	*
Bacterial vaginosis	50.3	43.9, 56.7	2,404	7,073	253	247 – 2,555	6	5	1 – 13	*
Peripheral parasitaemia	29.5	22.4, 36.5	4,125	18,375	157	86 – 2,459	8	19	1 – 9	*
Placental parasitaemia	26.5	16.7, 36.4	800	3,378	58	85 – 726	3	9	1 – 9	*
West and Central Africa										
Syphilis	2.5	0.4, 4.6	78	3,691	21	230 – 2,133	4	5	1 – 98	88.6%
<i>Neisseria gonorrhoeae</i>	1.6	0.0, 3.3	3	230	3	230	3	1	1 – 1	NA ³
<i>Chlamydia trachomatis</i>	1.9	0.2, 3.5	18	782	9	261 – 521	2	2	1 – 2	55.8%
<i>Trichomonas vaginalis</i>	4.5	2.5, 6.6	101	5,221	25	201 – 2,657	2	4	1 – 4	92.7%
Bacterial vaginosis	16.7	-12.6, 46.1	604	4,790	302	2,133 – 2,657	2	2	1 – 2	*
Peripheral parasitaemia	35.1	28.2, 41.9	6,699	26,641	97	38 – 6,370	8	36	1 – 55	*
Placental parasitaemia	38.0	28.4, 47.6	2,213	7,953	84	36 – 1,875	6	15	1 – 6	*

¹Note that dividing the total positive diagnoses by the total tested women does not account for diagnostic errors. A standard method of correcting errors of known magnitude has been applied to these data based on the sensitivity and specificity of individual diagnostic tests.

²The median number of women with a positive diagnosis.

³Not applicable as there is just one study

*Heterogeneity measure >97.0%

Figure 4.1a Curable STIs/RTIs and malaria infection: East and Southern Africa





Figure 4.1b Curable STIs/RTIs and malaria infection: West and Central Africa



Syphilis prevalence

The pooled mean prevalence of syphilis in East and Southern Africa was 4.5% (95% CI: 3.9, 5.1) as shown in Figure 4.2a with the highest estimate, 13.7% (95% CI: 9.0, 18.5), reported from Vilanculos, Mozambique, and based on RPR testing and confirmatory *Treponema pallidum* haemagglutination (TPHA) assays²⁰⁹ as presented in Table 4.2. In West and Central Africa, the pooled mean prevalence of serological syphilis was 3.5% (95% CI: 1.8, 5.2) as shown in Figure 4.2b. The highest point estimate of 16.3% (95% CI: 15.2, 17.4) was from Yaoundé, Cameroon where TPHA assays were used²¹⁰ as presented in Table 4.2.

Table 4.2 Syphilis point estimates: sub-Saharan Africa

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
East and Southern Africa										
1990-1999	Blantyre, Malawi (1990-93)	Taha (1999) ²¹¹	1001	9309	10.8	10.2, 11.4	RPR and TPHA	10.0	9.3, 10.6	1
	Umzingwane Zimbabwe (1991)	Rutgers (1993) ²¹²	197	1,433	13.8	12.0, 15.5	RPR only	10.5	8.9, 12.0	1
	Vilanculos, Mozambique (1991-92)	Vuylsteke (1993) ²⁰⁹	29	201	14.4	9.6, 19.3	RPR and TPHA	13.7	9.0, 18.5	1
	Zambizai, Mozambique (1992-93)	Cossa (1994) ²¹³	212	1,728	12.2	10.7, 13.8	RPR and MHA-TP	11.5	10.0, 13.0	14
	Nairobi, Kenya (1992-94)	Jenniskens (1995) ²¹⁴	854	13,131	6.5	6.1, 6.9	RPR only	2.3	2.0, 2.5	9
	Mwanza, Tanzania (1992-93)	Mayaud (1995) ²¹⁵	97	964	10.1	8.2, 12.0	RPR and TPHA	9.3	7.4, 11.1	12
	Nairobi, Kenya (1992-97)	Temmerman (1999) ²¹⁶	2,701	52,405	5.2	5.0, 5.3	RPR only	0.7	0.7, 0.8	10
	Dar es Salaam, Tanzania (1993)	Mwakagile (1996) ²¹⁷	31	777	4.0	2.6, 5.4	RPR and TPHA	0.1	1.8, 4.3	1
	Blantyre, Malawi (1993)	Taha (1998) ²¹⁸	264	2,161	12.2	10.8, 13.6	RPR and TPHA	11.5	9.4, 17.5	1
	Debrebabor, Ethiopia (1994)	Azeze (1995) ²¹⁹	37	270	13.7	9.6, 17.8	VDRL only	13.5	9.4, 17.5	1
	Nairobi, Kenya (1994)	Thomas (1996) ²²⁰	9	286	3.2	1.1, 5.2	RPR and TPHA	2.2	0.5, 3.9	1
	Rwandan camp, Tanzania (1994)	Mayaud (1997) ²²¹	2	100	2.0	-0.7, 4.7	RPR and TPHA	1.0	-1.0, 3.0	1
	Mwanza, Tanzania (not reported)	Mayaud (1997) ²²²	173	2,380	7.3	6.2, 8.3	RPR and TPHA	6.4	5.4, 7.4	12
	Mwanza, Tanzania (1994)	Mayaud (1998) ²²³	55	660	8.3	6.2, 10.4	RPR and TPHA	7.5	5.5, 9.5	1
	Blantyre, Malawi (1995)	Taha (1998) ²¹⁸	98	808	12.1	9.9, 14.4	RPR and TPHA	11.4	9.2, 13.5	1
	Dar es Salaam, Tanzania (1995-97)	Urassa (2001) ²²⁴	62	1,058	5.9	4.4, 7.3	VDRL and TPHA	5.0	3.7, 6.3	4
	Addis Ababa, Ethiopia (1995-2001)	Tsegaye (2002) ²²⁵	135	4,731	2.9	2.4, 3.3	RPR and TPHA	1.9	1.5, 2.3	4
	Blantyre, Malawi (1996)	Taha (1998) ²¹⁸	92	829	11.1	9.0, 13.2	RPR and TPHA	10.3	8.2, 12.4	1
	Kisumu, Kenya (1996-97)	Ayisi (2000) ²²⁶	65	2,844	2.3	1.7, 2.8	VDRL only	0.3	0.1, 0.5	1
	Addis Ababa, Ethiopia (1997)	Kebede (2000) ²²⁷	12	410	2.9	1.3, 4.6	VDRL and TPHA or VDRL and FTA-Abs	2.0	0.6, 3.3	3
	Nairobi, Kenya (1997)	Fonck (2000) ²²⁸	22	334	6.6	3.9, 9.3	RPR only	2.4	0.7, 4.0	2
	Gutu, Zimbabwe (not reported)	Majoko (2003) ²²⁹	9	85	10.6	4.1, 17.1	RPR only	6.9	1.5, 12.3	23
	Kisumu, Kenya (1996-99)	Ayisi (2003) ²³⁰	55	2,288	2.4	1.8, 3.0	RPR only	0.5*	0.2, 0.8	1
	Nairobi, Kenya (1997-98)	Fonck (2001) ²³¹	928	27,377	3.4	3.2, 3.6	RPR only	0.5*	0.4, 0.6	10
	Khartoum, Sudan (1999)	Ortashi (2004) ²³²	11	151	7.3	3.1, 11.4	RPR and TPHA	6.4	1.5, 12.3	1
2000-2011	Harare, Zimbabwe (Not reported)	Pham (2005) ²³³	74	2,969	2.5	1.9, 3.1	RPR and TPHA	1.5	1.1, 2.0	1
	Moshi, Tanzania (1999-2004)	Msuya (2007) ²³⁴	39	3,046	1.3	0.9, 1.7	RPR and MHA-TP	0.3	0.1, 0.5	3
	Gaborone, Botswana (2000-01)	Romoren (2006) ²³⁵	32	703	4.6	3.0, 6.1	RPR and TPHA	3.6	2.2, 5.0	13
	Blantyre, Malawi (2000-04)	Kwiek (2008) ²³⁶	198	3,824	5.2	4.5, 5.9	RPR and TPHA	4.3	3.6, 4.9	1
	Manhiça, Mozambique (2000)	Menendez (2010) ²³⁷	31	258	12.0	8.1, 16.0	RPR and IgG ELISA	11.24	7.39, 15.1	1
	Harare, Zimbabwe (2002-03)	Kurewa (2010) ²³⁸	8	678	1.2	0.4, 2.0	RPR and TPHA	0.2	-0.1, 0.5	3
	Mwanza, Tanzania (2002)	Watson-Jones (2002) ¹²⁰	106	1,809	5.9	4.8, 6.9	RPR and TPHA	5.0	3.0, 6.0	2
	Harare, Zimbabwe (2002-04)	Mapingure (2010) ²³⁹	8	662	1.2	0.4, 2.0	RPR and Determine Syphilis TP	0.2	-0.1, 0.5	1
	Moshi, Tanzania (2002-04)	Mapingure (2010) ²³⁹	23	2654	0.9	0.5, 1.3	RPR and Determine Syphilis TP	0.5*	0.2, 0.8	1
	Multicentre, Tanzania (2003-04)	Swai (2006) ²⁴⁰	1,261	17,277	7.3	6.9, 7.7	RPR only	3.2	2.9, 3.4	57
	Sofala, Mozambique (2003-04)	Montoya (2006) ²⁴¹	32	381	8.4	5.6, 11.2	RPR and TPHA	7.5	4.9, 10.2	6
	Rural Tanzania (2003-04)	Yahya-Malima (2008) ²⁴²	21	1,296	1.6	1.0, 2.5	RPR and TPHA	0.6	0.2, 1.1	6
	Manhiça, Mozambique (2003-05)	Menendez (2008) ⁷⁷	122	1,030	11.8	9.9, 13.8	RPR only	8.3	4.9, 10.2	1
	Entebbe, Uganda (2004)	Tann (2006) ²⁴³	4	245	1.6	0.1, 3.2	RPR and TPHA	0.7	-0.4, 1.7	1
	Multicentre, Mozambique (2004)	Lujan (2008) ²⁴⁴	53	1,117	4.7	3.5, 6.0	RPR and TPHA	3.8	2.7, 5.0	2
	Entebbe, Uganda (2003-05)	Woodburn (2009) ²⁴⁵	18	2,507	0.7	0.4, 1.0	RPR and TPHA	0.5*	0.2, 0.8	1
	Southern Malawi (2004-05)	Van Den Broek (2009) ¹⁰⁸	163	2,297	7.1	6.1, 8.2	VDRL only	5.9	4.9, 6.8	4
	North-west Somalia (2004)	Abdalla (2010) ²⁴⁶	21	1,559	1.3	0.8, 1.9	RPR and TPHA	0.4	-0.1, 0.2	4
	Gondar, Ethiopia (2005)	Mulu (2007) ²⁴⁷	5	480	1.0	0.1, 2.0	RPR and TPHA	4.5	3.9, 5.1	1

Table 4.2 Syphilis point estimates: sub-Saharan Africa (continued)

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
West and Central Africa										
1990-1999	Kinshasa, Zaire (1990)	Vuylsteke (1993) ¹³³	13	1,160	1.1	0.5, 1.7	RPR and TPHA	0.1	-0.1, 0.3	4
	Abidjan, Côte d'Ivoire (1992)	Diallo (1997) ²⁴⁸	6	545	1.1	0.2, 2.0	RPR and TPHA	0.1	-0.2, 0.4	1
	Cotonou, Benin (1993)	Rodier (1995) ²⁴⁹	5	205	2.4	0.3, 4.5	VDRL and TPHA	1.5	-0.2, 3.1	1
	Multicentre, Burkina Faso (1994)	Meda (1997) ²⁵⁰	23	645	3.6	2.1, 5.0	RPR and TPHA	2.6	1.4, 3.9	2
	Libreville, Gabon (1994-95)	Bourgeois (1998) ²⁵¹	19	646	2.9	1.6, 4.2	RPR only	0.5*	0.05, 1.0	3
	Yaounde, Cameroon (1994-96)	Mbopi Keou (1998) ²¹⁰	696	4,100	17.0	15.8, 18.1	TPHA only	16.3	15.2, 17.4	1
	Bangui, Central African Rep (1996)	Blankhart (1999) ²⁵²	30	451	6.7	4.4, 9.0	RPR / TPHA or VDRL / TPHA	5.8	3.6, 7.9	3
	Bobo-Dioulasso, Burkina Faso (1995-98)	Sombie (2000) ²⁵³	26	10,980	0.2	0.2, 0.3	RPR and TPHA	0.5*	0.4, 0.6	3
	Enugu, Nigeria (1997-2001)	Ikeme (2006) ²⁵⁴	86	6,881	1.3	1.0, 1.5	VDRL only	0.5*	0.4, 0.7	1
2000-2011	Ilorin, Nigeria (2000)	Aboyemi (2003) ²⁵⁵	4	230	1.7	0.1, 3.4	RPR and TPHA	0.8	-0.4, 1.9	1
	Maiduguri, Nigeria (1999-2008)	Bukar (2009) ²⁵⁶	9	18,101	0.1	0.0, 0.1	RPR and TPHA	0.5*	0.4, 0.6	1
	Accra, Ghana (2000-01)	Apea-Kubi (2004) ²⁵⁷	21	294	7.1	4.2, 10.1	RPR and TPHA	6.3	3.5, 9.0	1
	Jos, Nigeria (2002-03)	Sagay (2005) ²⁵⁸	7	2657	0.3	0.1, 0.5	RPR and TPHA	0.5*	0.2, 0.8	1
	Multicentre, Burkina Faso (2003)	Kirakoya (2010) ²⁵⁹	38	2133	1.8	1.2, 2.3	VDRL and TPHA	0.8	0.4, 1.2	98
	Kinshasa, DRC (2004)	Kinoshita-Moleka (2008) ²⁶⁰	0	529	0.0	0.0, 0.0	RPR and TPHA	0.5*	-0.1, 1.1	2
	Osogbo, Nigeria (2004-06)	Taiwo (2007) ²⁶¹	15	505	3.0	1.5, 4.5	RPR and TPHA	2.0	0.8, 3.2	2

RPR = Rapid plasma reagin

VDRL = Venereal disease research laboratory

TPHA = *Treponema pallidum* haemagglutination

MHA-TP = Micro haemagglutination assay–*Treponema pallidum*

IgG = Immunoglobulin G

ELISA= Enzyme-linked immunosorbent assay

FTA-Abs = Fluorescent treponemal antibody absorption

* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure

Figure 4.2a Syphilis pooled estimates: East and Southern Africa





Figure 4.2b Syphilis pooled estimates: West and Central Africa



***Neisseria gonorrhoeae* prevalence**

Amongst women in East and Southern Africa, the pooled prevalence was 3.7% (95% CI: 2.8, 4.6) as shown in Figure 4.3a with the highest point estimate of 23.3% (95% CI: 16.4, 30.2) observed in Manhica, Mozambique diagnosed by culture and gram stain²⁰⁹ as presented in Table 4.3. The pooled prevalence of *N. gonorrhoeae* in West and Central Africa was 3.5% (95% CI: 1.8, 5.2) as shown in Figure 4.3b. The highest individual estimate, 4.6% (95% CI: 2.8, 6.3), came from a study in Abidjan, Côte d'Ivoire, where culture diagnostic methods were used²⁴⁸ as presented in Table 4.3.

Table 4.3 *Neisseria gonorrhoeae* point estimates: sub-Saharan Africa

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
East and Southern Africa										
1990-1999	Blantyre, Malawi (1990-93)	Taha (1999) ²¹¹	376	9104	4.1	3.7, 4.5	Culture	5.2	4.7, 5.6	1
	Vilanculos, Mozambique (1991-92)	Vuylsteke (1993) ²⁰⁹	14	201	7.0	3.5, 10.5	Culture	8.7	4.8, 12.6	1
	Mwanza, Tanzania (1992-93)	Mayaud (1995) ²¹⁵	20	964	2.1	1.2, 3.0	Culture	2.6	1.6, 3.6	12
	Dar es Salaam, Tanzania (1993)	Mwakagile (1996) ²¹⁷	28	777	3.6	2.3, 4.9	Culture	4.5	3.1, 6.0	1
	Blantyre, Malawi (1993)	Taha (1998) ²¹⁸	54	2,161	2.5	1.8, 3.2	Culture	3.1	2.4, 3.9	1
	Nairobi, Kenya (1994)	Thomas (1996) ²²⁰	7	286	2.5	0.7, 4.2	Culture	3.1	1.1, 5.1	1
	Mwanza, Tanzania (1994)	Mayaud (1998) ²²³	15	660	2.3	1.1, 3.4	Culture	2.8	1.6, 4.1	1
	Rwandan camp, Tanzania (1994)	Mayaud (1997) ²²¹	3	100	3.0	-0.3, 6.3	Gram stain	0.5*	-0.9, 1.9	1**
	Blantyre, Malawi (1995)	Taha (1998) ²¹⁸	20	808	2.5	1.4, 3.	Culture	3.1	1.9, 4.3	1
	Nairobi, Kenya (1997)	Fonck (2000) ²²⁸	10	334	3.0	1.2, 4.8	Culture	3.7	1.7, 5.8	10
2000-2011	Khartoum, Sudan (1999)	Ortashi (2004) ²³²	3	151	2.0	-0.2, 4.2	Culture	2.5	0.0, 5.0	1
	Gaborone, Botswana (2000-01)	Romoren (2004) ²⁶²	21	561	3.7	2.2, 5.3	LCR cervical swab	2.8	1.5, 4.2	13
	Manhiça, Mozambique (2000)	Menendez (2010) ²³⁷	27	145	18.6	12.3, 25.0	Culture and gram stain	23.3	16.4, 30.2	1
	Dar es Salaam, Tanzania (2001-03)	Aboud (2008) ²⁶³	1	428	0.2	-0.2, 0.7	Gram stain	0.5*	-0.2, 1.2	1
	Blantyre, Malawi (2001-03)	Aboud (2008) ²⁶³	2	474	0.4	-0.2, 1.0	Gram stain	0.5*	-0.1, 1.1	1
	Lilongwe, Malawi (2001-03)	Aboud (2008) ²⁶³	26	748	3.5	2.2, 4.8	Gram stain	0.5*	-0.01, 1.0	1
	Lusaka, Zambia (2001-03)	Aboud (2008) ²⁶³	10	642	1.6	0.6, 2.5	Gram stain	0.5*	-0.05, 1.0	1
	Moshi, Tanzania (1999-2004)	Msuya (2007) ²³⁴	17	3,046	0.6	0.3, 0.8	Culture or gram stain	0.5*	0.3, 0.8	3
	Entebbe, Uganda (2004)	Tann (2006) ²⁴³	10	233	4.3	1.7, 6.9	PCR cervical swab	1.4	-0.1, 3.0	1
	Multicentre, Mozambique (2004)	Lujan (2008) ²⁴⁴	21	835	2.5	1.5, 3.6	PCR urine	2.8	1.7, 3.9	2
West and Central Africa										
1990-1999	Kinshasa, Zaire (1990)	Vuylsteke (1993) ¹³³	19	1,160	1.6	0.9, 2.3	Culture	2.1	1.2, 2.9	4
	Ile-Ife, Nigeria (1990-91)	Okonofua (1995) ²⁶⁴	9	86	10.5	4.0, 17.0	Gram stain	0.5*	-1.0, 2.0	1
	Abidjan, Côte d'Ivoire (1992)	Diallo (1997) ²⁴⁸	20	546	3.7	2.1, 5.2	Culture	4.6	2.8, 6.3	1
	Praia, Cape Verde (1993)	Wessel (1998) ²⁶⁵	17	350	4.9	2.6, 7.1	PCR cervical swab	2.1	0.6, 3.6	1
	Multi- Burkina Faso (1994)	Meda (1997) ²⁵⁰	23	645	3.6	2.1, 5.0	Gram stain	0.5*	-0.05, 1.0	2
	Libreville, Gabon (1994-95)	Bourgeois (1998) ²⁵¹	12	646	1.9	0.8, 2.9	Culture or gram stain	0.5*	-0.05, 1.0	3
	Bangui, Cent African Rep (1996)	Blankhart (1999) ²⁵²	14	451	3.1	1.5, 4.7	Culture	3.9	2.1, 5.7	3
	Abidjan, Côte d'Ivoire (1996-97)	Faye-Kette (2000) ²⁶⁶	9	551	1.6	0.6, 2.7	Gram stain	0.5*	-0.1, 1.1	1
	2000-2011	Ilorin, Nigeria (2000)	Aboyeyi (2003) ²⁵⁵	3	230	1.3	-0.2, 2.8	Culture	1.6	-0.0, 3.3
Accra, Ghana (2000-01)		Apea-Kubi (2004) ²⁵⁷	1	261	0.4	-0.4, 1.1	PCR cervical swab	0.5*	-0.4, 1.4	1
Kinshasa, Dem Rep Congo (2004)		Kinoshita-Moleka (2008) ²⁶⁰	2	521	0.4	-0.2, 0.9	PCR cervical swab	0.5*	-0.1, 1.1	2

PCR = Polymerase chain reaction

LCR = Ligase chain reaction

* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure

** Refugee camp

Figure 4.3a *Neisseria gonorrhoeae* pooled estimates: East and Southern Africa





Figure 4.3b *Neisseria gonorrhoeae* pooled estimates: West and Central Africa



***Chlamydia trachomatis* prevalence**

In East and Southern Africa, the pooled prevalence of *C. trachomatis* infection was 6.9% (95% CI: 5.1, 8.6) as shown in Figure 4.4a. Khartoum, Sudan, reported the highest prevalence estimate of 23.2% (95% CI: 16.5, 29.9) as detected by an enzyme immunoassay (EIA)²³² as presented in Table 4.4. In West and Central Africa, the pooled mean prevalence was 6.1% (95% CI: 4.0, 8.3) as shown in Figure 4.4b. The highest prevalence, 16.4% (95% CI: 12.6, 20.1) based on culture or EIA, was observed in Pikine, Senegal²⁶⁷ as presented in Table 4.4.

Table 4.4 *Chlamydia trachomatis* point estimates: sub-Saharan Africa

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
East and Southern Africa										
1990-1999	Vilanculos, Mozambique (1991-92)	Vuylsteke (1993) ²⁰⁹	11	141	7.8	3.4, 12.2	Culture cervical swab	0.5*	-0.7, 1.7	1
	Mwanza, Tanzania (1992-93)	Mayaud (1995) ²¹⁵	64	964	6.6	5.1, 8.2	EIA	6.0	4.5, 7.5	12
	Nairobi, Kenya (1994)	Thomas (1996) ²²⁰	25	286	8.7	5.5, 12.0	EIA	8.8	5.5, 12.0	1
	Mwanza, Tanzania (1994)	Mayaud (1998) ²²³	39	660	5.9	4.1, 7.7	EIA	5.1	3.4, 6.8	1
	Nairobi, Kenya (1997)	Fonck (2000) ²²⁸	36	334	10.8	7.5, 14.1	PCR cervical swab	10.4	7.2, 13.7	2
	Khartoum, Sudan (1999)	Ortashi (2004) ²³²	30	151	19.9	13.5, 26.2	EIA	23.2	16.5, 29.9	1
2000-2011	Gaborone, Botswana (2000-01)	Romoren (2004) ²⁶²	42	557	7.5	5.4, 9.7	LCR cervical swab	7.6	5.3, 9.7	13
	Manhiça, Mozambique (2000)	Menendez (2010) ²³⁷	15	151	9.9	5.2, 14.7	DNA ID-assay cervical swab	9.1	4.5, 13.7	1
	Lusaka, Zambia (2001-03)	Aboud (2008) ²⁶³	39	642	6.1	4.2, 7.9	EIA	5.3	3.6, 7.0	1
	Dar es Salaam, Tanzania (2001-03)	Aboud (2008) ²⁶³	12	343	3.5	1.6, 5.4	EIA	2.0	0.5, 3.4	1
	Blantyre, Malawi (2001-03)	Aboud (2008) ²⁶³	4	474	0.8	0.0, 1.7	EIA	0.5*	-0.1, 1.2	1
	Lilongwe, Malawi (2001-03)	Aboud (2008) ²⁶³	2	748	0.3	-0.1, 0.6	EIA	0.5*	0.01, 1.0	1
	Entebbe, Uganda (2004)	Tann (2006) ²⁴³	14	236	5.9	2.9, 9.0	PCR cervical swab	5.5	2.6, 8.4	1
	Multicentre, Mozambique (2004)	Lujan (2008) ²⁴⁴	34	835	4.1	2.7, 5.4	PCR urine	4.3	2.9, 5.7	2
	West and Central Africa									
1990-1999	Pikine, Senegal (1990)	Van Dyck (1992) ²⁶⁷	55	377	14.6	11.0, 18.2	Culture or EIA	16.4	12.6, 20.1	1
	Kinshasa, Zaire (1990)	Vuylsteke (1993) ¹³³	60	1,160	5.2	3.9, 6.5	EIA	4.1	3.0, 5.3	4
	Abidjan, Côte d'Ivoire (1992)	Diallo (1997) ²⁴⁸	25	452	5.5	3.4, 7.6	EIA	4.6	2.7, 6.5	1
	Praia, Cape Verde (1993)	Wessel (1998) ²⁶⁵	46	350	13.1	9.6, 16.7	PCR cervical swab	12.9	9.3, 16.3	1
	Multicentre, Burkina Faso (1994)	Meda (1997) ²⁵⁰	20	645	3.1	1.8, 4.4	EIA	1.4	0.5, 2.4	2
	Libreville, Gabon (1994-95)	Bourgeois (1998) ²⁵¹	64	646	9.9	7.6, 12.2	EIA	10.3	7.9, 12.6	3
	Bangui, CAR (1996)	Blankhart (1999) ²⁵²	28	451	6.2	4.0, 8.4	Indirect immunofluorescence	4.3	2.5, 6.2	3
	Abidjan, Côte d'Ivoire (1996-97)	Faye-Kette (2000) ²⁶⁶	41	551	7.4	5.3, 9.6	EIA	7.1	4.9, 9.2	1
	Accra, Ghana (2000-01)	Apea-Kubi (2004) ²⁵⁷	9	261	3.5	1.2, 5.7	PCR cervical swab	3.0	0.9, 5.1	1
2000-2011	Kinshasa, DRC (2004)	Kinoshita-Moleka (2008) ²⁶⁰	9	521	1.7	0.6, 2.9	PCR cervical swab	6.1	4.0, 8.3	2

PCR = Polymerase chain reaction

LCR = Ligase chain reaction

EIA = Enzyme immunoassay

* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure

Figure 4.4a *Chlamydia trachomatis* pooled estimates: East and Southern Africa





Figure 4.4b *Chlamydia trachomatis* pooled estimates: West and Central Africa



***Trichomonas vaginalis* prevalence**

The pooled prevalence of *T. vaginalis* infection was 29.1% (95% CI: 20.9, 37.2) amongst women in East and Southern Africa as shown in Figure 4.5a, compared to 17.8% (95% CI: 12.4, 23.1) in West and Central Africa illustrated in Figure 4.5b. Table 4.5 shows the highest point estimate in East and Southern Africa was 51.7% (95% CI: 41.9, 61.5), reported in Blantyre, Malawi²¹¹ as diagnosed by wet-mount microscopy, whereas the highest prevalence estimate in West and Central Africa, 52.0% (95% CI: 47.6, 56.4), was in Jos, Nigeria, where the same diagnostic method was used.²⁶⁸

Table 4.5 *Trichomonas vaginalis* point estimates: sub-Saharan Africa

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
East and Southern Africa										
1990-1999	Blantyre, Malawi (1990-93)	Taha (1999) ²¹¹	2,838	9,137	31.1	30.2, 32.1	Wet-mount microscopy	51.6	50.5, 52.6	1
	Vilanculos, Mozambique (1991-92)	Vuytsteke (1993) ²⁰⁹	46	201	22.9	17.1, 28.7	Wet-mount microscopy	38.1	31.4, 44.9	1
	Mwanza, Tanzania (1992-93)	Mayaud (1995) ²¹⁵	264	964	27.4	24.6, 30.2	Wet-mount microscopy	45.6	42.5, 48.8	12
	Dar es Salaam, Tanzania (1993)	Mwakagile (1996) ²¹⁷	176	777	22.7	19.7, 25.6	Wet-mount microscopy	37.8	34.3, 41.2	1
	Blantyre, Malawi (1993)	Taha (1998) ²¹⁸	62	2,161	2.9	2.2, 3.6	Wet-mount microscopy	4.8	3.8, 5.7	1
	Nairobi, Kenya (1994)	Thomas (1996) ²²⁰	57	286	19.9	15.3, 24.6	Wet-mount microscopy	33.2	27.8, 38.7	1
	Mwanza, Tanzania (1994)	Mayaud (1998) ²²³	108	660	16.4	13.5, 19.2	Wet-mount microscopy	27.3	23.9, 30.7	1
	Rwandan camp, Tanzania (1994)	Mayaud (1997) ²²¹	31	100	31.0	21.9, 40.1	Wet-mount microscopy	51.7	41.9, 61.5	1*
	Mwanza, Tanzania (not reported)	Mayaud (1997) ²²²	627	2,282	27.5	25.6, 29.3	Wet-mount microscopy	45.8	43.8, 47.8	12
	Blantyre, Malawi (1995)	Taha (1998) ²¹⁸	19	808	2.4	1.3, 3.4	Wet-mount microscopy	3.9	2.6, 5.3	1
2000-2011	Nairobi, Kenya (1997)	Fonck (2000) ²²⁸	86	334	25.8	21.1, 30.4	Wet-mount microscopy	42.9	37.6, 48.2	2
	Khartoum, Sudan (1999)	Ortashi (2004) ²³²	11	151	7.3	3.1, 11.4	Wet-mount microscopy	12.1	6.9, 17.4	1
	Moshi, Tanzania (1999-2004)	Msuya (2007) ²³⁴	207	2,917	7.1	6.2, 8.0	Wet-mount microscopy	11.8	10.7, 13.0	3
	Gaborone, Botswana (2000-01)	Romoren (2007) ²⁶⁹	132	703	18.8	15.9, 21.7	Wet-mount microscopy	31.3	27.9, 34.7	13
	Manhiça, Mozambique (2000)	Menendez (2010) ²³⁷	78	254	30.7	25.0, 36.4	Wet-mount microscopy	51.2	45.0, 57.3	1
	Lilongwe, Malawi (2001-03)	Aboud (2008) ²⁶³	180	748	24.1	21.0, 27.1	Wet-mount microscopy	40.1	36.6, 43.6	1
	Lusaka, Zambia (2001-03)	Aboud (2008) ²⁶³	134	642	20.9	17.7, 24.0	Wet-mount microscopy	34.8	31.1, 38.5	1
	Blantyre, Malawi (2001-03)	Aboud (2008) ²⁶³	98	474	20.7	17.0, 24.3	Wet-mount microscopy	34.5	30.2, 38.7	1
	Dar es Salaam, Tanzania (2001-03)	Aboud (2008) ²⁶³	18	428	4.2	2.3, 6.1	Wet-mount microscopy	7.0	4.6, 9.4	1
	Moshi, Tanzania (2002-04)	Mapingure (2010) ²³⁹	127	2,555	5.0	4.2, 5.9	Wet-mount microscopy	8.3	7.2, 9.4	1
	Harare, Zimbabwe (2002-04)	Mapingure (2010) ²³⁹	80	680	11.8	9.4, 14.2	Wet-mount microscopy	19.6	16.6, 22.6	1
	Harare, Zimbabwe (2002-03)	Kurewa (2010) ²³⁸	80	678	11.8	9.4, 14.2	Wet-mount microscopy	19.7	16.7, 22.7	3
	Entebbe, Uganda (2004)	Tann (2006) ²⁴³	43	249	17.3	12.6, 22.0	In-pouch culture	18.0	13.2, 22.8	1
	West and Central Africa									
1990-1999	Jos, Nigeria (not reported)	Ogbonna (1991) ²⁶⁸	156	500	31.2	27.1, 35.3	Wet-mount microscopy	52.0	47.6, 56.4	2
	Kinshasa, Zaire (1990)	Vuytsteke (1993) ¹³³	213	1,160	18.4	16.1, 20.6	Wet-mount microscopy	30.6	28.0, 33.3	4
	Ile-Ife, Nigeria (1990-91)	Okonofua (1995) ²⁶⁴	2	86	2.3	-0.9, 5.5	Wet-mount microscopy	3.9	-0.2, 8.0	1
	Abidjan, Côte d'Ivoire (1992)	Diallo (1997) ²⁴⁸	72	546	13.2	10.3, 16.0	Wet-mount microscopy	22.0	18.5, 25.5	1
	Multicentre, Burkina Faso (1994)	Meda (1997) ²⁵⁰	90	645	14.0	11.3, 16.6	Wet-mount microscopy	23.3	20.0, 26.5	2
	Libreville, Gabon (1994-95)	Bourgeois (1998) ²⁵¹	69	646	10.7	8.3, 13.1	Wet-mount microscopy	17.8	14.9, 20.8	3
	Bangui, Central African Rep (1996)	Blankhart (1999) ²⁵²	45	451	10.0	7.2, 12.7	Wet-mount microscopy	16.6	13.2, 20.1	3
	Abidjan, Côte d'Ivoire (1996-97)	Faye-Kette (2000) ²⁶⁶	74	551	13.4	10.6, 16.3	Wet-mount microscopy	22.4	18.9, 25.9	1
	Ilorin, Nigeria (2000)	Aboyaji (2003) ²⁵⁵	11	230	4.8	2.0, 7.5	Wet-mount microscopy	8.0	4.5, 11.5	1
2000-2011	Jos, Nigeria (2002-03)	Sagay (2005) ²⁵⁸	41	2,657	1.5	1.0, 2.0	Wet-mount microscopy	2.6	2.0, 3.2	1
	North-east Nigeria (2003-04)	Nwosu (2007) ²⁷⁰	17	201	8.4	4.6, 12.3	Wet-mount microscopy	14.1	9.3, 18.9	1
	Multicentre, Burkina Faso (2003)	Kirakoya (2008) ²⁷¹	32	2,133	1.5	1.0, 2.0	In-pouch culture	1.6	1.0, 2.1	4

* Refugee camp

Figure 4.5a *Trichomonas vaginalis* pooled estimates: East and Southern Africa





Figure 5.5b *Trichomonas vaginalis* pooled estimates: West and Central Africa



Bacterial vaginosis prevalence

The prevalence of bacterial vaginosis was higher than any other STI/RTI in both sub-regions. In East and Southern Africa, the pooled prevalence was 50.8% (95% CI: 43.4, 58.4) as shown in Figure 4.6a. The highest point estimate was 85.5% (95% CI: 82.8, 88.1) from Blantyre, Malawi where Amsel's criteria were used for diagnosis²¹¹ as presented in Table 4.6. In West and Central Africa the pooled prevalence estimate was 37.6% (95% CI: 18.0, 57.2) as shown in Figure 4.6b with the highest point estimate based on clue cell count being 74.5% (95% CI: 70.0, 79.1) in Praia, Cape Verde²⁶⁵ as presented in Table 4.6.

Table 4.6 Bacterial vaginosis point estimates: sub-Saharan Africa

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
East and Southern Africa										
1990-1999	Blantyre, Malawi (1990)	Taha (1999) ²¹¹	640	2077	30.8	28.8, 32.8	Amsel	58.8	56.7, 60.9	1
	Blantyre, Malawi (1993)	Taha (1999) ²¹¹	290	661	43.9	40.1, 47.7	Amsel	85.5	82.8, 88.1	1
	Nairobi, Kenya (1994)	Thomas (1996) ²²⁰	59	286	20.6	15.9, 25.3	Clue cell count	47.7	41.9, 53.4	1
	Rwandan camp, Tanzania (1994)	Mayaud (1997) ²²¹	16	100	16.0	8.8, 23.2	Clue cell count	35.1	25.8, 44.5	1*
	Mwanza, Tanzania (1994)	Mayaud (1998) ²²³	159	660	24.1	20.8, 27.4	Clue cell count	57.0	53.2, 60.8	1
	Multicentre, Zimbabwe (1999-2001)	Tolosa (2006) ²⁷²	51	209	24.4	18.6, 30.2	Nugent	23.5	17.8, 29.3	1
2000-2011	Moshi, Tanzania (1999-2004)	Msuya (2007) ²³⁴	661	3,046	21.7	20.2, 23.2	Amsel	40.2	38.5, 42.0	3
	Gaborone, Botswana (2000-01)	Romoren (2007) ²⁶⁹	264	703	37.6	34.0, 41.1	Nugent	39.5	35.9, 43.1	13
	Lilongwe, Malawi (2001-03)	Aboud (2008) ²⁶³	329	748	44.0	40.4, 47.5	Nugent	47.3	43.7, 50.8	1
	Blantyre, Malawi (2001-03)	Aboud (2008) ²⁶³	239	474	50.4	45.9, 54.9	Nugent	55.1	50.6, 59.6	1
	Lusaka, Zambia (2001-03)	Aboud (2008) ²⁶³	251	642	39.1	35.3, 42.9	Nugent	41.3	37.5, 45.14	1
	Dar es Salaam, Tanzania (2001-03)	Aboud (2008) ²⁶³	255	428	59.6	54.9, 64.2	Nugent	66.2	61.7, 70.7	1
	Harare, Zimbabwe (2002-04)	Mapingure (2010) ²³⁹	195	598	32.6	28.8, 36.4	Amsel	62.5	58.6, 66.4	1
	Moshi, Tanzania (2002-04)	Mapingure (2010) ²³⁹	533	2555	20.9	19.3, 22.5	Amsel	38.5	36.6, 40.4	1
	Harare, Zimbabwe (2002-03)	Kurewa (2010) ²³⁸	221	678	32.6	29.1, 36.1	Amsel	62.4	58.8, 66.1	3
	Entebbe, Uganda (2004)	Tann (2006) ²⁴³	117	247	47.4	41.1, 53.6	Nugent	51.4	45.1, 58.0	1
West and Central Africa										
1999-1999	Praia, Cape Verde (1993)	Wessel (1998) ²⁶⁵	107	350	30.6	25.7, 35.4	Clue cell count	74.5	70.0, 79.1	1
	Multicentre, Burkina Faso (1994)	Meda (1997) ²⁵⁰	83	645	12.9	10.3, 15.5	Amsel	22.2	19.0, 25.4	2
	Libreville, Gabon (1994-95)	Bourgeois (1998) ²⁵¹	148	646	22.9	19.7, 26.2	Nugent	21.8	18.5, 24.9	3
	Bangui, Central African Rep (1996)	Blankhart (1999) ²⁵²	132	453	29.1	25.0, 33.3	Clue cell count	70.7	66.5, 74.8	3
	Abidjan, Côte d'Ivoire (1996-97)	Faye-Kette (2000) ²⁶⁶	170	551	30.9	27.0, 34.7	Spiegel	41.1	37.0, 45.3	1
2000-2011	Jos, Nigeria (2002-03)	Sagay (2005) ²⁵⁸	466	2657	17.5	16.1, 18.9	Amsel	31.7	29.9, 33.5	1
	Multicentre, Burkina Faso (2003)	Kirakoya-Moleka (2008) ²⁷¹	138	2,133	6.5	5.4, 7.5	Nugent	1.8	1.2, 2.3	2

* Refugee camp

Figure 4.6a Bacterial vaginosis pooled estimates: East and Southern Africa





Figure 4.6b Bacterial vaginosis pooled estimates: West and Central Africa



Peripheral malaria prevalence

The pooled prevalence of peripheral malaria in East and Southern Africa was 32.0% (95% CI: 25.9, 38.0) as shown in Figure 4.7a. The highest prevalence in the sub-region, 87.9% (95% CI: 85.7, 90.1), was reported from Hoima, Uganda, where microscopy was used²⁷³ as presented in Table 4.7. In West and Central Africa, the pooled prevalence of peripheral parasitaemia was 38.2% (95% CI: 32.3, 44.1) as shown in Figure 4.7b. The highest point estimate was 94.9% (95% CI: 88.0, 102.0) in Ngali II, Nigeria, where PCR methods were used²⁷⁴ as presented in Table 4.7.

Table 4.7 Peripheral malaria point estimates: sub-Saharan Africa

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
East and Southern Africa										
1990-1999	Kilifi, Kenya (1993)	Shulman (1996) ²⁹	65	275	23.6	18.6, 28.7	Giemsa stain microscopy	28.7	23.3, 34.0	1
	Chikwawa, Malawi (1993-94)	Verhoeff (1998) ³⁸	109	575	18.9	15.7, 22.1	Giemsa stain microscopy	21.5	18.1, 24.8	1
	Chikwawa, Malawi (1993-95)	Verhoeff (1999) ¹⁶⁴	743	3,913	19.0	17.8, 20.2	Giemsa stain microscopy	21.5	20.2, 22.8	1
	Kisumu, Kenya (1994-96)	Parise (1998) ⁷⁴	330	736	44.8	41.2, 48.4	Giemsa stain microscopy	61.3	57.8, 64.8	2
	Hoima, Uganda (1996-98)	Ndyomugenyi (1999) ²⁷³	530	853	62.1	58.9, 65.4	Giemsa stain microscopy	87.9	85.7, 90.1	1
	Kisumu, Kenya (1996-97)	Ayisi (2000) ²²⁶	583	2,844	20.5	19.0, 22.0	Giemsa stain microscopy	23.9	22.3, 25.4	1
	Kisumu, Kenya (1996-98)	Van Eijk (2001) ²⁷⁵	953	4,608	20.7	19.5, 21.9	Giemsa stain microscopy	24.1	22.9, 25.4	1
	Kisumu, Kenya (1996-97)	Van Eijk (2003) ²⁷⁶	380	2,502	15.2	13.8, 16.6	Giemsa stain microscopy	15.7	14.3, 17.1	1
	Kisumu, Kenya (1996-99)	Van Eijk (2002) ²⁷⁷	1,105	5,093	21.7	20.6, 22.8	Giemsa stain microscopy	25.7	24.5, 26.9	1
	Kigoma, Tanzania (not reported)	Mnyika (2000) ²⁷⁸	66	705	9.4	7.2, 11.5	Giemsa stain microscopy	6.7	4.9, 8.6	1
	Blantyre, Malawi (1997-98)	Rogerson (2000) ¹⁸¹	2,034	4,764	42.7	41.3, 44.1	PCR	41.1	39.7, 42.5	1
	Kwale, Kenya (1997-98)	(Tobian 2000) ²⁷⁹	54	102	52.9	43.3, 62.6	PCR**	53.6	43.9, 63.3	1
	Blantyre, Malawi (1997-99)	Rogerson (2000) ¹⁸²	85	339	25.1	20.5, 29.7	Giemsa stain microscopy	30.9	26.0, 35.8	1
	Medani, Sudan (1997)	Ahmed (2002) ²⁸⁰	324	550	58.9	54.8, 63.0	Giemsa stain microscopy**	82.9	80.0, 86.1	1
	Kampala, Uganda (1998)	Kasumba (2000) ²⁸¹	46	537	8.6	6.2, 10.9	Giemsa stain microscopy**	5.5	3.6, 7.4	1
	Manhiça, Mozambique (1998)	Saute (2002) ²⁸²	156	672	23.2	20.0, 26.4	Giemsa stain microscopy	28.0	24.6, 31.4	10
2000-2011	Blantyre, Malawi (2000)	Mankhambo (2002) ²⁸³	70	135	51.9	43.4, 60.3	PCR**	52.3	43.8, 60.7	1
	Multi- (stable trans), Ethiopia (2000-01)	Newman (2003) ²⁸⁴	26	249	10.4	6.6, 14.2	Giemsa stain microscopy	0.5*	-0.4, 1.5	1
	Multi- (unstable trans), Ethiopia (2000-01)	Newman (2003) ²⁸⁴	13	713	1.8	0.8, 2.8	Giemsa stain microscopy	8.4	4.9, 11.8	3
	New Halfa, Sudan (2001-02)	Elghazali (2003) ²⁸⁵	15	86	17.4	9.4, 25.5	Giemsa stain microscopy	19.1	10.8, 27.5	1
	Morogoro, Tanzania (2001-02)	Wort (2006) ²⁸⁶	494	1,684	29.3	27.1, 31.5	Giemsa stain microscopy**	37.4	35.1, 39.8	1
	Multicentre, Rwanda (2002)	Van Geertruyden (2005) ²⁸⁷	195	1,432	13.6	11.8, 15.4	Giemsa stain microscopy	13.3	11.5, 15.0	6
	Blantyre, Malawi (2002-03)	Kalilani (2006) ²⁸⁸	372	1,172	31.7	29.1, 34.4	Giemsa stain microscopy	41.1	38.3, 44.0	2
	Multicentre, Kenya (2003)	Parise (2003) ²⁸⁹	157	339	46.3	41.0, 51.6	Giemsa stain microscopy	63.6	58.4, 68.7	9
	New Halfa, Sudan (2003-04)	Adam (2005) ²⁹⁰	102	744	13.7	11.2, 16.2	Giemsa stain microscopy	54.1	45.9, 62.3	1
	New Halfa, Sudan (2003-04)	Adam (2005) ²⁹¹	57	142	40.1	32.0, 48.2	Giemsa stain microscopy	13.4	11.0, 15.9	1
	Sofala, Mozambique (2003-04)	Montoya (2006) ²⁴¹	78	587	13.3	10.5, 16.0	Giemsa stain microscopy	12.8	10.1, 15.5	6
	Multicentre, Mozambique (2003-04)	Brentlinger (2007) ²⁹²	255	684	37.3	33.7, 40.9	Giemsa stain microscopy	49.7	45.9, 53.4	5
	Kisumu, Kenya (2003-04)	Ouma (2007) ²⁹³	123	684	18.0	15.1, 20.9	Giemsa stain microscopy	20.0	17.0, 23.0	1
	Entebbe, Uganda (2003-05)	Hillier (2008) ²⁹⁴	268	2,459	10.9	9.7, 2.1	Giemsa stain microscopy	9.1	7.9, 10.2	1
	Masindi, Uganda (2003-04)	Ndyomugenyi (2008) ²⁹⁵	281	802	35.0	31.7, 38.4	Giemsa stain microscopy	46.2	42.8, 49.7	1
	Mangochi, Malawi (2003-06)	Rantala (2010) ²⁹⁶	51	475	10.7	7.9, 13.5	PCR	2.1	0.8, 3.4	1
	Manhiça, Mozambique (2003-05)	Serra-Casas (2011) ²⁹⁷	120	399	30.0	25.5, 34.5	PCR	25.7	21.4, 30.0	1
	Southern Malawi (2004-05)	Van Den Broek (2009) ¹⁰⁸	572	2,297	24.9	23.1, 26.7	Giemsa stain microscopy	30.6	28.7, 32.5	4
	Mbarara, Uganda (2006-09)	Piola (2009) ²⁹⁸	329	1,197	27.5	25.0, 30.0	Giemsa stain microscopy	34.6	31.9, 37.3	1
	Mukono, Uganda (not reported)	Mbonye (2008) ²⁹⁹	573	2,344	24.5	22.7, 26.2	Giemsa stain microscopy	30.0	28.1, 31.8	3***
Multicentre, Mozambique (2004)	Lujan (2008) ²⁴⁴	53	1,117	4.7	3.5, 6.0	Giemsa stain microscopy	0.5*	0.1, 1.0	2	

PCR = Polymerase chain reaction

* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure

** Measured at delivery

*** ANC delivered through facilities and out-reach teams

Table 4.7 Peripheral malaria point estimates: sub-Saharan Africa (continued)

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
West and Central Africa										
1990-1999	North Kivu, DRC (NR)	Meuris (1993) ³⁰⁰	80	461	17.4	13.9, 20.8	Giemsa stain microscopy	19.0	15.4, 22.6	1
	Freetown, Sierra Leone (NR)	Morgan (1994) ³⁰¹	142	768	18.5	15.7, 21.2	Giemsa stain microscopy	20.8	17.9, 23.6	1
	Ibadan, Nigeria (NR)	Achidi (1997) ³⁰²	26	116	22.4	14.8, 30.0	Giemsa stain microscopy**	26.8	18.7, 34.9	1
	Dabou, Côte d'Ivoire (NR)	Watson (1998) ³⁰³	11	26	42.3	23.3, 61.3	Giemsa stain microscopy	57.4	38.4, 76.4	1
	Multicentre, Nigeria (1992)	Egwyunyenga (1997) ³⁰⁴	292	656	44.5	40.7, 48.3	Giemsa stain microscopy**	60.8	57.1, 64.5	3
	Farafenni, Gambia (1994)	Menendez (1994) ³⁰⁵	72	262	27.5	22.1, 32.9	Giemsa stain microscopy	34.6	28.8, 40.4	NA***
	Bauchi, Nigeria (1994-95)	Egwyunyenga (1996) ³⁰⁶	181	830	21.8	19.0, 24.6	Giemsa stain microscopy	25.9	22.9, 28.9	1
	Jos, Nigeria (1994-95)	Egwyunyenga (1996) ³⁰⁶	150	652	23.0	19.8, 26.2	Giemsa stain microscopy**	27.7	24.3, 31.1	1
	Ekur, Nigeria (1994-95)	Egwyunyenga (1996) ³⁰⁶	74	423	17.5	13.9, 21.1	Giemsa stain microscopy**	19.2	15.5, 23.0	1
	Kassena-Nankana, Ghana (1994-95)	Browne (2001) ³⁰⁷	527	928	56.8	53.6, 60.0	PCR	58.3	55.1, 61.5	17
	Yaounde, Cameroon (1994)	Tako (2005) ³⁰⁸	405	1,895	21.4	19.5, 23.2	Giemsa stain microscopy	25.2	23.2, 27.1	2
	Multicentre, Cameroon (1995-98)	Zhou (2002) ³⁰⁹	334	719	46.5	42.8, 50.1	Giemsa stain microscopy	63.7	60.3, 67.3	2
	Yaounde, Cameroon (1995-98)	Walker-Abbey (2005) ³¹⁰	77	278	27.7	22.4, 33.0	Giemsa stain microscopy	34.9	29.3, 40.5	3
	Yaounde, Cameroon (1996-2001)	Tako, (2005) ³⁰⁸	297	1,866	15.9	14.3, 17.6	Giemsa stain microscopy	16.8	15.1, 18.5	2
	Jos, Nigeria (1997-98)	Egwyunyenga (2001) ³¹¹	816	2,104	38.8	36.7, 40.9	Giemsa stain microscopy	52.0	49.8, 54.1	3
	Ebolowa, Cameroon (1997-98)	Salihi (2002) ³¹²	55	125	44.0	35.3, 52.7	Giemsa stain microscopy	60.0	51.4, 68.6	1
	Bansang, Gambia (1997)	Okoko (2002) ³¹³	116	313	37.1	31.7, 42.4	Giemsa stain microscopy	49.3	43.8, 54.9	1
	Lagos, Nigeria (1998)	Anorlu (2001) ³¹⁴	174	477	36.5	32.2, 40.8	Giemsa stain microscopy	48.4	43.9, 52.9	1
	Agogo, Ghana (1998)	Mockenhaupt (2008) ³¹⁵	335	530	63.2	59.1, 67.3	PCR**	66.1	62.1, 70.1	1
	Sagamu, Nigeria (NR)	Sule-Odu (2002) ³¹⁶	140	564	24.8	21.3, 28.4	Giemsa stain microscopy**	30.5	26.7, 34.3	1
	Lagos, Nigeria (1999)	Okwa (2003) ²⁷⁴	480	800	60.0	56.6, 63.4	Giemsa stain microscopy	84.6	82.1, 87.1	4
	Fako, Cameroon (1999-2001)	Achidi (2005) ³¹⁷	511	1,143	44.7	41.8, 47.6	Giemsa stain microscopy	61.1	58.3, 63.9	1
	Fako, Cameroon (1999-2000)	Akum (2005) ³¹⁸	248	735	33.7	30.3, 37.2	Giemsa stain microscopy**	44.2	40.6, 47.8	1

NR = Not reported

** Measured at delivery

*** ANC delivered as part of a national village-based system

Figure 4.7a Peripheral malaria pooled estimates: East and Southern Africa





Figure 4.7b Peripheral malaria pooled estimates: West and Central Africa



Placental malaria prevalence

As for placental malaria, the pooled prevalence in East and Southern Africa was 25.8% (95% CI: 19.7, 31.9) (Figure 4.8a). The highest point estimate, 74.7% (95% CI: 65.5, 84.0), from Kisumu, Kenya was based on histological diagnosis³¹⁹ as shown in Table 4.8. In West and Central Africa, the pooled prevalence was 39.9% (95% CI: 34.2, 45.7) (Figure 4.8b) with the highest point prevalence of 91.6% (95% CI: 84.8, 94.4) based on placental histology as well as blood and impression smears from Ebolowa, Cameroon¹⁶⁵ as shown in Table 4.8.

Table 4.8 Placental malaria point estimates at ANC: sub-Saharan Africa

Site (year study conducted)	Reference (year of publication)	No. women positive	No. women tested	Uncorrected prevalence (%)	95% CI	Diagnostic method	Corrected prevalence (%)	95% CI	No. ANC facilities	
East and Southern Africa										
1990-1999	Kisumu, Kenya (1996-99)	Van Eijk (2002) ²⁷⁷	475	2,502	19.0	17.4, 20.5	Placental impression and blood smears with microscopy	20.0	18.4, 21.6	1
	Blantyre, Malawi (1997-99)	Rogerson (2000) ¹⁸²	77	232	33.2	27.1, 39.2	Placental impression and blood smears with microscopy	35.8	29.6, 41.9	1
	Kampala, Uganda (1998)	Kasumba (2000) ²⁸¹	36	537	6.7	4.6, 8.8	Placental blood microscopy	8.5	6.1, 10.8	1
2000-2011	Blantyre, Malawi (NR)	Rogerson (2003) ³²⁰	124	464	26.7	22.7, 30.8	Placental histology, impression, smears with microscopy	28.6	24.5, 32.7	1
	Multicentre, Kenya (NR)	Parise (2003) ²⁸⁹	163	726	22.5	19.4, 25.5	Placental blood microscopy	34.1	30.6, 37.5	9
	Muheza, Tanzania (2002-05)	Kabyemela (2008) ³²¹	55	445	12.4	9.3, 15.5	Placental impress and blood smears with microscopy	25.8	19.7, 32.0	1
	Kisumu, Kenya (2003)	Kassam (2006) ³¹⁹	58	85	68.2	58.3, 78.1	Placental histology, impression, smears with microscopy	74.7	65.5, 84.0	3
	New Halfa, Sudan (2003-07)	Adam (2007) ³²²	94	293	32.1	26.7, 37.4	Placental histology, impression, smears with microscopy	34.5	29.1, 40.0	1
	Manhiça, Mozambique (2003-05)	Serra-Casas (2011) ²⁹⁷	110	343	32.1	27.2, 37.0	PCR	9.3	6.2, 12.4	1
	Chikwawa, Malawi (2004-05)	Senga (2007) ³²³	124	636	19.5	16.4, 22.6	Placental blood microscopy and tissue histology	20.6	17.4, 23.7	1
	Gadarif, Sudan (2007-08)	Abdelrahim (2009) ³²⁴	26	150	17.3	11.3, 23.4	Placental histology, impression, smears with microscopy	18.2	12.0, 24.3	1
	Gadafir, Sudan (2007-08)	Adam (2009) ³²⁵	46	236	19.5	14.4, 25.5	Placental histology, impression, smears with microscopy	20.6	15.4, 25.7	1
West and Central Africa										
1990-1999	North Kivu, DRC	Meuris (1993) ³⁰⁰	242	461	52.5	47.9, 57.1	Placental histology	57.0	52.5, 61.5	1
	Ebolowa, Cameroon (1991-92)	Cot (1995) ¹⁸⁵	37	64	57.8	45.7, 69.9	Placental blood microscopy	91.6	84.8, 98.4	1
	Farafenni, Gambia (1994)	Menendez (1994) ³⁰⁵	116	198	58.6	51.7, 65.4	Placental blood microscopy and tissue histology	64.0	57.3, 70.7	NA***
	Basse, Gambia (NR)	Rasheed (1995) ³²⁶	60	97	61.9	52.2, 71.5	Placental blood microscopy and tissue histology	67.6	58.3, 76.9	1
	Yaounde, Cameroon (1995-98)	Walker-Abbey (2005) ³¹⁰	229	278	82.4	77.9, 86.9	Placental blood microscopy	Adjusted prevalence >100%**		3
	Yaounde, Cameroon (1996-2001)	Tako (2005) ³⁰⁸	371	1,866	19.9	18.1, 21.7	Placental impression and blood smears with microscopy	21.0	19.1, 22.8	2
	Bansang, Gambia (1997)	Okoko (2002) ³¹³	160	313	51.1	45.6, 56.7	Placental blood microscopy and tissue histology	55.7	50.2, 61.2	1
	Guediawaye, Senegal (1998-99)	N'dao (2003) ³²⁷	674	8,310	8.1	7.5, 8.7	Placental blood microscopy	10.8	10.1, 11.4	1
	Dakar, Senegal (1998-99)	N'dao (2006) ³²⁷	785	8,273	9.5	8.9, 10.1	Placental impression and blood smears with microscopy	9.4	8.8, 10.1	1
	Fako, Cameroon (1999-2001)	Akum (2005) ³¹⁸	233	711	32.8	29.3, 36.2	Placental impression and blood smears with microscopy	23.0	20.6, 25.4	1
2000-2011	Fako, Cameroon (1999-2001)	Achidi (2005) ³¹⁷	248	1,143	33.7	19.3, 24.1	Placental impression and blood smears with microscopy	35.3	31.8, 38.8	1
	Agogo, Ghana (2000-01)	Mockenhaupt (2006) ³²⁸	495	839	59.0	55.7, 62.3	PCR	47.5	44.1, 50.9	1
	Koupéla, Burkina Faso (2001)	Sirima (2003) ⁷²	19	61	31.1	19.5, 42.8	Placental blood microscopy	48.2	35.7, 60.8	6
	Koupéla, Burkina Faso (2001)	Singer (2004) ³²⁹	247	484	51.0	46.6, 55.5	PCR	36.2	31.9, 40.5	2
	Ngali II, Cameroon (2001-05)	Leke (2010) ³³⁰	25	36	69.4	54.4, 84.5	Placental histology, impression, smears with microscopy	76.1	62.1, 90.0	1
	Kumasi, Ghana (2003)	Owens (2006) ³³¹	33	104	31.7	22.8, 40.6	Placental blood microscopy and tissue histology	34.2	25.0, 43.3	1
	Multicentre, Nigeria (2003-04)	Mokuolu (2009) ³³²	267	1,875	14.2	12.7, 15.8	Placental blood microscopy and tissue histology	14.7	13.1, 16.3	4
	Ibadan, Nigeria (2003-04)	Falade (2007) ³³³	29	171	17.0	11.3, 22.6	Method not reported	-	-	1
	Ibadan, Nigeria (2003-04)	Falade (2010) ³³⁴	128	983	13.1	11.0, 15.2	Placental blood microscopy	18.7	16.3, 21.2	1
	Koupéla, Burkina Faso (2004)	Sirima (2006) ¹⁸⁰	18	59	30.5	18.8, 42.3	Placental blood microscopy	47.2	34.4, 59.9	1
	Kinshasa, Dem Rep Congo (2004)	Lukuka (2006) ³³⁵	42	196	21.4	15.7, 27.2	Placental impression and blood smears with microscopy	22.7	16.8, 28.6	4
	Owerri, Nigeria (2004-05)	Ukaga (2007) ³³⁶	175	586	29.9	26.2, 33.6	Placental blood microscopy	46.1	42.1, 50.2	2
	Benin City, Nigeria (2004-05)	Enato (2007) ³³⁷	14	199	7.0	3.5, 10.6	Placental blood microscopy	9.0	5.0, 13.0	1
	Fako, Cameroon (2007)	Anchang-Kimbi (2009) ³³⁸	185	306	60.5	55.0, 65.9	Placental histology, impression, smears with microscopy	66.1	60.8, 71.4	1
	Benin Citv, Benin (2009)	Aziken (2011) Aziken	84	371	22.6	18.3, 26.9	Placental blood microscopv	34.4	34.2, 45.7	1

PCR = Polymerase chain reaction

NR = Not reported

** The adjusted point prevalence estimate was greater than 100 with no variance and is not shown in the corresponding figure

*** ANC delivered as part of a national village-based system

Figure 4.8a Placental malaria at ANC: East and Southern Africa




Figure 4.8b Placental malaria at ANC: West and Central Africa




Table 4.9 Diagnostic methods used: sensitivity and specificity

Infection	Diagnostic method	Sensitivity (%)	Specificity (%)	Source
Syphilis	<i>Treponema pallidum</i> haemagglutination (TPHA) only*	~100	~100	210
	Rapid plasma reagin (RPR) only	86-100	93-98	339
	Venereal disease research laboratory (VDRL) only	78-100	98	339
	RPR or VDRL and TPHA	~100	~100	-
	RPR and TPHA	~100	~100	-
	RPR and Determine Syphilis TP	~100	~100	-
	RPR and Microhemagglutination assay– <i>Treponema pallidum</i> (MHA-TP)	~100	~100	-
	RPR and Immunoglobulin G (ELISA test)	~100	~100	-
<i>Neisseria gonorrhoeae</i>	Gram stain	50-70	50-70	340
	Culture or gram stain (based on less precise, i.e. mean of gram stain)	50-70	50-70	-
	Polymerase chain reaction (PCR) with urine	36-75	98-100	341
	Culture	~80	100	342
	Culture and gram stain (based on more precise, i.e. mean of culture)	~80	100	-
	Ligase chain reaction (LCR) with cervical swab	95-100	98-100	342
	PCR with cervical swab	89-97	94-100	342
<i>Chlamydia trachomatis</i>	Indirect immunofluorescence	46-64	94-98	343
	Culture cervical swab	74-90	98-99	342
	Enzyme immunoassay (EIA)	71-87	97-99	342
	Culture cervical swab or EIA (based on the less precise, i.e. mean of EIA)	71-87	97-99	-
	PCR urine	78-89	99-100	341
	LCR cervical swab	90-97	99-100	342
	PCR cervical swab	99	99-100	342
	DNA ID-assay cervical swab	~100	~100	-
<i>Trichomonas vaginalis</i>	Wet-mount microscopy	38-82	100	342
	In-pouch culture	96	100	344
Bacterial vaginosis	Clue cells \geq 20% of epithelium	40	97	345
	Unspecified clue cell count	NA	NA	-
	Amsel criteria: 3 or 4 of 4	51	98	345
	Spiegel criteria	75	100	346
	Nugent score \geq 7 of 10	86-89	94-96	347,348

* TPHA is a confirmatory assay and is not recommended for use alone. Authors of the one paper who reported using TPHA alone wrote that a positive TPHA was considered to be related only to syphilis.²¹⁰ Thus, sensitivity and specificity of TPHA only, in this epidemiological context, are assumed to be similar to RPR and TPHA or VDRL and TPHA.

Table 4.9 Diagnostic methods used: sensitivity and specificity (continued)

Infection	Diagnostic method	Sensitivity (%)	Specificity (%)	Source
Peripheral parasitaemia	Giemsa stain microscopy	50-90	~95	349-351
	Polymerase chain reaction	91	91	296
	Antigen assay	(reported as equal to microscopy)		
	Rapid diagnostic test (as reported)	89	76	-
Placental parasitaemia	Diagnostic method not reported	NA	NA	-
	Placental blood microscopy	63	98-99	320
	Polymerase chain reaction	93-99	73-76	352
	Placental histology	91	98-99	320
	Placental blood microscopy and tissue histology (based on histology)	91	~100	-
	Placental histology, impression, smears w/ microscopy (based on histology)	91	~100	-
	Placental impression and blood smears with microscopy (based on impression)	91	~100	338

Discussion

This systematic review and meta-analysis of malaria infection and curable STIs/RTIs spanning a 20-year period suggests the prevalence remains high at the population level amongst pregnant women attending ANC facilities in sub-Saharan Africa. The GRADE method of assessing data quality that is commonly applied to evidence from clinical trials was not considered appropriate for this analysis. GRADE requires ranking evidence by outcomes of interest, scored as high, intermediate, low, or very low. Such, 'quality scores' could have been assigned to point prevalence estimates, but that could have introduced a degree of subjectivity. In this context, quality ranking in the context of prevalence estimates was driven by the diagnostic method used rather than any other factor. Thus, an objective alternative was used: the precision of each point prevalence estimate was adjusted using a standard method for correcting errors of known magnitude before incorporating data into the random effects models. This method has been used previously with prevalence data from Tanzania to compare STI/RTI estimates derived by disparate diagnostic tests. Uncorrected and corrected point prevalence estimates in this meta-analysis are shown by study in prevalence Tables 4.2 to 4.8.

Diagnostic methods have changed for many pathogens over the period covered in the systematic review. In recent years, for example, the advent of molecular tests such as PCR and LCR (ligase chain reaction) has allowed researchers to detect infection where older diagnostic methods may have failed to do so. Although statistical adjustments for diagnostic errors can make data more comparable, the pooled prevalence of curable STIs/RTIs and malaria infection is still probably an underestimate of the true

burden of disease. The degree to which this occurred is a function the specific infection and the assay used in diagnosis.

Amongst syphilis studies, 45 of 59 used the non-treponemal RPR or VDRL (venereal disease research laboratory) tests confirmed by a *Treponema*-specific test, reflecting wide acceptance of the diagnostic gold standard. However, because biological false-positive non-treponemal tests can be produced by concurrent malaria infection, as well as other infections such as bejel (*T. pallidum* subspecies *endemicum*), pinta (*T. pallidum* subspecies *carateum*), and yaws (*T. pallidum* subspecies *pertenue*), the burden of syphilis in 15 studies – one-quarter of all data syphilis points – that did not use treponemal confirmatory testing may be overstated. Corrected prevalence estimates for these studies are lower than the uncorrected numbers originally reported.

The most common assay used to test for *N. gonorrhoeae* was culture which tends to under-estimate true prevalence. This was corrected in 14 studies, slightly increasing those prevalence estimates. The next most frequent assay used was gram stain. The eight studies that employed this method overstated prevalence; gram stain methods have poor sensitivity and specificity in low prevalence settings and among women. Thus, gram stain will routinely overstate the true prevalence in an ANC setting; the method is more appropriate to use at STI clinics with ureteral samples from men. Prevalence estimates based on DNA amplification methods (PCR and LCR) were often corrected downward, which may be the result of detecting non-viable fragments of bacteria (personal communication; Professor David Mabey). An exception is PCR diagnosis of *N. gonorrhoeae* with urine samples from women; the assay has been found

to under-estimate true prevalence (personal communication; Professor Rosanna Peeling) that resulted in an upward correction.

Compared to assays used to for other infections in the systematic review, the tools to detect *C. trachomatis* were most likely captured the true prevalence. Of 24 total studies, enzyme immune-assays were used in 14 studies and eight studies employed DNA amplification. When corrected, prevalence estimates were commonly lower.

Wet-mount microscopy, as previously noted, was used in all but two studies reporting trichomoniasis prevalence, a method that notoriously lacks sensitivity compared to culture or molecular tests.^{353,354} Corrected prevalence estimates were nearly twice as high as uncorrected measures. In contrast, in-pouch methods are very precise, resulting in only minor adjustments to two corrected estimates.

Bacterial vaginosis was diagnosed using four different methods: (i) Nugent's score, (ii) Spiegel's criteria, (iii) Amsel's criteria, and (iv) clue cell prevalence estimates. Nugent's score is the preferred method and was applied in studies reporting the seven highest rates of infection in East and Southern Africa. Correction of Nugent's score prevalence estimates were slightly increased in high prevalence areas, but reduced where the uncorrected prevalence was single digit. The other methods – Spiegel's criteria (n = 1), Amsel's criteria (n = 8), and clue cell count (n = 5) – are not nearly as precise as Nugent's scoring. Consequently, the corrected prevalence for these assays was nearly double the uncorrected measures.

Even with correction, peripheral parasitaemia may be under-represented in this meta-analysis for two reasons. Prior reports of malaria in pregnancy have described the

peak prevalence as occurring between weeks 9-16, declining until term. Indeed, secondary analyses of data from Zambia as part of the third research question found the highest prevalence of malaria infection to be amongst pregnant women who enrolled in the study during gestational week 15. Despite this known variation over the course of pregnancy, studies identified through systematic review did not report the specific gestational age of participants when peripheral parasitaemia was measured. Another important source of under-estimated disease burden comes from the fact that most malaria diagnoses were based on microscopy without molecular-test correction. A study of pregnant women in Blantyre, Malawi, illustrates the extent to which under-diagnosis may occur with conventional microscopy; peripheral parasitaemia was found in 51.9% (43.4, 60.3) of women using PCR, while microscopy only detected infection in 14.9% (11.8, 18.0) of pregnant women.²⁸³ Overall, peripheral malaria was measured by microscopy only in 63 studies whereas 10 studies included PCR. Corrected microscopy estimates were higher than uncorrected measures. In contrast, PCR methods were corrected downward slightly, potentially accounting for an overstated prevalence attributable to the detection of non-viable parasite DNA fragments.

Histology was used to measure placental malaria in over 14 studies, or one-third overall, while microscopy and placental smears were the primary means of measurement in 11 and 8 studies, respectively. In all instances, corrected estimates were higher than uncorrected measures.

Dual prevalence in the sub-regions

Overall, pregnant women in East and Southern Africa had a higher prevalence of STIs/RTIs compared to expecting mothers in West and Central Africa. Several factors may contribute to this difference that are related to exposure including: (i) higher prevalence of STIs/RTIs circulating at the community level, (ii) patterns of male circumcision, (iii) sexual behaviour related to age of sexual debut, (iv) age at first marriage, (v) premarital sex, (vi) total lifetime partners, and (vii) concurrent sex partners. The prevalence of HIV, for example, remains substantially higher in East and Southern Africa compared to the West and Central sub-region. Indeed, the Joint United Nations Programme on HIV/AIDS estimates that 34% of the world's HIV-positive population were living in 10 countries of Southern Africa in 2010.³⁵⁵ Although the AIDS epidemic in East and Southern Africa has declined over the past decade, the prevalence remains higher than in West and Central Africa.

Evidence from this meta-analysis also suggests that peripheral and placental malaria is slightly higher in West and Central Africa compared to the East and Southern sub-region. This may be due to greater seasonal intensity of transmission within West and Central Africa. Recent declines in malaria transmission within selected locales of Africa will likely translate into fewer pregnant women acquiring immunity from one pregnancy to the next. Thus, all women in their reproductive years, rather than just primi- and secundigravidae, may remain vulnerable to the consequences of malaria infection in the years ahead until the absolute risk of exposure is negligible. This may be of particular concern if interest wanes in the provision of IPTp-SP in geographic areas where malaria transmission intensity is very low.

HIV and malaria infection interact to increase placental parasitaemia and the incidence of LBW.²³⁰ Infection by *P. falciparum* also increases viral load amongst HIV-positive pregnancy women.³⁵⁶ Recent evidence suggests that malaria parasites may be more likely to develop wild-type mutations following exposure to IPTp-SP when administered to HIV-positive women.³⁵⁷ Despite the known interaction between STIs/RTIs and HIV, presumptive treatment of STIs/RTIs amongst pregnant women in Rakai, Uganda, did not reduce the incidence of maternal to child transmission of HIV.³⁵⁸ However, malaria chemoprophylaxis was not provided in that study and, therefore, the potential modulating effect of malaria on vertical transmission in the presence of STIs/RTIs remains unknown.

Interestingly, just five publications of the 171 studies of the systematic review reported the prevalence of syphilis and malaria among participants,^{108,226,237,241,244} and only one paper reported the incidence of malaria and STI/RTI co-infection, a prospective cohort study of pregnant women in Tanzania. Co-infection was found amongst 48.3% of RPR-positive women who had placental parasitaemia; 35.0% of RPR-negative women had malaria-infected placentas ($P < 0.001$).¹⁴⁶ Separate analysis of the Zambia data used in the third research question showed that 38.7% (95% CI: 35.7, 41.6) of pregnant women were co-infected with malaria parasites and at least one curable STI/RTI, whereas half that number, 18.9% (95% CI: 16.5, 21.2), were infected with malaria parasites only.²⁰² This strengthens the evidence base for combination treatment that addresses the dual burden of malaria infection and curable STIs/RTIs and, indeed, evidence from Zambia shows that IPTp-SP is protective against this dual burden.

This systematic review and meta-analysis has limitations, not the least of which is the inherent delay between gathering evidence at the field level and publication. This is consequential because HIV-prevention campaigns, including STI/RTI screening and treatment programmes, have made inroads in reducing transmission in many settings. To capture these reductions, more data from the recent past are needed. Another limitation is that, even after stratifying by geography and age of study, heterogeneity amongst studies persisted. Consequently, random effects models were used, rather than fixed effects, but these produced wide confidence intervals in some instances. Finally, evidence was limited to English-language sources and abstracts that had been translated into English.

Considering the 171 studies of this systematic review, there is wide variability in prevalence estimates that has been extracted from a range of populations that cover large geographic areas over a 20-year period. Stratification of data into sub-regions has value for policymakers and programme managers for planning purposes as well as advocacy. Presenting the range of prevalence estimates by infection and sub-region has particular public health value that highlights inequities that merit intervention.

Q 5. Effect of azithromycin on curable STIs/RTIs in pregnancy

Methods

The effect of azithromycin monotherapy on malaria infection was summarised in the Literature Review section of this thesis. However, given the high dual burden of malaria infection and curable STIs/RTIs amongst pregnant women, would azithromycin be an efficacious drug against curable STIs/RTIs to be included as part of IPTp? A

systematic review and meta-analysis was conducted to characterise the *in vitro* and *in vivo* effect of azithromycin against the curable STIs/RTIs of interest.

PubMed, MEDLINE and EMBASE were searched between April and May 2013 using medical subject headings and free-text terms as shown in Table 5.1. Searches were limited to the English language. With each query, the infection and causal organism

Infection	Medical search headings	Free text terms
Syphilis	Topic=("Syphilis" OR " <i>Treponema pallidum</i> ")	<i>Treponema pallidum</i> OR Syphilis AND azithromycin OR macroide
<i>Neisseria gonorrhoeae</i>	Topic=("Neisseria gonorrhoeae") OR Topic=(Gonorrhea) OR Topic=(Gonorrhoea)	<i>Neisseria gonorrhoeae</i> OR gonorrhoea OR gonorrhea AND azithromycin OR macroide
<i>Chlamydia trachomatis</i>	Topic=("Chlamydia") OR Topic=(trachomatis)	<i>Chlamydia trachomatis</i> OR chlamydia AND azithromycin OR macroide
<i>Trichomonas vaginalis</i>	Topic=("Trichomonas vaginalis") OR Topic=("Trichomoniasis")	<i>Trichomonas vaginalis</i> OR trichomoniasis AND azithromycin OR macroide
Bacterial vaginosis	Topic=("Bacterial vaginosis") OR Topic=("Vaginalis bacterial")	Bacterial vaginosis OR Vaginalis bacterial AND azithromycin OR macroide


were used together; for example, 'Syphilis' OR '*Treponema pallidum*' were combined with search terms 'azithromycin' OR 'macrolide'. Reference lists were also reviewed for additional documents. As with prior systematic reviews, publication and author names were not blinded, but data abstraction was done in duplicate.

Table 5.1 Medical subject headings and free text terms

Results

As shown in Figure 1 below, a total of 122 articles met inclusion criteria for the systematic review.

Figure 5.1 PRISMA flowchart for systematic review



Syphilis and azithromycin

In vivo evidence

The WHO recommends treating pregnant women who have a syphilis infection with 2.4 million units (mμ) of benzathine penicillin G (BPG) administered by intramuscular injection.¹⁰⁹ Thus, the focus of *in vivo* evidence from this systematic review reflects findings from six clinical trials that reported outcomes amongst non-pregnant adults following treatment with BPG, azithromycin, or a combination of BPG and azithromycin as shown in Table 5.2a. The oldest data are from a trial in the United States (1993 to 1997) in which individuals who learned they had been exposed to infectious-stage syphilis through sexual intercourse in the preceding 30 days were given either 1 g azithromycin (n = 40) or BPG (n = 23). Three months post-treatment, RPR and fluorescent treponemal antibody absorption tests were negative for all participants in both treatment groups.³⁵⁹ Another trial, also in the United States and during the same period of time, was designed to measure treatment outcomes in a population at high risk of contracting STIs/RTIs. Diagnostic methods were not reported, but the trial was suspended after two of the first 12 patients given 1 g azithromycin went on to fail their tests of cure, whereas all 13 participants were cured using BPG ($P = 0.18$).³⁶⁰ A three-arm trial of early syphilis in the United States then compared treatment outcomes amongst patients given BPG, versus 2 g azithromycin once, versus 2 g azithromycin on two occasions with one week in between doses. RPR and fluorescent treponemal antibody absorption tests showed that cure was achieved in 85.7% (n = 14; 95% CI: 60.0% to 95.7%) of patients given BPG, 94.1% (n = 17; 95% CI: 72.7% to 98.6%) amongst recipients of 2 g azithromycin once and 82.8% (n = 29; 95% CI: 65.3% to 92.3%) in participants who twice received 2 g azithromycin.³⁶¹

Table 5.2a Syphilis RCTs of azithromycin vs. benzathine penicillin G

Low-risk and unspecified low-risk populations and high-risk populations

Reference	Country	Year(s)	Regimen	No. cured of treated	Percent cured	95% CI	Diagnostic methods used	Follow up	Stage of infection
Specified low-risk populations									
Hook (2010) ³⁶²	Madagascar United States	2000-2007	2 g azithromycin 2.4 mμ BPG	180/232 186/237	77.6% 78.5%	71.8% to 82.5% 72.8% to 83.2%	RPR and FTA-ABS	6 months	Primary, secondary, early latent syphilis
Kiddugavu (2005) ³⁶³	Uganda	1994-1998	1 g azithromycin 2.4 mμ BPG 1 g azithromycin plus 2.4 mμ BPG	55/94 66/93 221/313	58.5% 71.0% 70.6%	48.4% to 68.0% 61.0% to 79.2% 65.3% to 75.4%	TRUST and TPHA (initial TRUST titres ≤ 1:2)	10 months	Serologic syphilis
			1 g azithromycin 2.4 mμ BPG 1 g azithromycin plus 2.4 mμ BPG	38/71 31/75 169/309	53.3% 41.3% 54.7%	42.0% to 64.7% 30.9% to 52.7% 49.1% to 60.2%	TRUST and TPHA (initial TRUST titres ≥ 1:4)	10 months	Serologic syphilis
Unspecified low risk populations									
Klausner (2006) ³⁶⁰	United States	2004	1 g azithromycin 2.4 mμ BPG	10/12 13/13	83.3% 100.0%	54.6% to 95.0% NA	NR	NR	Exposed to infectious syphilis
Hook (2002) ³⁶¹	United States	1995-1997	2 g azithromycin 2 g azithromycin (x2) week apart 2.4 mμ BPG	14/14 19/22	100.0% 86.4%	NA 66.4% to 95.0%	RPR and MHA-TP or FTA-ABS	12 months	Primary, secondary, early latent syphilis
Hook (1999) ³⁵⁹	United States	1995-1997	1 g azithromycin 2.4 mμ BPG	40/40 23/23	100.0% 100.0	NA NA	RPR and FTA-ABS	3 months	Exposed to infectious syphilis
High-risk population									
Riedner (2005) ³⁶⁴	Tanzania	2000-2003	2 g azithromycin 2.4 mμ BPG	159/163 157/165	97.5% 95.2%	93.9% to 99.0% 90.7% to 97.5%	RPR and PCR	9 months	Primary, secondary, higher titre latent syphilis

2.4 mμ BPG = 2.4 million units benzathine penicillin G; RPR = Rapid plasma regain; FTA-AB S= Fluorescent treponemal antibody-absorption; TRUST = Tolidine Red Unheated Serum Test; TPHA = *Treponema pallidum* haemagglutination; MHA-TP = Microhaemagglutination assay-*Treponema pallidum*; PCR = Polymerase chain reaction; NR = Not reported; NA = Not applicable

Three trials have investigated BPG versus azithromycin in sub-Saharan Africa, the first being a community-randomised trial in Uganda (1994 to 1998) amongst non-pregnant adults with serological syphilis. Diagnosis pre- and post-treatment were based on toluidine red unheated serum tests (TRUST) and TPHA assays. Treatment efficacy varied across regimens depending on TRUST titres at enrolment. Amongst patients with initial titres $\leq 1:2$, BPG cured 71.0% (n = 93; 95% CI: 61.0% to 79.2%) of cases, compared to 58.5% (n = 94; 95% CI: 48.4% to 68.0%) in patients given 1 g azithromycin, and 70.6% (n = 313; 95% CI: 65.3% to 75.4%) of participants treated with 1 g azithromycin plus BPG. If titres at enrolment were $\geq 1:4$, the efficacy of BPG was reduced to 41.3% (n = 75; 95% CI: 30.9% to 52.7%). Treatment efficacy was also lower amongst groups given azithromycin, but higher than BPG alone. Recipients of 1 g azithromycin alone had a cure rate of 53.3% (n = 71; 95% CI: 42.0% to 64.7%), whereas 1 g azithromycin plus BPG cured 54.7% of cases (n = 309; 95% CI: 49.1% to 60.2%).³⁶³

These results were followed by a trial in Tanzania (2000 to 2003) amongst patients from high-risk populations. All 328 subjects had a titre of at least 1:8 on RPR tests; 106 had baseline titres of $\geq 1:64$, levels indicative of active syphilitic lesions. Serological cure was observed in 97.5% (n = 163; 95% CI: 93.9% to 99.0%) of participants treated with 2 g azithromycin versus 95.2% (n = 165; 95% CI: 90.7% to 97.5%) in the BPG group as measured by RPR test and TPPA assays.³⁶⁴

The most recent study comparing the efficacy of azithromycin versus BPG is a multi-centre trial (2000 to 2007) in Madagascar (n = 421) and North America (n = 94) amongst HIV-negative participants with early syphilis. Serological cure was reported in 77.6% of subjects given 2 g azithromycin (n = 232; 95% CI: 71.8% to 82.5%) and 78.5%

(n = 237; 95% CI: 72.8% to 83.3%) in the BPG group based on RPR testing. Non-serious adverse events were reported by 61.5% (n = 174; 95% CI: 55.7% to 67.0%) of individuals treated with 2 g azithromycin, most of whom had self-limiting gastrointestinal discomfort. In contrast, 46.1% (95% CI: 40.6% to 52.1%) of BPG recipients reported non-serious adverse events.³⁶²

***In vitro* evidence**

Fourteen *in vitro* studies met inclusion criteria, seven with isolates from low-risk and unspecified low-risk populations, Table 5.2b, and seven from high-risk or mixed-risk groups, Table 5.2c. The first report to associate azithromycin treatment failure with A→G mutations at the 2058 position of the 23S rRNA gene of *T. pallidum* came from surveillance monitoring in San Francisco.³⁶⁵ Retrospective analysis revealed that 4.0% (N = 25; 95% CI: 0.9% to 19.6%) of isolates had A→G mutations between 1999 and 2002. In 2003, the proportion of isolates with A→G mutations increased to 36.7% (N = 30; 95% CI: 21.9% to 54.6%); by 2004, 56.1% (N = 66; 95% CI: 44.0% to 67.3%) had selected for resistance.³⁶⁵ In Dublin, however, 88.2% (N = 17; 95% CI: 65.3% to 96.4%) of isolates already had A→G mutations by 2002.³⁶⁶

Macrolide resistance has been strongly associated with prior use in the previous year. Isolates from Seattle (2001 to 2005) were two-times more likely to be resistant if patients had been treated with macrolides in the past 12 months (RR = 2.2; 95% CI: 1.1 to 4.4; *P* = 0.02).³⁶⁷ This relationship persisted over the decade. Mutations A2058G and A2059G, which are associated with clinical failures of azithromycin, were found in 88.9% (N = 36; 95% CI: 74.6% to 95.5%) of isolates from 2001 to 2010 amongst patients exposed to macrolides in the preceding 12 months, whereas 61.2% (N = 98;

95% CI: 51.3% to 70.4%) of isolates from individuals who had not received prior macrolide treatment contained the same mutations.³⁶⁸ Similar mutations were found amongst *T. pallidum* isolates from eight cities across China (2008 to 2011). A2058G was present in 97.0% individuals who had taken macrolides in the previous 12 months versus 62.5% of patients who had not (N=211; OR=19.65; 95% CI: 5.8 to 66.9).³⁶⁹ In Taiwan (2009 to 2011) the opposite was observed; not one single A2058G or A2059G mutation was found amongst 211 isolates tested from a population where only one person had been given macrolide therapy in the previous year.³⁷⁰ Similarly, there was no evidence of resistance amongst 141 amplified samples from HIV-negative heterosexual patients in Madagascar.³⁷¹ Although use of macrolides in the previous year was not reported, the Essential Drugs List of the Malagasy Ministry of Health does not include macrolides.³⁷²

Table 5.2b Azithromycin and syphilis: low-risk populations

Reference	Country	Year(s)	Specimen source	Sample size	Resistant mutation	Number resistant	Percent resistant	95% CI	Additional details
Low-risk populations									
Chen (2013) ³⁷³	United States	2007-2009	Surveillance	129	A2058G A2058G A2059G	83 67 17	64.3% 51.9% 13.2%	55.8% to 72.1% 43.4% to 60.4% 8.4% to 20.1%	From patients with primary or secondary syphilis attending STI clinics
Van Damme (2009) ³⁷¹	Madagascar	NR	Randomised clinical trial	186	23S rRNA	0	0.0%	NA	DNA of <i>T. pallidum</i> was detected in 141 samples; 61% of patients were male; 98% were heterosexual
Unspecified low-risk populations									
Müller (2012) ³⁷⁴	South Africa Lesotho	2005-2010	Surveillance	100	A2058G A2059G	1 0	1.0% 0.0%	0.0% to 5.4%	117 ulcer specimens collected of which 100 were positive for <i>T. pallidum</i> .
A2058G Prevalence Workgroup (2012) ³⁷⁵	United States	2007-2009	Surveillance	141	A2058G	75	53.1%	45.0% to 61.2%	From patients with primary or secondary syphilis attending STI clinics; MSM were nearly 6 times more likely to have resistant syphilis compared to heterosexual women and men
Matějková (2009) ³⁷⁶	Czech Republic	2005-2008	Passive case detection	22	23S rRNA A2058G A2059G	8 4 4	36.4% 18.2% 18.2%	19.7% to 57.3% 7.5% to 38.8% 7.5% to 38.8%	
Martin (2009) ³⁷⁷	China	2007-2008	Passive case detection	38	A2058G	38	100.0%	NA	Patients presenting to STI clinic with symptoms compatible with primary syphilis
Lukehart (2004) ³⁶⁶	United States								PCR to detect 23S rRNA gene mutations; confirmation of azithromycin resistance was conducted through intradermal rabbit inoculation.
	San Francisco	1999-2002	Surveillance	25	23S rRNA	1	4.0%	1.0% to 19.6%	
	San Francisco	2003		30		11	36.7%	21.9% to 54.6%	
	Seattle	2001-03		23		3	13.0%	4.7% to 32.3%	
	Baltimore	1998-2000		19		2	10.5%	3.2% to 31.7%	
	Ireland								
	Dublin	2002	Surveillance	17	23S rRNA	15	88.2%	65.3% to 96.4%	
	Multiple locations	1912-1987	Historical	18	23S rRNA	1	5.6%	1.3% to 2.6%	

rRNA=Ribosomal ribonucleic acid; NA=Not applicable; DNA=Deoxyribonucleic acid; STI=Sexually transmitted infection; MSM=Men who has sex with men; PCR=Polymerase chain reaction

Table 5.2c Azithromycin and syphilis: high- and mixed-risk populations

Reference	Country	Year(s)	Specimen source	Sample size	Resistant mutation	Number resistant	Percent resistant	95% CI	Additional details
High-risk populations									
Tipple (2011) ³⁷⁸	United Kingdom	2006-2008	Cross-sectional	18	23S rRNA A2058G	12 11	66.6% 61.1%	43.4% to 83.7% 38.4% to 79.7%	Specimens from men, 94.1% were MSM
Rekart (2003) ³⁷⁹	Canada	2000	Mass drug administration	25	23S rRNA	0	0.0%	NA	1.8 g azithromycin given to sex workers and clients (N = 4,384)
Mixed-risk populations									
Chen (2012) ³⁶⁹	China	2008-2011	Cross-sectional	211	A2058G	194	91.9%	87.2% to 95.1%	391 samples collected; 6.1% from FSW, 71.8% reported sex with FSW, and 1.4% were MSM
Muldoon (2012) ³⁸⁰	Ireland	2009-2010	Cross-sectional	29	A2058G	27	93.1%	77.9% to 97.9%	34.6% (36/104) of samples were positive for <i>T. pallidum</i> by PCR; 29 sequenced
Martin (2010) ³⁸¹	Canada	2007-2009	Cross-sectional	43	A2058G	7	16.3%	8.2% to 30.1%	449 samples collected from 374 patients; 43 were positive for <i>T. pallidum</i> and sequenced.
Mitchell (2006) ³⁸²	United States	2000-2002	Retrospective	25	23S rRNA	1	4.0%	1.0% to 19.6%	Patients (N = 1,308) diagnosed primary or secondary syphilis; all treatment failure and resistance in MSM/bisexual patients
		2003		32		13	40.6%	25.5% to 57.9%	
		2004		66		37	56.1	44.0% to 67.4%	
Morshed (2006) ³⁸³	Canada	2000-2003	Retrospective	47	23S rRNA	1	2.1%	0.5% to 11.1%	MSM patients presenting to STI clinic with primary or secondary syphilis
		2004		9		4	44.4%	18.7% to 73.8%	

rRNA=Ribosomal ribonucleic acid; MSM=Men who have sex with men; NA=Not applicable; PCR=Polymerase chain reaction; FSW=Female sex worker; STI=sexually transmitted infection

***Neisseria gonorrhoeae* and azithromycin**

***In vivo* evidence**

The WHO recommends the treatment of pregnant women with *N. gonorrhoeae* infection using 400 mg cefixime as a single dose, or 125 mg ceftriaxone by intramuscular injection.¹¹⁰ However, azithromycin has been used for the treatment of gonorrhoea amongst non-pregnant adults during the past two decades. Eleven trials were identified by systematic review as shown in Table 5.3a. Nine trials between 1989 and 1999 were conducted amongst attendees of STI clinics using 1 g azithromycin. Three of these trials were open label without comparators,³⁸⁴⁻³⁸⁶ whereas six were two-arm trials that compared azithromycin to ciprofloxacin and/or doxycycline.³⁸⁷⁻³⁹² Meta-analysis using random effects models¹⁷⁵ suggests that the pooled efficacy of azithromycin against *N. gonorrhoeae* was 97.0% (N = 539; 95% CI: 95.5% to 98.5%). This is slightly higher than 96.5% (N = 539; 95% CI: 94.3% to 97.6%) reported in a 2010 review³⁹³ that added numerators and divided by the sum of denominators amongst the same nine trials. However, the methods used in that review were dubious, failing to account for heterogeneity across study populations and giving equal weight to all trials regardless of their individual study precision. Nevertheless, it is unlikely the same efficacy would be observed today using 1 g azithromycin in high-income countries following 25 years of cumulative drug pressure. However, the epidemiological context in sub-Saharan Africa is different where azithromycin use has been almost exclusively limited to trachoma eradication campaigns.³⁹⁴

Two RCTs investigated the use of 2 g azithromycin amongst patients at STI clinics. The first was a multi-centre trial in the United States (1991 and 1992) in which 98.9%

(N=374; 95% CI: 97.3% to 99.6%) of patients were cured.³⁹⁵ A similar RCT in New Delhi (2005 and 2006) involved 42 participants. The reported loss to follow up was high, 52.4%, but all 22 subjects who returned for a test of cure had their *N. gonorrhoeae* infections cleared.³⁹⁶

Table 5.3a *Neisseria gonorrhoeae* RCTs of azithromycin

Reference (year of publication)	Country	Year(s)	Azithromycin dose	No. of cured evaluated	Percent cured	95% CI	Diagnostic methods	Additional details
Dose of 2 g azithromycin								
Khaki (2007) ³⁹⁶	India	2005-2006	2 g	22/22	100%	NA	Gram stain TOC days 5-7	
Handsfield (1994) ³⁹⁵	United States	1991-1992	2 g	370/374	98.9%	97.3% to 99.6%		
Dose of 1 g azithromycin								
Rustomjee (2002) ³⁹²	South Africa	1999	1 g	30/31	96.8%	83.8% to 99.2%	LCR for NG/CT TOC day 14	100% (n = 21) NG infections cured 100% (n = 14) CT infections cured 90.0% (n = 10; 95% CI: 58.7 to 97.8%) co-infections cured
Swanston (2001) ³⁸⁶	Trinidad and Tobago	1996	1 g	125/127	98.4%	94.5% to 99.5%	ELISA for NG Culture for CT; TOC days 7-10	100% (n = 115) NG infections cured 95.7% (n = 23; 95% CI: 78.9 to 99.0%) CT infections cured 88.3% (n = 12; 95% CI: 54.6 to 95.0%) co-infections cured
Gruber (1997) ³⁹¹	Croatia	1994-1995	1 g	48/50	96.0%	86.5% to 98.8%	Culture and gram-stain for NG; TOC day 14	
Gruber (1995) ³⁹⁰	Croatia	1991-1993	1 g	24/24	96.0%	80.4% to 99.1%	Culture and gram-stain for NG; TOC day 14	
Steingrimsdottir (1994) ³⁸⁹	Iceland	NR	1 g	27/28	96.4%	82.4% to 99.2%	Culture for NG w/ DFA; Culture for CT; TOC day 28	92.4% (n = 79; 84.4 to 96.4%) CT infections cured
Waugh (1993) ³⁸⁵	United Kingdom	1990-1991	1 g	85/89	95.5%	89.0% to 98.2%	Culture and gram-stain for NG; Culture for CT; TOC day 10	100% (n = 22) NG/CT co-infections cured
Odugbemi (1993) ³⁸⁴	Nigeria	1989-1990	1 g	114/120	95.0%	89.5% to 97.6%	Culture for NG; TOC day 14	
Steingrimsdottir (1990) ³⁸⁸	Iceland	NR	1 g (day 0)	11/12	91.7%	64.0% to 98.1%	Culture for NG/CT; TOC day 28	97.7% (n = 44; 88.2 to 99.5%) CT infections cured
			500 mg (day 0 x 2)	7/8	87.5%	51.8% to 97.2%		96.3% (n = 27; 81.7 to 99.1%) CT infections cured
			500 mg (day 0) 250 g (day 1 & 2)	7/7	100%	NA		88.0% (n = 25; 69.8 to 95.6%) CT infections cured
Lassus (1990) ³⁸⁷	Finland	NR	1 (day 0)	15/15	100%	NA	Culture and gram-stain for NG/CT w/ DFA; TOC day 14	100% (n = 12) CT infections cured 100% (n = 5) co-infections cured
			500 mg (day 0) 250 mg (days 1 & 2)	14/14	100%	NA		100% (n = 9) CT infections cured 83.3% (n = 6; 95% CI: 42.1 to 96.3%) co-infections cured

TOC = Test of cure; NG = *Neisseria gonorrhoeae*; CT = *Chlamydia trachomatis*; LCR = Ligase chain reaction; DFA = direct fluorescent antibody; ELISA = Enzyme-linked immunosorbent assay; NR = Not reported ; NA = Not applicable

***In vitro* evidence**

Several *in vitro* studies have documented the loss of *N. gonorrhoeae* sensitivity to azithromycin over the past decade. There are no standard breakpoints of minimum inhibitory concentrations (MIC) used to categorize *N. gonorrhoeae* resistance to azithromycin, but ≥ 1 $\mu\text{g/mL}$ and ≥ 2 $\mu\text{g/mL}$ have both been used.³⁹⁷ This section summarises key regional observations from 36 *in vitro* studies as shown in Tables 5.3b and 5.3c.

The Public Health Agency of Canada reported that 0.17% (N = 40,875; 95% CI: 0.001% to 0.002%) of *N. gonorrhoeae* samples were resistant to azithromycin between 2000 and 2009. The numeric mode of the MIC shifted from 0.25 $\mu\text{g/mL}$ in 2001 to 0.5 $\mu\text{g/mL}$ between 2007 and 2009.³⁹⁸ During the same 10-year period, the Centers for Disease Control and Prevention in the United States reported that 0.04% (N = 87,566; 95% CI: 0.03% to 0.06%) of *N. gonorrhoeae* isolates tested had MICs ≥ 8 $\mu\text{g/mL}$ (including 25 with 8 $\mu\text{g/mL}$ and 14 with 16 $\mu\text{g/mL}$).³⁹⁹ This did not include five cases of azithromycin resistance reported later that had been found between August and October 2009 amongst men who have sex with men. Three samples investigated had MICs of 8 $\mu\text{g/mL}$, whereas two had MICs of 16 $\mu\text{g/mL}$.⁴⁰⁰

Table 5.3b Azithromycin and *Neisseria gonorrhoeae*: low-risk populations

Reference (year of publication)	Country	Year(s)	Sample size	MIC range (µg/mL)	% strains susceptible	Additional details
Olsen (2013) ⁴⁰¹	Vietnam	2011	108	NR	62%	11% isolates fully resistant, 29% intermediate susceptibility
Lahra (2012) ⁴⁰²	Australia	2011	3,293	≤4	98.1%	Isolates from all states in Australia
Sethi (2013) ⁴⁰³	India/Pakistan/Bhutan	2007-2011	65	0.016 to 4.0	76.9%	7.7% isolates fully resistant, 15.4% intermediate susceptibility
Lo (2012) ⁴⁰⁴	Hong Kong	2010	485	<0.25 to >256	69.7%	--
Lefebvre (2011) ⁴⁰⁵	Canada	2010	831	≤16	98.7%	--
Hottes (2013) ⁴⁰⁶	Canada	2006-2011	1,837	0.064 to 16	99%	Elevated MIC showed increasing trend over time
CDC (2011) ⁴⁰⁰	United States	2002-2009	87,566		99.9%	39 (0.04%) had MICs ≥8 µg/mL (25 with 8 µg/mL; 14 with 16 µg/mL)
Yuan (2011) ⁴⁰⁷	China	2008-2009	318	NR	94.7%	--
Takahashi (2013) ⁴⁰⁸	Japan	2007-2009	52	0.016 to 1	100%	100% of isolates from men ^a
Herchline (2010) ⁴⁰⁹	United States	2006-2008	286	0.032 to 1.0	99.0%	Median MIC 0.125 µg/mL
Cole (2010) ³⁹⁹	Europe (17 nations)	2006-2008	3,528	≤256	2.0% to 7.0%	High resistance (>256 µg/mL) in 4 isolates from Scotland and 1 in Ireland
Olsen (2012) ⁴¹⁰	Guinea-Bissau	2006-2008	31	NR	100%	Of resistant strains, 2 had MIC >64 µg/mL
Tanaka (2011) ⁴¹¹	Japan	2001- 2009	242	0.004 to 1.0	99.9%	Modal shift of MIC was 0.25-0.5 µg/mL
Martin (2011) ³⁹⁸	Canada	2000-2009	40,875	≤64	99.8%	100% isolates susceptible also to cefixime, ceftriaxone and spectinomycin.
Bala (2011) ⁴¹²	India	2000-2009	274	NR	99.7%	One isolate was resistant to azithromycin, quinolones and penicillin
Chisholm (2009) ⁴¹³	United Kingdom	2001-2007	108	<0.03 to >256	94.0%	6/108 isolates had MIC >256 µg/mL ; Shift to high level resistance
Khaki (2007) ⁴¹⁴	India	2004-2005	60	0.016 to 0.25	100%	--
Enders (2006) ⁴¹⁵	Southern Germany	2004-2005	65	0.016 to 5.0	100%	100% of isolates susceptible to azithromycin
Vorobieva (2007) ⁴¹⁶	Russia	2004	76	NR	100%	Although all susceptible, reduced susceptibility seen in 14%
Sutrisna (2006) ⁴¹⁷	Indonesia	2004	163	NR	100%	53% resistant to ciprofloxacin
Martin (2004) ⁴¹⁸	Western Europe	2004	965	NR	91.8%	31.2% (Austria 30/96) to 0% (France 0/101, Greece 0/79, Portugal 0/17)
Chaudhary (2005) ⁴¹⁹	Nepal	2003	16	0.008 to 0.5	100%	No isolates resistant, but 3/16 (19%) had reduced susceptibility
Chen (2009) ⁴²⁰	Taiwan	1999-2004	65	NR	100%	--
Hsueh (2005) ⁴²¹	Taiwan	1999-2003	55	0.03 to 9.0	72.7%	--
Aydin (2005) ⁴²²	Turkey	1998-2002	78	0.004 to 0.25	100%	100% of isolates from men ^a
Moodley (2001) ⁴²³	South Africa	1995-2000	58	0.015 to 1.0	100%	37% (37/100) resistant to penicillin; tetracyclines reduced susceptibility.
Kobayashi (2003) ⁴²⁴	Japan	1995-1999	699	0.015 to 1	100%	100% of isolates from men ^a
Llanes (2003) ⁴²⁵	Cuba	1995-1999	52	0.064 to 0.5	76.9%	23.1% intermediate susceptibility: MIC= 0.125 (10 isolates) MIC= 0.5 (2 isolates)
Sosa (2003) ⁴²⁶	Cuba	1995-1999	91	0.063 to 4.0	90.1%	Isolates with reduced susceptibility also resistant to penicillin and tetracycline
Dillon (2001) ⁴²⁷	Brazil	1998	81	0.032 to 0.5	100%	28% reduced susceptibility
Zarantonelli (1999) ⁴²⁸	Uruguay	1996-1997	51	0.032 to 0.5	100%	Decreased susceptibility (MIC 0.025 to 0.5) in 72%; isolates from men ^a
Young (1997) ⁴²⁹	Scotland	1996	67	0.023 to 0.75	100%	Isolates randomly selected from with penicillin MIC≥1
Mehaffey (1996) ⁴³⁰	United States	NR	105	0.06 to 2.0	100%	Two tests compared. Data from agar dilution method not Etest.
Dillon (2001)	Guyana & St Vincent	1992-1996	136	0.032 to 8.0	85.5% & 97.0%	2 isolates had MIC =8µg/L. 49% (67/137) reduced susceptibility (combined)
Van Rijsoort-Vos (1995) ⁴³¹	Netherlands	1991-1993	114	0.03 to 1.0	100%	1 isolate reduced susceptibility
Ison (1993) ⁴³²	South Africa	1989-1990	192	0.03 to 1.0	100%	Study in migrant mine-workers (men only) ^b

MIC = Minimum inhibitory concentration; NR = Not reported; CDC = Centers for Disease Control and Prevention ^aSexual practices were not reported; isolates are assumed not to be from men who have sex with men; ^bDislocated males workers are amongst high-risk populations;.

Table 5.3c Azithromycin and *Neisseria gonorrhoeae*: high-risk populations

Reference (year of publication)	Country	Year(s)	Sample size	MIC range (µg/mL)	% of strains susceptible	Additional details
High-risk populations						
CDC (2011) ⁴⁰⁰	United States	2009	55	NR	90.9%	9.1% resistant (95% CI: 4.0 to 19.6%); of 5 resistant (all from MSM), 3 had MIC equal to 8ug/mL and 2 had MIC equal to 16ug/ml
Starnino (2009) ⁴³³	Italy	2007-2008	219	1.0 to 256.0	90.0%	72.7% (95% CI: 51.6 to 86.8%) of resistant isolates from MSM
Donegan (2006) ⁴³⁴	Bali	2004	147	0.013 to 0.512	100%	Study in FSWs; prevalence of NG estimated to be 35-60%
Morris (2009) ⁴³⁵	United States	2000-2002	79	0.03 to 0.5	100%	Increased MIC values seen in MSM subject isolates
Ieven (2003) ⁴³⁶	Indonesia	1996	267	0.032 to 0.5	100%	Study in FSWs; prevalence of NG estimated to be 18-44%
CDC (2000) ⁴³⁷	United States	1999	12	1.0 to 4.0	NR	Median MIC was 2.0ug/mL. 6 of 12 samples were from men who had sex with a CSW; 2 of 12 were from HIV positive men
Mixed-risk populations						
Bruck (2012) ⁴³⁸	United Kingdom	2005-2006	147	NR	99.3%	Mixed male heterosexual, MSM and female heterosexual isolates
Dan (2010) ⁴³⁹	Israel	2002-2007	406	0.023 to 8.0	91.8%	Mixed male heterosexual, MSM and female heterosexual; resistance to azithromycin did not appear to rise over 5 year period
McLean (2004) ⁴⁴⁰	United States	1999-2001	1,248	≤4	97.4%	Mixed high risk and low risk population. Median MIC was 2.0ug.mL
Arreaza (2003) ⁴⁴¹	Spain	1992-2001	63	0.03 to 4.0	96.8%	58.7% of strains had reduced susceptibility (0.25-1.0ug/ml). 50% of resistant isolates were from FSW

* Mixed-risk population; MIC = Minimum inhibitory concentration; NR = Not reported; MSM = Men who have sex with men; FSWs = Female sex workers; NG = *Neisseria gonorrhoeae*; CSW = Commercial sex worker (gender not specified); CDC = Centers for Disease Control and Prevention

Gonococcal resistance may have appeared in Europe slightly before North America. Analysis of isolates from 17 European countries suggests that 3.2% (N = 836; 95% CI: 0.02% to 0.05%) of gonococcal isolates were resistant to azithromycin in 2006. By 2007, 6.8% (N = 973; 95% CI: 0.05 to 0.09) of samples were resistant. Sampling in 2008 found 1.8% (N = 940; 95% CI: 0.01% to 0.03%) of isolates to be resistant. However, only 5.2% (95% CI: 4.1% to 6.8%) of strains tested in the same year were fully susceptible to azithromycin and ciprofloxacin. Four isolates from Scotland and one from Ireland exhibited MICs >256 mg/l.³⁹⁹

Gonococcal isolates from South America and Cuba exhibited high but stable levels of resistance between 2000 and 2009 in most settings.⁴⁴² Collectively, azithromycin resistance was 13.0% (N = 8,373; 95% CI: 12.3% to 13.7%) based on data from six countries including Chile, an outlier. Averaged over the decade, 26.7% (N = 3,116; 95% CI: 25.2% to 28.3%) of samples from Chile were resistant, rising to 45.6% (N = 463; 95% CI: 41.1% to 50.1%) in the most recent data from 2009. Meta-analysis using random effects models, excluding data from Chile, suggests that only 4.4% (N = 5,257; 95% CI: 3.9% to 5.1%) of isolates were resistant over the decade.

All 60 gonococcal isolates from India between 2004 and 2005 were susceptible to azithromycin.⁴¹⁴ Published analysis of samples collected from India, Pakistan and Bhutan between 2007 and 2011 found that 76.9% (N = 65; 95% CI: 65.3% to 85.5%) were susceptible. Results were not stratified by country and, therefore, it is unknown whether the sensitivity of isolates from India had changed during the same period.⁴⁰³ Applying the more conservative breakpoint of $\geq 1 \mu\text{g/mL}$ to the *in vitro* studies

identified in this systematic review, 35% (7 of 20) of the *in vitro* studies reported upper-range MICs that included gonococcal isolates resistant to azithromycin. This percentage does not include 16 studies identified and included in Tables 5.3b and 5.3c that did not report MICs.

***Chlamydia trachomatis* and azithromycin**

***In vivo* evidence**

The WHO recommends treating pregnant women with *C. trachomatis* infection using 1 g azithromycin as a single oral dose.¹¹⁰ There were eight RCTs in the literature that reported the treatment efficacy of 1 g azithromycin amongst pregnant women⁴⁴³⁻⁴⁵⁰ as summarised in Table 5.4a. Meta-analysis using random effect models suggests the pooled treatment efficacy was 92.1% (N = 268; 95% CI: 88.4% to 95.7%). The estimated efficacy would be higher if two trials from the United States had been excluded. The first trial (1995 to 1997) reported a three-week test of cure rate to be 88.1% (N = 42; 95% CI: 74.9% to 94.7%).⁴⁴⁶ The second trial (1998 to 2000) was terminated early, however, as tests of cure conducted four or more weeks post-treatment showed that only 63.3% of infections had been cleared (N = 55; 95% CI: 50.4% to 75.1%).⁴⁴⁴ These results need to be interpreted with caution because no distinction was made between treatment failures and new infections. Moreover, sex partners were referred to treatment centres, and only 35% of women were seen by trial staff within seven days of the scheduled test of cure.

Table 5.4a Azithromycin and *Chlamydia trachomatis* in pregnant women

Reference (year of publication)	Country	Year(s)	No. cured of evaluated	Cured (%)	95% CI	Diagnostic method	Birth outcomes	Additional details
Kacmar (2001) ⁴⁴³	United States	1998-2000	18/19	94.7%	84.4% to 100%*	Ligase chain reaction; TOC 28-42 days	NR	52.6% (n = 19; 95% CI: 31.5% to 72.8%) had side effects; passive or active solicitation not reported; 13.6 weeks (± 8.0 SD) mean gestational age at enrolment
Jacobson (2001) ⁴⁴⁴	United States	1998-2000	35/55	63.6%	47.7% to 79.6%	DNA LCx STD assay; TOC 28 days	13.3% (6/45) preterm	10.1% (n = 55; 95% CI: 5.2% to 21.9%) had side effects; passive or active solicitation not reported; 20.6 weeks (± 8.8 SD) mean gestational age at enrolment
Wehbeh (1998) ⁴⁴⁵	United States	NR	26/27	96.3%	89.0% to 100%*	Culture	NR	100% (n=27) of partners treated
Adair (1998) ⁴⁴⁶	United States	1995-1997	37/42	88.1%	77.7% to 98.5%	DNA assay; TOC 28 days	NR	11.9% (n = 5; 95% CI: 5.3% to 25.1%) had side effects; passive or active solicitation was not reported; 21.6 weeks (± 9.5 SD) mean gestational age at enrolment; 54.8% (n = 23) of partners treated
Edwards (1996) ⁴⁴⁸	United States	1993-1994	61/65	93.8%	87.8% to 99.9%	DNA assay; TOC 14 days	9.2% (6/65) preterm, 3 due to PROM; Mean gestational age at delivery 38.8 wks ± 1.6	20.4 weeks mean gestational age at enrolment
Rosenn (1995) ⁴⁴⁹	United States	1994-1995	21/23	91.3%	79.3% to 100%*	PCR; TOC 21 days	NR	19.3 weeks (± 3.5 SD) mean gestational age at enrolment
Gunter (1996) ⁴⁴⁷	United States	NR	22/22	100.0%	NA	DNA assay; TOC 14 days	NR	13.6% (n = 3; 95% CI: 5.0% to 33.6%) had gastrointestinal side effects; passive or active solicitation not reported
Bush and Rosa (1994) ⁴⁵⁰	United States	NR	15/15	100.0%	NA	DNA assay; TOC 14 days	NR	0% of women experienced side effects; 100% (n = 15) of partners treated
Rahangdale (2006) ⁴⁵¹	United States	1999-2000	137/141	97.2%	94.4% to 99.9%	DNA assay; TOC days 7-20; 21-34; 35-55; >56	7.5% (16/221 'any' preterm azithromycin)	13.1% (n = 191; 95% CI: 9.0% to 18.6%) also had BV 14.1 weeks (± 6.3 SD) mean gestational age at enrolment
Miller (1995) ⁴⁵²	United States	1993-1994	132/138	95.6%	92.2% to 99.1%	DNA assay; TOC 10-14 days	15.2% (19/125) preterm	5.5% (n = 146; 95% CI: 2.8% to 10.4%) had side effects; 23.9% (n = 138; 17.6% to 31.7%) women also had NG; 17.4% (4/17) reported side effects (all GI); mean gestational age at enrolment not reported

Note that all studies used 1 g of azithromycin delivered as 1 dose; CI = Confidence interval; TOC = Test of cure; NR = Not reported; DNA = Deoxyribonucleic acid; PROM = Preterm premature rupture of the membranes; SD = Standard deviation; NG = *Neisseria gonorrhoeae*; BV = Bacterial vaginosis; GI = gastrointestinal; Upper confidence interval exceeded 100% and, therefore, was cut-off.

Studies investigating sexual activity following treatment may help to explain post-treatment infections; misclassification of treatment failures and *de novo* infections may have been at play. A trial in Seattle (1998 to 2003) found that persistent or recurrent chlamydial or gonorrhoeal infection occurred in 7.6% (N = 289; 95% CI: 5.1% to 4.9%) of female patients who reported no sexual intercourse after treatment.⁴⁵³ Another study reported that 19.0% (N = 79; 95% CI: 11.9% to 29.0%) of women were positive for *C. trachomatis* three months after treatment using 1 g azithromycin. Of these women, 13.3% (N = 15; 95% CI: 4.0% to 38.3%) reported being inactive sexually during the post-treatment period.⁴⁵⁴ These findings may be attributable to: (i) false reporting of sexual contact, (ii) treatment failure, or (iii) may lend credence to the hypothesis that *C. trachomatis* enters a latent asymptomatic state which is undetectable by culture or, possibly, Nucleic Acid Amplification Tests for a time-limited period and can later reactivate.⁴⁵⁵

***In vitro* evidence**

Specific thresholds for antimicrobial susceptibility and resistance of *C. trachomatis* are not universally standard, although MICs of > 4 µg/ml (microgram per millilitre) are often used to characterize therapeutic failure.⁴⁵⁶⁻⁴⁵⁹ The lowest concentration of antimicrobial needed to inhibit chlamydial development is between 0.03 and 0.125µg/ml, whereas the minimum bactericidal concentration (MBC; also referred to as the minimum chlamydicidal concentration, or MCC), is between 0.06 and 0.5µg/ml.^{460,461} Current evidence from *in vitro* studies suggest that azithromycin maintains high and widespread treatment efficacy against *C. trachomatis* as summarised in Table 5.4b. One exception, however, is a study of six isolates from

three patients who experienced treatment failure in Russia (2000 to 2002). Four isolates were resistant to azithromycin, doxycycline and ofloxacin at MICs and MBCs > 5.12µg/ml.⁴⁶² Not surprisingly, *in vitro* resistance appears to be more common amongst isolates from individuals with greater severity of disease or recurrent disease.⁴⁶³ A study in the United States during the early 1990s described decreased susceptibility and emerging resistance to azithromycin and doxycycline in isolates from women with mucopurulent cervicitis, whereas isolates from women with asymptomatic infections remained susceptible.⁴⁶⁴

Table 5.4b Azithromycin and *Chlamydia trachomatis*: low-risk populations

Reference (year of publication)	Country	Year(s)	Azithromycin		Other macrolides		Additional details
			MIC (µg/ml)	MBC/MCC (µg/ml)	MIC (µg/ml)	MBC (µg/ml)	
No resistance observed							
Ljubin-Sternak (2012) ⁴⁶⁵	Croatia	2010	0.064 to 0.125	0.064 to 2.0	Doxycycline: 0.016 to 0.064	0.032 to 1.0	24 urogenital strains assessed
Donati (2010) ⁴⁶⁶	Italy	2005-2006	0.25 to 0.5	0.5 to 1.0	Doxycycline: 0.03 to 0.06 Erythromycin: 0.5 to 1.0	0.06 to 0.125 1.0 to 2.0	All serovars had comparable susceptibilities. Azithromycin and doxycycline bactericidal with MBC at 1- 2 times the MIC. (50 strains)
Hong (2009) ⁴⁶⁷	Ethiopia	2006	0.25 to 0.5	0.25 to 1.0	Doxycycline: 0.015 to 0.03	0.03 to 0.06	Azithromycin unchanged between pre- and post-mass biannual treatment of trachoma (10 strains)
Samra (2001) ⁴⁵⁹	Israel	1997-1999	0.06 to 0.125	0.06 to 0.25	Doxycycline: 0.125 to 0.25 Tetracyclines: 0.25 to 0.5	0.125 to 4.0 0.25 to 4.0	Smallest MBC and MIC difference in azithromycin vs. doxycycline (4 dilutions differences; 50 isolates)
Lefèvre (1993) ⁴⁶⁸	France	NR	0.06 to 0.125	0.25 to 0.5	Clarithromycin: 0.008 Erythromycin : 0.06 to 0.125 Tetracyclines: 0.125 to 0.25	0.03 to 0.125 0.25 to 2.0 1.0 to 4.0	15 clinical isolates tested
Agacfidan (1993) ⁴⁶⁹	United States	1993	≤0.06 to 1	0.12 to 2.0	Doxycycline: 0.015 to 0.06 Tetracyclines: 0.03 to 0.12	0.015 to 0.06 0.06 to 0.12	Azithromycin highly active against CT in isolates from urethral and cervical samples (azithromycin 10 strains, doxycycline 22 strains, tetracycline 22 strains)
Scieux (1990) ⁴⁷⁰	United Kingdom	1990	0.064 to 0.25	2.0 to 8.0	Doxycycline: 0.016 to 0.064 Erythromycin: 0.064 to 0.128	0.5 to 8.0 0 to 64.0	10 strains used from the United States
Resistance observed							
Bhengraj (2010) ⁴⁶⁴	India	2006-2007	0.12 to 8	≤ 8.0	Doxycycline: 0.025 to 8.0)	≤8.0	Decreased antimicrobial susceptibility in recurrently infected female patients (21 isolates)
Misyurina (2004) ⁴⁶²	Russia	2000-2002	>5.12	> 5.12	Erythromycin: > 5.12	>5.12	Isolates from salpingitis, endocervicitis, and urethritis showed resistance (6 isolates)
Somani (2000) ⁴⁵⁸	United States	1995-1998	0.5 to >4.0	> 4.0	Doxycycline: 0.125 to > 4.0	>4.0	Resistance of strains causing relapsing or persistent infection in 3 patients (3 isolates)
Rice (1995) ⁴⁶³	United States	1995	0.125 to 2.0	0.5 to > 4.0	Doxycycline: 0.008 to 0.06	0.015 to 4.0	Isolates susceptible to azithromycin and doxycycline in asymptomatic infection

MIC = Minimum inhibitory concentrations; MBC = Minimum bactericidal concentration; MCC = Minimum chlamydicidal concentrations; NR = Not reported; CT = *C. trachomatis*; PID = Pelvic inflammatory disease

Trichomonas vaginalis

***In vivo* evidence**

Trichomonas vaginalis is a protozoal infection that produces cervicitis and non-gonococcal urethritis. Treatment of pregnant women with *T. vaginalis* infection after the first trimester, per WHO recommendations, requires the administration of 2g metronidazole as a single dose, or 400-500 mg twice daily for seven days, or 300 mg clindamycin orally twice a day for seven days.¹¹⁰ If treatment is imperative during the first trimester of pregnancy, the single-dose regimen of 2 g metronidazole orally is recommended.¹¹⁰ Azithromycin has not been used directly for prevention or treatment purposes because *T. vaginalis* is anaerobic. Nevertheless, azithromycin has demonstrated prophylactic protection against *T. vaginalis* in studies of mass STI/RTI treatment as summarised in Tables 5.5a and 5.5b.

In Kenya (1998 to 2002), 1 g azithromycin was compared to placebo and administered once per month to 466 HIV-negative female sex workers.⁴⁷¹ At the end of the trial, HIV incidence was the same across treatment groups, the primary endpoint, but the risk of *T. vaginalis* was reduced by one-half amongst female sex workers who were given azithromycin versus placebo (RR = 0.56; 96% CI, 0.40 to 0.78; $P < 0.001$).

Table 5.5a RCTs of azithromycin combinations amongst pregnant women

Reference (year of publication)	Country	Year(s)	Regimen	Number of cases post treatment (%)					Additional details
				<i>Treponema pallidum</i> *	<i>Neisseria gonorrhoeae</i>	<i>Chlamydia trachomatis</i>	<i>Trichomonas vaginalis</i>	Bacterial vaginosis	
Luntamo (2010) ¹⁰⁷	Malawi	2003- 2006	Intervention 1 g AZ x 2 + SP monthly	NR	0.5% (2/391)	0.3% (1/391)	11.0% (46/419)	NR	Significant protection against <i>T. vaginalis</i> <i>P</i> = 0.05
			Intervention SP monthly	NR	2.1% (8/384)	0.3% (1/384)	15.1% (62/411)	NR	
			Control SP x 2	NR	0.7% (3/391)	0.3% (1/391)	16.7% (69/411)	NR	
van den Broek (2009) ¹⁰⁸	Malawi	2004- 2005	Intervention 1 g AZ x 2 + SP x2	NR	NR	NR	NR	NR	No difference in preterm birth (16.8% versus 17.4%); potential explanatory factors include use of sub-optimal syphilis treatment ^{2,472}
			Control SP x 2	NR	NR	NR	NR	NR	
Gray (2001) ³⁵⁸	Uganda	1994- 1998	Intervention 1 g AZ + 250 mg CIPX + 2g MTZ	3.4% (57/1,677)	0.9% (14/1,503)	1.1% (16/1,503)	4.7% (4/1,779)	36.3% (645/1,779)	Neonatal death RR=0.83; 95% CI: 0.71 to 0.97; Low birth weight RR=0.68; 95% CI: 0.53 to 0.86; Preterm delivery RR=0.77; 95% CI: 0.56 to 1.05. Vertical transmission of HIV was no different between intervention and control groups.
			Control Iron-folate + 100 mg MBZ x2	3.3% (46/1,376)	1.7% (24/1,394)	2.7% (38/1,394)	15.9% (248/1,569)	48.5% (764/1,576)	
Wawer (1999) ⁴⁷³	Uganda	1994- 1998	Intervention 1 g AZ + 250 mg CIPX + 2 g MTZ	6.0% (80/1,323)	1.0% (8/770)	1.2% (9/770)	5.3% (72/1,350)	39.1% (533/1,364)	Vertical transmission of HIV was no different between intervention and control groups.
			Control Iron-folate + 100 mg MBZ x2	7.1% (75/1,056)	2.1% (15/714)	3.5% (25/714)	17.4% (198/1,137)	52.8% (609/1,154)	

*2.4µ benzathine Penicillin G was administered to pregnant women in all treatment groups per national guidelines (exception being ¹⁰⁸); AZ = Azithromycin; SP = Sulphadoxine-pyrimethamine; NR = Not reported; RR = Risk ratio; CI = Confidence interval; CIPX = Ciprofloxacin; HIV = Human immunodeficiency virus

Table 5.5b RCTs of azithromycin combinations amongst commercial sex workers

Reference (year of publication)	Country	Year(s)	Regimen		Proportion of cases cured (cases pre-treatment / cases post-treatment)					Additional details
					Syphilis*	<i>N. gonorrhoeae</i>	<i>C. trachomatis</i>	<i>T. vaginalis</i>	Bacterial vaginosis	
Kaul (2004) ⁴⁷¹	Kenya	1998- 2002	Intervention 1 g AZ monthly (multi-yr pd)		3.9%	2.6%	1.1%	11.3%	53.0%	Incidence reported per 100 women-years
			Control Placebo		3.8%	5.7%	6.5%	20.4%	57.4%	
Labbe (2012) ⁴⁷⁴	Benin Ghana	2001	Intervention 1 g AZ or 500 g CIPX monthly for 9 mo alternating AZ & CIPX		NR	5.6% (7/126)	1.6% (2/126)	NR	NR	Significant protection against NG <i>P</i> = 0.05
			Control Placebo		NR	12.5% (14/112)	2.7% (3/112)	NR	NR	
Cowan (2005) ⁴⁷⁵	Zimbabwe	NR	Intervention 1 g AZ + 2 g MTZ + 500 mg CIPX		Base: 5.0% (2.8, 8.7%); V2, V3, V4 = NR in any form	Base: 1.9% (0.5, 3.4%); graphs contain visible inaccuracies for V2, V3, V4	Base: 1.7% (0.3, 3.0%); graphs contain visible inaccuracies for V2, V3, V4	Base: 19.3% (15.2, 23.4%) V2: 4.3% (7.7 to 2.2%) V3: 12.6% (17.7 to 8.8%) V4: 11.5% (15.7 to 7.8%)	--	--
			Intervention 1 g AZ + 2 g MTZ							
Wi (2006) ⁴⁷⁶	Philippines	2001	Intervention 1 g AZ one time	Prior to intervention	NR	18.3% (207/1,130)	28.6% (323/1,130)	NR	NR	--
				1 mo post- intervention		11.9% (82/687)	15.1% (104/687)			
Williams (2003) ⁴⁷⁷	South Africa	1998- 2000	Intervention 1 g AZ 9x in 9 mo	Prior to intervention	9.8% (68/691)	6.9% (48/691)	7.9% (55/691)	NR	NR	HIV prevalence amongst CSW in the mining community was 68.6%
				9 mo post- intervention	18.7% (166/893)	8.6% (77/893)	13.8% (123/893)			
Steen (2000) ⁴⁷⁸	South Africa	1996- 1997	Intervention 1 g AZ every mo for 9 mo	Prior to intervention	NR	17.3% (70/407)	14.3% (58/407)	NR	NR	Pre-intervention NG and/or CT = 24.9% (101/407); Post-intervention NG and/or CT = 5.7% (6/108)
				9 mo post- intervention		4.7% (5/108)	0.9% (1/108)			

Note that none of the azithromycin combinations summarised are contraindicated in pregnancy

*2.4 mμ benzathine Penicillin G was administered to commercial sex workers who tested positive for syphilis in all treatment groups per national guidelines; AZ = Azithromycin; NR = Not reported; CIPX = Ciprofloxacin; MTZ = Metronidazole; HIV = Human immunodeficiency virus; Note that italicized values are approximate based on enlarged graphs published in Cowan *et al* and percentages in parentheses reflect the 95% confidence intervals ⁴⁷⁵; V2, V3, V4 = Visit 2, Visit 3, and Visit 4; HIV = Human immunodeficiency virus; NG = *Neisseria gonorrhoeae*; CT = *C. trachomatis*; CSW = Commercial sex worker

A similar observation was made in a three-arm IPTp trial conducted in Malawi (2003 to 2006) in a low-risk population of pregnant women.¹⁰⁷ Participants received standard IPTp-SP, or monthly IPTp-SP, or monthly IPTp-SP plus 1 g azithromycin during two antenatal visits. The prevalence of *T. vaginalis* at delivery was 16.7% (n = 411; 13.5% to 20.7%), 15.1% (n = 411; 95% CI: 12.0% to 18.9%), and 11.0% (n = 419; 95% CI: 8.3% to 14.3%), respectively. Thus, compared to recipients of monthly IPTp-SP alone, women who received monthly azithromycin plus IPTp-SP had 35% (RR = 0.65; 0.46 to 0.93; *P* = 0.02) fewer *T. vaginalis* infections at delivery.

A cluster randomised trial in Uganda (1994 to 1998) compared the incidence of HIV infections amongst non-pregnant adults who received three antibiotics (1 g azithromycin, 250 mg ciprofloxacin, and 2 g metronidazole) or multi-vitamins plus antihelminth treatment.⁴⁷³ Although the trial was terminated early for lack of protection against the primary endpoint (incidence of vertical transmission of HIV infection), the incidence of several curable STIs/RTIs was lower in the control group, most notably *T. vaginalis*. The cumulative incidence of newly diagnosed *T. vaginalis* infection was 4.8 per 100 person years (116/2397 person-years) in the intervention group, compared to 9.1 per 100 person-years (182/1993 person-years) in the control group (RR=0.52; 0.35 to 0.79). The same combination of antimicrobials (azithromycin, ciprofloxacin, and metronidazole) was provided to female sex workers in rural Zimbabwe as a one-time treatment followed by three monthly check-ups.⁴⁷⁵ The prevalence of *T. vaginalis* pre-dose was just under 20% and then decreased to approximately 5% at visit 2. It rose to nearly 13% at visit 3, and dropped again to just over 10%, one-half of the pre-treatment levels.

Bacterial vaginosis

The WHO recommendations are to treat bacterial vaginosis in pregnant women, preferably after the first trimester, using: (i) 200 or 250 mg metronidazole three times per day for seven days, or (ii) 5 g metronidazole gel (0.75%) applied intravaginally twice a day for five days, or (iii) 300 mg clindamycin 300 mg orally twice a day for seven days.¹⁰⁹ As with *T. vaginalis*, 2g metronidazole orally is recommended if treatment is imperative during the first trimester of pregnancy.¹⁰⁹ Bacterial vaginosis has no single causative agent, but is thought to result from destabilization of *Lactobacillus* species (spp.) which leads to secondary colonization of anaerobic organisms that include *Gardnerella vaginalis*, *Bacteroides* spp., *Mobiluncus* spp. and *Mycoplasma hominis*. These changes in flora accompany an increase in vaginal pH.^{479,480}

***In vivo* evidence**

There were no trials identified by systematic review that attempted to measure the treatment efficacy of azithromycin alone against bacterial vaginosis. However, one study in the United States (2002 to 2005) investigated the use of azithromycin as a partner drug with metronidazole for the treatment of symptomatic bacterial vaginosis. Non-pregnant women were randomised into four treatment groups and received 750 mg metronidazole once per day for 7 days, or metronidazole once per day for 7 days plus 1 g azithromycin on days 1 and 3, or metronidazole for 14 days, or metronidazole for 14 days plus azithromycin on days 1 and 3.⁴⁸¹ There was no additional benefit of cure observed amongst women who received metronidazole plus azithromycin compared to metronidazole alone. Because bacterial vaginosis is a syndrome that involves multiple micro-organisms, antibiotic treatment is challenging. However,

comparable data from other related macrolides do suggest potential therapeutic benefit for azithromycin in the treatment of bacterial vaginosis as shown in Table 5.6

Analysis of azithromycin against the anaerobic and carboxyphilic bacteria which replace the normal vaginal flora may provide a better understanding as to the potential role of azithromycin against bacterial vaginosis.

Table 5.6 Macrolides and isolates of key organisms in bacterial vaginosis

Unspecified low risk population

	Reference (year of publication)	Country	Year(s)	Minimum inhibitory concentrations of specific macrolides (µg/mL)					
				Azithromycin	Erythromycin	Clarithromycin	Roxithromycin	Clindamycin*	Telithromycin*
<i>Gardnerella vaginalis</i>	Jones (1988) ⁴⁸²	United Kingdom	NR	< 0.03 to 0.125	< 0.03 to 0.06	NR	NR	NR	NR
	Shanker (1982) ⁴⁸³	Australia	NR	NR	0.007 to 0.06	NR	NR	0.007 to 0.06	NR
	Ridgway (1987) ⁴⁸⁴ *		NR	NR	0.008 to 0.016	NR	0.016	NR	NR
<i>Bacteroides species</i>	Jones (1998) ⁴⁸²	United Kingdom	NR	0.06 to 16	< 0.03 to 32	NR	NR	NR	NR
	Dubreuil (1987) ⁴⁸⁵	England, France, Germany, Japan	NR	NR	0.003 to > 64	NR	0.003 to > 64	NR	NR
	Maskell (1990) ⁴⁸⁶	United Kingdom	NR	0.5 to > 16	< 0.25 to 16	NR	NR	NR	NR
	Chang (1995) ⁴⁸⁷	Taiwan	1989- 1992	1 to > 256	0.25 to > 256	≤0.03 to > 256	0.25 to > 256	NR	NR
	Ednie (1997) ⁴⁸⁸	United States	NR	1 to > 64	0.5 to > 64	0.5 to > 64	2 to > 64	≤ 0.06 to > 64	NR
	Mikamo (2003) ⁴⁸⁹	Japan	2000	0.125 to 32	0.125 to 32	0.063 to 16	NR	NR	0.032 to 16
	Marina (2009) ⁴⁹⁰	Bulgaria	1983- 2007	NR	0.5 to > 64	NR	NR	0.125 to 32	NR
	Chen (1992) ⁴⁹¹	Australia	1986- 1991	0.5 to 128	0.25 to 128	NR	NR	NR	NR
	Wexler (2001) ⁴⁹²	United States	NR	NR	NR	NR	NR	NR	0.25 to > 64
<i>Mycoplasma hominis</i>	Ridgway (1987) ⁴⁸⁴	United Kingdom	NR	NR	>32	NR	8 to 16	NR	NR
<i>Mobinculus species</i>	Spiegel (1987) ⁴⁹³	United States	NR	NR	≤0.2 to > 200	NR	NR	≤ 0.015 to 4	NR

*Not a macrolide but has similar mechanism of action and included for comparability; NR=Not reported

Discussion

This systematic review of *in vivo* efficacy and *in vitro* sensitivity of azithromycin against curable STIs/RTIs suggests the compound is an attractive option for preventing and curing *T. pallidum*, *N. gonorrhoeae* and *C. trachomatis* infections. Prior to the advent of antiretroviral therapies for HIV, the management of curable STIs/RTIs received notable importance as trials showed that treatment of *N. gonorrhoeae*, *C. trachomatis*, and *T. vaginalis* reduced the genital viral load of HIV amongst men and women.⁴⁹⁴⁻⁴⁹⁷ Thus, groups at high-risk for transmitting HIV have since been targeted by treatment campaigns using 1 g azithromycin. It is not surprising, therefore, that changes in azithromycin sensitivity in high-income settings have often been observed first amongst members of high-risk groups who may have had compromised immunity attributable to HIV infection. Pregnant women attending ANC facilities in sub-Saharan Africa do not share this risk profile. Thus, on this basis alone, it is less likely that the use of azithromycin in combination with an antimalarial compound, would be a catalyst for the rapid selection of azithromycin resistance, although such a potential cannot be ruled out.

The potential benefits of using azithromycin as part of an enhanced IPTp regimen may be best viewed through prior experience with mass drug administration amongst pregnant women as noted in the prior section on *T. vaginalis*. In the context of the AIDS epidemic and before the age of antiretroviral therapies, investigators attempted to prevent vertical transmission of HIV by providing pregnant women in Uganda 1 g azithromycin, in combination with 250 mg ciprofloxacin and 2 g metronidazole.³⁵⁸ The data safety monitoring board suspended the trial early for reasons of futility, despite

having cut neonatal deaths by 17% (RR = 0.83; 95% CI: 0.71 to 0.97), decreased the incidence of LBW by 32% (RR = 0.68; 95% CI: 0.53 to 0.86), and reduced the incidence of preterm delivery by 23% (RR = 0.77; 95% CI: 0.56 to 1.05). These impressive results were achieved at a time when neither IPTp-SP nor insecticide treated bed nets for the control of malaria in pregnancy had been deployed.

If azithromycin is provided as part of IPTp alongside a partner antimalarial drug, there are several key factors to consider that are pathogen specific. Regarding syphilis, no less than 1 g azithromycin should be used alongside 2.4 mμ BPG for three reasons: (i) combination therapy has been shown to achieve higher rates of cure than either therapy alone,⁴⁹⁸ (ii) use of azithromycin with BPG would likely reduce selection of the A→G mutation associated with azithromycin and preserve *T. pallidum* sensitivity, and (iii) most importantly, only BPG can be expected to cure congenital infection if the placenta has been invaded by spirochetes.¹¹¹

As for *N. gonorrhoeae*, 1 g azithromycin may be just above the minimum inhibitory concentration of fully susceptible strains and, therefore, more than 1 g azithromycin may be preferable from the standpoint of reducing selection pressure. However, a single 2 g dose may not be well tolerated as six in ten patients reported self-limiting gastrointestinal discomfort when treated for syphilis infection with such a regimen. Splitting the dose over two days may improve tolerability. This is an important issue based on the experience of azithromycin plus chloroquine in which 1 g azithromycin was given on three consecutive days. Treatment-related adverse events were experienced by nearly seven of ten women, 68.9% in total (n = 996). The most

frequent events were vomiting, dizziness, headache, and asthenia amongst 44.6%, 31.4%, 15.3%, and 15.2% of azithromycin plus chloroquine recipients, respectively.¹¹⁶

If the partner antimalarial drug is dihydroartemisinin-piperaquine, therapy that requires a three-day course, a split dose of 500 mg might be considered for each of the three days to achieve optimal tolerability. This would also simplify dosing, and likely improve compliance and adherence to the regimen.

A regimen of 1 g azithromycin, would be protective against *C. trachomatis* and, although the data are limited and the mechanism of action is not understood, 1 g azithromycin may protect against *T. vaginalis* based on reports from Malawi amongst pregnant women¹⁰⁷ and commercial sex workers in Kenya.⁴⁷¹ It is curious, however, that *T. vaginalis* infection during pregnancy is associated with adverse birth outcomes, but the first-line treatment of 2 g metronidazole does not always improve birth outcomes. A trial in Uganda reported that pregnant women treated for *T. vaginalis* infection were 2.5 times more likely to deliver a LBW infant than untreated women (RR = 2.49; 95% CI: 1.12 to 5.50).⁴⁹⁹ The authors suggest this may be attributable to metronidazole exposure. Another trial in the United States reported an increase in the risk of preterm delivery amongst pregnant women exposed to metronidazole for the treatment of asymptomatic trichomoniasis compared to those who were not treated (RR = 1.8; 95% CI: 1.2 to 2.7)⁵⁰⁰. In contrast to these findings from a high-income setting, data from a multi-centre trial in sub-Saharan Africa suggests that treatment of *T. vaginalis* infection using metronidazole does not increase the chances of preterm birth.⁵⁰¹ Apart from bacterial vaginosis, which is not transmitted through sexual

contact, re-infection will remain a risk for pregnant women and, therefore, providers should continue to offer education and screening as appropriate.

None of the studies identified in this review indicate that azithromycin offers preventive or curative effect against bacterial vaginosis, the most prevalent of curable STIs/RTIs. Antibiotic therapy with metronidazole has only been shown to reduce the risk of preterm delivery by one-half (RR = 0.53; 95% CI: 0.34 to 0.84) amongst pregnant women with bacterial vaginosis (Nugent score 7 to 10) or intermediate flora (Nugent score 4 to 6).⁵⁰² A Nugent score of 0 to 3 is considered normal,⁵⁰³ for which no protection against adverse birth outcomes has been observed.

Summary discussion

Since the WHO first recommended IPTp in 2004 for pregnant women resident in malaria endemic areas during antenatal visits, clinical researchers have been trying to identify replacements for SP.^{116,154,504-506} These efforts have proven elusive in large part because IPTp-SP has only been viewed as intervention that reduces the consequences of malaria infection on pregnancy outcomes. This has led investigators to assume that there must be a threshold of malaria transmission intensity in sub-Saharan at the population level below which IPTp-SP no longer protects against the incidence of LBW. There does not appear to be one based on evidence presented in this thesis as well as unpublished findings from analysis of Multiple Indicator Cluster Surveys (Eisele TP, personal communication). Evidence presented in this thesis does suggest that the protective effect of IPTp-SP against LBW is under threat by a higher prevalence of the biomarker A581G associated with SP resistance. However ≥ 2 doses of IPTp continues to protect primi- and secundigravidae against the incidence of LBW in areas where A581G can be found in over one-half of malaria parasites.

This protection could extend to higher prevalence levels, but there are no data available to support or refute this assertion. However, in areas with a prevalence of the A581G mutation $> 10.1\%$, IPTp-SP may not have a beneficial effect on LBW. This observation needs to be interpreted with caution because there were no data in areas with a prevalence between 10% and 50%.

IPTp-SP continues to protect against the incidence of LBW across all malaria transmission intensities, as well as in the presence of the A581G mutation, particularly amongst primi- and secundigravidae, because the causes of LBW are multifactorial. This has long-been assumed, but the secondary analysis of data from Zambia in this thesis is the first evidence that IPTp-SP is protective against adverse birth outcomes related to curable STIs/RTIs.

The systematic review and meta-analysis of the dual burden of malaria and curable STIs/RTIs produced the first published pooled estimates of peripheral (N = 90,755; 94 studies; 16 countries) and placental (N = 34,184; 35 studies; 13 countries) malaria infection amongst women attending ANC facilities in sub-Saharan Africa. The pooled estimates fall within the range of point estimates contained in prior reviews by Brabin and Steketee *et al.* This was also the first such meta-analysis of curable STIs/RTIs in the region, producing pooled estimates for syphilis (N = 147,477; 50 studies; 18 countries), *N. gonorrhoeae* (N = 19,957; 19 studies; 12 countries), *C. trachomatis* (N = 10,573; 22 studies; 15 countries), *T. vaginalis* (N = 37,995; 35 studies; 15 countries), and bacterial vaginosis (N = 21,547; 23 studies; 13 countries). For syphilis, *N. gonorrhoeae*, and *C. trachomatis* infections, the pooled prevalence estimates for East and Southern Africa, as well as West and Central Africa, all fell between the lowest and highest point estimates for the sub-Saharan region presented in the 2005 review of curable STIs/RTIs by Mullick *et al.*¹⁶⁸ However, pooled prevalence estimates for *T. vaginalis* in both sub-regions were greater than highest point estimate reported by Mullick *et al.*, as was the pooled prevalence of bacterial vaginosis in East and Southern Africa compared to Mullick's highest point estimate. It is not possible to assess

whether this reflects a regional trend, or if the review by Mullick *et al.* understated the prevalence of *T. vaginalis* and bacterial vaginosis.

Since publication of the systematic review and meta-analysis, Davey *et al.* conducted a similar analysis for the period 2010 to 2015.⁵⁰⁷ Their sub-regions were slightly different and 'Southern Africa' included South Africa, the only sub-Saharan country excluded from the analysis presented in this thesis because malaria is no longer endemic there. The authors stated, "Other systematic reviews of STI prevalence in pregnant women have found similarly high rates of STIs. A review article by Chico *et al.* in 2012⁹ found that the prevalence of syphilis was 3.5%, CT was 6.1%, and TV was 17.8% amongst pregnant women in West and Central Africa."

The fact that only one study of the 171 identified in the systematic review of malaria and curable STIs/RTIs actually reported the incidence of co-infection is partially the result of researchers operating in scientific silos. Investigating co-infections that cut across disciplines requires researchers to become subject matter experts in more than one field, or to work in multi-disciplinary teams. Neither approach is easy, but either is necessary since IPTp-SP contributes to preventing adverse birth outcomes attributable to malaria infection and curable STIs/RTIs in pregnancy. Importantly, even if sulphadoxine is only partially protective against a broad-spectrum of gram-positive and gram-negative bacteria, dosing at each scheduled ANC visit from the second trimester to delivery may be sufficient to curb bacterial densities, thus directly reducing the incidence of adverse birth outcomes. It is possible, as well, that reduced

bacterial densities produced by sulphadoxine exposure also inhibit maternal inflammatory responses to infection that are known to trigger preterm birth.⁵⁰⁸

However, can we do better?

In the case of curable STIs/RTIs, the ANC package recommended by the WHO includes screening for syphilis and the provision of BPG to women who test positive. Screening and treatment would need to continue even if dihydroartemisinin-piperaquine plus azithromycin were used because insufficient quantities of azithromycin perfuse the placenta to cure congenital cases. However, azithromycin would be curative of maternal syphilis, *N. gonorrhoeae*, *C. trachomatis*, and potentially *T. vaginalis*.

Management of bacterial vaginosis in pregnancy may be more difficult. Treatment of women who have Nugent scores of 1-3 has not reduced the incidence of preterm birth. Based on evidence from this monograph, it would appropriate to conduct *in vitro* sensitivity testing of sulphadoxine with isolates from *T. pallidum*, *N. gonorrhoeae*, *C. trachomatis*, *T. vaginalis*, and organisms associated with bacterial vaginosis including *G. vaginalis*, *Bacteroides* spp., *Mobiluncus* spp. and *M. hominis*.

In light of the protection against curable STIs/RTIs conferred by IPTp-SP, it would be appropriate to conduct *in vitro* sensitivity testing of sulphadoxine versus azithromycin exposed to the five curable STIs/RTIs of interest and, potentially, other pathogens to begin to elucidate the range of protective effect pregnant women are benefitting from in countries where IPTp-SP is policy.

HIV-infected pregnant women also need an alternative to SP. At present, HIV-infected women are given cotrimoxazole against opportunistic infections; IPTp-SP is contra-indicated for these women out of concerns related to potential sulpha-toxicity if both therapies are used concomitantly. The combination of dihydroartemisinin-piperaquine plus azithromycin may represent a therapy that could be used alongside cotrimoxazole. Drug-drug interaction studies would need to confirm the safety of such use and, importantly, that maternal viral load is not adversely impacted. Thus, studies are now needed to determine whether dihydroartemisinin-piperaquine plus azithromycin would be a better alternative to SP for IPTp.

There are concerns that use of azithromycin may select for resistances in the pneumococcus. A single 1g dose of azithromycin clears ocular strains of *Chlamydia* that cause trachoma. During the past two decades, azithromycin has been distributed in trachoma-endemic areas as part of the WHO-led trachoma elimination programme.⁵⁰⁹ Mass distribution has been shown also to reduce the incidence of respiratory infections,⁵¹⁰ diarrhoea,⁵¹¹ and malaria.⁵¹² These secondary benefits likely underlie the statistically significant reductions in all-cause childhood mortality reported in Ethiopia following trachoma treatment campaigns where odds were cut by one-half (OR = 0.51; 95% CI: 0.29-0.90) in a clinical trial⁵¹³ and 35% (OR = 0.35; 95% CI: 0.17–0.74) in a cohort study. However, there is significant evidence of clonal expansion of pneumococcal multi-locus sequence types *ermB* and *mefA/E* associated with resistance in the same geographic areas where four rounds of mass drug administration with azithromycin have been conducted.⁵¹⁴ Follow up surveillance

studies of six or more months post-exposure have found that the prevalence of resistant isolates do return to pre-dosing levels.^{515,516} Importantly, there is no evidence of noticeable increases in pneumococcal resistance over time in countries that have participated in mass campaigns where over 500 million doses have been administered to date.⁵¹⁷ Regardless, to address this concern, trials that investigate the use of dihydroartemisinin-piperaquine plus azithromycin should test for macrolide resistance in the pneumococcus pre- and six or more months post-exposure. In addition, if dihydroartemisinin-piperaquine plus azithromycin were to be adopted for preventive care as part of the ANC package, then countries should collect biological samples on a semi-annual basis from pregnant women at sentinel sites with the objective of monitoring *in vivo* and *in vitro* sensitivity to curable STIs/RTIs as well as pneumococcal infections.

Descriptive epidemiological studies are needed to understand better the extent to which symptomatic versus asymptomatic curable STIs/RTIs contribute to adverse birth outcomes. Such studies would be incomplete if the prevalence of co-infections were not also considered. The apparent failure to reduce the incidence of adverse birth outcomes following treatment for one infection may be masked by the presence of co-infection(s) that will only be mitigated with the use of combination therapies and consideration of downstream outcomes.

Finally, discussion of the future of IPTp, with SP or an alternative, needs to be placed in the context of broader malaria elimination efforts. As malaria transmission intensity decreases in endemic areas, pregnant women will be exposed to fewer infective bites.

This may mean that primi- and secundigravidae will not develop the protective immunoglobulin G that is associated with maternal parity and the *var 2 CSA* gene. Consequently, future multigravidae may be at greater risk of adverse birth outcomes attributable to malaria than multigravidae of today, warranting close surveillance at national and district levels of malaria cases by gravidae.

Conclusions

Evidence presented in this doctoral thesis suggests that IPTp-SP continues to provide valuable protection against the incidence of LBW amongst all gravidae until very low levels of malaria transmission and that this protective effect persists amongst primi- and secundigravidae in areas where one-half of malaria parasites carry the 'super resistant' A581G mutation. Amongst multigravidae, however, there is only evidence of continued protection against LBW in areas where $\leq 10.1\%$ of malaria parasites express the A581G mutation. The actual threshold for multigravidae may be higher, but is unknown with data that are currently available.

There has long been speculation that sulphadoxine, the antibiotic component of SP, is protective against more pathogens than simply malaria infection. Evidence presented in this thesis supports the assertion that SP is, indeed, also protective against the adverse birth outcomes attributable to curable STIs/RTIs. This finding would encourage improved operational planning and coordination between National Malaria Control Programmes and Maternal and Reproductive Health Programmes, and provide greater impetus to scale up the antenatal coverage of IPTp-SP. Regardless, the dual burden of malaria infection and curable STIs/RTIs is a public health concern and continues to exact a high toll on pregnancies in sub-Saharan Africa. Use of dihydroartemisinin-piperaquine plus azithromycin as IPTp could be superior to IPTp-SP in safeguarding against adverse birth outcomes attributable to malaria and curable STIs/RTIs. Head-to-head clinical research between SP and dihydroartemisinin-piperaquine plus azithromycin with robust microbiology is required to chart the pathway forward.

References

1. Chico RM, Pittrof R, Greenwood B, Chandramohan D. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. *Malaria Journal*. 2008;7(1):255.
2. Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. *Expert Opinion on Drug Metabolism & Toxicology* 2011;7(9):1153-1167.
3. Chico RM, Chandramohan D. Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. *Tropical Medicine & International Health*. 2011;16(7):774–785.
4. Chico RM, Cano J, Ariti C, Collier TJ, Chandramohan D, Roper C, Greenwood B. Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis. *Tropical Medicine & International Health*. 2015;20(12):1621-1633.
5. van Eijk AM, Hill J, Larsen DA, Webster J, Steketee RW, Eisele TP, Ter Kuile FO. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. *Lancet Infectious Diseases*. 2013.
6. Chico RM, Cano J, Cono A, Collier T, Chandramohan D, Greenwood B. Malaria-transmission intensity and the protective effect of intermittent preventive treatment (IPTp): policy implications for the antenatal care of pregnant women in sub-Saharan Africa (No. 1917). 63rd annual meeting of the American Society of Tropical Medicine and Hygiene (2-6 November 2014); 2014; New Orleans, LA, USA.
7. Chico RM, Chaponda EB, Ariti C, Chandramohan D. Sulfadoxine-pyrimethamine exhibits dose-response protection against adverse birth outcomes related to malaria and

- sexually transmitted and reproductive tract infections. *Clinical Infectious Diseases*. 2017;64(8):1043-1051.
8. Chico RM, Chaponda EB, Ariti C, D C. Dose-response effect of sulfadoxine-pyrimethamine administered as intermittent preventive treatment of malaria in pregnancy reduces adverse birth outcomes related to sexually transmitted and reproductive tract infections (No. 863). 65th annual meeting of the American Society of Tropical Medicine and Hygiene 13-17 November 2016, 2015; Atlanta, USA.
 9. Chico RM, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in Sub-Saharan Africa: a systematic review. *JAMA: Journal of the American Medical Association*. 2012;307(19):2079-2086.
 10. Mabey D, Gill G, Parry E, Weber MW, Whitty CJM, eds. *Principles of Medicine in Africa*. 4th Edition ed. United Kingdom: Cambridge University Press; 2013.
 11. Chico RM, Ariti C, Cano J, Chandramohan D, Greenwood B. Malaria transmission intensity and the protective effect of intermittent preventive therapy using sulphadoxine-pyrimethamine. Paper presented at: WHO Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy http://www.who.int/malaria/mpac/mpac_sep13_erg_ipt_malaria_pregnancy_report.pdf 11-14 July 2013; Geneva, Switzerland.
 12. Chico RM, Hack BB, Newport MJ, Ngulube E, Chandramohan D. On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections. *Expert Review of Anti-infective Therapy*. 2013;11(12):1303-1332.
 13. Chico RM, Moss WJ. Prevention of malaria in pregnancy: a fork in the road? *The Lancet*. 2015.
 14. Sprengell CF. *The Aphorisms of Hippocrates and the Sentences of Celsus: With Explanations and References By Hipócrates, Aulo Cornelio Celso*. London: Printed by R

- Bonwick, W Freeman, Tim Goodwin, John Withoe, Matt Wotton, John Nickolson, Samuel Manship, Richard Parker, Benj. Tooke and Ralph Smith; 1708.
15. Laveran A. *De la nature parasitaire de l'impaludisme. Bulletins et memoires de la Societe Medicale des Hopitaux de Paris* 1882(18):168-176.
 16. Laveran A. *Traité des fièvres palustres avec la description des microbes du paludisme*. 1st ed. Paris: Octave Doin; 1884.
 17. Blacklock DB, Gordon RM. Malaria infection as it occurs in late pregnancy; its relationship to labour and early infancy. *Annals of Tropical Medicine & Parasitology*. 1925;19(3).
 18. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. *American Journal of Tropical Medicine and Hygiene*. 2001;64(1-2 Suppl):28-35.
 19. Murphy SC, Breman JG. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. *American Journal of Tropical Medicine and Hygiene*. 2001;64(1-2 Suppl):57-67.
 20. World Health Organization. WHO Policy Recommendation: Intermittent Preventive Treatment of Malaria in Pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP). 2013;11 April 2013.
 21. Radeva-Petrova D, ter Kuile FO, Sinclair D, Kayentao K, Garner P. Drugs for preventing malaria in pregnant women (Review). *Cochrane Collaboration*. 2013.
 22. World Health Organization. *A Strategic Framework for Malaria Prevention and Control During Pregnancy in the Africa Region*. Vol AFR/MAL/04/01: World Health Organization Regional Office for Africa; 2004.

23. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM. Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: what next? *Trends in Parasitology*. 2001;17(12):582-588.
24. Peters W. *Chemotherapy and Drug Resistance in Malaria*. 2nd ed. London: Academic Press; 1987.
25. Triglia T, Cowman AF. Primary structure and expression of the dihydropteroate synthetase gene of *Plasmodium falciparum*. *Proceedings of the National Academy of Sciences of the United States of America*. 1994;91(15):7149-7153.
26. Naidoo I, Roper C. Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria. *Trends in Parasitology*. 2013.
27. World Health Organization. *World Malaria Report 2012*. Geneva: World Health Organization; 2012.
28. Gilles HM, Lawson JB, Sibelas M, Voller A, Allan N. Malaria, anaemia and pregnancy. *Annals of Tropical Medicine & Parasitology*. 1969;63(2):245-263.
29. Shulman CE, Graham WJ, Jilo H, Lowe BS, New L, Obiero J, Snow RW, Marsh K. Malaria is an important cause of anaemia in primigravidae: evidence from a district hospital in coastal Kenya. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1996;90(5):535-539.
30. Shulman CE, Dorman EK, Talisuna AO, Lowe BS, Nevill C, Snow RW, Jilo H, Peshu N, Bulmer JN, Graham S, Marsh K. A community randomized controlled trial of insecticide-treated bednets for the prevention of malaria and anaemia among primigravid women on the Kenyan coast. *Tropical Medicine & International Health*. 1998;3(3):197-204.
31. Guyatt HL, Snow RW. The epidemiology and burden of *Plasmodium falciparum*-related anemia among pregnant women in sub-Saharan Africa. *American Society of Tropical Medicine and Hygiene*. 2001;64(1-2 Suppl):36-44.

32. McGregor IA, Wilson ME, Billewicz WZ. Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1983;77(2):232-244.
33. Bader E, Alhaj AM, Hussan AA, Adam I. Malaria and stillbirth in Omdurman Maternity Hospital, Sudan. *International Journal of Gynecology and Obstetrics*. 2010;109(2):144-146.
34. Yatch NJ, Funkhouser E, Ehiri JE, Agbenyega T, Stiles JK, Rayner JC, Turpin A, Ellis WO, Jiang Y, Williams JH, Afriyie-Gwayu E, Phillips T, Jolly PE. Malaria, intestinal helminths and other risk factors for stillbirth in Ghana. *Infectious Diseases in Obstetrics and Gynecology*. 2010;2010:7.
35. Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, Breman JG. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. *American Journal of Tropical Medicine and Hygiene*. 1996;55(1 Suppl):33-41.
36. Sullivan AD, Nyirenda T, Cullinan T, Taylor T, Harlow SD, James SA, Meshnick SR. Malaria infection during pregnancy: intrauterine growth retardation and preterm delivery in Malawi. *Journal of Infectious Diseases*. 1999;179(6):1580-1583.
37. Greenwood AM, Armstrong JR, Byass P, Snow RW, Greenwood BM. Malaria chemoprophylaxis, birth weight and child survival. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1992;86(5):483-485.
38. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. *Annals of Tropical Medicine & Parasitology*. 1998;92(2):141-150.

39. Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. *Clinical Microbiology Reviews*. 2004;17(4):760-769.
40. Ylppö A. *Pathologisch-anatomische Studien bei Frühgeborenen Makroskopische und mikroskopische Untersuchungen mit Hinweisen auf die Klinik und mit besonderer Berücksichtigung der Hämorrhagien*. *European Journal of Pediatrics*. 1919;20(1):212-431.
41. Victora CG, Barros FC, Vaughan JP, Teixeira AM. Birthweight and infant mortality: a longitudinal study of 5914 Brazilian children. *International Journal of Epidemiology*. 1987;16(2):239-245.
42. McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. *New England Journal of Medicine*. 1985;312(2):82-90.
43. Ashworth A. Effects of intrauterine growth retardation on mortality and morbidity in infants and young children. *European Journal of Clinical Nutrition*. 1998;52 Suppl 1:S34-41; discussion S41-32.
44. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. *American Journal of Clinical Nutrition*. 2000;71(5 Suppl):1344S-1352S.
45. Osmond C, Barker DJ. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. *Environmental Health Perspectives*. 2000;108 Suppl 3:545-553.
46. Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJ. Early growth and coronary heart disease in later life: longitudinal study. *The BMJ*. 2001;322(7292):949-953.
47. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. *Lancet*. 2005;365(9461):785-799.
48. Takken W, Knols BG. Odor-mediated behavior of Afrotropical malaria mosquitoes. *Annual review of entomology*. 1999;44:131-157.
49. Spitzen J, Spoor CW, Grieco F, ter Braak C, Beeuwkes J, van Brugge SP, Kranenbarg S, Noldus LP, van Leeuwen JL, Takken W. A 3D analysis of flight behavior of *Anopheles*

- gambiae sensu stricto* malaria mosquitoes in response to human odor and heat. *PLOS ONE*. 2013;8(5):e62995.
50. Lindsay S, Ansell J, Selman C, Cox V, Hamilton K, Walraven G. Effect of pregnancy on exposure to malaria mosquitoes. *Lancet*. 2000;355(9219):1972.
 51. Miller JE, Lindsay SW, Armstrong JR. Experimental hut trials of bednets impregnated with synthetic pyrethroid or organophosphate insecticide for mosquito control in The Gambia. *Medical and veterinary entomology*. 1991;5(4):465-476.
 52. Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. *Symposia of the Society for Experimental Biology*. 1953;7(320-338).
 53. Brabin B. A comparison of maternal and foetal folacin and cobalamin activities at parturition in relation to *Plasmodium falciparum* infection. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1985;79(5):652-656.
 54. Suguitan AL, Cadigan TJ, Nguyen TA, Zhou AN, Leke RJI, Metenou S, Thuita L, Megnekou R, Fogako J, Leke RGF, Taylor DW. Malaria-associated cytokine changes in the placenta of women with pre-term deliveries in Yaounde, Cameroon. *American Journal of Tropical Medicine and Hygiene*. 2003;69(6):574-581.
 55. Ruizendaal E, van Leeuwen E, Mens PF. Peripheral and placental biomarkers in women with placental malaria: a systematic review. *Biomarkers in medicine*. 2015;9(3):217-239.
 56. Brabin BJ, Romagosa C, Abdelgalil S, Menendez C, Verhoeff FH, McGready R, Fletcher KA, Owens S, D'Alessandro U, Nosten F, Fischer PR, Ordi J. The sick placenta-the role of malaria. *Placenta*. 2004;25(5):359-378.
 57. McLaren DS WP, Nyabuzoki JN, Ndalawha JB, Wilfred E. Malaria infection of the placenta and foetal nutrition. *East African Medical Journal*. 1962;39:182-189.
 58. Reinhardt MC. Maternal anaemia in Abidjan--Its influence on placenta and newborns. *Helvetica Paediatrica Acta Supplementum* 1978(41):43-63.

59. Bulmer JN, Rasheed FN, Morrison L, Francis N, Greenwood BM. Placental malaria. II. A semi-quantitative investigation of the pathological features. *Histopathology*. 1993;22(3):219-225.
60. Walter PR, Garin Y, Blot P. Placental pathologic changes in malaria. A histologic and ultrastructural study. *The American Journal of Pathology*. 1982;109(3):330-342.
61. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. *Science*. 2005;308(5728):1592-1594.
62. Dorman EK, Shulman CE, Kingdom J, Bulmer JN, Mwendwa J, Peshu N, Marsh K. Impaired uteroplacental blood flow in pregnancies complicated by *falciparum* malaria. *Ultrasound in Obstetrics & Gynecology*. 2002;19(2):165-170.
63. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: pathogenesis and immunity. *Lancet Infectious Diseases*. 2007;7(2):105-117.
64. Greenwood B, Alonso P, ter Kuile FO, Hill J, Steketee RW. Malaria in pregnancy: priorities for research. *Lancet Infectious Diseases*. 2007;7(2):169-174.
65. Salanti A, Staalsoe T, Lavstsen T, Jensen AT, Sowa MP, Arnot DE, Hviid L, Theander TG. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria. *Molecular Microbiology*. 2003;49(1):179-191.
66. Duffy PE, Krzych U, Francis S, Fried M. Malaria vaccines: using models of immunity and functional genomics tools to accelerate the development of vaccines against *Plasmodium falciparum*. *Vaccine*. 2005;23(17-18):2235-2242.
67. Tuikue Ndam NG, Salanti A, Bertin G, Dahlback M, Fievet N, Turner L, Gaye A, Theander T, Deloron P. High level of var2csa transcription by *Plasmodium falciparum* isolated from the placenta. *Journal of Infectious Diseases*. 2005;192(2):331-335.
68. Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L, Magistrado P, Jensen AT, Lavstsen T, Ofori MF, Marsh K, Hviid L, Theander TG. Evidence for the involvement of

- var2csa in pregnancy-associated malaria. *Journal of Experimental Medicine*. 2004;200(9):1197-1203.
69. World Health Organization. WHO Expert Committee on Malaria, Technical Report Series 1986;Report 18(735):57-59.
 70. Steketee RW, Wirima JJ, Slutsker L, Heymann DL, Breman JG. The problem of malaria and malaria control in pregnancy in sub-Saharan Africa. *American Journal of Tropical Medicine and Hygiene*. 1996;55(1 Suppl):2-7.
 71. World Health Organization. *Antimalarial drug policies: data requirements, treatment of uncomplicated malaria and management of malaria in pregnancy. Report of an informal consultation*. Geneva: World Health Organization;1994.
 72. Sirima SB, Sawadogo R, Moran AC, Konate A, Diarra A, Yameogo M, Parise ME, Newman RD. Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupela District, Burkina Faso. *Clinical Infectious Diseases*. 2003;36(11):1374-1382.
 73. Brabin BJ, Verhoeff FH, Kazembe P, Chimsuku L, Broadhead R. Antimalarial drug policy in Malawi. *Annals of Tropical Medicine and Parasitology*. 1997;91(Supplement 1):113-116.
 74. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. *American Journal of Tropical Medicine and Hygiene*. 1998;59.
 75. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. *Lancet*. 1999;353(9153):632-636.

76. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental *Plasmodium falciparum* infection among pregnant women in Malawi. *American Journal of Tropical Medicine and Hygiene*. 1994;51(5):515-522.
77. Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, Macete E, Berenguera A, David C, Dobano C, Naniche D, Mayor A, Ordi J, Mandomando I, Aponte JJ, Mabunda S, Alonso PL. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. *PLOS ONE*. 2008;3(4):e1934.
78. Diagne N, Rogier C, Sokhna CS, Tall A, Fontenille D, Roussilhon C, Spiegel A, Trape JF. Increased susceptibility to malaria during the early postpartum period. *New England Journal of Medicine*. 2000;343(9):598-603.
79. Menendez C, Bardaji A, Sigauque B, Sanz S, Aponte JJ, Mabunda S, Alonso PL. Malaria prevention with IPTp during pregnancy reduces neonatal mortality. *PLOS ONE*. 2010;5(2):e9438.
80. Mbaye A, Richardson K, Balajo B, Dunyo S, Shulman C, Milligan P, Greenwood B, Walraven G. A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. *Tropical Medicine & International Health*. 2006;11(7):992-1002.
81. Ndyomugenyi R, Clarke SE, Hutchison CL, Hansen KS, Magnussen P. Efficacy of malaria prevention during pregnancy in an area of low and unstable transmission: an individually-randomised placebo-controlled trial using intermittent preventive treatment and insecticide-treated nets in the Kabale Highlands, southwestern Uganda. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2011;105(11):607-616.

82. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, Duffy PE. Competitive facilitation of drug-resistant *Plasmodium falciparum* malaria parasites in pregnant women who receive preventive treatment. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(22):9027-9032.
83. Clyde DF. *Malaria in Tanzania*. London: Oxford University Press; 1967.
84. Kouznetsov RL, Storey J, Kilama W, Payne D. *Spread of pyrimethamine-resistant strains of Plasmodium falciparum into new areas of North-East Tanzania in the absence of drug pressure*. Geneva, Switzerland: World Health Organization;1980.
85. Clyde DF. Cross-resistance of malaria parasites. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1960;54.6:597-598.
86. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. *Clinical Infectious Diseases*. 2011;53(3):224-230.
87. Harrington WE, Morrison R, Fried M, Duffy PE. Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring. *PLOS ONE*. 2013;8(2):e56183.
88. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D. High resistance of *Plasmodium falciparum* to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of *dhps* resistance mutation at codon 581. *PLOS ONE*. 2009;4(2):e4569.
89. Mockenhaupt FP, Bedu-Addo G, Junge C, Hommerich L, Eggelte TA, Bienzle U. Markers of sulfadoxine-pyrimethamine-resistant *Plasmodium falciparum* in placenta and circulation of pregnant women. *Antimicrobial Agents and Chemotherapy*. 2007;51(1):332-334.

90. de Roode JC, Helinski ME, Anwar MA, Read AF. Dynamics of multiple infection and within-host competition in genetically diverse malaria infections. *The American Naturalist*. 2005;166(5):531-542.
91. Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, Mwandama D, Khairallah C, Madanitsa M, Chaluluka E, Dzinjalama F, Ali D, Mathanga DP, Skarbinski J, Shi YP, Meshnick S, Ter Kuile FO. The A581G mutation in the gene encoding *Plasmodium falciparum* dihydropteroate synthetase reduces the effectiveness of sulfadoxine-pyrimethamine preventive therapy in Malawian pregnant women. *Journal of Infectious Diseases*. 2015.
92. Pfizer. Zithromax Product Label
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050693s014,050730s021/bl.pdf. 2009.
93. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for *Chlamydia trachomatis* infection during pregnancy: a meta-analysis of randomised controlled trials. *International Journal of Antimicrobial Agents*. 2007;30(3):213-221.
94. Oldfield EC 3rd, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, Chung R, Wagner KF, Paparello SF, Craig DB, Melcher G, Zajdowicz M, Williams RF, Kelly JW, Zelasky M, Heifets LB, Berman JD. Once weekly azithromycin therapy for prevention of *Mycobacterium avium* complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. *Clinical Infectious Diseases*. 1998;26(3):611-619.
95. Tseng AL, Dolovich L, Salit IE. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. *Clinical Infectious Diseases*. 1997;24(1):76-77.
96. Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA. *In vitro* efficacy, resistance selection, and structural modeling studies implicate the malarial parasite

- apicoplast as the target of azithromycin. *Journal of Biological Chemistry*. 2007;282(4):2494-2504.
97. van Eijk AM, Terlouw DJ. Azithromycin for treating uncomplicated malaria. *Cochrane Database Syst Rev*. 2011;CD006688.
 98. Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. *Clinical Infectious Diseases*. 1999;28:74–81.
 99. Heppner DG, Jr., Walsh DS, Uthaimongkol N, Tang DB, Tulyayon S, Permpanich B, Wimonwattrawatee T, Chuanak N, Laoboonthai A, Sookto P, Brewer TG, McDaniel P, Eamsila C, Yongvanitchit K, Uhl K, Kyle DE, Keep LW, Miller RE, Wongsrichanalai C. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of *Plasmodium vivax* malaria in Western Thailand. *American Journal of Tropical Medicine and Hygiene*. 2005;73(5):842-849.
 100. Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. *Clinical Infectious Diseases*. 1998;26(1):146-150.
 101. Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant *Plasmodium falciparum* in vitro. *Acta Tropica*. 2006;100(3):185-191.
 102. Ohrt C, Willingmyre G, Lee P, Knirsch C, Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against *Plasmodium falciparum* in vitro. *Antimicrobial Agents and Chemotherapy*. 2002;46:2518–2524.
 103. Sykes A, Hendriksen I, Mtove G, Mande V, Mrema H, Rutta B, Mapunda E, Manjurano A, Amos B, Reyburn H, Whitty CJ. Azithromycin plus artesunate versus artemether-

- lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. *Clinical Infectious Diseases*. 2009;49:1195-1201.
104. Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya H, Ohrt C, Knirsch C. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated *Plasmodium falciparum* malaria in adults: a randomized, phase 2 clinical trial in Thailand. *Clinical Infectious Diseases*. 2006;43(10):1264-1271.
 105. Thriemer K, Starzengruber P, Khan WA, Haque R, Marma AS, Ley B, Vossen MG, Swoboda P, Akter J, Noedl H. Azithromycin combination therapy for the treatment of uncomplicated *falciparum* malaria in Bangladesh: an open-label randomized, controlled clinical trial. *Journal of Infectious Diseases*. 2010;202(3):392-398.
 106. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. *Drugs*. 2005;65(1):75-87.
 107. Luntamo M, Kulmala T, Mbewe B, Cheung Y B, Maleta K, Ashorn P. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. *American Journal of Tropical Medicine and Hygiene*. 2010;83:1212-1220.
 108. van den Broek NR, White SA, Goodall M, Ntonya C, Kayira E, Kafulafula G, Neilson JP. The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. *PLOS Medicine*. 2009;6(12):e1000191.
 109. World Health Organization. *Guidelines for the management of sexually transmitted infections*. Geneva 2003.

110. World Health Organization. *Sexually transmitted and other reproductive tract infections: Guide to essential practice*. Geneva: Department of Reproductive Health and Research, World Health Organization; 2005.
111. Zhou P, Qian Y, Xu J, Gu Z, Liao K. Occurrence of congenital syphilis after maternal treatment with azithromycin during pregnancy. *Sexually Transmitted Diseases*. 2007;34(7):472-474.
112. Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CS, Robinson LJ, Rosanas-Urgell A, Wapling J, Lufele E, Kongs C, Samol P, Sui D, Singirok D, Bardaji A, Schofield L, Menendez C, Betuela I, Siba P, Mueller I, Rogerson SJ. Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial. *BMC medicine*. 2015;13(1):9.
113. ClinicalTrials.gov Website. Phase III: Evaluate parasitological clearance rates and pharmacokinetics of the combination of azithromycin and chloroquine In asymptomatic pregnant women with falciparum parasitemia in Africa: <http://www.clinicaltrials.gov>. NCT01103713(Access date: 17 November 2010).
114. ClinicalTrials.gov Website. Phase III: Evaluate azithromycin plus chloroquine and sulfadoxine plus pyrimethamine combinations for intermittent preventive treatment of falciparum malaria infection in pregnant women in Africa: <http://www.clinicaltrials.gov>. NCT01103063(Access date: 14 April 2015).
115. Wangnapi RA, Soso S, Unger HW, Sawera C, Ome M, Umbers AJ, Ndrewei N, Siba P, Li Wai Suen CS, Vallely A, Wapling J, Ryan C, Mueller I, Rogerson SJ. Prevalence and risk factors for *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* infection in pregnant women in Papua New Guinea. *Sexually Transmitted Infections*. 2014.
116. Kimani J, Phiri K, Kamiza S, Duparc S, Ayoub A, Rojo R, Robbins J, Orrico R, Vandenbroucke P. Efficacy and safety of azithromycin-chloroquine versus sulfadoxine-

- pyrimethamine for intermittent preventive treatment of *Plasmodium falciparum* malaria infection in pregnant women in Africa: an open-label, randomized trial. *PLoS One*. 2016;11(6):e0157045.
117. Dippel AL. The relationship of congenital syphilis to abortion and miscarriage, and the mechanism of intrauterine protection. *American Journal of Obstetrics and Gynecology*. 1944;47:369.
 118. Williams JW. *A textbook of obstetrics*. 6th ed. New York: D Appleton & Co; 1923.
 119. Ratnam AV, Din SN, Hira SK, Bhat GJ, Wacha DS, Rukmini A, Mulenga RC. Syphilis in pregnant women in Zambia. *British Journal of Venereal Diseases*. 1982;58(6):355-358.
 120. Watson-Jones D, Chagalucha J, Gumodoka B, Weiss H, Rusizoka M, Ndeki L, Whitehouse A, Balira R, Todd J, Ngeleja D, Ross D, Buve A, Hayes R, Mabey D. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. *Journal of Infectious Diseases*. 2002;186(7):940-947.
 121. Johnson HL, Ghanem KG, Zenilman JM, Erbelding EJ. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner-city public sexually transmitted diseases clinics. *Sexually Transmitted Diseases*. 2011;38(3):167-171.
 122. Elliott B, Brunham RC, Laga M, Piot P, Ndinya-Achola JO, Maitha G, Cheang M, Plummer FA. Maternal gonococcal infection as a preventable risk factor for low birth weight. *Journal of Infectious Diseases*. 1990;161(3):531-536.
 123. Association of *Chlamydia trachomatis* and *Mycoplasma hominis* with intrauterine growth retardation and preterm delivery. The Johns Hopkins Study of Cervicitis and Adverse Pregnancy Outcome. *American Journal of Epidemiology*. 1989;129(6):1247-1257.
 124. Gravett MG, Nelson HP, DeRouen T, Critchlow C, Eschenbach DA, Holmes KK. Independent associations of bacterial vaginosis and *Chlamydia trachomatis* infection

- with adverse pregnancy outcome. *JAMA: Journal of the American Medical Association*. 1986;256(14):1899-1903.
125. World Health Organization. *Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates*. Vol WHO/CDS/CSR/EDC/2001.10. Geneva: World Health Organization; 2001.
 126. Cotch MF, Pastorek JG, 2nd, Nugent RP, Hillier SL, Gibbs RS, Martin DH, Eschenbach DA, Edelman R, Carey JC, Regan JA, Krohn MA, Klebanoff MA, Rao AV, Rhoads GG. *Trichomonas vaginalis* associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. *Sexually Transmitted Diseases*. 1997;24(6):353-360.
 127. Meis PJ, Goldenberg RL, Mercer B, Moawad A, Das A, McNellis D, Johnson F, Iams JD, Thom E, Andrews WW. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *American Journal of Obstetrics and Gynecology*. 1995;173(4):1231-1235.
 128. Sutton MY, Sternberg M, Nsuami M, Behets F, Nelson AM, St Louis ME. Trichomoniasis in pregnant human immunodeficiency virus-infected and human immunodeficiency virus-uninfected Congolese women: prevalence, risk factors, and association with low birth weight. *American Journal of Obstetrics and Gynecology*. 1999;181(3):656-662.
 129. Leitch H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. *American Journal of Obstetrics and Gynecology*. 2003;189(1):139-147.
 130. McGregor JA, French JI, Parker R, Draper D, Patterson E, Jones W, Thorsgard K, McFee J. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. *American Journal of Obstetrics and Gynecology*. 1995;173(1):157-167.

131. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. *The BMJ*. 1994;308(6924):295-298.
132. Mayaud P, ka-Gina G, Cornelissen J, Todd J, Kaatano G, West B, Uledi E, Rwakatare M, Kopwe L, Manoko D, Laga M, Grosskurth H, Hayes R, Mabey D. Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. *Sexually Transmitted Infections*. 1998;74 Suppl 1:S77-84.
133. Vuylsteke B, Laga M, Alary M, Gerniers MM, Lebughe JP, Nzila N, Behets F, Van Dyck E, Piot P. Clinical algorithms for the screening of women for gonococcal and chlamydial infection: evaluation of pregnant women and prostitutes in Zaire. *Clinical Infectious Diseases*. 1993;17(1):82-88.
134. Daly CC, Wangel AM, Hoffman IF, Canner JK, Lule GS, Lema VM, Liomba NG, Dallabetta GA. Validation of the WHO diagnostic algorithm and development of an alternative scoring system for the management of women presenting with vaginal discharge in Malawi. *Sexually Transmitted Infections*. 1998;74:S50–58.
135. Temmerman M, Njagi E, Nagelkerke N, Ndinya-Achola J, Plummer FA, Meheus A. Mass antimicrobial treatment in pregnancy. A randomized, placebo-controlled trial in a population with high rates of sexually transmitted diseases. *Journal of Reproductive Medicine*. 1995;40(3):176-180.
136. McDermott J, Steketee R, Larsen S, Wirima J. Syphilis-associated perinatal and infant mortality in rural Malawi. *Bulletin of the World Health Organization*. 1993;71(6):773-780.
137. Donders GG, Desmyter J, De Wet DH, Van Assche FA. The association of gonorrhoea and syphilis with premature birth and low birthweight. *Genitourintological Medicine*. 1993;69(2):98-101.

138. Rours GI, Duijts L, Moll HA, Arends LR, de Groot R, Jaddoe VW, Hofman A, Steegers EA, Mackenbach JP, Ott A, Willemse HF, van der Zwaan EA, Verkooijen RP, Verbrugh HA. *Chlamydia trachomatis* infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. *European Journal of Epidemiology*. 2011;26(6):493-502.
139. Silveira MF, Ghanem KG, Erbeling EJ, Burke AE, Johnson HL, Singh RH, Zenilman JM. *Chlamydia trachomatis* infection during pregnancy and the risk of preterm birth: a case-control study. *International Journal of STD & AIDS*. 2009;20(7):465-469.
140. Wilkowska-Trojniel M, Zdrodowska-Stefanow B, Ostaszewska-Puchalska I, Redzko S, Przepiesc J, Zdrodowski M. The influence of *Chlamydia trachomatis* infection on spontaneous abortions. *Advances in Medical Sciences*. 2009;54(1):86-90.
141. Blas MM, Canchihuaman FA, Alva IE, Hawes SE. Pregnancy outcomes in women infected with *Chlamydia trachomatis*: a population-based cohort study in Washington State. *Sexually Transmitted Infections*. 2007;83(4):314-318.
142. Odendaal HJ, Schoeman J, Grove D, de Jager M, Theron GB, Orth H, McMahon C, Chalkley LJ. The association between *Chlamydia trachomatis* genital infection and spontaneous preterm labour. *South African Journal of Obstetrics and Gynaecology*. 2006;12(3):146-149.
143. Kovacs L, Nagy E, Berik I, Meszaros G, Deak J, Nyari T. The frequency and the role of *Chlamydia trachomatis* infection in premature labor. *Journal of Obstetrics & Gynaecology*. 1998;62(1):47-54.
144. Minkoff H, Grunebaum AN, Schwarz RH, Feldman J, Cummings M, Crombleholme W, Clark L, Pringle G, McCormack WM. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. *American Journal of Obstetrics and Gynecology*. 1984;150(8):965-972.

145. Svare JA, Schmidt H, Hansen BB, Lose G. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. *British Journal of Obstetrics and Gynaecology*. 2006;113(12):1419-1425.
146. Watson-Jones D, Weiss HA, Changalucha JM, Todd J, Gumodoka B, Bulmer J, Balira R, Ross D, Mugeye K, Hayes R, Mabey D. Adverse birth outcomes in United Republic of Tanzania--impact and prevention of maternal risk factors. *Bulletin of the World Health Organization*. 2007;85(1):9-18.
147. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, Cotch MF, Edelman R, Pastorek JG, 2nd, Rao AV, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. *New England Journal of Medicine*. 1995;333(26):1737-1742.
148. World Health Organization. *Malaria elimination: A field manual for low and moderate endemic countries*. Geneva, Switzerland: World Health Organization;2007.
149. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of *Plasmodium falciparum*. *Proceedings of the National Academy of Sciences of the United States of America*. 1988;85(23):9109-9113.
150. Peterson DS, Walliker D, Wellem TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in *falciparum* malaria. *Proceedings of the National Academy of Sciences of the United States of America*. 1988;85(23):9114-9118.
151. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, *Plasmodium falciparum*, with differing resistance to sulfadoxine. *European Journal of Biochemistry*. 1994;224(2):397-405.

152. Naidoo I. *Spatial and temporal analyses of sulphadoxine-pyrimethamine resistance in African Plasmodium falciparum malaria*. London: Department of Pathogen Molecular Biology London School of Hygiene & Tropical Medicine, University of London; 2015.
153. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, MacArthur JR, Luntamo M, Ashorn P, Doumbo OK, ter Kuile FO. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. *JAMA: The Journal of the American Medical Association*. 2013;309(6):594-604.
154. Desai M, Gutman J, L'Lanziva A, Otieno K, Juma E, Kariuki S, Ouma P, Were V, Laserson K, Katana A, Williamson J, ter Kuile FO. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. *Lancet*. 2015;386(10012):2507-2519.
155. Schurmann D, Bergmann F, Albrecht H, Padberg J, Wunsche T, Grunewald T, Schurmann M, Grobusch M, Vallee M, Ruf B, Suttorp N. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of *Pneumocystis carinii* pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. *European Journal of Clinical Microbiology & Infectious Diseases*. 2002;21(5):353-361.
156. World Health Organization. *Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendations for a public health approach*. Geneva, Switzerland: World Health Organization;2006.
157. Kampmeier RH. Introduction of sulfonamide therapy for gonorrhea. *Sexually Transmitted Diseases*. 1983;10(2):81-84.
158. Connor E. Sulfonamide antibiotics. Vol 5. New York, NY, USA: Elsevier; 1998:4.

159. Bhattacharyya MN, Jones BM. *Haemophilus vaginalis* infection. Diagnosis and treatment. *Journal of Reproductive Medicine*. 1980;24(2):71-75.
160. Brabin B. An analysis of malaria in pregnancy in Africa. *Bulletin of the World Health Organization*. 1983;61:1005–1016.
161. Walton G. On the control of malaria in Freetown, Sierra Leone: control methods and the effects upon the transmission of *Plasmodium falciparum* resulting from the reduced abundance of *Anopheles gambiae*. *Annals of Tropical Medicine & Parasitology*. 1949;43(2):117-139.
162. Schwetz J, Peel M. Congenital malaria and placental infections amongst the negroes of Central Africa. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1934;28(2):167-174.
163. Branden F. Congenital Malaria at Leopoldville, Belgian Congo. *Bulletin de la Société de Pathologie Exotique*. 1927;20(4):338-342.
164. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Broadhead RL. Malaria in pregnancy and its consequences for the infant in rural Malawi. *Annals of Tropical Medicine & Parasitology*. 1999;93 Suppl 1:S25-33.
165. Cot M, Le Hesran JY, Miaillhes P, Esveld M, Etya'ale D, Breart G. Increase of birth weight following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in Cameroon. *American Journal of Tropical Medicine and Hygiene*. 1995;53(6):581-585.
166. Cot M, Le Hesran J-Y, Miaillhes P, Roisin A, Fievet N, Barro D, Etya'Ale D, Deloron P, Carnevale P, Breart G. Effect of chloroquine prophylaxis during pregnancy on maternal haematocrit. *Annals of Tropical Medicine & Parasitology*. 1998;92(1):37-43.
167. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *The BMJ*. 2009;339:b2535.

168. Mullick S, Watson-Jones D, Beksinska M, Mabey D. Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. *Sexually Transmitted Infections*. 2005;81(4):294-302.
169. Brabin B. *The risks and severity of malaria in pregnant women. Applied field research in malaria reports*. Vol TDR/FIELDMAL/1. Geneva: Special Programme for Research and Training in Tropical Diseases. World Health Organization; 1991.
170. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature*. 2015;526(7572):207-211.
171. National Geospatial-Intelligence Agency. GEOnet Names Server,. <http://earth-info.nga.mil/gns/html/namefiles.htm>; 2013.
172. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. *JAMA: The Journal of the American Medical Association*. 2007;297(23):2603-2616.
173. Consortium for Spatial Information. Washington, DC,: <http://www.cgiar-csi.org>.
174. Balls MJ, Bodker R, Thomas CJ, Kisinza W, Msangeni HA, Lindsay SW. Effect of topography on the risk of malaria infection in the Usambara Mountains, Tanzania. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2004;98(7):400-408.
175. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials*. 1986;7(3):177-188.
176. Likwela JL, D'Alessandro U, Lokwa BL, Meuris S, Dramaix MW. Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a

- retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC). *Tropical Medicine & International Health*. 2012;17(3):322-329.
177. Gies S, Coulibaly SO, Ouattara FT, D'Alessandro U. Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weight. *Tropical Medicine & International Health*. 2009;14(2):174-182.
 178. Ramharther M, Schuster K, Bouyou-Akotet MK, Adegnikaa AA, Schmits K, Mombo-Ngoma G, Agnandji ST, Nemeth J, Afene SN, Issifou S, Onnas IN, Kombila M, Kremsner PG. Malaria in pregnancy before and after the implementation of a national IPTp program in Gabon. *American Journal of Tropical Medicine and Hygiene*. 2007;77(3):418-422.
 179. van Eijk AM, Ayisi JG, ter Kuile FO, Slutsker L, Otieno JA, Misore AO, Odondi JO, Rosen DH, Kager PA, Steketee RW, Nahlen BL. Implementation of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in Kisumu, western Kenya. *Tropical Medicine & International Health*. 2004;9(5):630-637.
 180. Sirima SB, Cotte AH, Konate A, Moran AC, Asamoah K, Bougouma EC, Diarra A, Ouedraogo A, Parise ME, Newman RD. Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso. *American Journal of Tropical Medicine and Hygiene*. 2006;75(2):205-211.
 181. Rogerson SJ, van den Broek NR, Chaluluka E, Qongwane C, Mhango CG, Molyneux ME. Malaria and anemia in antenatal women in Blantyre, Malawi: a twelve-month survey. *American Journal of Tropical Medicine and Hygiene*. 2000;62(3):335-340.
 182. Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME. Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-99. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2000;94(5):549-553.

183. Naidoo I, Roper C. Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. *Parasitology*. 2011;138(12):1469-1479.
184. Mockenhaupt FP, Teun Bousema J, Eggelte TA, Schreiber J, Ehrhardt S, Wassilew N, Otchwemah RN, Sauerwein RW, Bienzle U. *Plasmodium falciparum dhfr* but not *dhps* mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. *Tropical Medicine & International Health*. 2005;10(9):901-908.
185. Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, Kone A, Guindo A, Dicko A, Beavogui AH, Djimde AA, Lyke KE, Diallo DA, Doumbo OK, Plowe CV. Impact of trimethoprim-sulfamethoxazole prophylaxis on *falciparum* malaria infection and disease. *Journal of Infectious Diseases*. 2005;192(10):1823-1829.
186. Ibrahim ML, Steenkeste N, Khim N, Adam HH, Konate L, Coppee JY, Arieu F, Duchemin JB. Field-based evidence of fast and global increase of *Plasmodium falciparum* drug-resistance by DNA-microarrays and PCR/RFLP in Niger. *Malaria Journal*. 2009;8:32.
187. Taylor SM, Antonia AL, Parobek CM, Juliano JJ, Janko M, Emch M, Alam MT, Udhayakumar V, Tshefu AK, Meshnick SR. *Plasmodium falciparum* sulfadoxine resistance is geographically and genetically clustered within the DR Congo. *Scientific reports*. 2013;3:1165.
188. Alker AP, Kazadi WM, Kutelemini AK, Bloland PB, Tshefu AK, Meshnick SR. *dhfr* and *dhps* genotype and sulfadoxine-pyrimethamine treatment failure in children with *falciparum* malaria in the Democratic Republic of Congo. *Tropical Medicine & International Health*. 2008;13(11):1384-1391.
189. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, Naidoo I, Tibenderana J, Roper C. Emergence of a *dhfr* mutation conferring high-level drug resistance in *Plasmodium falciparum* populations from southwest Uganda. *Journal of Infectious Diseases*. 2008;197(11):1598-1604.

190. Karema C, Imwong M, Fanello CI, Stepniewska K, Uwimana A, Nakeesathit S, Dondorp A, Day NP, White NJ. Molecular correlates of high-level antifolate resistance in Rwandan children with *Plasmodium falciparum* malaria. *Antimicrobial Agents and Chemotherapy*. 2010;54(1):477-483.
191. Noranate N, Durand R, Tall A, Marrama L, Spiegel A, Sokhna C, Pradines B, Cojean S, Guillotte M, Bischoff E, Ekala MT, Bouchier C, Fandeur T, Arieu F, Patarapotikul J, Le Bras J, Trape JF, Rogier C, Mercereau-Puijalon O. Rapid dissemination of *Plasmodium falciparum* drug resistance despite strictly controlled antimalarial use. *PLOS ONE*. 2007;2(1):e139.
192. Raman J, Sharp B, Kleinschmidt I, Roper C, Streat E, Kelly V, Barnes KI. Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. *American Journal of Tropical Medicine and Hygiene*. 2008;78(2):256-261.
193. Kun JF, Lehman LG, Lell B, Schmidt-Ott R, Kremsner PG. Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant *Plasmodium falciparum* strains. *Antimicrobial Agents and Chemotherapy*. 1999;43(9):2205-2208.
194. Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, Bakary M, Le Bras J, Deloron P. *DHFR* and *DHPS* genotypes of *Plasmodium falciparum* isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. *Journal of Antimicrobial Chemotherapy*. 2003;52(1):43-49.
195. Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, Kamwendo DD, Tadesse E, Chaluluka E, Meshnick SR. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in *Plasmodium falciparum* isolates from Blantyre, Malawi. *Antimicrobial Agents and Chemotherapy*. 2005;49(9):3919-3921.

196. Bell DJ, Nyirongo SK, Mukaka M, Zijlstra EE, Plowe CV, Molyneux ME, Ward SA, Winstanley PA. Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. *PLOS ONE*. 2008;3(2):e1578.
197. Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for *dhps* and *dhfr* point mutations in *Plasmodium falciparum* infections be used to predict sulfadoxine-pyrimethamine treatment failure? *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2001;95(3):315-319.
198. Zhong D, Afrane Y, Githeko A, Cui L, Menge DM, Yan G. Molecular epidemiology of drug-resistant malaria in western Kenya highlands. *BMC Infectious Diseases*. 2008;8:105.
199. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, Duffy PE. Competitive facilitation of drug-resistant *Plasmodium falciparum* malaria parasites in pregnant women who receive preventive treatment. *Proc Natl Acad Sci U S A*. 2009;106(22):9027-9032.
200. Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, Coldren RL, Moss WJ, Waters NC. Increased prevalence of the *Pfdhfr/Phdhps* quintuple mutant and rapid emergence of *Pfdhps* resistance mutations at codons 581 and 613 in Kisumu, Kenya. *Malaria Journal*. 2010;9:338.
201. Chaponda EB, Chandramohan D, Michelo C, Mharakurwa S, Chipeta J, Chico RM. High burden of malaria infection in pregnant women in a rural district of Zambia: a cross-sectional study. *Malaria Journal*. 2015;14(1):1-12.
202. Chaponda EB, Chico RM, Bruce J, Michelo C, Vwalika B, Mharakurwa S, Chaponda M, Chipeta J, Chandramohan D. Malarial infection and curable sexually transmitted and reproductive tract infections among pregnant women in a rural district of Zambia. *American Journal of Tropical Medicine and Hygiene*. 2016;95(5):1069-1076.

203. World Health Organization. *Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach*. Geneva 2010.
204. González R, Ataíde R, Naniche D, Menéndez C, Mayor A. HIV and malaria interactions: where do we stand? *Expert Review of Anti-infective Therapy*. 2012;10(2):153-165.
205. Shulman CE, Dorman EK. Importance and prevention of malaria in pregnancy. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2003;97(1):30-35.
206. Dos Santos Silva I. Chapter 14: Dealing with confounding in the analysis. *Cancer Epidemiology*. Lyon, France: World Health Organization / International Agency for Research on Cancer; 1999:305-331.
207. Curtis CF, Maxwell CA, Maxwell CA, Finch RJ, Finch RJ, Njunwa KJ. A comparison of use of a pyrethroid either for house spraying or for bednet treatment against malaria vectors. *Tropical Medicine & International Health*. 1998;3(8):619-631.
208. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. *Methods in observational epidemiology*. 2nd edition ed. New York: Oxford University Press; 1996.
209. Vuylsteke B, Bastos R, Barreto J, Crucitti T, Folgosa E, Mondlane J, Dusauchoit T, Piot P, Laga M. High prevalence of sexually transmitted diseases in a rural area in Mozambique. *Genitourinary Medicine*. 1993;69(6):427-430.
210. Mbopi Keou FX, Mbu R, Mauciere P, Andela A, Tetanye E, Leke R, Chaouat G, Barre-Sinoussi F, Martin P, Belec L. Antenatal HIV prevalence in Yaounde, Cameroon. *International Journal of STD & AIDS*. 1998;9(7):400-402.
211. Taha TE, Gray RH, Kumwenda NI, Hoover DR, Mtimavalye LA, Liomba GN, Chipangwi JD, Dallabetta GA, Miotti PG. HIV infection and disturbances of vaginal flora during pregnancy. *Journal of Acquired Immune Deficiency Syndromes*. 1999;20(1):52-59.
212. Rutgers S. Syphilis in pregnancy: a medical audit in a rural district. *Central African Journal of Medicine*. 1993;39(12):248-253.

213. Cossa HA, Gloyd S, Vaz RG, Folgosa E, Simbine E, Diniz M, Kreiss JK. Syphilis and HIV infection among displaced pregnant women in rural Mozambique. *International Journal of STD & AIDS*. 1994;5(2):117-123.
214. Jenniskens F, Obwaka E, Kirusuah S, Moses S, Yusufali FM, Achola JO, Fransen L, Laga M, Temmerman M. Syphilis control in pregnancy: decentralization of screening facilities to primary care level, a demonstration project in Nairobi, Kenya. *International Journal of Gynecology & Obstetrics*. 1995;48 Suppl:S121-128.
215. Mayaud P, Grosskurth H, Changalucha J, Todd J, West B, Gabone R, Senkoro K, Rusizoka M, Laga M, Hayes R, et al. Risk assessment and other screening options for gonorrhoea and chlamydial infections in women attending rural Tanzanian antenatal clinics. *Bulletin of the World Health Organization*. 1995;73(5):621-630.
216. Temmerman M, Fonck K, Bashir F, Inion I, Ndinya-Achola JO, Bwayo J, Kirui P, Claeys P, Fransen L. Declining syphilis prevalence in pregnant women in Nairobi since 1995: another success story in the STD field? *International Journal of STD & AIDS*. 1999;10(6):405-408.
217. Mwakagile D, Swai ABM, Sandstrom E, Urassa E, Biberfeld G, Mhalu FS. High frequency of sexually transmitted diseases among pregnant women in Dar es Salaam, Tanzania: need for intervention. *East African Medical Journal*. 1996;73(10):675-678.
218. Taha TE, Dallabetta GA, Hoover DR, Chiphangwi JD, Mtimavalye LA, Liomba GN, Kumwenda NI, Miotti PG. Trends of HIV-1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi. *AIDS*. 1998;12(2):197-203.
219. Azeze B, Fantahun M, Kidan KG, Haile T. Seroprevalence of syphilis amongst pregnant women attending antenatal clinics in a rural hospital in north west Ethiopia. *Genitourinary Medicine*. 1995;71(6):347-350.

220. Thomas T, Choudhri S, Kariuki C, Moses S. Identifying cervical infection among pregnant women in Nairobi, Kenya: limitations of risk assessment and symptom-based approaches. *Genitourinary Medicine*. 1996;72(5):334-338.
221. Mayaud P, Msuya W, Todd J, Kaatano G, West B, Begkoyian G, Grosskurth H, Mabey D. STD rapid assessment in Rwandan refugee camps in Tanzania. *Genitourinary Medicine*. 1997;73(1):33-38.
222. Mayaud P, Mosha F, Todd J, Balira R, Mgara J, West B, Rusizoka M, Mwijarubi E, Gabone R, Gavyole A, Grosskurth H, Hayes R, Mabey D. Improved treatment services significantly reduce the prevalence of sexually transmitted diseases in rural Tanzania: results of a randomized controlled trial. *AIDS*. 1997;11(15):1873-1880.
223. Mayaud P, Uledi E, Cornelissen J, ka-Gina G, Todd J, Rwakatare M, West B, Kopwe L, Manoko D, Grosskurth H, Hayes R, Mabey D. Risk scores to detect cervical infections in urban antenatal clinic attenders in Mwanza, Tanzania. *Sexually Transmitted Infections*. 1998;74 Suppl 1:S139-146.
224. Urassa WK, Kapiga SH, Msamanga GI, Antelman G, Coley J, Fawzi WW. Risk factors for syphilis among HIV-1 infected pregnant women in Dar es Salaam, Tanzania. *African Journal of Reproductive Health*. 2001;5(3):54-62.
225. Tsegaye A, Rinke De Wit TF, Mekonnen Y, Beyene A, Aklilu M, Messele T, Abebe A, Coutinho R, Sanders E, Fontanet AL. Decline in prevalence of HIV-1 infection and syphilis among young women attending antenatal care clinics in Addis Ababa, Ethiopia: results from sentinel surveillance, 1995-2001. *Journal of Acquired Immune Deficiency Syndromes*. 2002;30(3):359-362.
226. Ayisi JG, van Eijk AM, ter Kuile FO, Kolczak MS, Otieno JA, Misore AO, Kager PA, Steketee RW, Nahlen BL. Risk factors for HIV infection among asymptomatic pregnant women attending an antenatal clinic in western Kenya. *International Journal of STD & AIDS*. 2000;11(6):393-401.

227. Kebede E, Chamiso B. Prevalence of syphilis in pregnancy in Addis Ababa. *East African Medical Journal*. 2000;77(4):212-216.
228. Fonck K, Kidula N, Jaoko W, Estambale B, Claeys P, Ndinya-Achola J, Kirui P, Bwayo J, Temmerman M. Validity of the vaginal discharge algorithm among pregnant and non-pregnant women in Nairobi, Kenya. *Sexually Transmitted Infections*. 2000;76(1):33-38.
229. Majoko F, Munjanja S, Nystrom L, Mason E, Lindmark G. Field efficiency of syphilis screening in antenatal care: lessons from Gutu District in Zimbabwe. *Central African Journal of Medicine*. 2003;49(7-8):90-93.
230. Ayisi JG, van Eijk AM, ter Kuile FO, Kolczak MS, Otieno JA, Misore AO, Kager PA, Steketee RW, Nahlen BL. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. *AIDS*. 2003;17(4):585-594.
231. Fonck K, Claeys P, Bashir F, Bwayo J, Fransen L, Temmerman M. Syphilis control during pregnancy: effectiveness and sustainability of a decentralized program. *American Journal of Public Health*. 2001;91(5):705-707.
232. Ortashi OM, El Khidir I, Herieka E. Prevalence of HIV, syphilis, *Chlamydia trachomatis*, *Neisseria gonorrhoea*, *Trichomonas vaginalis* and candidiasis among pregnant women attending an antenatal clinic in Khartoum, Sudan. *Journal of Obstetrics & Gynaecology*. 2004;24(5):513-515.
233. Pham L, Woelk GB, Ning Y, Madzime S, Mudzamiri S, Mahomed K, Williams MA. Seroprevalence and risk factors of syphilis infection in pregnant women delivering at Harare Maternity Hospital, Zimbabwe. *Central African Journal of Medicine*. 2005;51(3-4):24-30.
234. Msuya SE, Mbizvo EM, Stray-Pedersen B, Uriyo J, Sam NE, Rusakaniko S, Hussain A. Decline in HIV prevalence among women of childbearing age in Moshi urban, Tanzania. *International Journal of STD & AIDS*. 2007;18:680-687.

235. Romoren M, Rahman M. Syphilis screening in the antenatal care: a cross-sectional study from Botswana. *BMC International Health and Human Rights*. 2006;6:8.
236. Kwiek JJ, Mwapasa V, Alker AP, Muula AS, Misiri HE, Molyneux ME, Rogerson SJ, Behets FM, Meshnick SR. Socio-demographic characteristics associated with HIV and syphilis seroreactivity among pregnant women in Blantyre, Malawi, 2000-2004. *Malawi Medical Journal*. 2008;20(3):80-85.
237. Menendez C, Castellsague X, Renom M, Sacarlal J, Quinto L, Lloveras B, Klaustermeier J, Kornegay JR, Sigauque B, Bosch FX, Alonso PL. Prevalence and risk factors of sexually transmitted infections and cervical neoplasia in women from a rural area of southern Mozambique. *Infectious Diseases in Obstetrics and Gynecology*. 2010;2010.
238. Kurewa NE, Mapingure MP, Munjoma MW, Chirenje MZ, Rusakaniko S, Stray-Pedersen B. The burden and risk factors of Sexually Transmitted Infections and Reproductive Tract Infections among pregnant women in Zimbabwe. *BMC Infectious Diseases*. 2010;10:127.
239. Mapingure MP, Msuya S, Kurewa NE, Munjoma MW, Sam N, Chirenje MZ, Rusakaniko S, Saugstad LF, de Vlas SJ, Stray-Pedersen B. Sexual behaviour does not reflect HIV-1 prevalence differences: a comparison study of Zimbabwe and Tanzania. *Journal of the International AIDS Society*. 2010;13:45.
240. Swai RO, Somi GG, Matee MI, Killewo J, Lyamuya EF, Kwasigabo G, Tulli T, Kabalimu TK, Ng'ang'a L, Isingo R, Ndayongeje J. Surveillance of HIV and syphilis infections among antenatal clinic attendees in Tanzania-2003/2004. *BMC Public Health*. 2006;6:91.
241. Montoya PJ, Lukehart SA, Brentlinger PE, Blanco AJ, Floriano F, Sairosse J, Gloyd S. Comparison of the diagnostic accuracy of a rapid immunochromatographic test and the rapid plasma reagin test for antenatal syphilis screening in Mozambique. *Bulletin of the World Health Organization*. 2006;84(2):97-104.

242. Yahya-Malima KI, Evjen-Olsen B, Matee MI, Fylkesnes K, Haarr L. HIV-1, HSV-2 and syphilis among pregnant women in a rural area of Tanzania: prevalence and risk factors. *BMC Infectious Diseases*. 2008;8:75.
243. Tann CJ, Mpairwe H, Morison L, Nassimu K, Hughes P, Omara M, Mabey D, Muwanga M, Grosskurth H, Elliott AM. Lack of effectiveness of syndromic management in targeting vaginal infections in pregnancy in Entebbe, Uganda. *Sexually Transmitted Diseases*. 2006;82(4):285-289.
244. Lujan J, de Onate WA, Delva W, Claeys P, Sambola F, Temmerman M, Fernando J, Folgosa E. Prevalence of sexually transmitted infections in women attending antenatal care in Tete province, Mozambique. *South African Medical Journal*. 2008;98(1):49-51.
245. Woodburn PW, Muhangi L, Hillier S, Ndibazza J, Namujju PB, Kizza M, Ameke C, Omoding NE, Booth M, Elliott AM. Risk factors for helminth, malaria, and HIV infection in pregnancy in Entebbe, Uganda. *PLOS Neglected Tropical Diseases*. 2009;3(6):e473.
246. Abdalla E, Ekanem E, Said D, Arube P, Gboun M, Mohammed F. The need for a comprehensive response to HIV/ AIDS in north-western Somalia: evidence from a seroprevalence survey. *Eastern Mediterranean Health Journal*. 2010;16(2):141-145.
247. Mulu A, Kassu A, Tessema B, Yismaw G, Tiruneh M, Moges F, Wondmikun Y, Nishikawa T, Ota F. Seroprevalence of syphilis and HIV-1 during pregnancy in a teaching hospital in northwest Ethiopia. *Japanese Journal of Infectious Diseases*. 2007;60(4):193-195.
248. Diallo MO, Ettiegne-Traore V, Maran M, Kouadio J, Brattegaard K, Makke A, Van Dyck E, Laga M, De Cock KM. Sexually transmitted diseases and human immunodeficiency virus infections in women attending an antenatal clinic in Abidjan, Cote d'Ivoire. *International Journal of STD & AIDS*. 1997;8(10):636-638.
249. Rodier MH, Berthonneau J, Bourgoin A, Giraudeau G, Agius G, Burucoa C, Hekpazo A, Jacquemin JL. Seroprevalences of *Toxoplasma*, malaria, rubella, cytomegalovirus, HIV

- and *Treponemal* infections among pregnant women in Cotonou, Republic of Benin. *Acta Tropica*. 1995;59(4):271-277.
250. Meda N, Sangare L, Lankoande S, Sanou PT, Compaore PI, Catraye J, Cartoux M, Soudre RB. Pattern of sexually transmitted diseases among pregnant women in Burkina Faso, west Africa: potential for a clinical management based on simple approaches. *Genitourinary Medicine*. 1997;73(3):188-193.
 251. Bourgeois A, Henzel D, Malonga-Mouelet G, Dibanga G, Tsobou C, Peeters M, Delaporte E. Clinical algorithms for the screening of pregnant women for STDs in Libreville, Gabon: which alternatives? *Sexually Transmitted Diseases*. 1998;74(1):35-39.
 252. Blankhart D, Muller O, Gresenguet G, Weis P. Sexually transmitted infections in young pregnant women in Bangui, Central African Republic. *International Journal of STD & AIDS*. 1999;10(9):609-614.
 253. Sombie I, Meda N, Cartoux M, Tiendrebeogo S, Ouangre A, Yaro S, Ky-Zerbo O, Dao B, Van de Perre P, Mandelbrot L, Dabis F, The DITRAME Study Group. Seroprevalence of syphilis among women attending urban antenatal clinics in Burkina Faso, 1995-8. *Sexually Transmitted Diseases*. 2000;76(4):314-316.
 254. Ikeme AC, Okeke TC. The relevance of VDRL as routine test in pregnant women: a critical study. *Nigerian Journal of Clinical Practice*. 2006;9(1):65-67.
 255. Aboyaji AP, Nwabuisi C. Prevalence of sexually transmitted diseases among pregnant women in Ilorin, Nigeria. *Journal of Obstetrics & Gynaecology*. 2003;23(6):637-639.
 256. Bukar M, Audu BM, Takai UI, Ajayi BB, Kullima AA. Is routine antenatal screening for syphilis in Nigeria still justified clinically and economically? *Saudi Medical Journal*. 2009;30(10):1311-1315.
 257. Apea-Kubi KA, Yamaguchi S, Sakyi B, Kishimoto T, Ofori-Adjei D, Hagiwara T. *Neisseria gonorrhoea*, *Chlamydia trachomatis*, and *Treponema pallidum* infection in antenatal and

- gynecological patients at Korle-Bu Teaching Hospital, Ghana. *Japanese Journal of Infectious Diseases*. 2004;57(6):253-256.
258. Sagay AS, Kapiga SH, Imade GE, Sankale JL, Idoko J, Kanki P. HIV infection among pregnant women in Nigeria. *International Journal of Gynecology & Obstetrics*. 2005;90(1):61-67.
 259. Kirakoya-Samadoulougou F, Defer MC, Yaro S, Fao P, Ilboudo F, Langani Y, Meda N, Robert A, Nagot N. Low seroprevalence of syphilis in Burkina Faso. *Sexually Transmitted Diseases*. 2011;87(1):35-37.
 260. Kinoshita-Moleka R, Smith JS, Atibu J, Tshefu A, Hemingway-Foday J, Hobbs M, Bartz J, Koch MA, Rimoin AW, Ryder RW. Low prevalence of HIV and other selected sexually transmitted infections in 2004 in pregnant women from Kinshasa, the Democratic Republic of the Congo. *Epidemiology and Infection*. 2008;136(9):1290-1296.
 261. Taiwo SS, Adesiji YO, Adekanle DA. Screening for syphilis during pregnancy in Nigeria: a practice that must continue. *Sexually Transmitted Diseases*. 2007;83(5):357-358.
 262. Romoren M, Rahman M, Sundby J, Hjortdahl P. Chlamydia and gonorrhoea in pregnancy: effectiveness of diagnosis and treatment in Botswana. *Sexually Transmitted Infections*. 2004;80(5):395-400.
 263. Aboud S, Msamanga G, Read JS, Mwatha A, Chen YQ, Potter D, Valentine M, Sharma U, Hoffmann I, Taha TE, Goldenberg RL, Fawzi WW. Genital tract infections among HIV-infected pregnant women in Malawi, Tanzania and Zambia. *International Journal of STD & AIDS*. 2008;19(12):824-832.
 264. Okonofua FE, Ako-Nai KA, Dighitoghi MD. Lower genital tract infections in infertile Nigerian women compared with controls. *Genitourinary Medicine*. 1995;71(3):163-168.
 265. Wessel HF, Herrmann B, Dupret A, Moniz F, Brito C, Bergstrom S. Genital infections among antenatal care attendees in Cape Verde. *African Journal of Reproductive Health*. 1998;2(1):32-40.

266. Faye-Kette H, La Ruche G, Ali-Napo L, Messou N, Viho I, Welffens-Ekra C, Dosso M, Msellati P. Genital mycoplasmas among pregnant women in Cote d'Ivoire, West Africa: prevalence and risk factors. *International Journal of STD & AIDS*. 2000;11(9):599-602.
267. Van Dyck E, Samb N, Sarr AD, Van de Velden L, Moran J, Mboup S, Ndoeye I, Lamboray JL, Meheus A, Piot P. Accuracy of two enzyme immunoassays and cell culture in the detection of *Chlamydia trachomatis* in low and high risk populations in Senegal. *European Journal of Clinical Microbiology*. 1992;11(6):527-534.
268. Ogbonna CI, Ogbonna IB, Ogbonna AA, Anosike JC. Studies on the incidence of *Trichomonas vaginalis* amongst pregnant women in Jos area of Plateau State, Nigeria. *Angewandte Parasitologie*. 1991;32(4):198-204.
269. Romoren M, Velauthapillai M, Rahman M, Sundby J, Klouman E, Hjortdahl P. Trichomoniasis and bacterial vaginosis in pregnancy: inadequately managed with the syndromic approach. *Bulletin of the World Health Organization*. 2007;85(4):297-304.
270. Nwosu CO, Djieyep NA. Candidiasis and trichomoniasis among pregnant women in a rural community in the semi-arid zone, north-eastern Nigeria. *West African Journal of Medicine*. 2007;26(1):17-19.
271. Kirakoya-Samadoulougou F, Nagot N, Defer MC, Yaro S, Meda N, Robert A. Bacterial vaginosis among pregnant women in Burkina Faso. *Sexually Transmitted Diseases*. 2008;35(12):985-989.
272. Tolosa JE, Chaithongwongwatthana S, Daly S, Maw WW, Gaitan H, Lumbiganon P, Festin M, Chipato T, Sauvarin J, Goldenberg RL, Andrews WW, Whitney CG. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. *American Journal of Obstetrics and Gynecology*. 2006;195(5):1198-1204.

273. Ndyomugyen R, Magnussen P. Anaemia in pregnancy: *Plasmodium falciparum* infection is an important cause in primigravidae in Hoima district, western Uganda. *Annals of Tropical Medicine & Parasitology*. 1999;93(5):457-465.
274. Okwa OO. The status of malaria among pregnant women: a study in Lagos, Nigeria. *African Journal of Reproductive Health*. 2003;7(3):77-83.
275. van Eijk AM, Ayisi JG, Ter Kuile FO, Misore A, Otieno JA, Kolczak MS, Kager PA, Steketee RW, Nahlen BL. Human immunodeficiency virus seropositivity and malaria as risk factors for third-trimester anemia in asymptomatic pregnant women in western Kenya. *American Journal of Tropical Medicine and Hygiene*. 2001;65(5):623-630.
276. van Eijk AM, Ayisi JG, ter Kuile FO, Misore AO, Otieno JA, Rosen DH, Kager PA, Steketee RW, Nahlen BL. HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. *AIDS*. 2003;17(4):595-603.
277. van Eijk AM, Ayisi JG, ter Kuile FO, Misore AO, Otieno JA, Rosen DH, Kager PA, Steketee RW, Nahlen BL. Risk factors for malaria in pregnancy in an urban and peri-urban population in western Kenya. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2002;96(6):586-592.
278. Mnyika KS, Kabalimu TK, Rukinsha K, Mpanju-Shumbusho W. Randomised trial of alternative malaria chemoprophylaxis strategies among pregnant women in Kigoma, Tanzania: I. Rationale and design. *East African Medical Journal*. 2000;77(2):98-104.
279. Tobian AA, Mehlotra RK, Malhotra I, Wamachi A, Mungai P, Koech D, Ouma J, Zimmerman P, King CL. Frequent umbilical cord-blood and maternal-blood infections with *Plasmodium falciparum*, *P. malariae*, and *P. ovale* in Kenya. *Journal of Infectious Diseases*. 2000;182(2):558-563.
280. Ahmed SM, Abd Al-Rhim SK, Mohamedani AA, Habour AB, Sadek AA. Malaria parasitemia during delivery. *Saudi Medical Journal*. 2002;23(6):684-688.

281. Kasumba IN, Nalunkuma AJ, Mujuzi G, Kitaka FS, Byaruhanga R, Okong P, Egwang TG. Low birthweight associated with maternal anaemia and *Plasmodium falciparum* infection during pregnancy, in a peri-urban/urban area of low endemicity in Uganda. *Annals of Tropical Medicine and Parasitology*. 2000;94(1):7-13.
282. Saute F, Menendez C, Mayor A, Aponte J, Gomez-Olive X, Dgedge M, Alonso P. Malaria in pregnancy in rural Mozambique: the role of parity, submicroscopic and multiple *Plasmodium falciparum* infections. *Tropical Medicine & International Health*. 2002;7(1):19-28.
283. Mankhambo L, Kanjala M, Rudman S, Lema VM, Rogerson SJ. Evaluation of the OptiMAL rapid antigen test and species-specific PCR to detect placental *Plasmodium falciparum* infection at delivery. *Journal of Clinical Microbiology*. 2002;40(1):155-158.
284. Newman RD, Hailemariam A, Jimma D, Degifie A, Kebede D, Rietveld AEC, Nahlen BL, Barnwell JW, Steketee RW, Parise ME. Burden of malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a nonepidemic year. *Journal of Infectious Diseases*. 2003;187(11):1765-1772.
285. Elghazali G, Adam I, Hamad A, El-Bashir MI. *Plasmodium falciparum* infection during pregnancy in an unstable transmission area in eastern Sudan. *Eastern Mediterranean Health Journal*. 2003;9(4):570-580.
286. Wort UU, Warsame M, Brabin BJ. Birth outcomes in adolescent pregnancy in an area with intense malaria transmission in Tanzania. *Acta Obstetrica et Gynecologica Scandinavica*. 2006;85(8):949-954.
287. Van Geertruyden JP, Ntakirutimana D, Erhart A, Rwagacondo C, Kabano A, D'Alessandro U. Malaria infection among pregnant women attending antenatal clinics in six Rwandan districts. *Tropical Medicine & International Health*. 2005;10(7):681-688.

288. Kalilani L, Mofolo I, Chaponda M, Rogerson S, Meshnick S. The effect of timing and frequency of malaria infection during pregnancy on low birth weight and maternal anemia. *American Journal of Tropical Medicine and Hygiene*. 2006;75(5):414.
289. Parise ME, Lewis LS, Ayisi JG, Nahlen BL, Slutsker L, Muga R, Sharif SK, Hill J, Steketee RW. A rapid assessment approach for public, health decision-making related to the prevention of malaria during pregnancy. *Bulletin of the World Health Organization*. 2003;81(5):316-323.
290. Adam I, Khamis AH, Elbashir MI. Prevalence and risk factors for anaemia in pregnant women of eastern Sudan. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2005;99(10):739-743.
291. Adam I, IE AE, Salih I, Elbashir MI. Submicroscopic Plasmodium falciparum infections during pregnancy, in an area of Sudan with a low intensity of malaria transmission. *Annals of Tropical Medicine & Parasitology*. 2005;99(4):339-344.
292. Brentlinger PE, Dgedge M, Correia MA, Rojas AJ, Saute F, Gimbel-Sherr KH, Stubbs BA, Mercer MA, Gloyd S. Intermittent preventive treatment of malaria during pregnancy in central Mozambique. *Bulletin of the World Health Organization*. 2007;85(11):873-879.
293. Ouma P, van Eijk AM, Hamel MJ, Parise M, Ayisi JG, Otieno K, Kager PA, Slutsker L. Malaria and anaemia among pregnant women at first antenatal clinic visit in Kisumu, western Kenya. *Tropical Medicine & International Health*. 2007;12(12):1515-1523.
294. Hillier SD, Booth M, Muhangi L, Nkurunziza P, Khihembo M, Kakande M, Sewankambo M, Kizindo R, Kizza M, Muwanga M, Elliott AM. *Plasmodium falciparum* and helminth coinfection in a semiurban population of pregnant women in Uganda. *Journal of Infectious Diseases*. 2008;198(6):920-927.
295. Ndyomugenyi R, Kabatereine N, Olsen A, Magnussen P. Malaria and hookworm infections in relation to haemoglobin and serum ferritin levels in pregnancy in Masindi

- district, western Uganda. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2008;102(2):130-136.
296. Rantala AM, Taylor SM, Trottman PA, Luntamo M, Mbewe B, Maleta K, Kulmala T, Ashorn P, Meshnick SR. Comparison of real-time PCR and microscopy for malaria parasite detection in Malawian pregnant women. *Malaria Journal*. 2010;9:269.
 297. Serra-Casas E, Menendez C, Dobano C, Bardaji A, Quinto L, Ordi J, Sigauque B, Cistero P, Mandomando I, Alonso PL, Mayor A. Persistence after delivery of *Plasmodium falciparum* parasites infecting Mozambican pregnant women. *Infection and Immunity*. 2010.
 298. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, Snounou G, Ashley EA, McGready R, Nosten F, Guerin PJ. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated *Plasmodium falciparum* malaria: an open-label, randomised, non-inferiority trial. *Lancet Infectious Diseases*. 2010;10(11):762-769.
 299. Mbonye AK, Bygbjerg I, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda. *International Journal of Infectious Diseases*. 2008;12(1):22-29.
 300. Meuris S, Piko BB, Eerens P, Vanbellinchen AM, Dramaix M, Hennart P. Gestational malaria: assessment of its consequences on fetal growth. *American Journal of Tropical Medicine and Hygiene*. 1993;48(5):603-609.
 301. Morgan HG. Placental malaria and low birthweight neonates in urban Sierra Leone. *Annals of Tropical Medicine & Parasitology*. 1994;88(6):575-580.
 302. Achidi EA, Salimonu LS. Malaria parasitaemia and immunoglobulin levels in paired maternal-cord sera from south western Nigeria. *African Journal of Medicine and Medical Sciences*. 1997;26(3-4):167-170.

303. Watson PA. Asymptomatic *Plasmodium falciparum* parasitaemia in pregnant women. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1998;92(2):236.
304. Egwunyenga OA, Ajayi JA, Duhlińska-Popova DD. Transplacental passage of *Plasmodium falciparum* and seroevaluation of newborns in northern Nigeria. *Journal of Communicable Diseases*. 1995;27(2):77-83.
305. Menendez C, Todd J, Alonso PL, Francis N, Lulat S, Ceesay S, M'Boge B, Greenwood BM. The effects of iron supplementation during pregnancy, given by traditional birth attendants, on the prevalence of anaemia and malaria. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1994;88(5):590-593.
306. Egwunyenga OA, Ajayi JA, Popova-Duhlińska DD, Nmorsi OP. Malaria infection of the cord and birthweights in Nigerians. *Central African Journal of Medicine*. 1996;42(9):265-268.
307. Browne EN, Maude GH, Binka FN. The impact of insecticide-treated bednets on malaria and anaemia in pregnancy in Kassena-Nankana district, Ghana: a randomized controlled trial. *Tropical Medicine & International Health*. 2001;6(9):667-676.
308. Tako EA, Zhou A, Lohoue J, Leke R, Taylor DW, Leke RF. Risk factors for placental malaria and its effect on pregnancy outcome in Yaounde, Cameroon. *American Journal of Tropical Medicine and Hygiene*. 2005;72(3):236-242.
309. Zhou A, Megnekou R, Leke R, Fogako J, Metenou S, Trock B, Taylor DW, Leke RF. Prevalence of *Plasmodium falciparum* infection in pregnant Cameroonian women. *American Journal of Tropical Medicine and Hygiene*. 2002;67(6):566-570.
310. Walker-Abbey A, Djokam RR, Eno A, Leke RF, Titanji VP, Fogako J, Sama G, Thuita LH, Beardslee E, Snounou G, Zhou A, Taylor DW. Malaria in pregnant Cameroonian women: the effect of age and gravidity on submicroscopic and mixed-species infections and multiple parasite genotypes. *American Journal of Tropical Medicine and Hygiene*. 2005;72(3):229-235.

311. Egwunyenga AO, Ajayi JA, Nmorsi OP, Duhlińska-Popova DD. Plasmodium/intestinal helminth co-infections among pregnant Nigerian women. *Memórias do Instituto Oswaldo Cruz*. 2001;96(8):1055-1059.
312. Salihu HM, Naik EG, Tchuinguem G, Bosny JPL, Dagne G. Weekly chloroquine prophylaxis and the effect on maternal haemoglobin status at delivery. *Tropical Medicine and International Health*. 2002;7(1):29-34.
313. Okoko BJ, Ota MO, Yamuah LK, Idiong D, Mkpanam SN, Avieka A, Banya WA, Osinusi K. Influence of placental malaria infection on foetal outcome in the Gambia: twenty years after Ian McGregor. *Journal of Health, Population, and Nutrition*. 2002;20(1):4-11.
314. Anorlu RI, Odum CU, Essien EE. Asymptomatic malaria parasitaemia in pregnant women at booking in a primary health care facility in a periurban community in Lagos, Nigeria. *African Journal of Medicine and Medical Sciences*. 2001;30 Suppl:39-41.
315. Mockenhaupt FP, Bedu-Addo G, Eggelte TA, Hommerich L, Holmberg V, von Oertzen C, Bienzle U. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among *Plasmodium falciparum* isolated from pregnant women in Ghana. *Journal of Infectious Diseases*. 2008;198(10):1545-1549.
316. Sule-Odu AO, Ogunledun A, Olatunji AO. Impact of asymptomatic maternal malaria parasitaemia at parturition on perinatal outcome. *Journal of Obstetrics & Gynaecology*. 2002;22(1):25-28.
317. Achidi EA, Kuoh AJ, Minang JT, Ngum B, Achimbom BM, Motaze SC, Ahmadou MJ, Troye-Blomberg M. Malaria infection in pregnancy and its effects on haemoglobin levels in women from a malaria endemic area of Fako Division, South West Province, Cameroon. *Journal of Obstetrics & Gynaecology*. 2005;25(3):235-240.
318. Akum AE, Kuoh AJ, Minang JT, Achimbom BM, Ahmadou MJ, Troye-Blomberg M. The effect of maternal, umbilical cord and placental malaria parasitaemia on the birthweight of newborns from South-western Cameroon. *Acta Paediatrica*. 2005;94(7):917-923.

319. Kassam SN, Nesbitt S, Hunt LP, Oster N, Soothill P, Sergi C. Pregnancy outcomes in women with or without placental malaria infection. *International Journal of Obstetrics & Gynaecology*. 2006;93(3):225-232.
320. Rogerson SJ, Mkundika P, Kanjala MK. Diagnosis of *Plasmodium falciparum* malaria at delivery: comparison of blood film preparation methods and of blood films with histology. *Journal of Clinical Microbiology*. 2003;41(4):1370-1374.
321. Kabyemela ER, Fried M, Kurtis JD, Mutabingwa TK, Duffy PE. Decreased susceptibility to *Plasmodium falciparum* infection in pregnant women with iron deficiency. *Journal of Infectious Diseases*. 2008;198(2):163-166.
322. Adam I, Babiker S, Mohammed AA, Salih MM, Prins MH, Zaki ZM. ABO blood group system and placental malaria in an area of unstable malaria transmission in eastern Sudan. *Malaria Journal*. 2007;6:110.
323. Senga E, Loscertales MP, Makwakwa KE, Liomba GN, Dзамalala C, Kazembe PN, Brabin BJ. ABO blood group phenotypes influence parity specific immunity to *Plasmodium falciparum* malaria in Malawian women. *Malaria Journal*. 2007;6:102.
324. Abdelrahim, II, Adam GK, Mohammed AA, Salih MM, Ali NI, Elbashier MI, Adam I. Anaemia, folate and vitamin B12 deficiency among pregnant women in an area of unstable malaria transmission in eastern Sudan. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2009;103(5):493-496.
325. Adam I, Adam GK, Mohammed AA, Salih MM, Ibrahim SA, Ryan CA. Placental malaria and lack of prenatal care in an area of unstable malaria transmission in eastern Sudan. *Journal of Parasitology*. 2009;95(3):751-752.
326. Rasheed FN, Bulmer JN, De Francisco A, Jawla MF, Jakobsen PH, Jepson A, Greenwood BM. Relationships between maternal malaria and malarial immune responses in mothers and neonates. *Parasite Immunology*. 1995;17(1):1-10.

327. N'Dao CT, N'Diaye JL, Gaye A, Le Hesran JY. Placental malaria and pregnancy outcome in a peri urban area in Senegal *Revue d Épidémiologie et de Santé Publique*. 2006;54(2):149-156.
328. Mockenhaupt FP, Bedu-Addo G, von Gaertner C, Boye R, Fricke K, Hannibal I, Karakaya F, Schaller M, Ulmen U, Acquah PA, Dietz E, Eggelte TA, Bienzle U. Detection and clinical manifestation of placental malaria in southern Ghana. *Malaria Journal*. 2006;5:119.
329. Singer LM, Newman RD, Diarra A, Moran AC, Huber CS, Stennies G, Sirima SB, Konate A, Yameogo M, Sawadogo R, Barnwell JW, Parise ME. Evaluation of a malaria rapid diagnostic test for assessing the burden of malaria during pregnancy. *American Journal of Tropical Medicine and Hygiene*. 2004;70(5):481-485.
330. Leke RF, Bioga JD, Zhou J, Fouda GG, Leke RJ, Tchinda V, Megnekou R, Fogako J, Sama G, Gwanmesia P, Bomback G, Nama C, Diouf A, Bobbili N, Taylor DW. Longitudinal studies of *Plasmodium falciparum* malaria in pregnant women living in a rural Cameroonian village with high perennial transmission. *American Journal of Tropical Medicine and Hygiene*. 2010;83(5):996-1004.
331. Owens S, Harper G, Amuasi J, Offei-Larbi G, Ordi J, Brabin BJ. Placental malaria and immunity to infant measles. *Archives of Disease in Childhood*. 2006;91(6):507-508.
332. Mokuolu OA, Falade CO, Orogade AA, Okafor HU, Adedoyin OT, Oguonu TA, Dada-Adegbola HO, Oguntayo OA, Ernest SK, Hamer DH, Callahan MV. Malaria at parturition in Nigeria: current status and delivery outcome. *Infectious Diseases in Obstetrics and Gynecology*. 2009;2009:473971.
333. Falade CO, Yusuf BO, Fadero FF, Mokuolu OA, Hamer DH, Salako LA. Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. *Malaria Journal*. 2007;6.

334. Serra-Casas E, Menendez C, Bardaji A, Quinto L, Dobano C, Sigauque B, Jimenez A, Mandomando I, Chauhan VS, Chitnis CE, Alonso PL, Mayor A. The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes. *Journal of Infectious Diseases*. 2010;201(1):123-131.
335. Lukuka KA, Fumie OS, Mulumbu MR, Lokombe BJ, Muyembe TJ. Malaria prevalence at delivery in four maternity hospitals of Kinshasa City, Democratic Republic of Congo. *Bulletin de la Société de Pathologie Exotique* 2006;99(3):200-201.
336. Ukaga CN, Nwoke BE, Udujih OS, Udujih OG, Ohaeri AA, Anosike JC, Udujih BU, Nwachukwu MI. Placental malaria in Owerri, Imo State, south-eastern Nigeria. *Tanzania Health Research Bulletin* 2007;9(3):180-185.
337. Enato EF, Okhamafe AO, Okpere EE, Oseji FI. Prevalence of malaria during pregnancy and antimalarial intervention in an urban secondary health care facility in Southern Nigeria. *Medical Principles and Practice*. 2007;16(3):240-243.
338. Anchang-Kimbi JK, Achidi EA, Nkegoum B, Sverremark-Ekstrom E, Troye-Blomberg M. Diagnostic comparison of malaria infection in peripheral blood, placental blood and placental biopsies in Cameroonian parturient women. *Malaria Journal*. 2009;8:126.
339. Peeling RW, Ye H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an overview. *Bulletin of the World Health Organization*. 2004;82(6):439-446.
340. Kuypers J, Gaydos CA, Peeling RW. Principles of Laboratory Diagnosis of STIs. In: Holmes KK, Sparling FP, Stamm WE, et al., eds. *Sexually Transmitted Diseases*. 4th ed. New York: McGraw Hill; 2008:937-957.
341. Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB. Systematic review: noninvasive testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Annals of Internal Medicine*. 2005;142(11):914-925.

342. Kuypers J, World Health Organization. Laboratory tests for the detection of reproductive tract infections. In: Jejeebhoy S, Koenig M, Elias C, eds. *Reproductive Tract Infections and other Gynaecological Disorders*. Cambridge: Cambridge University Press; 2003:225-260.
343. Thejls H, Rahm VA, Gnarp J, Gnarp H. Diagnostic efficacy of chlamydial antibodies in cervical secretions from pregnant women and adolescent girls. *Genitourinary Medicine*. 1995;71(6):370-374.
344. Meehan M, Wawer M, Swerwadda D, Gray R, Quinn T. Laboratory methods for the diagnosis of reproductive tract infections and selected conditions in population-based studies. In: Jejeebhoy S, Koenig M, Elias C, eds. *Reproductive Tract Infections and other Gynaecological Disorders*. Cambridge: Cambridge University Press; 2003:261-282.
345. Dadhwal V, Hariprasad R, Mittal S, Kapil A. Prevalence of bacterial vaginosis in pregnant women and predictive value of clinical diagnosis. *Archives of Gynecology and Obstetrics*. 2010;281(1):101-104.
346. Goyal R, Sharma P, Kaur I, Aggarwal N, Talwar V. Bacterial vaginosis and vaginal anaerobes in preterm labour. *Journal of the Indian Medical Association*. 2004;102(10):548-550, 553.
347. Thomason JL, Anderson RJ, Gelbart SM, Osypowski PJ, Scaglione NJ, el Tabbakh G, James JA. Simplified gram stain interpretive method for diagnosis of bacterial vaginosis. *American Journal of Obstetrics and Gynecology*. 1992;167(1):16-19.
348. Schwebke JR, Hillier SL, Sobel JD, McGregor JA, Sweet RL. Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. *Obstetrics & Gynecology*. 1996;88(4 Pt 1):573-576.
349. Reyburn H, Ruanda J, Mwerinde O, Drakeley C. The contribution of microscopy to targeting antimalarial treatment in a low transmission area of Tanzania. *Malaria Journal*. 2006;5:4.

350. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, Saganda K, Shao J, Kitua A, Olomi R, Greenwood BM, Whitty CJ. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. *The BMJ*. 2004;329(7476):1212.
351. Barat L, Chipipa J, Kolczak M, Sukwa T. Does the availability of blood slide microscopy for malaria at health centers improve the management of persons with fever in Zambia? *American Journal of Tropical Medicine and Hygiene*. 1999;60(6):1024-1030.
352. Mockenhaupt FP, Ulmen U, von Gaertner C, Bedu-Addo G, Bienzle U. Diagnosis of placental malaria. *Journal of Clinical Microbiology*. 2002;40(1):306-308.
353. Fouts AC, Kraus SJ. *Trichomonas vaginalis*: reevaluation of its clinical presentation and laboratory diagnosis. *Journal of Infectious Diseases*. 1980;141(2):137-143.
354. van Der Schee C, van Belkum A, Zwiijgers L, van Der Brugge E, O'Neill E L, Luijendijk A, van Rijsoort-Vos T, van Der Meijden WI, Verbrugh H, Sluiters HJ. Improved diagnosis of *Trichomonas vaginalis* infection by PCR using vaginal swabs and urine specimens compared to diagnosis by wet mount microscopy, culture, and fluorescent staining. *Journal of Clinical Microbiology*. 1999;37(12):4127-4130.
355. UNAIDS. *Report on the global AIDS epidemic 2010*. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS;2010.
356. Ayisi JG, van Eijk AM, Newman RD, ter Kuile FO, Shi YP, Yang C, Kolczak MS, Otieno JA, Misore AO, Kager PA, Lal RB, Steketee RW, Nahlen BL. Maternal malaria and perinatal HIV transmission, western Kenya. *Emerging Infectious Diseases*. 2004;10(4):643-652.
357. Menendez C, Serra-Casas E, Scahill MD, Sanz S, Nhabomba A, Bardaji A, Sigauque B, Cistero P, Mandomando I, Dobano C, Alonso PL, Mayor A. HIV and placental infection modulate the appearance of drug-resistant *Plasmodium falciparum* in pregnant women who receive intermittent preventive treatment. *Clinical Infectious Diseases*. 2011;52(1):41-48.

358. Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo NK, Serwadda D, Moulton LH, Quinn TC, O'Brien KL, Meehan M, Abramowsky C, Robb M, Wawer MJ. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. *American Journal of Obstetrics and Gynecology*. 2001;185(5):1209-1217.
359. Hook EW, 3rd, Stephens J, Ennis DM. Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis. *Annals of Internal Medicine*. 1999;131(6):434-437.
360. Klausner JD, Kohn RP, Kent CK. Azithromycin versus penicillin for early syphilis. *New England Journal of Medicine*. 2006;354(2):203-205; author reply 203-205.
361. Hook EW, 3rd, Martin DH, Stephens J, Smith BS, Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. *Sexually Transmitted Diseases*. 2002;29(8):486-490.
362. Hook EW, 3rd, Behets F, Van Damme K, Ravelomanana N, Leone P, Sena AC, Martin D, Langley C, McNeil L, Wolff M. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. *Journal of Infectious Diseases*. 2010;201(11):1729-1735.
363. Kiddugavu MG, Kiwanuka N, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Makumbi F, Li X, Reynolds SJ, Quinn TC, Gray RH. Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. *Sexually Transmitted Diseases*. 2005;32(1):1-6.
364. Riedner G, Rusizoka M, Todd J, Maboko L, Hoelscher M, Mmbando D, Samky E, Lyamuya E, Mabey D, Grosskurth H, Hayes R. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. *New England Journal of Medicine*. 2005;353(12):1236-1244.

365. Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. *Clinical Infectious Diseases*. 2006;42(3):337-345.
366. Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, Engelman J, Mitchell SJ, Rompalo AM, Marra CM, Klausner JD. Macrolide resistance in *Treponema pallidum* in the United States and Ireland. *New England Journal of Medicine*. 2004;351(2):154-158.
367. Marra CM, Colina AP, Godornes C, Tantaló LC, Puray M, Centurion-Lara A, Lukehart SA. Antibiotic selection may contribute to increases in macrolide-resistant *Treponema pallidum*. *Journal of Infectious Diseases*. 2006;194(12):1771-1773.
368. Grimes M, Sahi SK, Godornes BC, Tantaló LC, Roberts N, Bostick D, Marra CM, Lukehart SA. Two mutations associated with macrolide resistance in *Treponema pallidum*: increasing prevalence and correlation with molecular strain type in Seattle, Washington. *Sexually Transmitted Diseases*. 2012;39(12):954-958.
369. Chen XS, Yin YP, Wei WH, Wang HC, Peng RR, Zheng HP, Zhang JP, Zhu BY, Liu QZ, Huang SJ. High prevalence of azithromycin resistance to *Treponema pallidum* in geographically different areas of China. *Clinical Microbiology and Infection*. 2012.
370. Wu H, Chang S-Y, Lee N-Y, Huang W-C, Wu B-R, Yang C-J, Liang S-H, Lee C-H, Ko W-C, Lin H-H. Evaluation of macrolide resistance and enhanced molecular typing of *Treponema pallidum* in patients with syphilis in Taiwan: a prospective multicenter study. *Journal of Clinical Microbiology*. 2012;50(7):2299-2304.
371. Van Damme K, Behets F, Ravelomanana N, Godornes C, Khan M, Randrianasolo B, Rabenja NL, Lukehart S, Cohen M, Hook E. Evaluation of azithromycin resistance in *Treponema pallidum* specimens from Madagascar. *Sexually Transmitted Diseases*. 2009;36(12):775-776.

372. ReMeD (Network for Medicine and Development). *Essential Medicines: Madagascar*. World Health Organization; http://www.who.int/selection_medicines/country_lists/mdg/en/.
373. Chen C-Y, Chi K-H, Pillay A, Nachamkin E, Su JR, Ballard RC. Detection of the A2058G and A2059G 23S rRNA gene point mutations associated with azithromycin resistance in *Treponema pallidum* by use of a TaqMan real-time multiplex PCR assay. *Journal of Clinical Microbiology*. 2013;51(3):908-913.
374. Müller EE, Paz-Bailey G, Lewis DA. Macrolide resistance testing and molecular subtyping of *Treponema pallidum* strains from southern Africa. *Sexually Transmitted Infections*. 2012;88(6):470-474.
375. Grabenstein MV, Harbison HS, Klausner JD. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in *Treponema pallidum* in the United States, 2007 to 2009. *Sexually Transmitted Diseases*. 2012;39(10):794-798.
376. Matějková P, Flasarova M, Zakoucka H, Bořek M, Křemenová S, Arenberger P, Woznicova V, Weinstock GM, Šmajš D. Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of *Treponema pallidum* subsp. *pallidum*. *Journal of medical microbiology*. 2009;58(6):832-836.
377. Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance and molecular types of *Treponema pallidum* causing primary syphilis in Shanghai, China. *Clinical Infectious Diseases*. 2009;49(4):515-521.
378. Tiple C, McClure MO, Taylor GP. High prevalence of macrolide resistant *Treponema pallidum* strains in a London centre. *Sexually Transmitted Infections*. 2011;87(6):486-488.
379. Rekart ML, Patrick DM, Chakraborty B, Maginley JJ, Jones HD, Bajdik CD, Pourbohloul B, Brunham RC. Targeted mass treatment for syphilis with oral azithromycin. *Lancet*. 2003;361(9354):313-314.

380. Muldoon EG, Walsh A, Crowley B, Mulcahy F. *Treponema pallidum* azithromycin resistance in Dublin, Ireland. *Sexually Transmitted Diseases*. 2012;39(10):784-786.
381. Martin IE, Tsang RS, Sutherland K, Anderson B, Read R, Roy C, Yanow S, Fonseca K, White W, Kandola K. Molecular typing of *Treponema pallidum* strains in western Canada: predominance of 14d subtypes. *Sexually Transmitted Diseases*. 2010;37(9):544-548.
382. Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000–2004. *Clinical Infectious Diseases*. 2006;42(3):337-345.
383. Morshed MG, Jones HD. *Treponema Pallidum* macrolide resistance in BC. *CMAJ : Canadian Medical Association Journal / Journal de l'Association Medicale Canadienne*. 2006;174(3):349.
384. Odugbemi T, Oyewole F, Isichei CS, Onwukeme KE, Adeyemi-Doro FA. Single oral dose of azithromycin for therapy of susceptible sexually transmitted diseases: a multicenter open evaluation. *West African Journal of Medicine*. 1993;12(3):136-140.
385. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. *Journal of Antimicrobial Chemotherapy*. 1993;31 Suppl E:193-198.
386. Swanston WH, Prabhakar P, Barrow L, Mahabir BS, Furlonge C. Single dose (direct observed) azithromycin therapy for *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in STD clinic attenders with genital discharge in Trinidad and Tobago. *West Indian Medical Journal*. 2001;50(3):198-202.
387. Lassus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by *Neisseria* and *Chlamydia* species. *Journal of Antimicrobial Chemotherapy*. 1990;25 Suppl A:115-121.

388. Steingrímsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. *Journal of Antimicrobial Chemotherapy*. 1990;25 Suppl A:109-114.
389. Steingrímsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Single dose azithromycin treatment of gonorrhea and infections caused by *C. trachomatis* and *U. urealyticum* in men. *Sexually Transmitted Diseases*. 1994;21(1):43-46.
390. Gruber F, Grubisic-Greblo H, Jonjic A, Markusic J. Treatment of gonococcal and chlamydial urethritis with azitromycin or doxycycline. *Chronica Dermatologica*. 1995;5:213-213.
391. Gruber F, Brajac I, Jonjic A, Grubisic-Greblo H, Lenkovic M, Stasic A. Comparative trial of azithromycin and ciprofloxacin in the treatment of gonorrhea. *Journal of Chemotherapy*. 1997;9(4):263-266.
392. Rustomjee R, Kharsany AB, Connolly CA, Karim SS. A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting. *Journal of Antimicrobial Chemotherapy*. 2002;49(5):875-878.
393. Bignell C, Garley J. Azithromycin in the treatment of infection with *Neisseria gonorrhoeae*. *Sexually Transmitted Infections*. 2010;86(6):422-426.
394. Solomon AW, World Health Organization, International Trachoma Initiative. Trachoma control: a guide for programme managers. 2006.
395. Handsfield HH, Dalu Z, Martin DH, Douglas Jr JM, Mccarty JM, Schlossberg D, Group AGS. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. *Sexually Transmitted Diseases*. 1994;21(2):107-111.
396. Khaki P, Bhalla P, Sharma A, Kumar V. Correlation between In vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: a prospective study. *Indian Journal of Medical Microbiology*. 2007;Oct 25(4):354-357.

397. Johnson SR, Sandul AL, Parekh M, Wang SA, Knapp JS, Trees DL. Mutations causing in vitro resistance to azithromycin in *Neisseria gonorrhoeae*. *International Journal of Antimicrobial Agents*. 2003;21(5):414-419.
398. Martin I, Jayaraman G, Wong T, Liu G, Gilmour M, Network CPHL. Trends in antimicrobial resistance in *Neisseria gonorrhoeae* isolated in Canada: 2000–2009. *Sexually Transmitted Diseases*. 2011;38(10):892-898.
399. Cole MJ, Chisholm SA, Hoffmann S, Stary A, Lowndes CM, Ison CA, Network ESoSTI. European surveillance of antimicrobial resistance in *Neisseria gonorrhoeae*. *Sexually Transmitted Infections*. 2010;86(6):427-432.
400. Centers for Disease Control and Prevention. *Neisseria gonorrhoeae* with reduced susceptibility to azithromycin--San Diego County, California, 2009. *MMWR: Morbidity and Mortality Weekly Report*. 2011;60(18):579.
401. Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M. Antimicrobial susceptibility and genetic characteristics of *Neisseria gonorrhoeae* isolates from Vietnam, 2011. *BMC Infectious Diseases*. 2013;13:40.
402. Lahra MM. Annual report of the Australian gonococcal surveillance programme, 2011. *Communicable Diseases Intelligence Quarterly Report*. 2012;36(2):E166.
403. Sethi S, Golparian D, Bala M, Dorji D, Ibrahim M, Jabeen K, Unemo M. Antimicrobial susceptibility and genetic characteristics of *Neisseria gonorrhoeae* isolates from India, Pakistan and Bhutan in 2007-2011. *BMC Infectious Diseases*. 2013;13:35.
404. Lo Janice YC, Ho King M, Lo Angus CT. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. *Journal of Antimicrobial Chemotherapy*. 2012;67(6):1422-1426.
405. Lefebvre B, Bourgault A. P1-S1. 44 Antimicrobial susceptibility profile of *Neisseria gonorrhoeae* isolates in the Province of Quebec-2010. *Sexually Transmitted Infections*. 2011;87(Suppl 1):A117-A117.

406. Hottes TS, Lester RT, Hoang LM, McKay R, Imperial M, Gilbert M, Patrick DM, Wong T, Martin I, Ogilvie G. Cephalosporin and azithromycin susceptibility in *Neisseria gonorrhoeae* isolates by site of infection, British Columbia, 2006 to 2011. *Sexually Transmitted Diseases*. 2013;40(1):46-51.
407. Yuan L-F, Yin Y-P, Dai X-Q, Pearline RV, Xiang Z, Unemo M, Chen X-S. Resistance to azithromycin of *Neisseria gonorrhoeae* isolates from 2 cities in China. *Sexually Transmitted Diseases*. 2011;38(8):764-768.
408. Takahashi S, Kurimura Y, Hashimoto J, Uehara T, Hiyama Y, Tsukamoto T, Iwasawa A, Nishimura M, Sunaoshi K, Takeda K. Antimicrobial susceptibility and penicillin-binding protein 1 and 2 mutations in *Neisseria gonorrhoeae* isolated from male urethritis in Sapporo, Japan. *Journal of Infection and Chemotherapy*. 2013;19(1):50-56.
409. Herchline TE, Inkrott BP. Resistance trends in *Neisseria gonorrhoeae* in southwestern Ohio. *Sexually Transmitted Diseases*. 2010;37(2):121-122.
410. Olsen B, Månsson F, Camara C, Monteiro M, Biai A, Alves A, Andersson S, Norrgren H, Unemo M. Phenotypic and genetic characterisation of bacterial sexually transmitted infections in Bissau, Guinea-Bissau, West Africa: a prospective cohort study. *BMJ Open*. 2012;2(2):e000636.
411. Tanaka M, Koga Y, Nakayama H, Kanayama A, Kobayashi I, Saika T, Iyoda T. Antibiotic-resistant phenotypes and genotypes of *Neisseria gonorrhoeae* isolates in Japan: identification of strain clusters with multidrug-resistant phenotypes. *Sexually Transmitted Diseases*. 2011;38(9):871-875.
412. Bala M. Characterization of profile of multidrug-resistant *Neisseria gonorrhoeae* using old and new definitions in India over a decade: 2000–2009. *Sexually Transmitted Diseases*. 2011;38(11):1056-1058.

413. Chisholm S, Neal T, Alawattegama A, Birley H, Howe R, Ison C. Emergence of high-level azithromycin resistance in *Neisseria gonorrhoeae* in England and Wales. *Journal of Antimicrobial Chemotherapy*. 2009;64(2):353-358.
414. Khaki P, Bhalla P, Sharma P, Chawla R, Bhalla K. Epidemiological analysis of *Neisseria gonorrhoeae* isolates by antimicrobial susceptibility testing, auxotyping and serotyping. *Indian Journal of Medical Microbiology*. 2007;25(3):225.
415. Enders M, Turnwald-Maschler A, Regnath T. Antimicrobial resistance of *Neisseria gonorrhoeae* isolates from the Stuttgart and Heidelberg areas of southern Germany. *European Journal of Clinical Microbiology and Infectious Diseases*. 2006;25(5):318-322.
416. Vorobieva V, Firsova N, Ababkova T, Leniv I, Haldorsen BC, Unemo M, Skogen V. Antibiotic susceptibility of *Neisseria gonorrhoeae* in Arkhangelsk, Russia. *Sexually Transmitted Infections*. 2007;83(2):133-135.
417. Sutrisna A, Soebjakto O, Wignall F, Kaul S, Limnios E, Ray S, Nguyen N, Tapsall J. Increasing resistance to ciprofloxacin and other antibiotics in *Neisseria gonorrhoeae* from East Java and Papua, Indonesia, in 2004—implications for treatment. *International Journal of STD & AIDS*. 2006;17(12):810-812.
418. Martin IMC, Hoffmann S, Ison CA, European Surveillance of Sexually Transmitted Infections network. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for *Neisseria gonorrhoeae* in Western Europe. *Journal of Antimicrobial Chemotherapy*. 2006;58(3):587-593.
419. Chaudhary C, Chaudhary FAH, Pandey AR, Karki N, Kansaker P, Das AK, Ross JL, Malla S, Hossain A, Neilsen G. A pilot study on antimicrobial susceptibility of *Neisseria gonorrhoeae* isolates from Nepal. *Sexually Transmitted Diseases*. 2005;32(10):641-643.
420. Chen PL, Hsieh YH, Lee HC, Ko NY, Lee NY, Wu CJ, Chang CM, Lee CC, Ko WC. Suboptimal therapy and clinical management of gonorrhoea in an area with high-level antimicrobial resistance. *International Journal of STD & AIDS*. 2009;20(4):225-228.

421. Hsueh PR, Tseng SP, Teng LJ, Ho SW. High prevalence of ciprofloxacin-resistant *Neisseria gonorrhoeae* in Northern Taiwan. *Clinical Infectious Diseases*. 2005;40(1):188-192.
422. Aydin D, Küçükbasmaci Ö, Gönüllü N, Aktas Z. Susceptibilities of *Neisseria gonorrhoeae* and *Ureaplasma urealyticum* isolates from male patients with urethritis to several antibiotics including telithromycin. *Chemotherapy*. 2005;51(2-3):89.
423. Moodley P, Pillay C, Goga R, Kharsany AB, Sturm AW. Evolution in the trends of antimicrobial resistance in *Neisseria gonorrhoeae* isolated in Durban over a 5 year period: impact of the introduction of syndromic management. *Journal of Antimicrobial Chemotherapy*. 2001;48(6):853-859.
424. Kobayashi I, Kanayama A, Saika T, Nishida M, Nakayama H, Tanaka M, Naito S. Tendency toward increase in the frequency of isolation of β -lactamase-nonproducing *Neisseria gonorrhoeae* exhibiting penicillin resistance, and recent emergence of multidrug-resistant isolates in Japan. *Journal of Infection and Chemotherapy*. 2003;9(2):126-130.
425. Llanes R, Sosa J, Guzman D, Llop A, Valdes EA, Martinez I, Palma S, Lantero MI. Antimicrobial susceptibility of *Neisseria gonorrhoeae* in Cuba (1995-1999): implications for treatment of gonorrhea. *Sexually Transmitted Diseases*. 2003;30(1):10-14.
426. Sosa J, Ramirez-Arcos S, Ruben M, Li H, Llanes R, Llop A, Dillon JA. High percentages of resistance to tetracycline and penicillin and reduced susceptibility to azithromycin characterize the majority of strain types of *Neisseria gonorrhoeae* isolates in Cuba, 1995-1998. *Sexually Transmitted Diseases*. 2003;30(5):443-448.
427. Dillon JA, Rubabaza JP, Benzaken AS, Sardinha JC, Li H, Bandeira MG, dos Santos Fernando Filho E. Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in *Neisseria gonorrhoeae* isolates from Manaus, Brazil, 1998. *Sexually Transmitted Diseases*. 2001;28(9):521-526.

428. Zarantonelli L, Borthagaray G, Lee EH, Veal W, Shafer WM. Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in *Neisseria gonorrhoeae*. *Journal of Antimicrobial Chemotherapy*. 2001;47(5):651-654.
429. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant *Neisseria gonorrhoeae* following treatment with azithromycin. *International Journal of STD & AIDS*. 1997;8(5):299-302.
430. Mehaffey PC, Putnam SD, Barrett MS, Jones RN. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of *Neisseria gonorrhoeae* by reference agar dilution, disk diffusion, and Etest methods. *Journal of Clinical Microbiology*. 1996;34(2):479-481.
431. van Rijsoort-Vos JH, Stolz E, Verbrugh HA, Kluytmans JA. In-vitro activity of a new quinolone (CP-99,219) compared with ciprofloxacin, pefloxacin, azithromycin and penicillin against *Neisseria gonorrhoeae*. *Journal of Antimicrobial Chemotherapy*. 1995;36(1):215-218.
432. Ison C, Roope N, Dangor Y, Radebe F, Ballard R. Antimicrobial susceptibilities and serotyping of *Neisseria gonorrhoeae* in southern Africa: influence of geographical source of infection. *Epidemiology and Infection*. 1993;110(02):297-305.
433. Starnino S, Stefanelli P, Group NgIS. Azithromycin-resistant *Neisseria gonorrhoeae* strains recently isolated in Italy. *Journal of Antimicrobial Chemotherapy*. 2009;63(6):1200-1204.
434. Donegan EA, Wirawan DN, Muliawan P, Schachter J, Moncada J, Parekh M, Knapp JS. Fluoroquinolone-resistant *Neisseria gonorrhoeae* in Bali, Indonesia: 2004. *Sexually Transmitted Diseases*. 2006;33(10):625-629.
435. Morris SR, Moore DF, Hannah PB, Wang SA, Wolfe J, Trees DL, Bolan G, Bauer HM. Strain typing and antimicrobial resistance of fluoroquinolone-resistant *Neisseria*

- gonorrhoeae* causing a California infection outbreak. *Journal of Clinical Microbiology*. 2009;47(9):2944-2949.
436. Ieven M, Van Looveren M, Sudigdoadi S, Rosana Y, Goossens W, Lammens C, Meheus A, Goossens H. Antimicrobial susceptibilities of *Neisseria gonorrhoeae* strains isolated in Java, Indonesia. *Sexually Transmitted Diseases*. 2003;30(1):25-29.
 437. Centers for Disease Control Prevention. Fluoroquinolone-resistance in *Neisseria gonorrhoeae*, Hawaii, 1999, and decreased susceptibility to azithromycin in *N. gonorrhoeae*, Missouri, 1999. *MMWR Morbidity and Mortality Weekly Report*. 2000;49(37):833.
 438. Bruck P, Robertson C, Allan P. Management of *Neisseria gonorrhoeae* infection over 12 months in a genitourinary medicine setting against British Association for Sexual Health and HIV auditable outcome measures. *International Journal of STD & AIDS*. 2012;23(3):e30-e32.
 439. Dan M, Mor Z, Gottlieb S, Sheinberg B, Shohat T. Trends in antimicrobial susceptibility of *Neisseria gonorrhoeae* in Israel, 2002 to 2007, with special reference to fluoroquinolone resistance. *Sexually Transmitted Diseases*. 2010;37(7):451-453.
 440. McLean CA, Wang SA, Hoff GL, Dennis LY, Trees DL, Knapp JS, Markowitz LE, Levine WC. The emergence of *Neisseria gonorrhoeae* with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. *Sexually Transmitted Diseases*. 2004;31(2):73-78.
 441. Arreaza L, Vazquez F, Alcalá B, Otero L, Salcedo C, Vazquez J. Emergence of gonococcal strains with resistance to azithromycin in Spain. *Journal of Antimicrobial Chemotherapy*. 2002.
 442. Starnino S, Galarza P, Carvallo MET, Benzaken AS, Ballesteros AM, Cruz OMS, Hernandez AL, Carbajal JLP, Borthagaray G, Payares D. Retrospective analysis of antimicrobial susceptibility trends (2000–2009) in *Neisseria gonorrhoeae* isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin,

- azithromycin and decreased susceptibility to ceftriaxone. *Sexually Transmitted Diseases*. 2012;39(10):813-821.
443. Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of *Chlamydia trachomatis* in pregnancy. *Infectious Diseases in Obstetrics and Gynecology*. 2001;9(4):197-202.
 444. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of *Chlamydia trachomatis* in pregnancy. *American Journal of Obstetrics and Gynecology*. 2001;184(7):1352-1356.
 445. Wehbeh HA, Rugeirio RM, Shahem S, Lopez G, Ali Y. Single-dose azithromycin for Chlamydia in pregnant women. *Journal of Reproductive Medicine*. 1998;43(6):509-514.
 446. Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. *Obstetrics & Gynecology*. 1998;91(2):165-168.
 447. Gunter ME AC, Ernest JM, McElroy G,. Azithromycin powder versus erythromycin in the treatment of chlamydial cervicitis in pregnancy. *Infectious Diseases in Obstetrics and Gynecology*. 1996;4(53).
 448. Edwards MS, Newman RB, Carter SG, Leboeuf FW, Menard MK, Rainwater KP. Randomized clinical trial of azithromycin vs. erythromycin for the treatment of chlamydia cervicitis in pregnancy. *Infectious Diseases in Obstetrics and Gynecology*. 1996;4(6):333-337.
 449. Rosenn MF, Macones GA, Silverman NS. Randomized trial of erythromycin and azithromycin for treatment of chlamydial infection in pregnancy. *Infectious Diseases in Obstetrics and Gynecology*. 1995;3(6):241-244.
 450. Bush MR, Rosa C. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. *Obstetrics & Gynecology*. 1994;84(1):61-63.

451. Rahangdale L, Guerry S, Bauer HM, Packel L, Rhew M, Baxter R, Chow J, Bolan G. An observational cohort study of *Chlamydia trachomatis* treatment in pregnancy. *Sexually Transmitted Diseases*. 2006;33(2):106-110.
452. Miller JM. Efficacy and Tolerance of Single-dose Azithromycin for Treatment of Chlamydial Cervicitis During Pregnancy. *Infect Dis Obstet Gynecol*. 1995;3(5):189-192.
453. Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, Clark A, Malinski C, Helmers JR, Thomas KK, Holmes KK. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. *The New England Journal of Medicine*. 2005;352(7):676-685.
454. Katz BP FD, Orr DP. Factors affecting chlamydial persistence or recurrence one and three months after treatment. Chlamydial infections. In, Stephens RS, Byrne GI, Christiansen G, et al, eds. Proceedings of the ninth international symposium on human chlamydial infection, USA, International Chlamydia Symposium. 1998:35–38.
455. Horner P. The case for further treatment studies of uncomplicated genital *Chlamydia trachomatis* infection. *Sexually Transmitted Infections*. 2006;82(4):340-343.
456. Jones RB, Van Der Pol B, Martin DH, Shepard MK. Partial characterization of *Chlamydia trachomatis* isolates resistant to multiple antibiotics. *Journal of Infectious Diseases*. 1990;162(6):1309-1315.
457. Lefevre J-C, LePargneur J-P. Comparative *in vitro* susceptibility of a tetracycline-resistant *Chlamydia trachomatis* strain isolated in Toulouse (France). *Sexually Transmitted Diseases*. 1998;25(7):350-352.
458. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant *Chlamydia trachomatis* associated with clinical treatment failure. *Journal of Infectious Diseases*. 2000;181(4):1421-1427.

459. Samra Z, Rosenberg S, Soffer Y, Dan M. *In vitro* susceptibility of recent clinical isolates of *Chlamydia trachomatis* to macrolides and tetracyclines. *Diagnostic Microbiology and Infectious Disease*. 2001;39(3):177-179.
460. Dreses-Werringloer U, Padubrin I, Zeidler H, Kohler L. Effects of azithromycin and rifampin on *Chlamydia trachomatis* infection in vitro. *Antimicrobial Agents and Chemotherapy*. 2001;45(11):3001-3008.
461. Donati M, Rodriguez Fermepin M, Olmo A, D'Apote L, Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against *Chlamydia* spp. *Journal of Antimicrobial Chemotherapy*. 1999;43(6):825-827.
462. Misyurina OY, Chipitsyna EV, Finashutina YP, Lazarev VN, Akopian TA, Savicheva AM, Govorun VM. Mutations in a 23S rRNA gene of *Chlamydia trachomatis* associated with resistance to macrolides. *Antimicrobial Agents and Chemotherapy*. 2004;48(4):1347-1349.
463. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS. Susceptibilities of *Chlamydia trachomatis* isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. *Antimicrobial Agents and Chemotherapy*. 1995;39(3):760-762.
464. Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of *Chlamydia trachomatis* obtained from recurrently infected female patients in India. *Chemotherapy*. 2010;56(5):371-377.
465. Ljubin-Sternak S, Mestrovic T, Vilibic-Cavlek T, Mlinaric-Galinovic G, Sviben M, Markotic A, Skerk V. In vitro susceptibility of urogenital *Chlamydia trachomatis* strains in a country with high azithromycin consumption rate. *Folia microbiologica*. 2013;58(5):361-365.
466. Donati M, Di Francesco A, D'Antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R. *In vitro* activities of several antimicrobial agents against recently isolated

- and genotyped *Chlamydia trachomatis* urogenital serovars D through K. *Antimicrobial Agents and Chemotherapy*. 2010;54(12):5379-5380.
467. Hong KC, Schachter J, Moncada J, Zhou Z, House J, Lietman TM. Lack of macrolide resistance in *Chlamydia trachomatis* after mass azithromycin distributions for trachoma. *Emerging Infectious Diseases*. 2009;15(7):1088-1090.
 468. Lefevre JC, Escaffre MC, Courdil M, Lareng MB. *In vitro* evaluation of activities of azithromycin, clarithromycin and sparflaxacin against *Chlamydia trachomatis*. *Pathologie Biologie*. 1993;41(4):313-315.
 469. Agacfidan A, Moncada J, Schachter J. *In vitro* activity of azithromycin (CP-62,993) against *Chlamydia trachomatis* and *Chlamydia pneumoniae*. *Antimicrobial Agents and Chemotherapy*. 1993;37(9):1746-1748.
 470. Scieux C, Bianchi A, Chappey B, Vassias I, Perol Y. *In vitro* activity of azithromycin against *Chlamydia trachomatis*. *Journal of Antimicrobial Chemotherapy*. 1990;25 Suppl A:7-10.
 471. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M, Ronald AR, Moses S. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. *JAMA: Journal of the American Medical Association*. 2004;291(21):2555-2562.
 472. Luntamo M, Kulmala T, Cheung YB, Maleta K, Ashorn P. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. *Tropical Medicine and International Health*. 2013;18(4):386-397.
 473. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, Wabwire-Mangen F, Li C, Lutalo T, Nalugoda F, Gaydos CA, Moulton LH, Meehan MO, Ahmed S, Gray RH. Control of sexually transmitted diseases for AIDS prevention in Uganda: a

- randomised community trial. Rakai Project Study Group. *Lancet*. 1999;353(9152):525-535.
474. Labbe AC, Pepin J, Khonde N, Dzokoto A, Meda H, Asamoah-Adu C, Mayaud P, Mabey D, Demers E, Alary M. Periodical antibiotic treatment for the control of gonococcal and chlamydial infections among sex workers in Benin and Ghana: a cluster-randomized placebo-controlled trial. *Sexually Transmitted Diseases*. 2012;39(4):253-259.
475. Cowan FM, Hargrove JW, Langhaug LF, Jaffar S, Mhuriyengwe L, Swarthout TD, Peeling R, Latif A, Bassett MT, Brown DW, Mabey D, Hayes RJ, Wilson D. The appropriateness of core group interventions using presumptive periodic treatment among rural Zimbabwean women who exchange sex for gifts or money. *Journal of Acquired Immune Deficiency Syndromes*. 2005;38(2):202-207.
476. Wi T, Ramos ER, Steen R, Esguerra TA, Roces MC, Lim-Quizon MC, Neilsen G, Dallabetta G. STI declines among sex workers and clients following outreach, one time presumptive treatment, and regular screening of sex workers in the Philippines. *Sexually Transmitted Infections*. 2006;82(5):386-391.
477. Williams BG, Taljaard D, Campbell CM, Gouws E, Ndhlovu L, Van Dam J, Carael M, Auvert B. Changing patterns of knowledge, reported behaviour and sexually transmitted infections in a South African gold mining community. *AIDS*. 2003;17(14):2099-2107.
478. Steen R, Vuylsteke B, DeCoito T, Ralepeli S, Fehler G, Conley J, Bruckers L, Dallabetta G, Ballard R. Evidence of declining STD prevalence in a South African mining community following a core-group intervention. *Sexually Transmitted Diseases*. 2000;27(1):1-8.
479. Hay PE. Therapy of bacterial vaginosis. *Journal of Antimicrobial Chemotherapy*. 1998;41(1):6-9.
480. Eschenbach DA. Bacterial vaginosis: resistance, recurrence, and/or reinfection? *Clinical Infectious Diseases*. 2007;44(2):220-221.

481. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. *Clinical Infectious Diseases*. 2007;44(2):213-219.
482. Jones BM, Kinghorn GR, Duerden BI. *In vitro* activity of azithromycin and erythromycin against organisms associated with bacterial vaginosis and chancroid. *European Journal of Clinical Microbiology & Infectious Diseases*. 1988;7(4):551-553.
483. Shanker S, Toohey M, Munro R. *In vitro* activity of seventeen antimicrobial agents against *Gardnerella vaginalis*. *European Journal of Clinical Microbiology*. 1982;1(5):298-300.
484. Ridgway GL. A review of the *in vitro* activity of roxithromycin against genital pathogens. *Journal of Antimicrobial Chemotherapy*. 1987;20 Suppl B:7-11.
485. Dubreuil L. *In vitro* comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains. *Journal of Antimicrobial Chemotherapy*. 1987;20 Suppl B:13-19.
486. Maskell JP, Sefton AM, Williams JD. Comparative *in vitro* activity of azithromycin and erythromycin against Gram-positive cocci, *Haemophilus influenzae* and anaerobes. *Journal of Antimicrobial Chemotherapy*. 1990;25 Suppl A:19-24.
487. Chang SC, Chen YC, Luh KT, Hsieh WC. Macrolides resistance of common bacteria isolated from Taiwan. *Diagnostic Microbiology and Infectious Disease*. 1995;23(4):147-154.
488. Ednie LM, Spangler SK, Jacobs MR, Appelbaum PC. Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole. *Antimicrobial Agents and Chemotherapy*. 1997;41(5):1037-1041.
489. Mikamo H, Yin XH, Ninomiya M, Tamaya T. *In vitro* and *in vivo* antibacterial activities of telithromycin. *Chemotherapy*. 2003;49(1-2):62-65.

490. Marina M, Ivanova M, Kantardjiev T. Antimicrobial susceptibility of anaerobic bacteria in Bulgaria. *Anaerobe*. 2009;15(4):127-132.
491. Chen JY. Maximum inspiratory pressure: a neonatal criterion for weaning from mechanical ventilation. *Kaohsiung Journal of Medical Sciences*. 1992;8(10):535-541.
492. Wexler HM, Molitoris E, Molitoris D, Finegold SM. *In vitro* activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria. *Journal of Antimicrobial Chemotherapy*. 2001;47(4):467-469.
493. Spiegel CA. Susceptibility of *Mobiluncus* species to 23 antimicrobial agents and 15 other compounds. *Antimicrobial Agents and Chemotherapy*. 1987;31(2):249-252.
494. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, Zimba D, Vernazza PL, Maida M, Fiscus SA, Eron JJ, Jr. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDS CAP Malawi Research Group. *Lancet*. 1997;349(9069):1868-1873.
495. McClelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, Lavreys L, Ndinya-Achola J, Bwayo JJ, Kreiss JK. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. *AIDS*. 2001;15(1):105-110.
496. Wang CC, McClelland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, Chohan B, Ndinya-Achola J, Bwayo J, Kreiss JK. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. *Journal of Infectious Diseases*. 2001;183(7):1017-1022.
497. Price MA, Zimba D, Hoffman IF, Kaydos-Daniels SC, Miller WC, Martinson F, Chilongozi D, Kip E, Msowoya E, Hobbs MM, Kazembe P, Cohen MS. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. *Sexually Transmitted Diseases*. 2003;30(6):516-522.
498. Aires FT, Soares RP, Bernardo WM. Efficacy of azithromycin on the treatment of syphilis. *Revista da Associacao Medica Brasileira*. 2010;56(5):496.

499. Kigozi GG, Brahmbhatt H, Wabwire-Mangen F, Wawer MJ, Serwadda D, Sewankambo N, Gray RH. Treatment of *Trichomonas* in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. *American Journal of Obstetrics and Gynecology*. 2003;189(5):1398-1400.
500. Klebanoff MA, Carey JC, Hauth JC, Hillier SL, Nugent RP, Thom EA, Ernest JM, Heine RP, Wapner RJ, Trout W, Moawad A, Leveno KJ, Miodovnik M, Sibai BM, Van Dorsten JP, Dombrowski MP, O'Sullivan MJ, Varner M, Langer O, McNellis D, Roberts JM. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic *Trichomonas vaginalis* infection. *New England Journal of Medicine*. 2001;345(7):487-493.
501. Stringer E, Read JS, Hoffman I, Valentine M, Aboud S, Goldenberg RL. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. *SAMJ: South African Medical Journal*. 2010;100(1):58-64.
502. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. *Cochrane database of systematic reviews (Online)*. 2013;1:CD000262.
503. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *Journal of Clinical Microbiology*. 1991;29(2):297-301.
504. Clerk CA, Bruce J, Affipunguh PK, Mensah N, Hodgson A, Greenwood B, Chandramohan D. A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. *Journal of Infectious Diseases*. 2008;198(8):1202-1211.
505. Tagbor H, Bruce J, Agbo M, Greenwood B, Chandramohan D. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: A randomised controlled non-inferiority trial. *PLOS ONE*. 2010;5(12):e14425.

506. Gonzalez R, Mombo-Ngoma G, Ouedraogo S, Kakolwa MA, Abdulla S, Accrombessi M, Aponte JJ, Akerey-Diop D, Basra A, Briand V, Capan M, Cot M, Kabanywany AM, Kleine C, Kremsner PG, Macete E, Mackanga JR, Massougbdgi A, Mayor A, Nhacolo A, Pahlavan G, Ramharther M, Ruperez M, Sevene E, Vala A, Zoleko-Manego R, Menendez C. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. *PLOS Medicine*. 2014;11(9):e1001733.
507. Joseph Davey DL, Shull HI, Billings JD, Wang D, Adachi K, Klausner JD. Prevalence of curable sexually transmitted infections in pregnant women in low- and middle-income countries from 2010 to 2015: a systematic review. *Sexually Transmitted Diseases*. 2016;43(7):450-458.
508. von Linsingen R, Bicalho MdG, de Carvalho NS. Baby born too soon: an overview and the impact beyond the infection. *Journal of Maternal-Fetal & Neonatal Medicine*. 2016:1-5.
509. World Health Organization. Prevention of blindness and deafness. Global initiative for the elimination of avoidable blindness. Vol PBL/97.61. Geneva, Switerland: WHO; 2000.
510. Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. *Pediatric Infectious Disease Journal*. 2012;31(4):341-346.
511. Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S. Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. *American Journal of Tropical Medicine and Hygiene*. 2011;85(4):691-696.
512. Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, Dumler JS, Munoz B, West S, Sullivan DJ. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. *Emerging Infectious Diseases*. 2014;20(6):941.

513. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. *JAMA: Journal of the American Medical Association*. 2009;302(9):962-968.
514. Keenan JD, Klugman KP, McGee L, Vidal JE, Chochua S, Hawkins P, Cevallos V, Gebre T, Tadesse Z, Emerson PM. Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments. *Journal of Infectious Diseases*. 2014:jiu552.
515. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of *Streptococcus pneumoniae*. *Clinical Infectious Diseases*. 1997;24(3):356-362.
516. Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, Safari S, Sam NE, Everett D, Mabey DC, Gillespie SH. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant *Streptococcus pneumoniae*. *Antimicrobial Agents and Chemotherapy*. 2003;47(9):2765-2769.
517. Global partners announce donation of 500 millionth dose of azithromycin, marking exceptional progress to help alleviate the suffering from trachoma. *Reuters News*. 16 November, 2015.